"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the AmerisourceBergen 2012 First Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our ho",45,"Ladies and gentlemen, thank you for standing by. Welcome to the AmerisourceBergen 2012 First Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Barbara Brungess. Please go ahead."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Good morning, everyone, and welcome to AmerisourceBergen's Earnings Conference Call covering our 2012 first quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations. And joining me today are Steve Collis, AmerisourceBerge",161,"Good morning, everyone, and welcome to AmerisourceBergen's Earnings Conference Call covering our 2012 first quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations. And joining me today are Steve Collis, AmerisourceBergen's President and CEO; and Mike Dicandilo, Executive Vice President and CFO.
During the conference call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011.
Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by telephone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen delivered solid results in the first quarter of our fiscal year 2012.Our revenues were up 2% to $20.4 billion. Earnings per share were up 9% to $0.62. We gener",1391,"Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen delivered solid results in the first quarter of our fiscal year 2012.
Our revenues were up 2% to $20.4 billion. Earnings per share were up 9% to $0.62. We generated $432 million in operating cash flow and we repurchased $128 million of our shares. Our financial results were in line with our expectations and position us well to meet our objectives for the remainder of the year.
Our excellent cash generation and strong balance sheet provide us with outstanding financial flexibility and give us the ability to fund our strategic initiatives and grow our business.
AmerisourceBergen is fortunate to be an important part of a growing industry. As I discussed at our Investor Day in December, demographics in the expansion of health care coverage should you driver our growth in our industry over the next several years. In addition, launches of new pharmaceuticals as well as new indications for existing drugs should also drive sales growth. The tremendous wave of over 30 brand to generic drug conversions that we expect in our fiscal 2012 as well as additional conversions expected in subsequent years will mitigate the top line dollar growth in our industry. And it will drive tremendous value for wholesalers, healthcare providers and patients alike.
These trends bode well for AmerisourceBergen in particular. Our diverse revenue base positions us well to benefit from organic growth driven by demographics as well as from the influx of the uninsured over the next few years. Our customer mix also puts us in a favorable position to benefit from the historic influx of generics. In addition, cost-containment efforts underway by the federal government and other payers drive demand for our services most notably in our Consulting Services group.
Today, we are more entrenched than ever before with our manufactured customers and we expect that to continue to increase. As our provided customers face reimbursement and other challenges, they increasingly turn to AmerisourceBergen for help in making their healthcare practices run as efficiently as possible without sacrificing excellent patient care.
Over the last several months, a few large contracts in our industry have been the subject of much dialogue for various different reasons. Over all, however, the market continues to be competitive but stable. We continue to participate in discussions that are important to our business, our industry and our customers in Washington, D.C., educating lawmakers about our business and the value we and our customers provide in the healthcare system.
I discussed our core tenants several times over the year but they continue to drive our efforts and that's very repeating. Firstly, to corroborate to drive innovation for all stakeholders, increasing customer and supplier value, expanding our business in targeted markets, maximizing operating efficiency and maintain a high-performance culture. Our associates creatively tackle challenges and identify new opportunities to add value on a daily basis. They will focus in meeting objectives for the year both in terms of the service we provide to customers and supplies and in our financial performance and I'm honored to work with all of them.
Turning now to our business units. AmerisourceBergen Corporation had solid revenue growth in the quarter up 2%. We had positive revenue growth in both retail and institutional segments, even with the previously discussed large retail -- retail customer in September of 2011. Our ultimate segment was particularly strong in the quarter and hospitals and independents had very solid growth. We now have over 4,600 members in our Good Neighbor Pharmacy network which makes it the third largest network of pharmacies in the U.S. that is a powerful endorsement of the independent retail pharmacy play in the complex healthcare landscape today.
Patients preferred choice when determining where to fill their prescriptions and our retail customers are very adept at fulfilling unique patient needs. Our SAP implementation continues to run smoothly with 3 distributions and our conversion is complete and the remainder plans for the beginning of 2013. Our investments in our Canadian operations to support significant new business wins are also well underway. We are very pleased to be the leading distributor independent pharmacy in the Canadian market as well as the leader in Specialty Distribution and services.
AmerisourceBergen Specialty Group had another strong quarter, with revenues up 4% with particularly strong performance in third-party logistics and good performance at Oncology Supply. The integration of IntrinsiQ has gone very well, and our customers have responded favorably to the tools at office. While our Specialty Group is based for oncology franchise we are an instrumental part of the commercialization strategy for any infeasible product launched in the position marketplace.
In addition, our Specialty Group often collaborates our Consulting Services group to help ensure patients have access to products by utilizing the full capabilities of our physician networks, as well as our reimbursement and patient support program expertise. For example, during the quarter, we executed very well on the launch of a new branded ophthalmology product, establishing significant market share in just the first few months of introduction. This is a great example not only of excellent cross-company collaboration, but also the strength and tremendous value of our diverse offerings.
AmerisourceBergen Consulting Services delivered a strong quarter while making excellent progress in the integration of TheraCom and Premier Source. Our Consulting and Packaging business book performed well in the quarter. And while the group only represents about 1% of our revenues, we believe our Packaging and Consulting associates are providing essential expertise to pharmaceutical manufacturers to help ensure that their products are brought to market as safely, quickly and efficiently as possible.
In addition, our reimbursement expertise helps ensure that patients who can benefit from both new and mature therapies have access to the products. 
Given the continued strength of our balance sheet, we continue to look for acquisitions that meet the criteria we had in place for quite some time. Patient increase our value offering to existing customers both up and down the channel. They should be within our established core competency and they should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions and we continue to be interested in opportunities in pharmaceutical and Specialty Distribution services, as well as Consulting and Packaging services. While we historically have been very comfortable in that $200 million to $300 million range, we will consider selling larger if we make good strategic sense and we deliver value to our company and our shareholders.
Looking ahead, the results we've had in our first quarter have positioned us well to meet our objectives for the full fiscal year. We have a difficult comparison to overcome in 2012, but we continue to expect earnings per share to be in the range of $2.74 to $2.84, an increase of 8% to 12% over fiscal 2011.
Looking further ahead to 2013, we should have a carryover from some of the launches that occur late in our fiscal 2012 including the relaunch of and we should begin to benefit from the completion of our SAP implementation.
In fiscal 2014, we should begin to see the $30 million to $40 million uninsured patient in the healthcare market driving demand for pharmaceutical that should carry over into 2015 and beyond. In addition, 2014 and 2015 are expected to be good years with generic conversions, and of course, there's a chance that biosimilars may also come to market in that timeframe.
Before I turn it over to Mike for a detailed look at the financials, I want to reiterate the confidence that I have in our business and our future because demand is strong for the products we distribute and the services we provide. We were pleased to be recently be ranked 24th on Bloomberg BusinessWeek's list of the top 50 performing companies in the U.S. in recognition of our historic financial performance and our future growth opportunities.
As I stated earlier, we have essential role in the pharmaceutical supply channel. We positioned ourselves well to benefit from generics and specialty products and we have continued to invest in our existing businesses and opportunities we see in our future.
Finally, our exceptional associates at ABC support in our industry and I'm proud to be their leader. Here is Mike."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and good morning, everyone. I'm very pleased to report first quarter fiscal 2012 results on track with our internal plans, highlighted by good performance on new generic launches, strong expense discipline, significant progress towards inte",1228,"Thanks, Steve, and good morning, everyone. I'm very pleased to report first quarter fiscal 2012 results on track with our internal plans, highlighted by good performance on new generic launches, strong expense discipline, significant progress towards integrating thorough comp and to our consulting group and exceptional cash generation, all of which gives us confidence in reaffirming our annual EPS guidance.
As we go through our quarterly results, keep in mind that last year's first quarter included a $12 million or $0.03 benefit reflected in gross profit from the Duane Reade contract termination last December.
So let's turn to the quarter and starting with the top line revenues were $20.4 billion, a 2.4% increase over last year's quarter. Drug company revenue was up 2% as strong growth in the alternate site hospital and independent customer groups offset the expected decline on the chain side, as this is our first quarter without the Longs CVS contract. 
The Specialty Group revenues increased 4% with our 3PL business especially strong this quarter. The Consulting group, though small to the overall company top line, had a very strong quarter in our acquisitions with TheraCom, being the biggest contributor, added about 0.6% to overall ABC revenue growth of the quarter.
Gross profit was $593 million in the quarter, up 2% from last December and gross margins of 291 basis points in the quarter, were down 1 basis point from last year. As I mentioned earlier, the prior year quarter included a $12 million benefit related to the completion of the Duane Reade contract and the contribution to current quarter gross profit from our acquired companies helped to offset this headwind.
Performance from new generic launches were in line with our expectations as were benefits from price appreciation. We give an early update during our Investor Day in December on trends with generic Lipitor Scripps. And since then, trends have normalized very much in line with our expectation of approximately a 70% conversion rate to the generic. Specialty generic trends were also in line with our expectations.
Our LIFO charge in quarter was $3.2 million compared to $9.9 million last year, reflecting the brand to generic conversions, and we continue to expect a full year charge of approximately $15 million.
We did very nice job managing our operating expenses this quarter despite our acquisition-related transaction costs and the inclusion of our acquired companies ongoing operating costs, including 2 months of TheraCom's results.
Operating expenses were $308 million, up 1.6% and included $3.6 million of acquisition-related transaction costs. Operating expenses in the quarter would have been down year-over-year ex the impact over acquisitions, fueled by a year-over-year decline in compensation costs including favorable benefit comparisons.
Keep in mind that our operating expenses are usually at their lowest level in our first quarter and should increase sequentially as we progress throughout the year.
Our guidance continues to include an annual expense increase of about 3% related primarily to our acquisitions.
Operating income of $285 million in the quarter increased 3% and operating margins expanded by 1 basis point compared to last December. Again, this year-over-year growth was slowed by the $3.6 million of acquisition costs in the current quarter and the previously mentioned $12 million gross profit benefit realized in the first quarter of fiscal '11.
Moving below the operating income line, interest expense of $23 million in the December quarter increased 18% compared to last year, primarily as a result of our $500 million 3.5% bonds that we issued in mid-November. Proceeds from this debt offering helped to fund our acquisitions and will also contribute to the retirement of our 2012 bonds that mature in mid-September. As a result, our expected interest rate expense will continue to trend higher than last year for the rest of fiscal '12.
Our effective income tax rate of 38.2% was slightly higher than last year's 38.1% and slightly below our expected annualized rate of approximately 38.4%. Our diluted earnings per share of $0.62 was up $0.05 or 9% compared to last year and exceeded our net income growth due to the reduction in our average diluted shares related to our ongoing share repurchase program. Average diluted shares outstanding for the quarter were 263.1 million, down over 6% from last December.
Now let's turn to our balance sheet in cash flow where trends continue to be very favorable. We generated $432 million of cash from operations in the quarter compared to using $99 million of cash in last year's first quarter. Much of that increase came from very favorable working capital at quarter end, particularly in the timing of our payments to vendors. As I have discussed often with our daily volume exceeding $300 million per business day, our quarter end working capital snapshots are subject to great volatility and one should be careful not to extrapolate the first quarter's results to the full year cash flow forecast.
Capital expenditures were $48 million in the quarter compared to $50 million last year, and as we mentioned in December, included significant investments to expand our infrastructure in Canada as well as some discretionary buyouts on leased equipment, offset in part by declining ERP spend.
We continue to expect the capital spend for the year in the $150 million range. We bought back $128 million of our shares during the quarter and we also closed our $250 million TheraCom acquisition. 
With our strong free cash flow performance in the quarter, we continue to be comfortable with our estimate of free cash flow in the range of $700 million to $800 million for all of fiscal '12. We had our normal seasonal increase in inventory in December. But despite the higher ending balance, our average day sales inventory for the quarter remained at 25, consistent with fiscal '11. Average DSOs of 17.7 in the December quarter were up slightly from 17.4 days last year and a favorable payables timing helped raise average quarterly DPOs by over 2 days compared to fiscal '11.
With our recent debt offering, our gross debt to total debt to capital ratio at the end of December was 39.9%, above our target range of 30% to 35% and will remain above the range in the next couple of quarters until we pay off our $392 million of debt, which matures in September.
Our cash balance was just under $2.4 billion at the end of December leaves us with greater financial flexibility to fund our strategic initiatives, return significant amount of capital to our shareholders and pay off our maturing debt.
Now let's turn to fiscal '12 guidance. And with our first quarter on track, our outlook is unchanged. Our diluted EPS guidance remains at a range of $2.74 to $2.84. Our assumptions behind this guidance also remain the same and include flat-to-modest revenue growth, operating margin expansion in the high single-digit to low double-digit basis point range and free cash flow in the $700 million to $800 million range. Additionally, we continue to expect to spend approximately $400 million for share repurchases.
So before I turn it back to Barbara, let me reiterate that 3 months into the year, we are performing well in our key areas in the business and despite some tough comparisons ahead in the next couple of quarters, we are well-positioned to meet our financial targets for all of fiscal '12.
Now here's Barbara for Q&A."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Mike. We will now open the call to questions. [Operator Instructions] Please go ahead, Cara.",17,"Thank you, Mike. We will now open the call to questions. [Operator Instructions] Please go ahead, Cara."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] The first question comes from the line of Tom Gallucci.",12,"[Operator Instructions] The first question comes from the line of Tom Gallucci."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I think you touched on in your prepared remarks briefly I was wondering if you could sort of expand a little bit in the competitive landscape obviously it's got a lot of attention in the investment community lately, whether it's because of the DA o",111,"Steve, I think you touched on in your prepared remarks briefly I was wondering if you could sort of expand a little bit in the competitive landscape obviously it's got a lot of attention in the investment community lately, whether it's because of the DA or the impact of the various M&A activity out there potentially. What are you expecting in terms of contract churn over the next year? Similar to the last year, if it's higher, is it because of certain unique reasons? Or do you see sort of the potential for more churn out there because of other types of reasons and maybe decisions that specific customers maybe making?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think that these are really 2 or 3 really isolated events. I mean the VA comes up every 8 years. It's not a surprise to anyone that it comes up in this particular time frame. And obviously, we've gone to great lengths at point out that the industry is a",184,"I think that these are really 2 or 3 really isolated events. I mean the VA comes up every 8 years. It's not a surprise to anyone that it comes up in this particular time frame. And obviously, we've gone to great lengths at point out that the industry is a lot different than it was in 2003. And we bid that as you would expect as a bit of a large contract. And of course, a couple of big M&A deals, which one in particular was not at all expected, but we expect to participate in that. Our focus is being on servicing the company that we do service the best of our abilities. And I think we'll do a great job for them. And we expect it will be a part of any discussion going forward on those businesses. So just to sum it up, the competitive environment remains very similar to how it's been in the past. And we don't have a particular large amount of contracts coming up in the next couple of quarters. I mean, Mike, anything to add?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, Steve. I think you said it well. The atmosphere has always been competitive but stable as you mentioned.",19,"No, Steve. I think you said it well. The atmosphere has always been competitive but stable as you mentioned."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. Now just as follow up there, maybe a smaller topic but there's been some activity around generic Lovenox today. Just curious if you could frame that drug for us and the potential impact, your roughly speaking, if there was more supply in the",46,"Okay, great. Now just as follow up there, maybe a smaller topic but there's been some activity around generic Lovenox today. Just curious if you could frame that drug for us and the potential impact, your roughly speaking, if there was more supply in the market."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, Tom, generic Lovenox, we have done very well with that. It's part of our pro-generics offering and we already have had expectations that there would be competition in the marketplace. And that's built into our expectations.",37,"Well, Tom, generic Lovenox, we have done very well with that. It's part of our pro-generics offering and we already have had expectations that there would be competition in the marketplace. And that's built into our expectations."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Robert Jones with Goldman Sachs.",12,"The next question comes the line of Robert Jones with Goldman Sachs."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Just trying to get the better sense of some of the individual impacts in the quarter. First, I guess in the acquisition side, aside from the announced severance costs, was there an impact on operating expenses from the acquisitions in the quarter? And the",68,"Just trying to get the better sense of some of the individual impacts in the quarter. First, I guess in the acquisition side, aside from the announced severance costs, was there an impact on operating expenses from the acquisitions in the quarter? And then I guess along those lines if you could give us some color around how Lipitor and contributions ultimately shaped up relative to your expectations?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, let me -- I'll start with the cost of the acquisitions. I think we highlighted on the phase of the P&L that we had $3.6 million of transaction costs related to closing the deal that we did in this quarter, the TheraCom deal. In addition, we obviousl",134,"Well, let me -- I'll start with the cost of the acquisitions. I think we highlighted on the phase of the P&L that we had $3.6 million of transaction costs related to closing the deal that we did in this quarter, the TheraCom deal. In addition, we obviously, also have ongoing operating cost from all 3 of the companies we've acquired in the last few months that are incremental to last year's first quarter. And as I mentioned, they are included in our normal SG&A. And if you took out the normal ongoing operating costs, our year-over-year SG&A would have been down. So I think that speaks well to the rest of our business and the continued impact of our productivity efforts throughout the company and our continued focus on keeping our costs down."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, and on the 2 big generic launches in the quarter, I mean, we have said it on best today that we're really into the very big one the prominent one we we're only about one week or so into it, that the conversion rates we're slightly lower than expected",123,"Yes, and on the 2 big generic launches in the quarter, I mean, we have said it on best today that we're really into the very big one the prominent one we we're only about one week or so into it, that the conversion rates we're slightly lower than expected but it settle down around that 70% level, which is a little bit less than you'd expect. But it's definitely trending in the right direction. And right around where we've expected it, around 80%. And we performed very much and expectations for both of them with the exception of the Lipitor, which we discussed at Investor Day, which we now feel is back on track as we said at the end of January."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And just a follow-up I guess on the buyback with $750 million left on the authorization and reiterating the $400 million that's based in the guidance. I was wondering what point in the year, what would trigger you to maybe look to upsize the buyback",49,"Okay. And just a follow-up I guess on the buyback with $750 million left on the authorization and reiterating the $400 million that's based in the guidance. I was wondering what point in the year, what would trigger you to maybe look to upsize the buyback in fiscal '12?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","First off, let me just clarify, we've got $380 million remaining on our current authorization. And obviously, our guidance for the year is $400 million of share repurchases. And I think you can look back to our historical performance to understand how we",106,"First off, let me just clarify, we've got $380 million remaining on our current authorization. And obviously, our guidance for the year is $400 million of share repurchases. And I think you can look back to our historical performance to understand how we might deploy additional capital for repurchases. If we don't make any other larger strategic moves, we certainly have the capacity to increase the share repurchase and once again, we've shown that we would do that similar to what we did last year if that's how the year progresses and we continue to meet our cash forecast. So we're in a very good position."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Larry Marsh with Barclays Capital.",12,"The next question comes the line of Larry Marsh with Barclays Capital."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","This is actually Keith Davids in for Larry. So this is just sort of a follow-up on Lipitor. So it sounds like you're communicating that it came a little bit slower initially than you'd expected in terms of generic conversion. Now your sort of more comfort",111,"This is actually Keith Davids in for Larry. So this is just sort of a follow-up on Lipitor. So it sounds like you're communicating that it came a little bit slower initially than you'd expected in terms of generic conversion. Now your sort of more comfortable with where it is. Just kind of curious after we think about Zyprexa, of course, other generics that come online, how have your thoughts changed for the rest of the year? What do you think some of the key variables are with regard to whether it's manufacture, strategies, et cetera, that might cause you to change your thoughts about the generic contributions throughout the year?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","This is -- Lipitor was as we said a lot, is really a unique product. I mean, first the size of the it is fit. And we think that it's also uniquely an order drug. So Pfizer was able to contract with large purchases of the product directly. We think that th",107,"This is -- Lipitor was as we said a lot, is really a unique product. I mean, first the size of the it is fit. And we think that it's also uniquely an order drug. So Pfizer was able to contract with large purchases of the product directly. We think that this is an unusual situation. We don't think it's been particularly successful. And we don't -- we have not changed any of our about generic launches this year. And as I said, we feel very reassured by the fact that the conversion rate is now approaching 70% and looks like it could go up from there."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, that's helpful. And then just a follow-up. This is sort of around consolidation. How do we think about with a broad specialty offering, how do we think about customer consolidation in the specialty space? And would we think that specialty would alwa",88,"Okay, that's helpful. And then just a follow-up. This is sort of around consolidation. How do we think about with a broad specialty offering, how do we think about customer consolidation in the specialty space? And would we think that specialty would always be service sort of just a part of a larger PBM contract or that sort of business potentially be carved out? How do we think about that sort of relationship there? I don't know if that's a question for James or any of you folks."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, you raised a good question. I understand -- I think I understand what you're getting at. First of all, let me distinguish that our Specialty Distribution business is really dealing with physicians who administer products in their office. And there's",142,"Well, you raised a good question. I understand -- I think I understand what you're getting at. First of all, let me distinguish that our Specialty Distribution business is really dealing with physicians who administer products in their office. And there's been numerous calls, there's no doubt that AmerisourceBergen Specialty Group is the leading company in that area. And we're very, very successful there. In our Drug company we have several large companies that are involved specialty products more on the mail-order side and on the patient delivery side. And we definitely have expertise in servicing those customers. So overall, AmerisourceBergen really services a huge part of the specialty industry. And we expect that to continue, so I hope that's helpful. I think both aspects of the Specialty Distribution are important to our company, important to manufacturers and important to the patients."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Eric Coldwell with Robert W. Baird.",13,"The next question comes the line of Eric Coldwell with Robert W. Baird."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I realize that one of your major customers purchase generics through AmeriSource. But there have been rumblings of the market that perhaps 1 or 2 of the largest retail systems are looking at the internal licensing and generics perhaps slowly but aren't te",75,"I realize that one of your major customers purchase generics through AmeriSource. But there have been rumblings of the market that perhaps 1 or 2 of the largest retail systems are looking at the internal licensing and generics perhaps slowly but aren't testing the market there. Have you seen any shift in your customers buying behavior around generics recently, whether it be asking for greater discounts or looking to perhaps internalize some of the work?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I mean obviously generics becoming more and more important. They are a bigger part of the prescriptions that the patients get in the U.S. every day, and it's and that's certainly what we expected. But we really haven't seen any different shifts. We be",83,"No, I mean obviously generics becoming more and more important. They are a bigger part of the prescriptions that the patients get in the U.S. every day, and it's and that's certainly what we expected. But we really haven't seen any different shifts. We believe that our progen and our overall generic offering offers the best everyday value to our customers. And we continue to work very hard at keeping that to be the case. And I think our customers appreciate it, Eric."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","That's great. Just one quick follow-up another healthcare just give it to this morning highlighted the physician activity was slower than they expected. They saw a less flu, seasonal flu impact due to lower illness rates in the weather, obviously. I reali",83,"That's great. Just one quick follow-up another healthcare just give it to this morning highlighted the physician activity was slower than they expected. They saw a less flu, seasonal flu impact due to lower illness rates in the weather, obviously. I realized that's also a very small piece of your total business, but can you give us any comments and what you're seeing around primary care and the flu market, both for the December quarter and where we are early this year?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","The flu vaccine has become a very small part of over $8 billion in revenues. The most activity actually takes place for flu vaccine in our fourth quarter of our fiscal year, so the September quarter last fiscal year. We have some modest activity in this q",113,"The flu vaccine has become a very small part of over $8 billion in revenues. The most activity actually takes place for flu vaccine in our fourth quarter of our fiscal year, so the September quarter last fiscal year. We have some modest activity in this quarter so that really is primarily now become that September quarter. Of course, our retailers are impacted by seasonal rains. If there's a lot of flu like cold, it does help patient traffic. But we really focus on overall top line growth with not as much an individual prescription train at the retail level. So hopefully, that's helpful for you. Mark, do you have anything to add?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, and they've been good, Eric, we've been up year-over-year despite the completion of the Longs CVS contract last quarter which I think is an indication of our strategy in the top line force.",34,"No, and they've been good, Eric, we've been up year-over-year despite the completion of the Longs CVS contract last quarter which I think is an indication of our strategy in the top line force."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Lisa Gill with JPMorgan.",11,"The next question comes the line of Lisa Gill with JPMorgan."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, you made a comment on the revenue line that you're seeing strength on the hospital side as well as the independence. Can you maybe just talk about heavy pick up any incremental customers? Or is there some other reason why you're seeing increased st",58,"Steve, you made a comment on the revenue line that you're seeing strength on the hospital side as well as the independence. Can you maybe just talk about heavy pick up any incremental customers? Or is there some other reason why you're seeing increased strength in those customers? Because revenue came in much better than we would've anticipated."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No. I think we had some mix the big customers group in the quarter. Our hospital business is we believe we have good market share there and really nothing extraordinary that happens just good solid demand for our products.",39,"No. I think we had some mix the big customers group in the quarter. Our hospital business is we believe we have good market share there and really nothing extraordinary that happens just good solid demand for our products."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","But did revenue come in while you were thinking? So do we have it wrong? Or is it just that this is what you were expecting based on what you've seen in the book and all of us got a little carried away on what our expectations were for the impact of gener",53,"But did revenue come in while you were thinking? So do we have it wrong? Or is it just that this is what you were expecting based on what you've seen in the book and all of us got a little carried away on what our expectations were for the impact of generics?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Revenues came in very close to what we're expecting. I mean maybe slightly ahead of expectations. But very close to what we were expecting.",25,"Revenues came in very close to what we're expecting. I mean maybe slightly ahead of expectations. But very close to what we were expecting."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. Just as a follow-up us to think about the oncology offices and we think about reimbursement as well as some of the programs, for example, that United is doing around bundling of services et cetera, are you starting to see any change as you mo",78,"Okay, great. Just as a follow-up us to think about the oncology offices and we think about reimbursement as well as some of the programs, for example, that United is doing around bundling of services et cetera, are you starting to see any change as you move into the next year starting to about planned design changes and changes with the managed care companies around how they pay for oncology. Has there been any noted change this year?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","This discussion has been around for several years and I think it's just really while offering is so important. I mean, you look at why we acquired IntrinsiQ and you looked at the investments we make in our eye on business, our physician services company.",184,"This discussion has been around for several years and I think it's just really while offering is so important. I mean, you look at why we acquired IntrinsiQ and you looked at the investments we make in our eye on business, our physician services company. We really want to enhance the dialogue between managed companies in our community oncologists there. Our strategy is not to be a principal in those negotiations between but really to assist our customers so they have information available and they have the sort of data that managed care companies are looking at. And we think are definitely enhancing that dialogues. It's not -- we're stopping that trend. I think as we sit here today, I was in D.C. last weekend with some of our large oncology practices, people are starting to recognize us. It's very important to keep cancer care in the community setting, not only from a patient point of view, clinical point of view. That's obviously a trend at AmerisourceBergen supports and a big part of what our Specialty Group practice is able to demonstrate everyday."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","So just to understand it, then you're not seeing anything as far as trends go as we think about how that impact your revenue you're not seeing any changes the utilization or the way that the product is delivered based on these discussions.",43,"So just to understand it, then you're not seeing anything as far as trends go as we think about how that impact your revenue you're not seeing any changes the utilization or the way that the product is delivered based on these discussions."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No. And again, we've had our ASP for over 6 years now. So I think our practitioners are used to it. Everything as we said in the release, everything went very well in the oncology business this quarter.",38,"No. And again, we've had our ASP for over 6 years now. So I think our practitioners are used to it. Everything as we said in the release, everything went very well in the oncology business this quarter."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of AJ Rice with Susquehanna.",11,"The next question comes the line of AJ Rice with Susquehanna."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I guess because there's so much focus on the VA contract, I'd love to get any perspective you'd be willing to offer on sort of the rebidding and the ask for additional information and say taking a second look, what does that imply about what they're tryin",103,"I guess because there's so much focus on the VA contract, I'd love to get any perspective you'd be willing to offer on sort of the rebidding and the ask for additional information and say taking a second look, what does that imply about what they're trying to do there? And I guess, I'll ask you a similar question to the one I asked at the Investor Day if you guys with what you now know, if you were to be successful and get the contract, would you consider that to be something that would be additive to your results almost immediately?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Mike, I'll give a go at it and then let Steve add any additional comments. When we got the additional information from the VA, it essentially clarified that there is a small part of purchases approximately 3% that were off contract and clarified that fact",172,"Mike, I'll give a go at it and then let Steve add any additional comments. When we got the additional information from the VA, it essentially clarified that there is a small part of purchases approximately 3% that were off contract and clarified that fact and asked us to rebid based upon that you information. We go back to what we said, when we bid this contract back in June, we consider that to be our last and final bid. We took it very seriously. We considered a new information. We made the appropriate modifications, but it did not change our bid material from what we had done at the end of June. Should we get the VA contract? Yes, I think it would add right away. I think our expectations it's a several billion dollar contract, there's not many of those out there and typically the largest contracts in our industry get the best price I would expect this to be similar and have the appropriate contribution for a large contract."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I think Steve made this comment about outpatient in the drug Corporation being particularly strong. And I was just wondering maybe there's a little more color on what was exactly going on there in your opinion.",36,"I think Steve made this comment about outpatient in the drug Corporation being particularly strong. And I was just wondering maybe there's a little more color on what was exactly going on there in your opinion."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think, AJ, you talked about really our old. That maybe my accent. That's really nonhospital institutional business, mail-order scale facilities institutional, pharmaceutical trend. We did have good revenue trend in that segment. And we have a couple of",55,"I think, AJ, you talked about really our old. That maybe my accent. That's really nonhospital institutional business, mail-order scale facilities institutional, pharmaceutical trend. We did have good revenue trend in that segment. And we have a couple of new customer wins, particularly we've talked about the contract where we have a good revenue performance."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I just was curious if it was underlying pickup and trend or is it new business so it sounds like it's mostly new business maybe?",26,"I just was curious if it was underlying pickup and trend or is it new business so it sounds like it's mostly new business maybe?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Yes, you could say a new business. But good high-growth sector, I mean benefiting from favorable demographics.",18,"Yes. Yes, you could say a new business. But good high-growth sector, I mean benefiting from favorable demographics."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Charles Reid with Cowen & Co.",12,"The next question comes the line of Charles Reid with Cowen & Co."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","One real quick follow-up about the VA here. Obviously, investors and analysts are all focused on this contract, but can you tell us essentially when you're in discussions with clients, is this something that comes up? Or is this something that people ever",50,"One real quick follow-up about the VA here. Obviously, investors and analysts are all focused on this contract, but can you tell us essentially when you're in discussions with clients, is this something that comes up? Or is this something that people ever look at or ever refer to?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think everyone understand it's a very, very different contract. The way it works, it's very unique both in DOD, that doesn't really come up.",26,"I think everyone understand it's a very, very different contract. The way it works, it's very unique both in DOD, that doesn't really come up."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, that's great. And then Mike, maybe a question from you, and I guess this gets back to your original comment about how you see Lipitor come on. When you look at the LIFO charge in the quarter obviously, down less than a year ago. Should we expect tha",95,"Okay, that's great. And then Mike, maybe a question from you, and I guess this gets back to your original comment about how you see Lipitor come on. When you look at the LIFO charge in the quarter obviously, down less than a year ago. Should we expect that the sort of increase as we see more of the rate of adoption on like Lipitor and some of the generics come on? Is that a good proxy then for us to think about how do generics are coming onto the course of this fiscal year?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, the LIFO charge as expected, Charles, to be significantly below what it was last year and really 2 reasons. Last year was actually much higher than we expected because of how high the brand price appreciation was. And again our expectation is it's st",165,"Yes, the LIFO charge as expected, Charles, to be significantly below what it was last year and really 2 reasons. Last year was actually much higher than we expected because of how high the brand price appreciation was. And again our expectation is it's still going to be strong this year but may moderate a little bit versus last year on the brand side. But certainly, with all the new generic introductions and 34 launches there's going to be a big impact on the generic price deflation this year from products coming off exclusivity. And that has led to lower overall expectation what a LIFO charge is going to be and that's really starting to be in the beginning of the year and will be pretty consistent the rest of the year as a lot of the launches are pretty well spaced throughout the year. And we will continue to have launches next quarter and all the way through to the end of the year."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","And so did that sequential change is that a good signal for us? And was this quarter sort of in line with what you had expected?",26,"And so did that sequential change is that a good signal for us? And was this quarter sort of in line with what you had expected?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Yes, very much in line. And again it's a $15 million -- $15 million annual expectation. We're always a little bit higher in the second quarter because that's where a lot of the brand inflation occurs. But otherwise, very much as we expected.",44,"Yes. Yes, very much in line. And again it's a $15 million -- $15 million annual expectation. We're always a little bit higher in the second quarter because that's where a lot of the brand inflation occurs. But otherwise, very much as we expected."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Ricky Goldwasser with Morgan Stanley.",12,"The next question comes the line of Ricky Goldwasser with Morgan Stanley."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","So just as a thought to the last question but took it from a revenue perspective, so you grew revenue at about 2.4% and you're guiding us for flat revenues. So should we assume that second half revenues might decline given the timing of drugs going off 18",52,"So just as a thought to the last question but took it from a revenue perspective, so you grew revenue at about 2.4% and you're guiding us for flat revenues. So should we assume that second half revenues might decline given the timing of drugs going off 180s that you just mentioned?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Some of that sequential change, Ricky, has to do obviously with our largest customer who only buys brand-name drugs from us and products go generic their revs will moderate some over the rest of the year.",36,"Some of that sequential change, Ricky, has to do obviously with our largest customer who only buys brand-name drugs from us and products go generic their revs will moderate some over the rest of the year."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So when we model, I just want to make sure that our model is accurate, should we assume kind of like a first half kind of like 2%? And then sort of like negative growth in the second half to get flat year-over-year or is it going to be smoother than",53,"Okay. So when we model, I just want to make sure that our model is accurate, should we assume kind of like a first half kind of like 2%? And then sort of like negative growth in the second half to get flat year-over-year or is it going to be smoother than that?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think it's going to be a little bit smoother.",11,"I think it's going to be a little bit smoother."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And then on the generic side, you talked a lot about that, but can you quantify the EPS impact for you generics. Is it back at this quarter? Just to give us a sense for how does it relate to $0.05, $0.06 of benefit that you're seeing from gemsar and",52,"Okay. And then on the generic side, you talked a lot about that, but can you quantify the EPS impact for you generics. Is it back at this quarter? Just to give us a sense for how does it relate to $0.05, $0.06 of benefit that you're seeing from gemsar and here?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Ricky, I don't think we really want to get into a quarter quantification of the impact of the new generics. And obviously, what happened last year has an impact as well year-over-year impact. I think again our guidance for the year's we expect the cumulat",152,"Ricky, I don't think we really want to get into a quarter quantification of the impact of the new generics. And obviously, what happened last year has an impact as well year-over-year impact. I think again our guidance for the year's we expect the cumulative impact of the 34 launches wasn't the decline especially on the generics side. From the Specialty Generic perspective, we had about a $0.06 and benefit in the first quarter of last year. And this year was pretty similar down about $0.50 or so. Those comparisons will get more difficult the next couple of quarters as they we're very big quarters here for specialty. But I think the beneficial impact of the will also increase in those next couple of quarters as well. So we really haven't changed our viewpoint on the year about the offset on the oral side to the headwind on the specialty generic side."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Directionally will Lipitor and Zyprexa no specific numbers higher or lower than that kind of like $0.05 to $0.06.",19,"Directionally will Lipitor and Zyprexa no specific numbers higher or lower than that kind of like $0.05 to $0.06."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Again, Ricky, I don't want to get into the quantification. I think we gave a pretty good view at Investor Day that the top 2 players were significant part of the year, in the 40% range I believe we gave. And I think that's the best quantification we want",55,"Again, Ricky, I don't want to get into the quantification. I think we gave a pretty good view at Investor Day that the top 2 players were significant part of the year, in the 40% range I believe we gave. And I think that's the best quantification we want to get into at this time."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question goes to the line of George Hill with Citigroup.",12,"The next question goes to the line of George Hill with Citigroup."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Most of my questions have been answered. Mike, I just want to ask another guidance question directionally. I know you guys don't like to give quarterly guidance but straight expectations for  for Q2 or for a big number. And as we think about the branded L",159,"Most of my questions have been answered. Mike, I just want to ask another guidance question directionally. I know you guys don't like to give quarterly guidance but straight expectations for  for Q2 or for a big number. And as we think about the branded Lipitor to generic conversion, I guess, 2 questions, one do you expect the Pfizer retention rate to stay at the 30-ish percent range? Or how quickly do you guys think that will continue to fall? And if it hovers at 30%, it could look like the most profitable period for generic Lipitor to be kind of even first month right after May when there's no limit on multisource introductions and the whack won't probably won't catch up but you can acquire the price. I guess, is it your sense that we might be, I guess, is the consensus maybe seem too ambitious for fiscal Q2? And we should be more optimistic for fiscal Q3?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I'd say, again we do not, let me make clear we do not give quarterly guidance. And directionally, the March quarter has always been our strongest quarter because of the timing and the impact of manufacturer, our brand price increases and the impact th",266,"No, I'd say, again we do not, let me make clear we do not give quarterly guidance. And directionally, the March quarter has always been our strongest quarter because of the timing and the impact of manufacturer, our brand price increases and the impact that has some of our fee-for-service agreements, that trend is -- continues to be our expectation this year. Certainly, the second quarter is a big quarter for the oral solid generics as well. Keep in mind, the first quarter we only had a month of the Lipitor, 2 months of the Zyprexa generics. In the second quarter, we have a full quarter benefit from those plus some new introductions. So certainly, we think the year-over-year benefit from oral solid is going to increase in the next quarter from the first quarter. So the trending I think is again very similar to where it's been historically. The second quarter continues to be our peak. The number of suppliers that come on board after the exclusionary period for Lipitor can impact our numbers somewhat. But again, we're expecting a handful of people there, and we're expecting a pretty significant price drop after exclusivity is over. As far as the 70 to 30, that's inline with our expectations if it's a little bit more generic, it helps us. It helps us. But again, I think the historical trending as far as our quarterly progression is still intact. And as I've mentioned we've got tough comparisons 2, 3 on the specialty side good performance on more solid the fourth quarter continues to be our easiest comparison."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And maybe just a quick follow-up to Tom's question that's actually where investors worry about client trend being unusually high given what's going on in the M&A space. A lot of the big clients tend to be relationship the wholesalers is pretty trans",53,"Okay. And maybe just a quick follow-up to Tom's question that's actually where investors worry about client trend being unusually high given what's going on in the M&A space. A lot of the big clients tend to be relationship the wholesalers is pretty transaction. What can AmeriSource due to make these more sticky?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think obviously the smaller customers, we have different services larger customers. I think we've proven time and again that our relationship to our largest customer is very valuable to them. We were happy to receive the VAP award the last 2 years in a",165,"I think obviously the smaller customers, we have different services larger customers. I think we've proven time and again that our relationship to our largest customer is very valuable to them. We were happy to receive the VAP award the last 2 years in a row. And I think we can do different services especially around logistics, cash flow, joint negotiations, even look at some generic last for large customers I think there's a lot of opportunities in the industry to work together. And then, of course, I just -- I'll be remiss if I didn't mention our specialty franchise, which I think is of great interest to almost anybody in the healthcare space. Specialty is really where the innovation, action's going to be in the years ahead. And definitely have expertise, our physician productivity, our understanding of the trends there, some of the contracting we do with manufacturers will be of interest to all large participants from mail-order to retail the hospital, et cetera."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Steven Valiquette with UBS.",11,"The next question comes the line of Steven Valiquette with UBS."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","So just to confirm, it sounds like there's no change to the $0.14 to $0.15 EPS, I expected from the fiscal '12 from the big specialty generics. And then the reintroduction of generic in August, does that account for any material portion of that or is that",59,"So just to confirm, it sounds like there's no change to the $0.14 to $0.15 EPS, I expected from the fiscal '12 from the big specialty generics. And then the reintroduction of generic in August, does that account for any material portion of that or is that going to be basically within the end of today within fiscal '12?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","It's included in the $0.14 to $0.15. But I just said it's only a little bit more than one month of inclusion in our fiscal '12. But it is in there.",32,"It's included in the $0.14 to $0.15. But I just said it's only a little bit more than one month of inclusion in our fiscal '12. But it is in there."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","Next question comes the line of Matthew Covina with Morningstar.",10,"Next question comes the line of Matthew Covina with Morningstar."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Two quick questions. So you said before that Medco is only about 5% of earnings. Maybe you can help us give a better understanding of the flexibility of the cost structure here, what from a specific standpoint, can you do in terms of reducing SG&A when yo",53,"Two quick questions. So you said before that Medco is only about 5% of earnings. Maybe you can help us give a better understanding of the flexibility of the cost structure here, what from a specific standpoint, can you do in terms of reducing SG&A when you lose a large customer like that?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think you look at our year and we always do a good job. I think ABC's got a history of always continuing to look for new efficiencies. And we continue that trend. I think I highlighted in my remarks. Medco is unusual because we really had very few",113,"Well, I think you look at our year and we always do a good job. I think ABC's got a history of always continuing to look for new efficiencies. And we continue that trend. I think I highlighted in my remarks. Medco is unusual because we really had very few starts concentrated. That actually work primarily with our large greenfields. So highly automate facilities so I think that that's why we pointed to a 5% contribution. That was to contemplate the operating expense increase. But in that particular case it's unlikely we would shutdown any distribution centers or anything like that because of the way the business is currently contracted for and operates."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I think that's right. Most of the impact is on the gross profit side. Our expense service is very low and that contract as this is for high-volume concentrated location type customers as Steve mentioned.",36,"No, I think that's right. Most of the impact is on the gross profit side. Our expense service is very low and that contract as this is for high-volume concentrated location type customers as Steve mentioned."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Great. And how do we think about as Express Scripps in there, subsidiary and would that be seen as a competitor to you? And how do you think they'll be thinking about that?",33,"Great. And how do we think about as Express Scripps in there, subsidiary and would that be seen as a competitor to you? And how do you think they'll be thinking about that?"
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think they have physician distribution business they also have I believe the large amount of specialty pharmacy business. But nothing extraordinary. We work with all channel participants. We do have some business relationships already with Express",56,"Well, I think they have physician distribution business they also have I believe the large amount of specialty pharmacy business. But nothing extraordinary. We work with all channel participants. We do have some business relationships already with Express Scripts. And obviously, we think that there will be a subject for discussion should the merger be moved."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","There are no further questions. I turn the call back over to you, Barbara Brungess.",15,"There are no further questions. I turn the call back over to you, Barbara Brungess."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Cara. And now, I think Steve would just like to make a few closing remarks.",17,"Thank you, Cara. And now, I think Steve would just like to make a few closing remarks."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, everyone, for your interest and for joining the call today. We, Mark and Barbara and I certainly do enjoyed the exchanges. Our take away message that you shall all receive from ABC today is that we're off to a solid start with our results for t",83,"Thank you, everyone, for your interest and for joining the call today. We, Mark and Barbara and I certainly do enjoyed the exchanges. Our take away message that you shall all receive from ABC today is that we're off to a solid start with our results for this first quarter. And we are well-positioned to meet our objectives for the year. And we also hope to see you at one of the upcoming conferences that we'll be presenting at. Thanks for your attention."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Steve. And before we go, I'll just highlight a couple of our upcoming events. On February 8, we'll be attending the UBS Healthcare Conference in New York. On February 28, we'll be attending the Citi Healthcare Conference, also in New York. And",67,"Thank you, Steve. And before we go, I'll just highlight a couple of our upcoming events. On February 8, we'll be attending the UBS Healthcare Conference in New York. On February 28, we'll be attending the Citi Healthcare Conference, also in New York. And finally on March 14, we'll be attending the Barclays Healthcare Conference in Miami. So thank you all very much for joining us today."
24809,145552360,211250,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, this conference will be available for replay today after 1:00 p.m. through February 2, 2012 at midnight. You may access the AT&T Teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering the access code 231917.",72,"Ladies and gentlemen, this conference will be available for replay today after 1:00 p.m. through February 2, 2012 at midnight. You may access the AT&T Teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering the access code 231917. International participants, please dial (320) 365-3844. Access code 23197. That does conclude our conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the AmerisourceBergen first quarter earnings. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Barbara Brungess.",42,"Ladies and gentlemen, thank you for standing by. Welcome to the AmerisourceBergen first quarter earnings. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Barbara Brungess. Please go ahead."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 first quarter results. I'm Barbara Brungess, Vice President of Corporate and Investor Relations. And joining me today are Steve Collis, Amerisourc",161,"Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 first quarter results. I'm Barbara Brungess, Vice President of Corporate and Investor Relations. And joining me today are Steve Collis, AmerisourceBergen President and CEO; and Mike Dicandilo, Executive Vice President and CFO.
During the conference call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011.
Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by phone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen delivered solid results in the first quarter of our fiscal year 2012.Our revenues were up 2% to $20.4 billion. Earnings per share were up 9% to $0.62. We gener",1404,"Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen delivered solid results in the first quarter of our fiscal year 2012.
Our revenues were up 2% to $20.4 billion. Earnings per share were up 9% to $0.62. We generated $432 million in operating cash flow and we repurchased $128 million of our shares. Our financial results were in line with our expectations and position us well to meet our objectives for the remainder of the year.
Our excellent cash generation and strong balance sheet provide us with outstanding financial flexibility and give us the ability to fund our strategic initiatives and grow our business.
AmerisourceBergen is fortunate to be an important part of a growing industry. As I discussed at our Investor Day in December, demographics in the expansion of health care coverage should you drive organic growth in our industry over the next several years. In addition, launches of new pharmaceuticals as well as new indications for existing drugs should also drive sales growth. The tremendous wave of over 30 brand to generic drug conversions that we expect in our fiscal 2012 as well as additional conversions expected in subsequent years will mitigate the top line dollar growth in our industry. It will drive tremendous value for wholesalers, healthcare providers and patients alike.
These trends bode well for AmerisourceBergen in particular. Our diverse revenue base positions us well to benefit from organic growth driven by demographics as well as from the influx of the uninsured over the next few years. Our customer mix also puts us in a favorable position to benefit from the historic influx of generics. In addition, cost-containment efforts underway by the federal government and other payers drive demand for our services most notably in our Consulting Services group.
Today, we are more entrenched than ever before with our manufactured customers and we expect that to continue to increase. As our provider customers face reimbursement and other challenges, they increasingly turn to AmerisourceBergen for help in making their healthcare practices run as efficiently as possible without sacrificing excellent patient care.
Over the last several months, a few large contracts in our industry have been the subject of much dialogue for various different reasons. Over all, however, the market continues to be competitive but stable. We continue to participate in discussions that are important to our business, our industry and our customers in Washington, D.C., educating lawmakers about our business and the value we and our customers provide to the healthcare system.
I've discussed our core tenants several times over the last year but they continue to drive our efforts and that's bare repeating. Firstly, collaborate to drive innovation for all stakeholders, increasing customer and supplier value, expanding our business in targeted markets, maximizing operating efficiency and maintain a high-performance culture. Our associates creatively tackle challenges and identify new opportunities to add value on a daily basis. They'll focus on meeting our objectives for the year, both in terms of the service we provide to customers and suppliers and in our financial performance, and I'm honored to work with beside them.
Turning now to our business units. AmerisourceBergen Drug Corporation had solid revenue growth in the quarter, up 2%. We had positive revenue growth in both retail and institutional segments, even with the previously discussed last of the large retail -- retail customer in September of 2011. Our ultimate side segment was particularly strong in the quarter and hospitals and independents had very solid growth. 
We now have over 4,600 members in our Good Neighbor Pharmacy network which makes it the third largest network of pharmacies in the U.S. That is a powerful endorsement of the role that independent retail pharmacy plays in the complex healthcare landscape today.
Patients preferred choice when determining where to fill their prescriptions and our retail customers are very adept at fulfilling unique patient needs. Our SAP implementation continues to run smoothly with 3 distributions and a conversion's complete, and the remainder plans for the beginning of 2013. Our investments in our Canadian operations to support significant new business wins are also well underway. We are very pleased to be the leading distributor independent pharmacy in the Canadian market as well as the leader in Specialty Distribution and services.
AmerisourceBergen Specialty Group had another strong quarter with revenues up 4%, with particularly strong performance in third-party logistics and good performance at Oncology Supply. The integration of IntrinsiQ has gone very well, and our customers have responded favorably to the tools at office. While our Specialty Group is based after our oncology franchise, we are an instrumental part of the commercialization strategy for any infusible product launched in the physician marketplace.
In addition, our Specialty Group often collaborates with our Consulting Services group to help ensure patients have access to products by utilizing the full capabilities of our physician networks, as well as our reimbursement and patient support program expertise. For example, during the quarter, we executed very well on the launch of a new brand of ophthalmology product, establishing significant market share in just the first few months of the introduction. This is a great example, not only of excellent cross-company collaboration, but also the strength and tremendous value of our diverse offerings.
AmerisourceBergen Consulting Services delivered a strong quarter while making excellent progress in the integration of TheraCom and Premier Source. Our Consulting and Packaging business both performed well in the quarter. And while the group only represents about 1% of our revenues, we believe our packaging and consulting associates are providing essential expertise to pharmaceutical manufacturers to help ensure that their products are brought to market as safely, quickly and efficiently as possible.
In addition, our reimbursement expertise helps ensure that patients who can benefit from both new and mature therapies have access to the products. 
Given the continued strength of our balance sheet, we continue to look for acquisitions that meet the criteria we've had in place for quite some time. They should increase our value offering to existing customers both up and down the channel. They should be within our established core competency and they should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions and we continue to be interested in opportunities in pharmaceutical and Specialty Distribution and Services, as well as Consulting and Packaging services. While we historically have been very comfortable in the $200 million to $300 million range, we will consider selling larger if we make good strategic sense and we deliver value to our company and our shareholders.
Looking ahead, the results we've had in our first quarter have positioned us well to meet our objectives for the full fiscal year. We have a difficult comparison to overcome in 2012, but we continue to expect earnings per share to be in the range of $2.74 to $2.84, an increase of 8% to 12% over fiscal 2011.
Looking further ahead to 2013, we should have a carryover from some of the launches that occur late in our fiscal 2012 including the relaunch of Oxaliplatin, and we should begin to benefit from the completion of our SAP implementation.
In fiscal 2014, we should begin to see the 30 million to 40 million uninsured patients in the healthcare market driving demand for pharmaceutical that should carry over into 2015 and beyond. In addition, 2014 and 2015 are expected to be good years with generic conversions, and of course, there's a chance that biosimilars may also come to market in that timeframe.
Before I turn it over to Mike for a detailed look at the financials, I want to reiterate the confidence that I have in our business and our future because demand is strong for the products we distribute and the services we provide. We were pleased to be recently be ranked 24th on Bloomberg Businessweek's list of the top 50 performing companies in the U.S. in recognition of our historic financial performance and our future growth opportunities.
As I stated earlier, we're playing essential role in the pharmaceutical supply channel, we positioned ourselves well to benefit from generics and specialty products, and we have continued to invest in our existing businesses and opportunities we see in our future.
Finally, our exceptional associates at ABC send a support in our industry and I'm proud to be their leader. Here is Mike."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and good morning, everyone. I'm very pleased to report first quarter fiscal 2012 results on track with our internal plans, highlighted by good performance on new generic launches, strong expense discipline, significant progress towards inte",1231,"Thanks, Steve, and good morning, everyone. I'm very pleased to report first quarter fiscal 2012 results on track with our internal plans, highlighted by good performance on new generic launches, strong expense discipline, significant progress towards integrating TheraCom and to our consulting group and exceptional cash generation, all of which gives us confidence in reaffirming our annual EPS guidance.
As we go through our quarterly results, keep in mind that last year's first quarter included a $12 million or $0.03 benefit reflected in gross profit from the Duane Reade contract termination last December.
So let's turn to the quarter, and starting with the top line, revenues were $20.4 billion, a 2.4% increase over last year's quarter. Drug company revenue was up 2% as strong growth in the alternate site hospital and independent customer groups offset the expected decline on the chain side, as this is our first quarter without the Longs/CVS contract. 
The Specialty Group revenues increased 4% with our 3PL business especially strong this quarter. The Consulting group, though small to the overall company top line, had a very strong quarter in our acquisitions, with TheraCom being the biggest contributor, added about 0.6% to overall ABC revenue growth in the quarter.
Gross profit was $593 million in the quarter, up 2% from last December, and gross margins of 291 basis points in the quarter were down 1 basis point from last year. As I mentioned earlier, the prior year quarter included a $12 million benefit related to the completion of the Duane Reade contract and the contribution to current quarter gross profit from our acquired companies helped to offset this headwind.
Performance from new generic launches were in line with our expectations as were benefits from price appreciation. We gave an early update during our Investor Day in December on trends with generic Lipitor scripts. And since then, trends have normalized very much in line with our expectation of approximately a 70% conversion rate to the generic. Specialty generic trends were also in line with our expectations.
Our LIFO charge in the quarter was $3.2 million compared to $9.9 million last year, reflecting the brand to generic conversions, and we continue to expect a full year charge of approximately $15 million.
We did a very nice job managing our operating expenses this quarter despite our acquisition-related transaction costs and the inclusion of our acquired companies ongoing operating costs, including 2 months of TheraCom's results.
Operating expenses were $308 million, up 1.6% and included $3.6 million of acquisition-related transaction costs. Operating expenses in the quarter would have been down year-over-year x the impact of our acquisitions, fueled by a year-over-year decline in compensation costs including favorable benefit comparisons. Keep in mind that our operating expenses are usually at their lowest level in our first quarter and should increase sequentially as we progress throughout the year. Our guidance continues to include an annual expense increase of about 3% related primarily to our acquisitions.
Operating income of $285 million in the quarter increased 3% and operating margins expanded by 1 basis point compared to last December. Again, this year-over-year growth was slowed by the $3.6 million of acquisition costs in the current quarter and the previously mentioned $12 million gross profit benefit realized in the first quarter of fiscal '11.
Moving below the operating income line, interest expense of $23 million in the December quarter increased 18% compared to last year, primarily as a result of our $500 million, 3.5% bonds that we issued in mid-November. Proceeds from this debt offering helped to fund our acquisitions and will also contribute to the retirement of our 2012 bonds that mature in mid-September. As a result, our expected interest rate expense will continue to trend higher than last year for the rest of fiscal '12.
Our effective income tax rate of 38.2% was slightly higher than last year's 38.1% and slightly below our expected annualized rate of approximately 38.4%. Our diluted earnings per share of $0.62 was up $0.05 or 9% compared to last year and exceeded our net income growth due to the reduction in our average diluted shares related to our ongoing share repurchase program. Average diluted shares outstanding for the quarter were 263.1 million, down over 6% from last December.
Now let's turn to our balance sheet and cash flows where trends continue to be very favorable. We generated $432 million of cash from operations in the quarter compared to using $99 million of cash in last year's first quarter. Much of that increase came from a very favorable working capital at quarter end, particularly in the timing of our payments to vendors. As I have discussed often with our daily volume exceeding $300 million per business day, our quarter end working capital snapshots are subject to great volatility, and one should be careful not to extrapolate the first quarter's results to the full year cash flow forecast.
Capital expenditures were $48 million in the quarter compared to $50 million last year, and as we mentioned in December, included significant investments to expand our infrastructure in Canada as well as some discretionary buyouts on leased equipment, offset in part by declining ERP spend.
We continue to expect the capital spend for the year in the $150 million range. We bought back $128 million of our shares during the quarter and we also closed our $250 million TheraCom acquisition. 
With our strong free cash flow performance in the quarter, we continue to be comfortable with our estimate of free cash flow in the range of $700 million to $800 million for all of fiscal '12. We had our normal seasonal increase in inventory in December. But despite the higher ending balance, our average day sales in inventory for the quarter remained at 25, consistent with fiscal '11. Average DSOs of 17.7 in the December quarter were up slightly from 17.4 days last year and the favorable payables timing helped raise average quarterly DPOs by over 2 days compared to fiscal '11.
With our recent debt offering, our gross debt to total debt in capital ratio at the end of December was 39.9%, above our target range of 30% to 35%, and will remain above the range in the next couple of quarters until we pay off our $392 million of debt, which matures in September.
Our cash balance was just under $2.4 billion at the end of December leaves us with great financial flexibility to fund our strategic initiatives, return significant amounts of capital to our shareholders and pay off our maturing debt.
Now let's turn to fiscal '12 guidance. And with our first quarter on track, our outlook is unchanged. Our diluted EPS guidance remains at a range of $2.74 to $2.84. Our assumptions behind this guidance also remain the same and include flat-to-modest revenue growth, operating margin expansion in the high single-digit to low double-digit basis point range and free cash flow in the $700 million to $800 million range. Additionally, we continue to expect to spend approximately $400 million for share repurchases.
So before I turn it back to Barbara, let me reiterate that 3 months into the year, we are performing well in our key areas of the business. And despite some tough comparisons ahead in the next couple of quarters, we are well-positioned to meet our financial targets for all of fiscal '12.
Now here's Barbara for Q&A."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Mike. We will now open the call to questions. [Operator Instructions] Please go ahead, Cara.",17,"Thank you, Mike. We will now open the call to questions. [Operator Instructions] Please go ahead, Cara."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] The first question comes from the line of Tom Gallucci.",12,"[Operator Instructions] The first question comes from the line of Tom Gallucci."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I think you touched on in your prepared remarks briefly, but I was wondering if you could sort of expand a little bit the competitive landscape. Obviously, it's got a lot of attention in the investment community lately, whether it's because of the",111,"Steve, I think you touched on in your prepared remarks briefly, but I was wondering if you could sort of expand a little bit the competitive landscape. Obviously, it's got a lot of attention in the investment community lately, whether it's because of the VA or the impact of the various M&A activity out there potentially. What are you expecting in terms of contract churn over the next year? Similar to the last year? If it's higher, is it because of certain unique reasons? Or do you see sort of the potential for more churn out there because of other types of reasons and maybe decisions that specific customers maybe making?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think that these are really 2 or 3 really isolated events. I mean the VA comes up every 8 years. It's not a surprise to anyone that it comes up in this particular time frame. And obviously, we've gone to great lengths to point out that the industry is a",187,"I think that these are really 2 or 3 really isolated events. I mean the VA comes up every 8 years. It's not a surprise to anyone that it comes up in this particular time frame. And obviously, we've gone to great lengths to point out that the industry is a lot different than it was in 2003. And we bid that as you would expect us to bid a large contract. And then of course, there's been a couple of big M&A deals, which one in particular was not at all expected, but we expect to participate in that. Our focus has been on servicing the companies that we do service to the best of our abilities. And I think we do a great job for them. And we expect that will be a part of any discussion going forward with those businesses. So just to sum it up, the competitive environment remains very similar to how it's been in the past. And we don't have a particular large amount of contracts coming up in the next couple of quarters. I mean, Mike, anything to add?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, Steve. I think you said it well. The atmosphere is always competitive but stable as you mentioned.",18,"No, Steve. I think you said it well. The atmosphere is always competitive but stable as you mentioned."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And then now just on the follow up there, maybe a smaller topic but there's been some activity around generic Lovenox today. Just curious if you could frame that drug for us and the potential impact, your roughly speaking, if there are more s",49,"Okay, great. And then now just on the follow up there, maybe a smaller topic but there's been some activity around generic Lovenox today. Just curious if you could frame that drug for us and the potential impact, your roughly speaking, if there are more supply on the market."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, Tom, generic Lovenox, we have done very well with that. It's part of our pro-generics offering and we already have had expectations that there would be competition in the marketplace. And that's built into our expectations.",37,"Well, Tom, generic Lovenox, we have done very well with that. It's part of our pro-generics offering and we already have had expectations that there would be competition in the marketplace. And that's built into our expectations."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Robert Jones with Goldman Sachs.",12,"The next question comes the line of Robert Jones with Goldman Sachs."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Just trying to get a better sense of some of the individual impacts in the quarter. First, I guess in the acquisition side, aside from the announced severance costs, was there an impact on operating expenses from the acquisitions in the quarter? And then",70,"Just trying to get a better sense of some of the individual impacts in the quarter. First, I guess in the acquisition side, aside from the announced severance costs, was there an impact on operating expenses from the acquisitions in the quarter? And then I guess along those lines, if you could give us some color around how Lipitor and dyproxic [ph] contributions ultimately shaped up relative to your expectations?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, let me -- I'll start with the cost of the acquisitions. I think we highlighted on the phase of the P&L that we had $3.6 million of transaction costs related to closing the deal that we did in this quarter, the TheraCom deal. In addition, we obviousl",136,"Well, let me -- I'll start with the cost of the acquisitions. I think we highlighted on the phase of the P&L that we had $3.6 million of transaction costs related to closing the deal that we did in this quarter, the TheraCom deal. In addition, we obviously have an ongoing operating cost from all 3 of the companies we've acquired in the last few months that are incremental to last year's first quarter. And as I mentioned, they're included in our normal SG&A. And if you took out the normal run -- the ongoing operating costs, our year-over-year SG&A would have been down. So I think that speaks well to the rest of our business and the continued impact of our productivity efforts throughout the company and our continued focus on keeping our costs down."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. And on the 2 big generic launches in the quarter, I mean, we have said it on our Investor Day which we really we're into the very big one -- the prominent one, we we're only about one week or so into it that conversion rates we're slightly lower than",128,"Yes. And on the 2 big generic launches in the quarter, I mean, we have said it on our Investor Day which we really we're into the very big one -- the prominent one, we we're only about one week or so into it that conversion rates we're slightly lower than expected, but it settled down around about that 70% level, which is a little bit less than you'd expect. But it's definitely trending in the right direction. And Zyprexa's right around where we expected it, around 80%. And we performed very much at expectations for both of them with the exception of the Lipitor, which we discussed at Investor Day, but which we now feel is back on track as we sit at the end of January."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, got it. And just a follow-up, I guess around the buyback, it's $750 million left on the authorization and reiterating the $400 million that's stays in the guidance. I was wondering at what point in the year, what would trigger you to maybe look to u",52,"Okay, got it. And just a follow-up, I guess around the buyback, it's $750 million left on the authorization and reiterating the $400 million that's stays in the guidance. I was wondering at what point in the year, what would trigger you to maybe look to upsize the buyback in fiscal '12?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","First off, let me just clarify, we've got $380 million remaining on our current authorization. And obviously, our guidance for the year is $400 million of share repurchases. And I think you can look back to our historical performance to understand how we",106,"First off, let me just clarify, we've got $380 million remaining on our current authorization. And obviously, our guidance for the year is $400 million of share repurchases. And I think you can look back to our historical performance to understand how we might deploy additional capital for repurchases. If we don't make any other larger strategic moves, we certainly have the capacity to increase the share repurchase. And once again, we've shown that we would do that, similar to what we did last year if that's how the year progresses and we continue to meet our cash forecast. So we're in a very good position."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Larry Marsh with Barclays Capital.",12,"The next question comes the line of Larry Marsh with Barclays Capital."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","This is actually Kipp Davis in for Larry. So this is just sort of a follow-up on Lipitor. So it sounds like you're communicating that it came a little bit slower initially than you would expect it in terms of generic conversion. Now your sort of more comf",116,"This is actually Kipp Davis in for Larry. So this is just sort of a follow-up on Lipitor. So it sounds like you're communicating that it came a little bit slower initially than you would expect it in terms of generic conversion. Now your sort of more comfortable with where it is. Just kind of curious after we think about Zyprexa, and of course, other generics that are going to become online, have your thoughts changed for the rest of the year? What do you think some of the key variables are with regard to whether it's manufacturer, strategies, et cetera, that might cause you to change your thoughts about the generic contributions throughout the year?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, this is -- Lipitor was as we said a lot, is really a unique product. I mean, first of all, just the size of it, just the prominence of it. And we think that it's also uniquely a mail-ordered drug. So Pfizer was able to contract with large purchases o",116,"Yes, this is -- Lipitor was as we said a lot, is really a unique product. I mean, first of all, just the size of it, just the prominence of it. And we think that it's also uniquely a mail-ordered drug. So Pfizer was able to contract with large purchases of the product directly. We think that this is an unusual situation. We don't think it's been particularly successful. And we don't -- we have not changed any of our plans for any other generic launches this year. And as I said, we feel very reassured by the fact that the conversion rate is now approaching 70% and looks like it could go up from there."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, that's helpful. And then just a follow-up. This is also sort of around consolidation. How do we think about -- with a broadened specialty offering, how do we think about customer consolidation in the specialty space? And would we think that specialt",87,"Okay, that's helpful. And then just a follow-up. This is also sort of around consolidation. How do we think about -- with a broadened specialty offering, how do we think about customer consolidation in the specialty space? And would we think that specialty would always be service as part of a larger PBM contract or that sort of business potentially be carved out? How do we think about that sort of relationship there? I don't know if that's a question for James or any of you folks."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, you raised a good question. I understand -- I think I understand what you're getting at. First of all, let me distinguish that our Specialty Distribution business is really dealing with physicians who administer products in their office. And there's",149,"Well, you raised a good question. I understand -- I think I understand what you're getting at. First of all, let me distinguish that our Specialty Distribution business is really dealing with physicians who administer products in their office. And there's been numerous articles, there's no doubt that AmerisourceBergen Specialty Group is the leading company in that area. And we're very, very successful there. In our drug company, we do have, within our ultimate side segment, several large companies that are involved with specialty products more on the mail-order side and on the patient delivery side. And we definitely have expertise in servicing those customers. So overall, AmerisourceBergen really services a huge part of the specialty industry, and we expect that to continue. So I hope that's helpful. I think both aspects of the Specialty Distribution are important to our company, important to manufacturers and important to the patients."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Eric Coldwell with Robert W. Baird.",13,"The next question comes the line of Eric Coldwell with Robert W. Baird."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I realize that one of your major customers purchase generics through AmeriSource. But there have been rumblings in the market that perhaps 1 or 2 of the larger retail systems are looking at the internalizing generics, perhaps slowly but are testing the ma",73,"I realize that one of your major customers purchase generics through AmeriSource. But there have been rumblings in the market that perhaps 1 or 2 of the larger retail systems are looking at the internalizing generics, perhaps slowly but are testing the market there. Have you seen any shift in your customers buying behavior around generics recently? Whether it be asking for greater discounts or looking to perhaps internalize some of the work?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I mean obviously, generics' becoming more and more important. They're a bigger part of the prescriptions that the patients get in the U.S. every day, and that's certainly what we expected. But we really haven't seen any different shifts. I mean, we be",83,"No, I mean obviously, generics' becoming more and more important. They're a bigger part of the prescriptions that the patients get in the U.S. every day, and that's certainly what we expected. But we really haven't seen any different shifts. I mean, we believe that our ProGen formerly and our overall generic offering offers the best everyday value to our customers. And we continue to work very hard at keeping that to be the case. And I think our customers appreciate it, Eric."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","That's great. Just one quick follow-up. Another healthcare distributor this morning highlighted the physician activity was slower than they expected. They saw less flu -- seasonal flu impact due to lower illness rates in the weather, obviously. I realized",79,"That's great. Just one quick follow-up. Another healthcare distributor this morning highlighted the physician activity was slower than they expected. They saw less flu -- seasonal flu impact due to lower illness rates in the weather, obviously. I realized that's also a very small piece of your total business, but can you give us any comments on what you're seeing around primary care and the flu market, both for December quarter and where we are early this year?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","The flu vaccine has become a very small part of over $8 billion in revenues. The most activity actually takes place for flu vaccine in our fourth quarter of our fiscal year, so the September quarter last fiscal year. We have some modest activity in this q",112,"The flu vaccine has become a very small part of over $8 billion in revenues. The most activity actually takes place for flu vaccine in our fourth quarter of our fiscal year, so the September quarter last fiscal year. We have some modest activity in this quarter but it really is primarily now become that September quarter. Yes, of course, our retailers are impacted by seasonal trends. If there's a lot of flu, a lot of cold, that does help patient traffic. But we really focus on overall top line growth, not as much an individual prescription trend at the retail level. So hopefully, that's helpful for you. Mark, anything to add?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, and they've been good, Eric. We're up year-over-year despite the completion of the Longs/CVS contract last quarter, which I think is an indication of strength in the top line force.",31,"No, and they've been good, Eric. We're up year-over-year despite the completion of the Longs/CVS contract last quarter, which I think is an indication of strength in the top line force."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes from the line of Lisa Gill with JPMorgan.",12,"The next question comes from the line of Lisa Gill with JPMorgan."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, you made a comment on the revenue line that you're seeing strength on the hospital side as well as in the independents. Can you maybe just talk about -- is this that you've picked up any incremental customers? Or is there some other reason why you'",64,"Steve, you made a comment on the revenue line that you're seeing strength on the hospital side as well as in the independents. Can you maybe just talk about -- is this that you've picked up any incremental customers? Or is there some other reason why you're seeing increased strength in those customers? Because your revenue came in much better than we would've anticipated."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think we had some mix. I mean, the big customers' group grew pretty well in the quarter. But our hospital business is -- we believe we have good market share there. And really nothing extraordinary that happened, I mean, just good solid demand for our p",47,"I think we had some mix. I mean, the big customers' group grew pretty well in the quarter. But our hospital business is -- we believe we have good market share there. And really nothing extraordinary that happened, I mean, just good solid demand for our products."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","What was -- did revenue come in where you were thinking? Or so do we have it wrong? Or is it just that this is what you were expecting based on what you've seen in your book and all of us got a little carried away on what our expectations were for the imp",56,"What was -- did revenue come in where you were thinking? Or so do we have it wrong? Or is it just that this is what you were expecting based on what you've seen in your book and all of us got a little carried away on what our expectations were for the impact of generics?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Revenues came in very close to what we're expecting. I mean, maybe slightly ahead of expectations. But very close to what we were expecting.",25,"Revenues came in very close to what we're expecting. I mean, maybe slightly ahead of expectations. But very close to what we were expecting."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And then just as a follow-up, as we think about the oncology offices and we think about reimbursement as well as some of the programs. For example, that United is doing around bundling of services, et cetera, are you starting to see any chang",82,"Okay, great. And then just as a follow-up, as we think about the oncology offices and we think about reimbursement as well as some of the programs. For example, that United is doing around bundling of services, et cetera, are you starting to see any change as we move into the next year? And we start thinking about planned design changes and changes with the managed care companies around how they pay for oncology. Has there been any noted change this year?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","This discussion has been around for several years and I think it's just really -- it's why our offering is so important. I mean, you look at why we acquired IntrinsiQ and you looked at the investments we make in our ION business, our physician services co",201,"This discussion has been around for several years and I think it's just really -- it's why our offering is so important. I mean, you look at why we acquired IntrinsiQ and you looked at the investments we make in our ION business, our physician services company. We really want to enhance the dialogue between managed care companies and our community oncologists then. Our strategy is not to be a principal in those negotiations, but really to assist our customers so they have information available and they have the sort of data that managed care companies are looking at. And we think are definitely enhancing that dialogue. It's not -- we're stopping that trend. I think as we sit here today -- I was in D.C. last week and often obviously with some of our large oncology practices, people are starting to recognize us. They're very important to keep cancer care in the community setting, not only from a patient point of view, clinical point of view, but it was from an economic point of view. And that's obviously a trend that AmerisourceBergen supports and a big part of what our Specialty Group practice -- is able to demonstrate everyday."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","So just to understand it, then you're not seeing anything as far as trends go -- and we think about how would it impact your revenue, you're not seeing any changes to utilization or the way that the product is delivered based on these discussions?",45,"So just to understand it, then you're not seeing anything as far as trends go -- and we think about how would it impact your revenue, you're not seeing any changes to utilization or the way that the product is delivered based on these discussions?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No. And again, we've had our ASP formerly for over 6 years now. So I think our practitioners are used to it. Everything as we said in the release, everything went very well in the oncology business this quarter.",39,"No. And again, we've had our ASP formerly for over 6 years now. So I think our practitioners are used to it. Everything as we said in the release, everything went very well in the oncology business this quarter."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of A.J. Rice with Susquehanna.",12,"The next question comes the line of A.J. Rice with Susquehanna."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I guess because there's so much focus on the VA contract, I'd love to get any perspective you'd be willing to offer on sort of the rebidding and the ask for additional information and say taking a second look, what does that imply about what they're tryin",104,"I guess because there's so much focus on the VA contract, I'd love to get any perspective you'd be willing to offer on sort of the rebidding and the ask for additional information and say taking a second look, what does that imply about what they're trying to do there? And I guess, I'll ask you a similar question to the one I asked you at the Investor Day, if you guys, with what you now know, if you were to be successful and get the contract, would you consider that to be something that would be additive to your results almost immediately?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, A.J., this is Mike. I'll give a go at it and I'll let Steve add any additional comments. But when we got the additional information from the VA, it essentially clarified that there is a small part of purchases approximately 3% that were off contract",179,"Yes, A.J., this is Mike. I'll give a go at it and I'll let Steve add any additional comments. But when we got the additional information from the VA, it essentially clarified that there is a small part of purchases approximately 3% that were off contract and clarified that fact and asked us to rebid based upon that new information. I would go back to what we said, when we bid this contract back in June, we considered that to be our last and final bid. We took it very seriously. We considered the new information. We made the appropriate modifications, but it did not change our bid material from what we had done at the end of June. Should we get the VA contract? Yes, we think it would add right away. I think our expectations, it's a several billion dollar contract. There's not many of those out there. And typically, the largest contracts in our industry get the best price. And I would expect this to be similar and have the appropriate contribution for a large contract."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. This may be then a follow-up on the comments you made in the prepared remarks. I think, maybe Steve made this comment about outpatient in the drug corporation being particularly strong. And I just was wondering -- maybe there's a little more color o",54,"Okay. This may be then a follow-up on the comments you made in the prepared remarks. I think, maybe Steve made this comment about outpatient in the drug corporation being particularly strong. And I just was wondering -- maybe there's a little more color on what was exactly going on there in your opinion."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think, A.J., you talked about really our old site? That maybe my accent. That's really our nonhospital institutional business, our mail-order, skilled nursing facility, institutional pharmacy, et cetera. And we did have good revenue trend in that sector",63,"I think, A.J., you talked about really our old site? That maybe my accent. That's really our nonhospital institutional business, our mail-order, skilled nursing facility, institutional pharmacy, et cetera. And we did have good revenue trend in that sector. And we have a couple of new customer wins there, particularly we've talked about the Humana contract where we had a good revenue performance."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. Yes, and I understood it was the ultimate side. I guess, I missed my modeling. I was just curious if it was -- if there was underlying pickup and trend or is it new business? So it sounds like it's mostly new business, maybe?",45,"Okay. Yes, and I understood it was the ultimate side. I guess, I missed my modeling. I was just curious if it was -- if there was underlying pickup and trend or is it new business? So it sounds like it's mostly new business, maybe?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Yes, you could say a new business. But just good high-growth sector. I mean, benefiting from favorable demographics.",19,"Yes. Yes, you could say a new business. But just good high-growth sector. I mean, benefiting from favorable demographics."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Charles Rhyee with Cowen and Company.",13,"The next question comes the line of Charles Rhyee with Cowen and Company."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I guess, one real quick follow-up about the VA here. Obviously, investors and analysts are all focused on this contract, but can you tell us essentially when you're in discussions with clients, I mean, is this something that ever comes up? Or is this some",53,"I guess, one real quick follow-up about the VA here. Obviously, investors and analysts are all focused on this contract, but can you tell us essentially when you're in discussions with clients, I mean, is this something that ever comes up? Or is this something that people ever look at and refer to?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I think everyone understands that it's a very, very different contract. The way it works, it's very unique both as in the DOD and that doesn't really come up.",30,"No, I think everyone understands that it's a very, very different contract. The way it works, it's very unique both as in the DOD and that doesn't really come up."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, that's great. And then, Mike, maybe a question for you. And I guess this kind of gets back to your original comments about how you see Lipitor come on. When you look at the LIFO charge in the quarter, obviously down less than a year ago. Should we e",102,"Okay, that's great. And then, Mike, maybe a question for you. And I guess this kind of gets back to your original comments about how you see Lipitor come on. When you look at the LIFO charge in the quarter, obviously down less than a year ago. Should we expect that to sort of increase as we see more of this -- the rate of adoption on like Lipitor and some of the other generics come on? Is that a good proxy then for us to think about how the phase of generics are coming onto the course of this fiscal year?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. The LIFO charge as expected, Charles, to be significantly below what it was last year and really 2 reasons. Last year was actually much higher than we expected because of how high the brand price appreciation was. And again our expectation is it's st",162,"Yes. The LIFO charge as expected, Charles, to be significantly below what it was last year and really 2 reasons. Last year was actually much higher than we expected because of how high the brand price appreciation was. And again our expectation is it's still going to be strong this year but may moderate a little bit versus last year on the brand side. But certainly, with all the new generic introductions and 34 launches, there's going to be a big impact on the generic price deflation this year from products coming off exclusivity. And that has led to lower overall expectation what a LIFO charge is going to be. And that's really starting in the beginning of the year and will be pretty consistent the rest of the year as a lot of the launches are pretty well spaced throughout the year. And we'll continue to have launches next quarter and all the way through to the end of the year."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","And so did that sequential change, is that a good signal for us? And was this quarter sort of in line with what you had expected?",26,"And so did that sequential change, is that a good signal for us? And was this quarter sort of in line with what you had expected?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Yes, very much in line. And again, it's a $15 million annual expectation. We're always a little bit higher in the second quarter because that's where a lot of the brand inflation occurs. But otherwise, very much as we expected.",41,"Yes. Yes, very much in line. And again, it's a $15 million annual expectation. We're always a little bit higher in the second quarter because that's where a lot of the brand inflation occurs. But otherwise, very much as we expected."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes from the line of Ricky Goldwasser with Morgan Stanley.",13,"The next question comes from the line of Ricky Goldwasser with Morgan Stanley."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","So just as a thought to the last question but taking it from a revenue perspective, so you grew revenue at about 2.4% and you're guiding us for flat revenues. So should we assume that second half revenues might decline given the timing of drugs going off",52,"So just as a thought to the last question but taking it from a revenue perspective, so you grew revenue at about 2.4% and you're guiding us for flat revenues. So should we assume that second half revenues might decline given the timing of drugs going off 180s that you just mentioned?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, some of that sequential change, Ricky, has to do obviously with our largest customer who only buys brand-name drugs from us and there's more products, though generic, their revs will moderate some over the rest of the year.",39,"Yes, some of that sequential change, Ricky, has to do obviously with our largest customer who only buys brand-name drugs from us and there's more products, though generic, their revs will moderate some over the rest of the year."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So when we model, I just want to make sure that our model is kind of like accurate, should we assume kind of like a first half kind of like 2%? And then sort of like negative growth in the second half to get to kind of like flat year-over-year? Or i",60,"Okay. So when we model, I just want to make sure that our model is kind of like accurate, should we assume kind of like a first half kind of like 2%? And then sort of like negative growth in the second half to get to kind of like flat year-over-year? Or is it going to be smoother than that?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think it's going to be a little bit smoother.",11,"I think it's going to be a little bit smoother."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And then on the generic side, I know we talked a lot about that, but can you quantify kind of like the EPS impact for new generics? Is it back at this quarter? Just to give us a sense of how does it relate to kind of like this $0.05, $0.06 of benefi",61,"Okay. And then on the generic side, I know we talked a lot about that, but can you quantify kind of like the EPS impact for new generics? Is it back at this quarter? Just to give us a sense of how does it relate to kind of like this $0.05, $0.06 of benefit that you're seeing from Gemzar and Taxotere?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Ricky, I don't think we went -- get into a quarter by quantification of the impact of the new generics. And obviously, what happened last year has an impact as well the year-over-year impact. I think again our guidance for the year's, we expect that the c",157,"Ricky, I don't think we went -- get into a quarter by quantification of the impact of the new generics. And obviously, what happened last year has an impact as well the year-over-year impact. I think again our guidance for the year's, we expect that the cumulative impact of the 34 launches will offset the decline on the specialty generics side. From a specialty generic perspective, we had about a $0.06 benefit in the first quarter of last year. And this year was pretty similar down about $0.005 or so. Those comparisons will get more difficult the next couple of quarters as they we're very big quarters here for Specialty. But I think the beneficial impact of the oral solids will also increase in those next couple of quarters as well. So we really haven't changed our viewpoint on the year about the offset on the oral solid side to the headwind on the specialty generic side."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Directionally, will Lipitor and Zyprexa confine again -- directionally, no specific numbers higher or lower than that kind of like $0.05 to $0.06?",23,"Directionally, will Lipitor and Zyprexa confine again -- directionally, no specific numbers higher or lower than that kind of like $0.05 to $0.06?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Again, Ricky, I don't want to get into the quantification. I think we gave a pretty good view at Investor Day that the top 2 players were significant part of the year, in the 40% range, I believe we gave. And I think that's the best quantification that we",56,"Again, Ricky, I don't want to get into the quantification. I think we gave a pretty good view at Investor Day that the top 2 players were significant part of the year, in the 40% range, I believe we gave. And I think that's the best quantification that we want to get into at this time."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question goes to the line of George Hill with Citigroup.",12,"The next question goes to the line of George Hill with Citigroup."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Most of my questions have been answered. Mike, I just want to ask another guidance question directionally. I know that you guys don't like to give quarterly guidance but straight expectations for Q2 or for a big number. And as we think about the branded L",168,"Most of my questions have been answered. Mike, I just want to ask another guidance question directionally. I know that you guys don't like to give quarterly guidance but straight expectations for Q2 or for a big number. And as we think about the branded Lipitor to generic conversion, I guess, I'd ask 2 questions, one, do you expect the Pfizer retention rate to stay at the 30-ish percent range? Or how quickly do you guys think that'll continue to fall? And if it hovers at 30%, it would look like the most profitable period for generic Lipitor to kind of be that first month right after May when there's no limit on multisource introductions and the whack probably won't catch up with the falling rate at which you guys can acquire the price. I guess, is it your sense that we might be -- I guess, is the consensus maybe seem too ambitious for fiscal Q2? And maybe should be a little more optimistic on fiscal Q3?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I'd say, again we do not -- let me make clear, we do not give quarterly guidance. And directionally, the March quarter has always been our strongest quarter because of the timing and the impact of manufacturer, our brand price increases and the impact",271,"No, I'd say, again we do not -- let me make clear, we do not give quarterly guidance. And directionally, the March quarter has always been our strongest quarter because of the timing and the impact of manufacturer, our brand price increases and the impact that has on some of our fee-for-service agreements, that trend is -- continues to be our expectation this year. Certainly, the second quarter is a big quarter for the oral solid generics as well. Keep in mind, the first quarter, we only had a month of the Lipitor, 2 months of the Zyprexa generics. In the second quarter, we have a full quarter benefit from those plus some new introductions. So certainly, we think the year-over-year benefit from oral solids is going to increase in the next quarter from the first quarter. So the trending, I think is, again, very similar to where it's been historically. The second quarter continues to be our peak. The number of suppliers that come on board after the exclusionary period for Lipitor can impact our numbers somewhat. But again, we're expecting a handful of people there, and we're expecting a pretty significant price drop after exclusivity is over. As far as the 70:30, that's inline with our expectations. If it's a little bit more generic, it helps us. It helps us. But again, I think the historical trending, as far as our quarterly progression is still intact, and as I've mentioned, we've got tough comparisons of 2, 3 on the specialty side, but good performance on the oral solid side. And the fourth quarter continues to be our easiest comparison."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And maybe just a quick follow-up to Tom's question that's actually where investors worry about clients' trend being unusually high given what's going on in the M&A space. A lot of the big clients tend to see their relationships with the wholesalers",63,"Okay. And maybe just a quick follow-up to Tom's question that's actually where investors worry about clients' trend being unusually high given what's going on in the M&A space. A lot of the big clients tend to see their relationships with the wholesalers is pretty transactional with low switch in cost. What can AmeriSource do, I guess, to make these relationships more sticky?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think obviously, with the smaller customers, we have different services. But in the larger customers, I think we've proven time and again that our relationship to our largest customer is very valuable to them. We were happy to receive the VIP awar",169,"Well, I think obviously, with the smaller customers, we have different services. But in the larger customers, I think we've proven time and again that our relationship to our largest customer is very valuable to them. We were happy to receive the VIP award the last 2 years in a row. And I think we can do different services especially around logistics, cash flow, joint negotiations, even look at some generic lines with large customers. I think there's lots of opportunities in the industry to work together. And then, of course, I just -- I'll be remiss if I didn't mention our specialty franchise, which I think is of great interest to almost anybody in the healthcare space. Specialty is really where the innovation, action's going to be in the years ahead. And definitely our expertise, our physician connectivity, our understanding of the trends there, some of the contracting we do with manufacturers is definitely of interest to all large participants from mail-order to retail to hospital, et cetera."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes from the line of Steven Valiquette with UBS.",12,"The next question comes from the line of Steven Valiquette with UBS."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","So just to confirm, it sounds like there's no change to the $0.14 to $0.15 EPS I expected from the fiscal '12 from the big specialty generics. And then, is the reintroduction of generic Oxaliplatin in August, does that account for any material portion of",64,"So just to confirm, it sounds like there's no change to the $0.14 to $0.15 EPS I expected from the fiscal '12 from the big specialty generics. And then, is the reintroduction of generic Oxaliplatin in August, does that account for any material portion of that? Or is that going to be basically a rounding area at the end of today within fiscal '12?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","It's included in the $0.14 to $0.15. But I just said, it's only a little bit more than a month of inclusion in our fiscal '12. But it is in there.",32,"It's included in the $0.14 to $0.15. But I just said, it's only a little bit more than a month of inclusion in our fiscal '12. But it is in there."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","Next question comes from the line of Matthew Coffina with Morningstar.",11,"Next question comes from the line of Matthew Coffina with Morningstar."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Two quick questions. So you said before that Medco is only about 5% of earnings. Maybe to help us get a better understanding of the flexibility in the cost structure here, what, from a specific standpoint -- what, from a practical standpoint, can you do i",58,"Two quick questions. So you said before that Medco is only about 5% of earnings. Maybe to help us get a better understanding of the flexibility in the cost structure here, what, from a specific standpoint -- what, from a practical standpoint, can you do in terms of reducing SG&A when you lose a large customer like that?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think you look at our year and we always do a good job. I think ABC's got a history of always continuing to look for new efficiencies. And we continue that trend. I think I highlighted it in my remarks. Medco is unusual because we really had very",123,"Well, I think you look at our year and we always do a good job. I think ABC's got a history of always continuing to look for new efficiencies. And we continue that trend. I think I highlighted it in my remarks. Medco is unusual because we really had very few sides, it's a concentrated delivery that actually work primarily with our large greenfields, so highly automated facilities. So I think that, that's why we pointed to a 5% contribution that also did contemplate the operating expense increase. But in that particular case, it's unlikely we would shutdown any distribution centers or anything like that because of the way the business is currently contracted for and operates. Want to say anything else, Mike?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I think that's right. I mean, most of that impact is on the gross profit side. Our expense to service is very low in that contract as it is with high-volume concentrated location type customers as Steve mentioned.",39,"No, I think that's right. I mean, most of that impact is on the gross profit side. Our expense to service is very low in that contract as it is with high-volume concentrated location type customers as Steve mentioned."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And how do we think about Express Scripts in there, a CuraScript subsidiary? And would that be seen as a competitor to you? And how do you think they'll be thinking about that?",35,"Okay, great. And how do we think about Express Scripts in there, a CuraScript subsidiary? And would that be seen as a competitor to you? And how do you think they'll be thinking about that?"
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think CuraScript does have the physician distribution business. They also have, I believe, a large amount of order specialty pharmacy business. But nothing extraordinary. We work with all channel participants. We do have some business relationship",59,"Well, I think CuraScript does have the physician distribution business. They also have, I believe, a large amount of order specialty pharmacy business. But nothing extraordinary. We work with all channel participants. We do have some business relationships already with Express Scripts. And obviously, we think that there will be a subject for discussion should the merger be approved."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","There are no further questions. I turn the call back over to Barbara Brungess.",14,"There are no further questions. I turn the call back over to Barbara Brungess."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Cara. And now, I think Steve would just like to make a few closing remarks.",17,"Thank you, Cara. And now, I think Steve would just like to make a few closing remarks."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Thank you, everyone, for your interest and for joining the call today. We -- Mark and Barbara and I certainly do enjoy the exchanges. Our take away message that you shall all receive from ABC today is that we're off to a solid start with our results",85,"Yes. Thank you, everyone, for your interest and for joining the call today. We -- Mark and Barbara and I certainly do enjoy the exchanges. Our take away message that you shall all receive from ABC today is that we're off to a solid start with our results for this first quarter. And we are well-positioned to meet our objectives for the year. And we also hope to see you at one of the upcoming conferences that we'll be presenting at. Thanks for your attention."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steven. Before we go, I'll just highlight a couple of our upcoming events. On February 8, we'll be attending the UBS Healthcare Conference in New York. On February 28, we'll be attending the Citi Healthcare Conference, also in New York. And finall",65,"Thanks, Steven. Before we go, I'll just highlight a couple of our upcoming events. On February 8, we'll be attending the UBS Healthcare Conference in New York. On February 28, we'll be attending the Citi Healthcare Conference, also in New York. And finally on March 14, we'll be attending the Barclays Healthcare Conference in Miami. So thank you, all, very much for joining us today."
24809,145552360,211548,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, this conference will be available for replay today after 1:00 p.m. through February 2, 2012 at midnight. You may access the AT&T Teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering the access code 231917.",72,"Ladies and gentlemen, this conference will be available for replay today after 1:00 p.m. through February 2, 2012 at midnight. You may access the AT&T Teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering the access code 231917. International participants, please dial (320) 365-3844, access code 23197. That does conclude our conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the AmerisourceBergen first quarter earnings. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Barbara Brungess.",42,"Ladies and gentlemen, thank you for standing by. Welcome to the AmerisourceBergen first quarter earnings. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Barbara Brungess. Please go ahead."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 first quarter results. I'm Barbara Brungess, Vice President of Corporate and Investor Relations. And joining me today are Steve Collis, Amerisourc",161,"Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 first quarter results. I'm Barbara Brungess, Vice President of Corporate and Investor Relations. And joining me today are Steve Collis, AmerisourceBergen President and CEO; and Mike Dicandilo, Executive Vice President and CFO.
During the conference call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011.
Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by phone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen delivered solid results in the first quarter of our fiscal year 2012.Our revenues were up 2% to $20.4 billion. Earnings per share were up 9% to $0.62. We gener",1400,"Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen delivered solid results in the first quarter of our fiscal year 2012.
Our revenues were up 2% to $20.4 billion. Earnings per share were up 9% to $0.62. We generated $432 million in operating cash flow and we repurchased $128 million of our shares. Our financial results were in line with our expectations and position us well to meet our objectives for the remainder of the year.
Our excellent cash generation and strong balance sheet provide us with outstanding financial flexibility and give us the ability to fund our strategic initiatives and grow our business.
AmerisourceBergen is fortunate to be an important part of a growing industry. As I discussed at our Investor Day in December, demographics in the expansion of health care coverage should drive organic growth in our industry over the next several years. In addition, launches of new pharmaceuticals as well as new indications for existing drugs should also drive sales growth. The tremendous wave of over 30 brand to generic drug conversions that we expect in our fiscal 2012 as well as additional conversions expected in subsequent years will mitigate the top line dollar growth in our industry. It will drive tremendous value for wholesalers, healthcare providers and patients alike.
These trends bode well for AmerisourceBergen in particular. Our diverse revenue base positions us well to benefit from organic growth driven by demographics as well as from the influx of the uninsured over the next few years. Our customer mix also puts us in a favorable position to benefit from the historic influx of generics. In addition, cost-containment efforts underway by the federal government and other payers drive demand for our services most notably in our Consulting Services group.
Today, we are more entrenched than ever before with our manufacture customers and we expect that to continue to increase. As our provider customers face reimbursement and other challenges, they increasingly turn to AmerisourceBergen for help in making their healthcare practices run as efficiently as possible without sacrificing excellent patient care.
Over the last several months, a few large contracts in our industry have been the subject of much dialogue for various different reasons. Overall, however, the market continues to be competitive but stable. We continue to participate in discussions that are important to our business, our industry and our customers in Washington, D.C., educating lawmakers about our business and the value we and our customers provide to the healthcare system.
I've discussed our core tenets several times over the last year but they continue to drive our efforts and that bears repeating. Firstly, collaborate to drive innovation for all stakeholders, increasing customer and supplier value, expanding our business in targeted markets, maximizing operating efficiency and maintain a high-performance culture. Our associates creatively tackle challenges and identify new opportunities to add value on a daily basis. They'll focus on meeting our objectives for the year, both in terms of the service we provide to customers and suppliers and in our financial performance, and I'm honored to work beside them.
Turning now to our business units. AmerisourceBergen Drug Corporation had solid revenue growth in the quarter, up 2%. We had positive revenue growth in both retail and institutional segments, even with the previously-discussed loss of a large retail -- retail customer in September of 2011. Our ultimate side segment was particularly strong in the quarter and hospitals and independents had very solid growth. 
We now have over 4,600 members in our Good Neighbor Pharmacy network which makes it the third largest network of pharmacies in the U.S. That is a powerful endorsement of the role that independent retail pharmacy plays in the complex healthcare landscape today.
Patients preferred choice when determining where to fill their prescriptions and our retail customers are very adept at fulfilling unique patient needs. Our SAP implementation continues to run smoothly with redistributions and our conversions complete, and the remainder plans for the beginning of 2013. Our investments in our Canadian operations to support significant new business wins are also well underway. We are very pleased to be the leading distributor independent pharmacy in the Canadian market as well as the leader in Specialty Distribution and services.
AmerisourceBergen Specialty Group had another strong quarter with revenues up 4%, with particularly strong performance in third-party logistics and good performance in Oncology Supply. The integration of IntrinsiQ has gone very well, and our customers have responded favorably to the tools at office. While our Specialty Group is based after our oncology franchise, we are an instrumental part of the commercialization strategy for any infusible product launched in the physician marketplace.
In addition, our Specialty Group often collaborates with our Consulting Services group to help ensure patients have access to products by utilizing the full capabilities of our physician networks, as well as our reimbursement and patient support program expertise. For example, during the quarter, we executed very well on the launch of a new brand of ophthalmology product, establishing significant market share in just the first few months of introduction. This is a great example, not only of excellent cross-company collaboration, but also of the strength and tremendous value of our diverse offerings.
AmerisourceBergen Consulting Services delivered a strong quarter while making excellent progress in the integration of TheraCom and Premier Source. Our Consulting and Packaging business both performed well in the quarter. And while the group only represents about 1% of our revenues, we believe our packaging and consulting associates are providing essential expertise to pharmaceutical manufacturers to help ensure that their products are brought to market as safely, quickly and efficiently as possible.
In addition, our reimbursement expertise helps ensure that patients who can benefit from both new and mature therapies have access to the products. 
Given the continued strength of our balance sheet, we continue to look for acquisitions that meet the criteria we've had in place for quite some time. They should increase our value offering to existing customers both up and down the channel. They should be within our established core competency and they should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions and we continue to be interested in opportunities in pharmaceutical and Specialty Distribution and Services, as well as Consulting and Packaging services. While we historically have been very comfortable in the $200 million to $300 million range, we would consider selling larger if it made good strategic sense and would deliver value to our company and our shareholders.
Looking ahead, the results we've had in our first quarter have positioned us well to meet our objectives for the full fiscal year. We have a difficult comparison to overcome in 2012, but we continue to expect earnings per share to be in the range of $2.74 to $2.84, an increase of 8% to 12% over fiscal 2011.
Looking further ahead to 2013, we should have a carryover from some of the launches that occur late in our fiscal 2012 including the relaunch of Oxaliplatin, and we should begin to benefit from the completion of our SAP implementation.
In fiscal 2014, we should begin to see the 30 million to 40 million uninsured patients in the healthcare market driving demand for pharmaceuticals that should carry over into 2015 and beyond. In addition, 2014 and 2015 are expected to be good years with generic conversions, and of course, there's a chance that biosimilars may also come to market in that timeframe.
Before I turn it over to Mike for a detailed look at the financials, I want to reiterate the confidence that I have in our business and our future because demand is strong for the products we distribute and the services we provide. We were pleased to be recently be ranked 24th on Bloomberg Businessweek's list of the top 50 performing companies in the U.S. in recognition of our historic financial performance and our future growth opportunities.
As I stated earlier, we play an essential role in the pharmaceutical supply channel, we positioned ourselves well to benefit from generics and specialty products, and we have continued to invest in our existing businesses and opportunities we see in our future.
Finally, our exceptional associates at ABC set us apart in our industry and I'm proud to be their leader. Here is Mike."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and good morning, everyone. I'm very pleased to report first quarter fiscal 2012 results on track with our internal plans, highlighted by good performance on new generic launches, strong expense discipline, significant progress towards inte",1227,"Thanks, Steve, and good morning, everyone. I'm very pleased to report first quarter fiscal 2012 results on track with our internal plans, highlighted by good performance on new generic launches, strong expense discipline, significant progress towards integrating TheraCom into our consulting group and exceptional cash generation, all of which gives us confidence in reaffirming our annual EPS guidance.
As we go through our quarterly results, keep in mind that last year's first quarter included a $12 million or $0.03 benefit reflected in gross profit from the Duane Reade contract termination last December.
So let's turn to the quarter, and starting with the top line, revenues were $20.4 billion, a 2.4% increase over last year's quarter. Drug company revenue was up 2% as strong growth in the alternate site hospital and independent customer groups offset the expected decline on the chain side, as this is our first quarter without the Longs/CVS contract. 
The Specialty Group revenues increased 4% with our 3PL business especially strong this quarter. The Consulting group, though small to the overall company top line, had a very strong quarter in our acquisitions, with TheraCom being the biggest contributor, added about 0.6% to overall ABC revenue growth in the quarter.
Gross profit was $593 million in the quarter, up 2% from last December, and gross margins of 291 basis points in the quarter were down 1 basis point from last year. As I mentioned earlier, the prior year quarter included a $12 million benefit related to the completion of the Duane Reade contract and the contribution to current quarter gross profit from our acquired companies helped to offset this headwind.
Performance from new generic launches were in line with our expectations as were benefits from price appreciation. We gave an early update during our Investor Day in December on trends with generic Lipitor scripts. And since then, trends have normalized very much in line with our expectation of approximately a 70% conversion rate to the generic. Specialty generic trends were also in line with our expectations.
Our LIFO charge in the quarter was $3.2 million compared to $9.9 million last year, reflecting the brand to generic conversions, and we continue to expect a full year charge of approximately $15 million.
We did a very nice job managing our operating expenses this quarter despite our acquisition-related transaction costs and the inclusion of our acquired companies' ongoing operating costs, including 2 months of TheraCom's results.
Operating expenses were $308 million, up 1.6% and included $3.6 million of acquisition-related transaction costs. Operating expenses in the quarter would have been down year-over-year x the impact of our acquisitions, fueled by a year-over-year decline in compensation costs including favorable benefit comparisons. Keep in mind that our operating expenses are usually at their lowest level in our first quarter and should increase sequentially as we progress throughout the year. Our guidance continues to include an annual expense increase of about 3% related primarily to our acquisitions.
Operating income of $285 million in the quarter increased 3% and operating margins expanded by 1 basis point compared to last December. Again, this year-over-year growth was slowed by the $3.6 million of acquisition costs in the current quarter and the previously-mentioned $12 million gross profit benefit realized in the first quarter of fiscal '11.
Moving below the operating income line, interest expense of $23 million in the December quarter increased 18% compared to last year, primarily as a result of our $500 million, 3.5% bonds that we issued in mid-November. Proceeds from this debt offering helped to fund our acquisitions and will also contribute to the retirement of our 2012 bonds that mature in mid-September. As a result, our expected interest rate expense will continue to trend higher than last year for the rest of fiscal '12.
Our effective income tax rate of 38.2% was slightly higher than last year's 38.1% and slightly below our expected annualized rate of approximately 38.4%. Our diluted earnings per share of $0.62 was up $0.05 or 9% compared to last year and exceeded our net income growth due to the reduction in our average diluted shares related to our ongoing share repurchase program. Average diluted shares outstanding for the quarter were 263.1 million, down over 6% from last December.
Now let's turn to our balance sheet and cash flows where trends continue to be very favorable. We generated $432 million of cash from operations in the quarter compared to using $99 million of cash in last year's first quarter. Much of that increase came from very favorable working capital at quarter end, particularly in the timing of our payments to vendors. As I have discussed often with our daily volume exceeding $300 million per business day, our quarter end working capital snapshots are subject to great volatility, and one should be careful not to extrapolate the first quarter's results to the full year cash flow forecast.
Capital expenditures were $48 million in the quarter compared to $50 million last year, and as we mentioned in December, included significant investments to expand our infrastructure in Canada as well as some discretionary buyouts on leased equipment, offset in part by declining ERP spend.
We continue to expect the capital spend for the year in the $150 million range. We bought back $128 million of our shares during the quarter and we also closed our $250 million TheraCom acquisition. 
With our strong free cash flow performance in the quarter, we continue to be comfortable with our estimate of free cash flow in a range of $700 million to $800 million for all of fiscal '12. We had our normal seasonal increase in inventory in December. But despite the higher-ending balance, our average day sales in inventory for the quarter remained at 25, consistent with fiscal '11. Average DSOs of 17.7 in the December quarter were up slightly from 17.4 days last year and the favorable payables timing helped raise average quarterly DPOs by over 2 days compared to fiscal '11.
With our recent debt offering, our gross debt to total debt in capital ratio at the end of December was 39.9%, above our target range of 30% to 35%, and will remain above the range in the next couple of quarters until we pay off our $392 million of debt, which matures in September.
Our cash balance of just under $2.4 billion at the end of December leaves us with great financial flexibility to fund our strategic initiatives, return significant amounts of capital to our shareholders and pay off our maturing debt.
Now let's turn to fiscal '12 guidance. And with our first quarter on track, our outlook is unchanged. Our diluted EPS guidance remains at a range of $2.74 to $2.84. Our assumptions behind this guidance also remain the same and include flat-to-modest revenue growth, operating margin expansion in the high single-digit to low double-digit basis point range and free cash flow in the $700 million to $800 million range. Additionally, we continue to expect to spend approximately $400 million for share repurchases.
So before I turn it back to Barbara, let me reiterate that 3 months into the year, we are performing well in our key areas of the business. And despite some tough comparisons ahead in the next couple of quarters, we are well-positioned to meet our financial targets for all of fiscal '12.
Now here's Barbara for Q&A."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Mike. We will now open the call to questions. [Operator Instructions] Please go ahead, Cara.",17,"Thank you, Mike. We will now open the call to questions. [Operator Instructions] Please go ahead, Cara."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] The first question comes from the line of Tom Gallucci.",12,"[Operator Instructions] The first question comes from the line of Tom Gallucci."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I think you touched on in your prepared remarks briefly, but I was wondering if you could sort of expand a little bit. The competitive landscape obviously has got a lot of attention in the investment community lately, whether it's because of the VA",112,"Steve, I think you touched on in your prepared remarks briefly, but I was wondering if you could sort of expand a little bit. The competitive landscape obviously has got a lot of attention in the investment community lately, whether it's because of the VA or the impact of the various M&A activity out there potentially. What are you expecting in terms of contract churn over the next year? Similar to the last year? If it's higher, is it because of certain unique reasons? Or do you see sort of the potential for more churn out there because of other types of reasons and maybe decisions that specific customers may be making?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think that these are really 2 or 3 really isolated events. I mean the VA comes up every 8 years. It's not a surprise to anyone that it comes up in this particular time frame. And obviously, we've gone to great lengths to point out that the industry is a",187,"I think that these are really 2 or 3 really isolated events. I mean the VA comes up every 8 years. It's not a surprise to anyone that it comes up in this particular time frame. And obviously, we've gone to great lengths to point out that the industry is a lot different than it was in 2003. And we bid that as you would expect us to bid a large contract. And then, of course, there's been a couple of big M&A deals, which one in particular was not at all expected, but we expect to participate in that. Our focus has been on servicing the companies that we do service to the best of our abilities. And I think we do a great job for them. And we expect that will be a part of any discussion going forward with those businesses. So just to sum it up, the competitive environment remains very similar to how it's been in the past. And we don't have a particular large amount of contracts coming up in the next couple of quarters. I mean, Mike, anything to add?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, Steve. I think you said it well. The atmosphere is always competitive but stable as you mentioned.",18,"No, Steve. I think you said it well. The atmosphere is always competitive but stable as you mentioned."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And then now just on the follow up there, maybe a smaller topic but there's been some activity around generic Lovenox today. Just curious if you could frame that drug for us and the potential impact, roughly speaking, if there were more suppl",48,"Okay, great. And then now just on the follow up there, maybe a smaller topic but there's been some activity around generic Lovenox today. Just curious if you could frame that drug for us and the potential impact, roughly speaking, if there were more supply on the market."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, Tom, generic Lovenox, we have done very well with that. It's part of our pro-generics offering and we already have had expectations that there would be competition in the marketplace. And that's built into our expectations.",37,"Well, Tom, generic Lovenox, we have done very well with that. It's part of our pro-generics offering and we already have had expectations that there would be competition in the marketplace. And that's built into our expectations."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Robert Jones with Goldman Sachs.",12,"The next question comes the line of Robert Jones with Goldman Sachs."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Just trying to get a better sense of some of the individual impacts in the quarter. First, I guess in the acquisition side, aside from the announced severance costs, was there an impact on operating expenses from the acquisitions in the quarter? And then",69,"Just trying to get a better sense of some of the individual impacts in the quarter. First, I guess in the acquisition side, aside from the announced severance costs, was there an impact on operating expenses from the acquisitions in the quarter? And then I guess along those lines, if you could give us some color around how Lipitor and Zyprexa contributions ultimately shaped up relative to your expectations?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, let me -- I'll start with the cost of the acquisitions. I think we highlighted on the face of the P&L that we had $3.6 million of transaction costs related to closing the deal that we did in this quarter, the TheraCom deal. In addition, we obviously",136,"Well, let me -- I'll start with the cost of the acquisitions. I think we highlighted on the face of the P&L that we had $3.6 million of transaction costs related to closing the deal that we did in this quarter, the TheraCom deal. In addition, we obviously have an ongoing operating cost from all 3 of the companies we've acquired in the last few months that are incremental to last year's first quarter. And as I mentioned, they're included in our normal SG&A. And if you took out the normal run -- the ongoing operating costs, our year-over-year SG&A would have been down. So I think that speaks well to the rest of our business and the continued impact of our productivity efforts throughout the company and our continued focus on keeping our costs down."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. And on the 2 big generic launches in the quarter, I mean, we had said on our Investor Day which we really were into the very big one -- the prominent one, we were only about a week or so into it that conversion rates were slightly lower than expected",127,"Yes. And on the 2 big generic launches in the quarter, I mean, we had said on our Investor Day which we really were into the very big one -- the prominent one, we were only about a week or so into it that conversion rates were slightly lower than expected, but it settled down around about that 70% level, which is a little bit less than you'd expect. But it's definitely trending in the right direction. And Zyprexa's right around where we expected it, around 80%. And we performed very much at expectations for both of them with the exception of the Lipitor, which we discussed at Investor Day, but which we now feel is back on track as we sit at the end of January."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, got it. And just a follow-up, I guess around the buyback, it's $750 million left on the authorization and reiterating the $400 million that's stays in the guidance. I was wondering at what point in the year, what would trigger you to maybe look to u",52,"Okay, got it. And just a follow-up, I guess around the buyback, it's $750 million left on the authorization and reiterating the $400 million that's stays in the guidance. I was wondering at what point in the year, what would trigger you to maybe look to upsize the buyback in fiscal '12?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","First off, let me just clarify, we've got $380 million remaining on our current authorization. And obviously, our guidance for the year is $400 million of share repurchases. And I think you can look back to our historical performance to understand how we",106,"First off, let me just clarify, we've got $380 million remaining on our current authorization. And obviously, our guidance for the year is $400 million of share repurchases. And I think you can look back to our historical performance to understand how we might deploy additional capital for repurchases. If we don't make any other larger strategic moves, we certainly have the capacity to increase the share repurchase. And once again, we've shown that we would do that, similar to what we did last year if that's how the year progresses and we continue to meet our cash forecast. So we're in a very good position."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Larry Marsh with Barclays Capital.",12,"The next question comes the line of Larry Marsh with Barclays Capital."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","This is actually Kipp Davis in for Larry. So this is just sort of a follow-up on Lipitor. So it sounds like you're communicating that it came a little bit slower initially than you would expect it in terms of generic conversion. Now you're sort of more co",118,"This is actually Kipp Davis in for Larry. So this is just sort of a follow-up on Lipitor. So it sounds like you're communicating that it came a little bit slower initially than you would expect it in terms of generic conversion. Now you're sort of more comfortable with where it is. Just kind of curious after we think about Zyprexa, and of course, other generics that are going to come on line, how have your thoughts changed for the rest of the year? What do you think some of the key variables are with regard to whether it's manufacturer, strategies, et cetera, that might cause you to change your thoughts about the generic contributions throughout the year?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, this is -- Lipitor was as we said a lot, is really a unique product. I mean, first of all, just the size of it, just the prominence of it. And we think that it's also uniquely a mail-ordered drug. So Pfizer was able to contract with large purchases o",116,"Yes, this is -- Lipitor was as we said a lot, is really a unique product. I mean, first of all, just the size of it, just the prominence of it. And we think that it's also uniquely a mail-ordered drug. So Pfizer was able to contract with large purchases of the product directly. We think that this is an unusual situation. We don't think it's been particularly successful. And we don't -- we have not changed any of our plans for any other generic launches this year. And as I said, we feel very reassured by the fact that the conversion rate is now approaching 70% and looks like it could go up from there."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, that's helpful. And then just a follow-up. This is also sort of around consolidation. How do we think about -- with a broadened specialty offering, how do we think about customer consolidation in the specialty space? And would we think that specialt",88,"Okay, that's helpful. And then just a follow-up. This is also sort of around consolidation. How do we think about -- with a broadened specialty offering, how do we think about customer consolidation in the specialty space? And would we think that specialty would always be serviced as part of a larger PBM contract or would that sort of business potentially be carved out? How do we think about that sort of relationship there? I don't know if that's a question for James or any of you folks."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, you raise a good question. I understand -- I think I understand what you're getting at. First of all, let me distinguish that our Specialty Distribution business is really dealing with physicians who administer products in their office. And there's",149,"Well, you raise a good question. I understand -- I think I understand what you're getting at. First of all, let me distinguish that our Specialty Distribution business is really dealing with physicians who administer products in their office. And there's been numerous articles, there's no doubt that AmerisourceBergen Specialty Group is the leading company in that area. And we're very, very successful there. In our drug company, we do have, within our ultimate side segment, several large companies that are involved with specialty products more on the mail-order side and on the patient delivery side. And we definitely have expertise in servicing those customers. So overall, AmerisourceBergen really services a huge part of the specialty industry, and we expect that to continue. So I hope that's helpful. I think both aspects of the Specialty Distribution are important to our company, important to manufacturers and important to the patients."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Eric Coldwell with Robert W. Baird.",13,"The next question comes the line of Eric Coldwell with Robert W. Baird."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I realize that all but one of your major customers purchase generics through AmeriSource. But there have been rumblings in the market that perhaps 1 or 2 of the larger retail systems are looking at  internalizing generics, perhaps slowly but are testing t",74,"I realize that all but one of your major customers purchase generics through AmeriSource. But there have been rumblings in the market that perhaps 1 or 2 of the larger retail systems are looking at  internalizing generics, perhaps slowly but are testing the market there. Have you seen any shift in your customers' buying behavior around generics recently? Whether it be asking for greater discounts or looking to perhaps internalize some of the work?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I mean obviously, generics are becoming more and more important. They're a bigger part of the prescriptions that the patients get in the U.S. every day, and that's certainly what we expected. But we really haven't seen any different shifts. I mean, we",84,"No, I mean obviously, generics are becoming more and more important. They're a bigger part of the prescriptions that the patients get in the U.S. every day, and that's certainly what we expected. But we really haven't seen any different shifts. I mean, we believe that our ProGen formerly and our overall generic offering offers the best everyday value to our customers. And we continue to work very hard at keeping that to be the case. And I think our customers appreciate it, Eric."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","That's great. Just one quick follow-up. Another healthcare distributor this morning highlighted that physician activity was slower than they expected. They saw less flu -- seasonal flu impact due to lower illness rates and the weather, obviously. I realiz",79,"That's great. Just one quick follow-up. Another healthcare distributor this morning highlighted that physician activity was slower than they expected. They saw less flu -- seasonal flu impact due to lower illness rates and the weather, obviously. I realize that's also a very small piece of your total business, but can you give us any comments on what you're seeing around primary care and the flu market, both for December quarter and where we are early this year?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","The flu vaccine has become a very small part of our over $8 billion in revenues. The most activity actually takes place for flu vaccine in our fourth quarter of our fiscal year, so the September quarter last fiscal year. We have some modest activity in th",112,"The flu vaccine has become a very small part of our over $8 billion in revenues. The most activity actually takes place for flu vaccine in our fourth quarter of our fiscal year, so the September quarter last fiscal year. We have some modest activity in this quarter but it really is primarily now become that September quarter. Of course, our retailers are impacted by seasonal trends. If there's a lot of flu, a lot of cold, that does help patient traffic. But we really focus on overall top line growth, not as much on individual prescription trends at the retail level. So hopefully, that's helpful for you. Mark, anything to add?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, and they've been good, Eric. We're up year-over-year despite the completion of the Longs/CVS contract last quarter, which I think is an indication of strength in the top line force.",31,"No, and they've been good, Eric. We're up year-over-year despite the completion of the Longs/CVS contract last quarter, which I think is an indication of strength in the top line force."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes from the line of Lisa Gill with JPMorgan.",12,"The next question comes from the line of Lisa Gill with JPMorgan."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, you made a comment on the revenue line that you're seeing strength on the hospital side as well as in the independents. Can you maybe just talk about -- is this that you've picked up any incremental customers? Or is there some other reason why you'",64,"Steve, you made a comment on the revenue line that you're seeing strength on the hospital side as well as in the independents. Can you maybe just talk about -- is this that you've picked up any incremental customers? Or is there some other reason why you're seeing increased strength in those customers? Because your revenue came in much better than we would've anticipated."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think we had some mix. I mean, the big customers grew pretty well in the quarter. But our hospital business is -- we believe we have good market share there. And really nothing extraordinary that happened, I mean, just good solid demand for our products",46,"I think we had some mix. I mean, the big customers grew pretty well in the quarter. But our hospital business is -- we believe we have good market share there. And really nothing extraordinary that happened, I mean, just good solid demand for our products."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","What was -- did revenue come in where you were thinking? Or so do we have it wrong? Or is it just that this is what you were expecting based on what you've seen in your book and all of us got a little carried away on what our expectations were for the imp",56,"What was -- did revenue come in where you were thinking? Or so do we have it wrong? Or is it just that this is what you were expecting based on what you've seen in your book and all of us got a little carried away on what our expectations were for the impact of generics?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Revenues came in very close to what we're expecting. I mean, maybe slightly ahead of expectations. But very close to what we were expecting.",25,"Revenues came in very close to what we're expecting. I mean, maybe slightly ahead of expectations. But very close to what we were expecting."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And then just as a follow-up, as we think about the oncology offices and we think about reimbursement as well as some of the programs for example, that United is doing around bundling of services, et cetera, are you starting to see any change",82,"Okay, great. And then just as a follow-up, as we think about the oncology offices and we think about reimbursement as well as some of the programs for example, that United is doing around bundling of services, et cetera, are you starting to see any change as we move into the next year? And we start thinking about planned design changes and changes with the managed care companies around how they pay for oncology. Has there been any noted change this year?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","This discussion has been around for several years and I think it's just really -- it's why our offering is so important. I mean, you look at why we acquired IntrinsiQ and you look at the investments we make in our ION business, our physician services comp",201,"This discussion has been around for several years and I think it's just really -- it's why our offering is so important. I mean, you look at why we acquired IntrinsiQ and you look at the investments we make in our ION business, our physician services company. We really want to enhance the dialogue between managed care companies and our community oncologists then. Our strategy is not to be a principal in those negotiations, but really to assist our customers so they have the information available and they have the sort of data that managed care companies are looking at. And we think are definitely enhancing that dialogue. It's not -- we're stopping that trend. I think as we sit here today -- I was in D.C. last week and often obviously with some of our large oncology practices, people are starting to recognize us. It's very important to keep cancer care in the community setting, not only from a patient point of view, clinical point of view, but also from an economic point of view. And that's obviously a trend that AmerisourceBergen supports and a big part of what our Specialty Group practice -- is able to demonstrate everyday."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","So just to understand it, then you're not seeing anything as far as trends go -- and we think about how would it impact your revenue, you're not seeing any changes to utilization or the way that the product is delivered based on these discussions?",45,"So just to understand it, then you're not seeing anything as far as trends go -- and we think about how would it impact your revenue, you're not seeing any changes to utilization or the way that the product is delivered based on these discussions?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No. And again, we've had that SP formerly -- for over 6 years now. So I think our practitioners are used to it. Everything as we said in the release, everything went very well in our oncology business this quarter.",40,"No. And again, we've had that SP formerly -- for over 6 years now. So I think our practitioners are used to it. Everything as we said in the release, everything went very well in our oncology business this quarter."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of A.J. Rice with Susquehanna.",12,"The next question comes the line of A.J. Rice with Susquehanna."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I guess because there's so much focus on the VA contract, I'd love to get any perspective you'd be willing to offer on sort of the rebidding and the ask for additional information and say taking a second look, what does that imply about what they're tryin",103,"I guess because there's so much focus on the VA contract, I'd love to get any perspective you'd be willing to offer on sort of the rebidding and the ask for additional information and say taking a second look, what does that imply about what they're trying to do there? And I guess, I'll ask you a similar question to the one I asked at the Investor Day. If you guys, with what you now know, if you were to be successful and get the contract, would you consider that to be something that would be additive to your results almost immediately?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, A.J., this is Mike. I'll give a go at it and I'll let Steve add any additional comments. But when we got the additional information from the VA, it essentially clarified that there is a small part of purchases approximately 3% that were off contract",179,"Yes, A.J., this is Mike. I'll give a go at it and I'll let Steve add any additional comments. But when we got the additional information from the VA, it essentially clarified that there is a small part of purchases approximately 3% that were off contract and clarified that fact and asked us to rebid based upon that new information. I would go back to what we said, when we bid this contract back in June, we considered that to be our last and final bid. We took it very seriously. We considered the new information. We made the appropriate modifications, but it did not change our bid material from what we had done at the end of June. Should we get the VA contract? Yes, we think it would add right away. I think our expectations, it's a several billion dollar contract. There's not many of those out there. And typically, the largest contracts in our industry get the best price. And I would expect this to be similar and have the appropriate contribution for a large contract."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. Just maybe then a follow-up on the comments you made in the prepared remarks. I think, maybe Steve made this comment about outpatient in the drug corporation being particularly strong. And I just was wondering -- maybe there's a little more color on",53,"Okay. Just maybe then a follow-up on the comments you made in the prepared remarks. I think, maybe Steve made this comment about outpatient in the drug corporation being particularly strong. And I just was wondering -- maybe there's a little more color on what was exactly going on there in your opinion."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think, A.J., you talked about really our old site? That maybe my accent. That's really our nonhospital institutional business, our mail-order, skilled nursing facility, institutional pharmacy, et cetera. And we did have good revenue trends in that secto",62,"I think, A.J., you talked about really our old site? That maybe my accent. That's really our nonhospital institutional business, our mail-order, skilled nursing facility, institutional pharmacy, et cetera. And we did have good revenue trends in that sector. And we have a couple of new customer wins there, particularly we've talked about the Humana contract where we had good revenue performance."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. Yes, and I understood it was the alternate site. I guess, that's probably my lingo. I was just curious if it was -- if there was underlying pickup in trend or is it new business? So it sounds like it's mostly new business, maybe?",45,"Okay. Yes, and I understood it was the alternate site. I guess, that's probably my lingo. I was just curious if it was -- if there was underlying pickup in trend or is it new business? So it sounds like it's mostly new business, maybe?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Yes, you could say new business. But just good high-growth sector. I mean, benefiting from favorable demographics.",18,"Yes. Yes, you could say new business. But just good high-growth sector. I mean, benefiting from favorable demographics."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Charles Rhyee with Cowen and Company.",13,"The next question comes the line of Charles Rhyee with Cowen and Company."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I guess, one real quick follow-up about the VA here. Obviously, investors and analysts are all focused on this contract, but can you tell us essentially when you're in discussions with clients, I mean, is this something that ever comes up? Or is this some",53,"I guess, one real quick follow-up about the VA here. Obviously, investors and analysts are all focused on this contract, but can you tell us essentially when you're in discussions with clients, I mean, is this something that ever comes up? Or is this something that people ever look at and refer to?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I think everyone understands that it's a very, very different contract. The way it works, it's very unique both as in the DOD and it doesn't really come up.",30,"No, I think everyone understands that it's a very, very different contract. The way it works, it's very unique both as in the DOD and it doesn't really come up."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, that's great. And then, Mike, maybe a question for you. And I guess this kind of gets back to your original comments about how you see Lipitor come on. When we look at the LIFO charge in the quarter, obviously down less than a year ago. Should we ex",102,"Okay, that's great. And then, Mike, maybe a question for you. And I guess this kind of gets back to your original comments about how you see Lipitor come on. When we look at the LIFO charge in the quarter, obviously down less than a year ago. Should we expect that to sort of increase as we see more of this -- the rate of adoption on like Lipitor and some of the other generics come on? Is that a good proxy then for us to think about how the pace of generics are coming onto the course of this fiscal year?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. The LIFO charge as expected, Charles, to be significantly below what it was last year and really 2 reasons. Last year was actually much higher than we expected because of how high the brand price appreciation was. And again our expectation is it's st",163,"Yes. The LIFO charge as expected, Charles, to be significantly below what it was last year and really 2 reasons. Last year was actually much higher than we expected because of how high the brand price appreciation was. And again our expectation is it's still going to be strong this year but may moderate a little bit versus last year on the brand side. But certainly, with all the new generic introductions and 34 launches, there's going to be a big impact on the generic price deflation this year from products coming off exclusivity. And that has led to lower overall expectation of what a LIFO charge is going to be. And that's really starting in the beginning of the year and will be pretty consistent the rest of the year as a lot of the launches are pretty well spaced throughout the year. And we'll continue to have launches next quarter and all the way through to the end of the year."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","And so that sequential change, that's a good signal for us? And was this quarter sort of in line with what you had expected?",24,"And so that sequential change, that's a good signal for us? And was this quarter sort of in line with what you had expected?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Yes, very much in line. And again, it's a $15 million annual expectation. We're always a little bit higher in the second quarter because that's where a lot of the brand inflation occurs. But otherwise, very much as we expected.",41,"Yes. Yes, very much in line. And again, it's a $15 million annual expectation. We're always a little bit higher in the second quarter because that's where a lot of the brand inflation occurs. But otherwise, very much as we expected."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes from the line of Ricky Goldwasser with Morgan Stanley.",13,"The next question comes from the line of Ricky Goldwasser with Morgan Stanley."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","So just as a thought to the last question but taking it from a revenue perspective, so you grew revenue at about 2.4% and you're guiding us for flat revenues. So should we assume that second half revenues might decline given the timing of drugs going off",52,"So just as a thought to the last question but taking it from a revenue perspective, so you grew revenue at about 2.4% and you're guiding us for flat revenues. So should we assume that second half revenues might decline given the timing of drugs going off 180s that you just mentioned?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, some of that sequential change, Ricky, has to do obviously with our largest customer who only buys brand-name drugs from us and there's more products, though generic, their revs will moderate some over the rest of the year.",39,"Yes, some of that sequential change, Ricky, has to do obviously with our largest customer who only buys brand-name drugs from us and there's more products, though generic, their revs will moderate some over the rest of the year."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So when we model, I just want to make sure that our model is kind of like accurate, should we assume kind of like a first half kind of like 2%? And then sort of like negative growth in the second half to get to kind of like flat year-over-year? Or i",60,"Okay. So when we model, I just want to make sure that our model is kind of like accurate, should we assume kind of like a first half kind of like 2%? And then sort of like negative growth in the second half to get to kind of like flat year-over-year? Or is it going to be smoother than that?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think it's going to be a little bit smoother.",11,"I think it's going to be a little bit smoother."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And then on the generic side, I know we talked a lot about that, but can you quantify kind of like the EPS impact for new generics? Is it back at this quarter? Just to give us a sense of how does it relate to kind of like this $0.05, $0.06 of benefi",61,"Okay. And then on the generic side, I know we talked a lot about that, but can you quantify kind of like the EPS impact for new generics? Is it back at this quarter? Just to give us a sense of how does it relate to kind of like this $0.05, $0.06 of benefit that you're seeing from Gemzar and Taxotere?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Ricky, I don't think we went -- get into a quarter by quantification of the impact of the new generics. And obviously, what happened last year has an impact as well the year-over-year impact. I think again our guidance for the year's, we expect that the c",157,"Ricky, I don't think we went -- get into a quarter by quantification of the impact of the new generics. And obviously, what happened last year has an impact as well the year-over-year impact. I think again our guidance for the year's, we expect that the cumulative impact of the 34 launches will offset the decline on the specialty generics side. From a specialty generic perspective, we had about a $0.06 benefit in the first quarter of last year. And this year was pretty similar down about $0.005 or so. Those comparisons will get more difficult the next couple of quarters as they were very big quarters here for Specialty. But I think the beneficial impact of the oral solids will also increase in those next couple of quarters as well. So we really haven't changed our viewpoint on the year about the offset on the oral solid side to the headwind on the specialty generic side."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Directionally, will Lipitor and Zyprexa combine again directionally, no specific numbers higher or lower than that kind of like $0.05 to $0.06?",22,"Directionally, will Lipitor and Zyprexa combine again directionally, no specific numbers higher or lower than that kind of like $0.05 to $0.06?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Again, Ricky, I don't want to get into the quantification. I think we gave a pretty good view at Investor Day that the top 2 players were a significant part of the year, in the 40% range, I believe we gave. And I think that's the best quantification that",57,"Again, Ricky, I don't want to get into the quantification. I think we gave a pretty good view at Investor Day that the top 2 players were a significant part of the year, in the 40% range, I believe we gave. And I think that's the best quantification that we want to get into at this time."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question goes to the line of George Hill with Citigroup.",12,"The next question goes to the line of George Hill with Citigroup."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Most of my questions have been been answered. Mike, I just want to ask another guidance question directionally. I know that you guys don't like to give quarterly guidance but straight expectations for Q2 or for a big number. And as we think about the bran",169,"Most of my questions have been been answered. Mike, I just want to ask another guidance question directionally. I know that you guys don't like to give quarterly guidance but straight expectations for Q2 or for a big number. And as we think about the branded Lipitor to generic conversion, I guess, I'd ask 2 questions, one, do you expect the Pfizer retention rate to stay at the 30-ish percent range? Or how quickly do you guys think that'll continue to fall? And if it hovers at 30%, it would look like the most profitable period for generic Lipitor to kind of be that first month right after May when there's no limit on multisource introductions and the whack probably won't catch up with the falling rate at which you guys can acquire the price. I guess, is it your sense that we might be -- I guess, is the consensus maybe seem too ambitious for fiscal Q2? And maybe should be a little more optimistic on fiscal Q3?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I'd say, again we do not -- let me make clear, we do not give quarterly guidance. And directionally, the March quarter has always been our strongest quarter because of the timing and the impact of manufacturer, our brand price increases and the impact",272,"No, I'd say, again we do not -- let me make clear, we do not give quarterly guidance. And directionally, the March quarter has always been our strongest quarter because of the timing and the impact of manufacturer, our brand price increases and the impact that has on some of our fee-for-service agreements, that trend is -- continues to be our expectation this year. Certainly, the second quarter is a big quarter for the oral solid generics as well. Keep in mind, the first quarter, we only had a month of the Lipitor, 2 months of the Zyprexa generics. In the second quarter, we have a full quarter benefit from those plus some new introductions. So certainly, we think the year-over-year benefit from oral solids is going to increase in the next quarter from the first quarter. So the trending, I think is, again, very similar to where it's been historically. The second quarter continues to be our peak. The number of suppliers that come on board after the exclusionary period for Lipitor can impact our numbers somewhat. But again, we're expecting a handful of people there, and we're expecting a pretty significant price drop after exclusivity is over. As far as the 70:30, that's in line with our expectations. If it's a little bit more generic, it helps us. It helps us. But again, I think the historical trending, as far as quarterly progression is still intact, and as I've mentioned, we've got tough comparisons of 2 and 3 on the specialty side, but good performance on the oral solid side. And the fourth quarter continues to be our easiest comparison."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And maybe just a quick follow-up to Tom's question that's actually where investors worry about clients' trend being unusually high given what's going on in the M&A space. A lot of the big clients tend to see their relationships with the wholesalers",63,"Okay. And maybe just a quick follow-up to Tom's question that's actually where investors worry about clients' trend being unusually high given what's going on in the M&A space. A lot of the big clients tend to see their relationships with the wholesalers as pretty transactional with low switch in costs. What can AmeriSource do, I guess, to make these relationships more sticky?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think obviously, with the smaller customers, we have different services. But in the larger customers, I think we've proven time and again that our relationship to our largest customer is very valuable to them. We were happy to receive theie VIP aw",169,"Well, I think obviously, with the smaller customers, we have different services. But in the larger customers, I think we've proven time and again that our relationship to our largest customer is very valuable to them. We were happy to receive theie VIP award the last 2 years in a row. And I think we can do different services especially around logistics, cash flow, joint negotiations, even look at some generic lines with large customers. I think there's lots of opportunities in the industry to work together. And then, of course, I just -- I'd be remiss if I didn't mention our specialty franchise, which I think is of great interest to almost anybody in the healthcare space. Specialty is really where the innovation, action's going to be in the years ahead. And definitely our expertise, our physician connectivity, our understanding of the trends there, some of the contracting we do with manufacturers is definitely of interest to all large participants from mail-order to retail to hospital, et cetera."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes from the line of Steven Valiquette with UBS.",12,"The next question comes from the line of Steven Valiquette with UBS."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","So just to confirm, it sounds like there's no change to the $0.14 to $0.15 EPS expected from the -- in fiscal '12 from the big specialty generics. And then, is the reintroduction of generic Oxaliplatin in August, does that account for any material portion",65,"So just to confirm, it sounds like there's no change to the $0.14 to $0.15 EPS expected from the -- in fiscal '12 from the big specialty generics. And then, is the reintroduction of generic Oxaliplatin in August, does that account for any material portion of that? Or is that going to be basically a rounding error at the end of today within fiscal '12?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","It's included in the $0.14 to $0.15. But as you said, it's only a little bit more than a month of inclusion in our fiscal '12. But it is in there.",32,"It's included in the $0.14 to $0.15. But as you said, it's only a little bit more than a month of inclusion in our fiscal '12. But it is in there."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","Next question comes from the line of Matthew Coffina with Morningstar.",11,"Next question comes from the line of Matthew Coffina with Morningstar."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Two quick questions. So you said before that Medco is only about 5% of earnings. Maybe to help us get a better understanding of the flexibility in the cost structure here, what, from a specific standpoint -- what, from a practical standpoint, can you do i",58,"Two quick questions. So you said before that Medco is only about 5% of earnings. Maybe to help us get a better understanding of the flexibility in the cost structure here, what, from a specific standpoint -- what, from a practical standpoint, can you do in terms of reducing SG&A when you lose a large customer like that?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think you look at our year and we always do a good job. I think ABC's got a history of always continuing to look for new efficiencies. And we continue that trend I think I highlighted in my remarks. Medco is unusual because we really had very few",123,"Well, I think you look at our year and we always do a good job. I think ABC's got a history of always continuing to look for new efficiencies. And we continue that trend I think I highlighted in my remarks. Medco is unusual because we really had very few sites, it's a concentrated delivery, they actually work primarily with our large greenfields, so highly automated facilities. So I think that, that's why we pointed to a 5% contribution that also did contemplate the operating expense increase. But in that particular case, it's unlikely we would shut down any distribution centers or anything like that because of the way the business is currently contracted for and operates. Want to say anything else, Mike?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I think that's right. I mean, most of that impact is on the gross profit side. Our expense to serve is very low in that contract as it is with high-volume concentrated location type customers as Steve mentioned.",39,"No, I think that's right. I mean, most of that impact is on the gross profit side. Our expense to serve is very low in that contract as it is with high-volume concentrated location type customers as Steve mentioned."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And how do we think about Express Scripts in there, a CuraScript subsidiary? And would that be seen as a competitor to you? And how do you think they'll be thinking about that?",35,"Okay, great. And how do we think about Express Scripts in there, a CuraScript subsidiary? And would that be seen as a competitor to you? And how do you think they'll be thinking about that?"
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think CuraScript does have the physician distribution business. They also have, I believe, a large amount of order specialty pharmacy business. But nothing extraordinary. We work with all channel participants. We do have some business relationship",59,"Well, I think CuraScript does have the physician distribution business. They also have, I believe, a large amount of order specialty pharmacy business. But nothing extraordinary. We work with all channel participants. We do have some business relationships already with Express Scripts. And obviously, we think that there will be a subject for discussion should the merger be approved."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","There are no further questions. I turn the call back over to Barbara Brungess.",14,"There are no further questions. I turn the call back over to Barbara Brungess."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Cara. And now, I think Steve would just like to make a few closing remarks.",17,"Thank you, Cara. And now, I think Steve would just like to make a few closing remarks."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Thank you, everyone, for your interest and for joining the call today. We -- Mark and Barbara and I certainly do enjoy the exchanges. Our take away message that you should all receive from ABC today is that we're off to a solid start with our results",85,"Yes. Thank you, everyone, for your interest and for joining the call today. We -- Mark and Barbara and I certainly do enjoy the exchanges. Our take away message that you should all receive from ABC today is that we're off to a solid start with our results for this first quarter. And we are well-positioned to meet our objectives for the year. And we also hope to see you at one of the upcoming conferences that we'll be presenting at. Thanks for your attention."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steven. Before we go, I'll just highlight a couple of our upcoming events. On February 8, we'll be attending the UBS Healthcare Conference in New York. On February 28, we'll be attending the Citi Healthcare Conference, also in New York. And finall",65,"Thanks, Steven. Before we go, I'll just highlight a couple of our upcoming events. On February 8, we'll be attending the UBS Healthcare Conference in New York. On February 28, we'll be attending the Citi Healthcare Conference, also in New York. And finally on March 14, we'll be attending the Barclays Healthcare Conference in Miami. So thank you, all, very much for joining us today."
24809,145552360,211738,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, this conference will be available for replay today after 1:00 p.m. through February 2, 2012 at midnight. You may access the AT&T Teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering the access code 231917.",72,"Ladies and gentlemen, this conference will be available for replay today after 1:00 p.m. through February 2, 2012 at midnight. You may access the AT&T Teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering the access code 231917. International participants, please dial (320) 365-3844, access code 231917. That does conclude our conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the AmerisourceBergen first quarter earnings. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Barbara Brungess.",42,"Ladies and gentlemen, thank you for standing by. Welcome to the AmerisourceBergen first quarter earnings. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Barbara Brungess. Please go ahead."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 first quarter results. I'm Barbara Brungess, Vice President of Corporate and Investor Relations. And joining me today are Steve Collis, Amerisourc",161,"Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 first quarter results. I'm Barbara Brungess, Vice President of Corporate and Investor Relations. And joining me today are Steve Collis, AmerisourceBergen President and CEO; and Mike Dicandilo, Executive Vice President and CFO.
During the conference call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011.
Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by phone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen delivered solid results in the first quarter of our fiscal year 2012.Our revenues were up 2% to $20.4 billion. Earnings per share were up 9% to $0.62. We gener",1400,"Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen delivered solid results in the first quarter of our fiscal year 2012.
Our revenues were up 2% to $20.4 billion. Earnings per share were up 9% to $0.62. We generated $432 million in operating cash flow and we repurchased $128 million of our shares. Our financial results were in line with our expectations and position us well to meet our objectives for the remainder of the year.
Our excellent cash generation and strong balance sheet provide us with outstanding financial flexibility and give us the ability to fund our strategic initiatives and grow our business.
AmerisourceBergen is fortunate to be an important part of a growing industry. As I discussed at our Investor Day in December, demographics in the expansion of health care coverage should drive organic growth in our industry over the next several years. In addition, launches of new pharmaceuticals as well as new indications for existing drugs should also drive sales growth. The tremendous wave of over 30 brand to generic drug conversions that we expect in our fiscal 2012 as well as additional conversions expected in subsequent years will mitigate the top line dollar growth in our industry. It will drive tremendous value for wholesalers, healthcare providers and patients alike.
These trends bode well for AmerisourceBergen in particular. Our diverse revenue base positions us well to benefit from organic growth driven by demographics as well as from the influx of the uninsured over the next few years. Our customer mix also puts us in a favorable position to benefit from the historic influx of generics. In addition, cost-containment efforts underway by the federal government and other payers drive demand for our services most notably in our Consulting Services group.
Today, we are more entrenched than ever before with our manufacture customers and we expect that to continue to increase. As our provider customers face reimbursement and other challenges, they increasingly turn to AmerisourceBergen for help in making their healthcare practices run as efficiently as possible without sacrificing excellent patient care.
Over the last several months, a few large contracts in our industry have been the subject of much dialogue for various different reasons. Overall, however, the market continues to be competitive but stable. We continue to participate in discussions that are important to our business, our industry and our customers in Washington, D.C., educating lawmakers about our business and the value we and our customers provide to the healthcare system.
I've discussed our core tenets several times over the last year but they continue to drive our efforts and that bears repeating. Firstly, collaborate to drive innovation for all stakeholders, increasing customer and supplier value, expanding our business in targeted markets, maximizing operating efficiency and maintain a high-performance culture. Our associates creatively tackle challenges and identify new opportunities to add value on a daily basis. They'll focus on meeting our objectives for the year, both in terms of the service we provide to customers and suppliers and in our financial performance, and I'm honored to work beside them.
Turning now to our business units. AmerisourceBergen Drug Corporation had solid revenue growth in the quarter, up 2%. We had positive revenue growth in both retail and institutional segments, even with the previously-discussed loss of a large retail -- retail customer in September of 2011. Our ultimate side segment was particularly strong in the quarter and hospitals and independents had very solid growth. 
We now have over 4,600 members in our Good Neighbor Pharmacy network which makes it the third largest network of pharmacies in the U.S. That is a powerful endorsement of the role that independent retail pharmacy plays in the complex healthcare landscape today.
Patients preferred choice when determining where to fill their prescriptions and our retail customers are very adept at fulfilling unique patient needs. Our SAP implementation continues to run smoothly with redistributions and our conversions complete, and the remainder plans for the beginning of 2013. Our investments in our Canadian operations to support significant new business wins are also well underway. We are very pleased to be the leading distributor independent pharmacy in the Canadian market as well as the leader in Specialty Distribution and services.
AmerisourceBergen Specialty Group had another strong quarter with revenues up 4%, with particularly strong performance in third-party logistics and good performance in Oncology Supply. The integration of IntrinsiQ has gone very well, and our customers have responded favorably to the tools at office. While our Specialty Group is based after our oncology franchise, we are an instrumental part of the commercialization strategy for any infusible product launched in the physician marketplace.
In addition, our Specialty Group often collaborates with our Consulting Services group to help ensure patients have access to products by utilizing the full capabilities of our physician networks, as well as our reimbursement and patient support program expertise. For example, during the quarter, we executed very well on the launch of a new brand of ophthalmology product, establishing significant market share in just the first few months of introduction. This is a great example, not only of excellent cross-company collaboration, but also of the strength and tremendous value of our diverse offerings.
AmerisourceBergen Consulting Services delivered a strong quarter while making excellent progress in the integration of TheraCom and Premier Source. Our Consulting and Packaging business both performed well in the quarter. And while the group only represents about 1% of our revenues, we believe our packaging and consulting associates are providing essential expertise to pharmaceutical manufacturers to help ensure that their products are brought to market as safely, quickly and efficiently as possible.
In addition, our reimbursement expertise helps ensure that patients who can benefit from both new and mature therapies have access to the products. 
Given the continued strength of our balance sheet, we continue to look for acquisitions that meet the criteria we've had in place for quite some time. They should increase our value offering to existing customers both up and down the channel. They should be within our established core competency and they should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions and we continue to be interested in opportunities in pharmaceutical and Specialty Distribution and Services, as well as Consulting and Packaging services. While we historically have been very comfortable in the $200 million to $300 million range, we would consider selling larger if it made good strategic sense and would deliver value to our company and our shareholders.
Looking ahead, the results we've had in our first quarter have positioned us well to meet our objectives for the full fiscal year. We have a difficult comparison to overcome in 2012, but we continue to expect earnings per share to be in the range of $2.74 to $2.84, an increase of 8% to 12% over fiscal 2011.
Looking further ahead to 2013, we should have a carryover from some of the launches that occur late in our fiscal 2012 including the relaunch of Oxaliplatin, and we should begin to benefit from the completion of our SAP implementation.
In fiscal 2014, we should begin to see the 30 million to 40 million uninsured patients in the healthcare market driving demand for pharmaceuticals that should carry over into 2015 and beyond. In addition, 2014 and 2015 are expected to be good years with generic conversions, and of course, there's a chance that biosimilars may also come to market in that timeframe.
Before I turn it over to Mike for a detailed look at the financials, I want to reiterate the confidence that I have in our business and our future because demand is strong for the products we distribute and the services we provide. We were pleased to be recently be ranked 24th on Bloomberg Businessweek's list of the top 50 performing companies in the U.S. in recognition of our historic financial performance and our future growth opportunities.
As I stated earlier, we play an essential role in the pharmaceutical supply channel, we positioned ourselves well to benefit from generics and specialty products, and we have continued to invest in our existing businesses and opportunities we see in our future.
Finally, our exceptional associates at ABC set us apart in our industry and I'm proud to be their leader. Here is Mike."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and good morning, everyone. I'm very pleased to report first quarter fiscal 2012 results on track with our internal plans, highlighted by good performance on new generic launches, strong expense discipline, significant progress towards inte",1227,"Thanks, Steve, and good morning, everyone. I'm very pleased to report first quarter fiscal 2012 results on track with our internal plans, highlighted by good performance on new generic launches, strong expense discipline, significant progress towards integrating TheraCom into our consulting group and exceptional cash generation, all of which gives us confidence in reaffirming our annual EPS guidance.
As we go through our quarterly results, keep in mind that last year's first quarter included a $12 million or $0.03 benefit reflected in gross profit from the Duane Reade contract termination last December.
So let's turn to the quarter, and starting with the top line, revenues were $20.4 billion, a 2.4% increase over last year's quarter. Drug company revenue was up 2% as strong growth in the alternate site hospital and independent customer groups offset the expected decline on the chain side, as this is our first quarter without the Longs/CVS contract. 
The Specialty Group revenues increased 4% with our 3PL business especially strong this quarter. The Consulting group, though small to the overall company top line, had a very strong quarter in our acquisitions, with TheraCom being the biggest contributor, added about 0.6% to overall ABC revenue growth in the quarter.
Gross profit was $593 million in the quarter, up 2% from last December, and gross margins of 291 basis points in the quarter were down 1 basis point from last year. As I mentioned earlier, the prior year quarter included a $12 million benefit related to the completion of the Duane Reade contract and the contribution to current quarter gross profit from our acquired companies helped to offset this headwind.
Performance from new generic launches were in line with our expectations as were benefits from price appreciation. We gave an early update during our Investor Day in December on trends with generic Lipitor scripts. And since then, trends have normalized very much in line with our expectation of approximately a 70% conversion rate to the generic. Specialty generic trends were also in line with our expectations.
Our LIFO charge in the quarter was $3.2 million compared to $9.9 million last year, reflecting the brand to generic conversions, and we continue to expect a full year charge of approximately $15 million.
We did a very nice job managing our operating expenses this quarter despite our acquisition-related transaction costs and the inclusion of our acquired companies' ongoing operating costs, including 2 months of TheraCom's results.
Operating expenses were $308 million, up 1.6% and included $3.6 million of acquisition-related transaction costs. Operating expenses in the quarter would have been down year-over-year x the impact of our acquisitions, fueled by a year-over-year decline in compensation costs including favorable benefit comparisons. Keep in mind that our operating expenses are usually at their lowest level in our first quarter and should increase sequentially as we progress throughout the year. Our guidance continues to include an annual expense increase of about 3% related primarily to our acquisitions.
Operating income of $285 million in the quarter increased 3% and operating margins expanded by 1 basis point compared to last December. Again, this year-over-year growth was slowed by the $3.6 million of acquisition costs in the current quarter and the previously-mentioned $12 million gross profit benefit realized in the first quarter of fiscal '11.
Moving below the operating income line, interest expense of $23 million in the December quarter increased 18% compared to last year, primarily as a result of our $500 million, 3.5% bonds that we issued in mid-November. Proceeds from this debt offering helped to fund our acquisitions and will also contribute to the retirement of our 2012 bonds that mature in mid-September. As a result, our expected interest rate expense will continue to trend higher than last year for the rest of fiscal '12.
Our effective income tax rate of 38.2% was slightly higher than last year's 38.1% and slightly below our expected annualized rate of approximately 38.4%. Our diluted earnings per share of $0.62 was up $0.05 or 9% compared to last year and exceeded our net income growth due to the reduction in our average diluted shares related to our ongoing share repurchase program. Average diluted shares outstanding for the quarter were 263.1 million, down over 6% from last December.
Now let's turn to our balance sheet and cash flows where trends continue to be very favorable. We generated $432 million of cash from operations in the quarter compared to using $99 million of cash in last year's first quarter. Much of that increase came from very favorable working capital at quarter end, particularly in the timing of our payments to vendors. As I have discussed often with our daily volume exceeding $300 million per business day, our quarter end working capital snapshots are subject to great volatility, and one should be careful not to extrapolate the first quarter's results to the full year cash flow forecast.
Capital expenditures were $48 million in the quarter compared to $50 million last year, and as we mentioned in December, included significant investments to expand our infrastructure in Canada as well as some discretionary buyouts on leased equipment, offset in part by declining ERP spend.
We continue to expect the capital spend for the year in the $150 million range. We bought back $128 million of our shares during the quarter and we also closed our $250 million TheraCom acquisition. 
With our strong free cash flow performance in the quarter, we continue to be comfortable with our estimate of free cash flow in a range of $700 million to $800 million for all of fiscal '12. We had our normal seasonal increase in inventory in December. But despite the higher-ending balance, our average day sales in inventory for the quarter remained at 25, consistent with fiscal '11. Average DSOs of 17.7 in the December quarter were up slightly from 17.4 days last year and the favorable payables timing helped raise average quarterly DPOs by over 2 days compared to fiscal '11.
With our recent debt offering, our gross debt to total debt in capital ratio at the end of December was 39.9%, above our target range of 30% to 35%, and will remain above the range in the next couple of quarters until we pay off our $392 million of debt, which matures in September.
Our cash balance of just under $2.4 billion at the end of December leaves us with great financial flexibility to fund our strategic initiatives, return significant amounts of capital to our shareholders and pay off our maturing debt.
Now let's turn to fiscal '12 guidance. And with our first quarter on track, our outlook is unchanged. Our diluted EPS guidance remains at a range of $2.74 to $2.84. Our assumptions behind this guidance also remain the same and include flat-to-modest revenue growth, operating margin expansion in the high single-digit to low double-digit basis point range and free cash flow in the $700 million to $800 million range. Additionally, we continue to expect to spend approximately $400 million for share repurchases.
So before I turn it back to Barbara, let me reiterate that 3 months into the year, we are performing well in our key areas of the business. And despite some tough comparisons ahead in the next couple of quarters, we are well-positioned to meet our financial targets for all of fiscal '12.
Now here's Barbara for Q&A."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Mike. We will now open the call to questions. [Operator Instructions] Please go ahead, Cara.",17,"Thank you, Mike. We will now open the call to questions. [Operator Instructions] Please go ahead, Cara."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] The first question comes from the line of Tom Gallucci.",12,"[Operator Instructions] The first question comes from the line of Tom Gallucci."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I think you touched on in your prepared remarks briefly, but I was wondering if you could sort of expand a little bit. The competitive landscape obviously has got a lot of attention in the investment community lately, whether it's because of the VA",112,"Steve, I think you touched on in your prepared remarks briefly, but I was wondering if you could sort of expand a little bit. The competitive landscape obviously has got a lot of attention in the investment community lately, whether it's because of the VA or the impact of the various M&A activity out there potentially. What are you expecting in terms of contract churn over the next year? Similar to the last year? If it's higher, is it because of certain unique reasons? Or do you see sort of the potential for more churn out there because of other types of reasons and maybe decisions that specific customers may be making?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think that these are really 2 or 3 really isolated events. I mean the VA comes up every 8 years. It's not a surprise to anyone that it comes up in this particular time frame. And obviously, we've gone to great lengths to point out that the industry is a",187,"I think that these are really 2 or 3 really isolated events. I mean the VA comes up every 8 years. It's not a surprise to anyone that it comes up in this particular time frame. And obviously, we've gone to great lengths to point out that the industry is a lot different than it was in 2003. And we bid that as you would expect us to bid a large contract. And then, of course, there's been a couple of big M&A deals, which one in particular was not at all expected, but we expect to participate in that. Our focus has been on servicing the companies that we do service to the best of our abilities. And I think we do a great job for them. And we expect that will be a part of any discussion going forward with those businesses. So just to sum it up, the competitive environment remains very similar to how it's been in the past. And we don't have a particular large amount of contracts coming up in the next couple of quarters. I mean, Mike, anything to add?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, Steve. I think you said it well. The atmosphere is always competitive but stable as you mentioned.",18,"No, Steve. I think you said it well. The atmosphere is always competitive but stable as you mentioned."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And then now just on the follow up there, maybe a smaller topic but there's been some activity around generic Lovenox today. Just curious if you could frame that drug for us and the potential impact, roughly speaking, if there were more suppl",48,"Okay, great. And then now just on the follow up there, maybe a smaller topic but there's been some activity around generic Lovenox today. Just curious if you could frame that drug for us and the potential impact, roughly speaking, if there were more supply on the market."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, Tom, generic Lovenox, we have done very well with that. It's part of our pro-generics offering and we already have had expectations that there would be competition in the marketplace. And that's built into our expectations.",37,"Well, Tom, generic Lovenox, we have done very well with that. It's part of our pro-generics offering and we already have had expectations that there would be competition in the marketplace. And that's built into our expectations."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Robert Jones with Goldman Sachs.",12,"The next question comes the line of Robert Jones with Goldman Sachs."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Just trying to get a better sense of some of the individual impacts in the quarter. First, I guess in the acquisition side, aside from the announced severance costs, was there an impact on operating expenses from the acquisitions in the quarter? And then",69,"Just trying to get a better sense of some of the individual impacts in the quarter. First, I guess in the acquisition side, aside from the announced severance costs, was there an impact on operating expenses from the acquisitions in the quarter? And then I guess along those lines, if you could give us some color around how Lipitor and Zyprexa contributions ultimately shaped up relative to your expectations?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, let me -- I'll start with the cost of the acquisitions. I think we highlighted on the face of the P&L that we had $3.6 million of transaction costs related to closing the deal that we did in this quarter, the TheraCom deal. In addition, we obviously",136,"Well, let me -- I'll start with the cost of the acquisitions. I think we highlighted on the face of the P&L that we had $3.6 million of transaction costs related to closing the deal that we did in this quarter, the TheraCom deal. In addition, we obviously have an ongoing operating cost from all 3 of the companies we've acquired in the last few months that are incremental to last year's first quarter. And as I mentioned, they're included in our normal SG&A. And if you took out the normal run -- the ongoing operating costs, our year-over-year SG&A would have been down. So I think that speaks well to the rest of our business and the continued impact of our productivity efforts throughout the company and our continued focus on keeping our costs down."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. And on the 2 big generic launches in the quarter, I mean, we had said on our Investor Day which we really were into the very big one -- the prominent one, we were only about a week or so into it that conversion rates were slightly lower than expected",127,"Yes. And on the 2 big generic launches in the quarter, I mean, we had said on our Investor Day which we really were into the very big one -- the prominent one, we were only about a week or so into it that conversion rates were slightly lower than expected, but it settled down around about that 70% level, which is a little bit less than you'd expect. But it's definitely trending in the right direction. And Zyprexa's right around where we expected it, around 80%. And we performed very much at expectations for both of them with the exception of the Lipitor, which we discussed at Investor Day, but which we now feel is back on track as we sit at the end of January."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, got it. And just a follow-up, I guess around the buyback, it's $750 million left on the authorization and reiterating the $400 million that's stays in the guidance. I was wondering at what point in the year, what would trigger you to maybe look to u",52,"Okay, got it. And just a follow-up, I guess around the buyback, it's $750 million left on the authorization and reiterating the $400 million that's stays in the guidance. I was wondering at what point in the year, what would trigger you to maybe look to upsize the buyback in fiscal '12?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","First off, let me just clarify, we've got $380 million remaining on our current authorization. And obviously, our guidance for the year is $400 million of share repurchases. And I think you can look back to our historical performance to understand how we",106,"First off, let me just clarify, we've got $380 million remaining on our current authorization. And obviously, our guidance for the year is $400 million of share repurchases. And I think you can look back to our historical performance to understand how we might deploy additional capital for repurchases. If we don't make any other larger strategic moves, we certainly have the capacity to increase the share repurchase. And once again, we've shown that we would do that, similar to what we did last year if that's how the year progresses and we continue to meet our cash forecast. So we're in a very good position."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Larry Marsh with Barclays Capital.",12,"The next question comes the line of Larry Marsh with Barclays Capital."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","This is actually Kipp Davis in for Larry. So this is just sort of a follow-up on Lipitor. So it sounds like you're communicating that it came a little bit slower initially than you would expect it in terms of generic conversion. Now you're sort of more co",118,"This is actually Kipp Davis in for Larry. So this is just sort of a follow-up on Lipitor. So it sounds like you're communicating that it came a little bit slower initially than you would expect it in terms of generic conversion. Now you're sort of more comfortable with where it is. Just kind of curious after we think about Zyprexa, and of course, other generics that are going to come on line, how have your thoughts changed for the rest of the year? What do you think some of the key variables are with regard to whether it's manufacturer, strategies, et cetera, that might cause you to change your thoughts about the generic contributions throughout the year?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, this is -- Lipitor was as we said a lot, is really a unique product. I mean, first of all, just the size of it, just the prominence of it. And we think that it's also uniquely a mail-ordered drug. So Pfizer was able to contract with large purchases o",116,"Yes, this is -- Lipitor was as we said a lot, is really a unique product. I mean, first of all, just the size of it, just the prominence of it. And we think that it's also uniquely a mail-ordered drug. So Pfizer was able to contract with large purchases of the product directly. We think that this is an unusual situation. We don't think it's been particularly successful. And we don't -- we have not changed any of our plans for any other generic launches this year. And as I said, we feel very reassured by the fact that the conversion rate is now approaching 70% and looks like it could go up from there."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, that's helpful. And then just a follow-up. This is also sort of around consolidation. How do we think about -- with a broadened specialty offering, how do we think about customer consolidation in the specialty space? And would we think that specialt",88,"Okay, that's helpful. And then just a follow-up. This is also sort of around consolidation. How do we think about -- with a broadened specialty offering, how do we think about customer consolidation in the specialty space? And would we think that specialty would always be serviced as part of a larger PBM contract or would that sort of business potentially be carved out? How do we think about that sort of relationship there? I don't know if that's a question for James or any of you folks."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, you raise a good question. I understand -- I think I understand what you're getting at. First of all, let me distinguish that our Specialty Distribution business is really dealing with physicians who administer products in their office. And there's",149,"Well, you raise a good question. I understand -- I think I understand what you're getting at. First of all, let me distinguish that our Specialty Distribution business is really dealing with physicians who administer products in their office. And there's been numerous articles, there's no doubt that AmerisourceBergen Specialty Group is the leading company in that area. And we're very, very successful there. In our drug company, we do have, within our ultimate side segment, several large companies that are involved with specialty products more on the mail-order side and on the patient delivery side. And we definitely have expertise in servicing those customers. So overall, AmerisourceBergen really services a huge part of the specialty industry, and we expect that to continue. So I hope that's helpful. I think both aspects of the Specialty Distribution are important to our company, important to manufacturers and important to the patients."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Eric Coldwell with Robert W. Baird.",13,"The next question comes the line of Eric Coldwell with Robert W. Baird."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I realize that all but one of your major customers purchase generics through AmeriSource. But there have been rumblings in the market that perhaps 1 or 2 of the larger retail systems are looking at  internalizing generics, perhaps slowly but are testing t",74,"I realize that all but one of your major customers purchase generics through AmeriSource. But there have been rumblings in the market that perhaps 1 or 2 of the larger retail systems are looking at  internalizing generics, perhaps slowly but are testing the market there. Have you seen any shift in your customers' buying behavior around generics recently? Whether it be asking for greater discounts or looking to perhaps internalize some of the work?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I mean obviously, generics are becoming more and more important. They're a bigger part of the prescriptions that the patients get in the U.S. every day, and that's certainly what we expected. But we really haven't seen any different shifts. I mean, we",84,"No, I mean obviously, generics are becoming more and more important. They're a bigger part of the prescriptions that the patients get in the U.S. every day, and that's certainly what we expected. But we really haven't seen any different shifts. I mean, we believe that our ProGen formerly and our overall generic offering offers the best everyday value to our customers. And we continue to work very hard at keeping that to be the case. And I think our customers appreciate it, Eric."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","That's great. Just one quick follow-up. Another healthcare distributor this morning highlighted that physician activity was slower than they expected. They saw less flu -- seasonal flu impact due to lower illness rates and the weather, obviously. I realiz",79,"That's great. Just one quick follow-up. Another healthcare distributor this morning highlighted that physician activity was slower than they expected. They saw less flu -- seasonal flu impact due to lower illness rates and the weather, obviously. I realize that's also a very small piece of your total business, but can you give us any comments on what you're seeing around primary care and the flu market, both for December quarter and where we are early this year?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","The flu vaccine has become a very small part of our over $8 billion in revenues. The most activity actually takes place for flu vaccine in our fourth quarter of our fiscal year, so the September quarter last fiscal year. We have some modest activity in th",112,"The flu vaccine has become a very small part of our over $8 billion in revenues. The most activity actually takes place for flu vaccine in our fourth quarter of our fiscal year, so the September quarter last fiscal year. We have some modest activity in this quarter but it really is primarily now become that September quarter. Of course, our retailers are impacted by seasonal trends. If there's a lot of flu, a lot of cold, that does help patient traffic. But we really focus on overall top line growth, not as much on individual prescription trends at the retail level. So hopefully, that's helpful for you. Mark, anything to add?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, and they've been good, Eric. We're up year-over-year despite the completion of the Longs/CVS contract last quarter, which I think is an indication of strength in the top line force.",31,"No, and they've been good, Eric. We're up year-over-year despite the completion of the Longs/CVS contract last quarter, which I think is an indication of strength in the top line force."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes from the line of Lisa Gill with JPMorgan.",12,"The next question comes from the line of Lisa Gill with JPMorgan."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, you made a comment on the revenue line that you're seeing strength on the hospital side as well as in the independents. Can you maybe just talk about -- is this that you've picked up any incremental customers? Or is there some other reason why you'",64,"Steve, you made a comment on the revenue line that you're seeing strength on the hospital side as well as in the independents. Can you maybe just talk about -- is this that you've picked up any incremental customers? Or is there some other reason why you're seeing increased strength in those customers? Because your revenue came in much better than we would've anticipated."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think we had some mix. I mean, the big customers grew pretty well in the quarter. But our hospital business is -- we believe we have good market share there. And really nothing extraordinary that happened, I mean, just good solid demand for our products",46,"I think we had some mix. I mean, the big customers grew pretty well in the quarter. But our hospital business is -- we believe we have good market share there. And really nothing extraordinary that happened, I mean, just good solid demand for our products."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","What was -- did revenue come in where you were thinking? Or so do we have it wrong? Or is it just that this is what you were expecting based on what you've seen in your book and all of us got a little carried away on what our expectations were for the imp",56,"What was -- did revenue come in where you were thinking? Or so do we have it wrong? Or is it just that this is what you were expecting based on what you've seen in your book and all of us got a little carried away on what our expectations were for the impact of generics?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Revenues came in very close to what we're expecting. I mean, maybe slightly ahead of expectations. But very close to what we were expecting.",25,"Revenues came in very close to what we're expecting. I mean, maybe slightly ahead of expectations. But very close to what we were expecting."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And then just as a follow-up, as we think about the oncology offices and we think about reimbursement as well as some of the programs for example, that United is doing around bundling of services, et cetera, are you starting to see any change",82,"Okay, great. And then just as a follow-up, as we think about the oncology offices and we think about reimbursement as well as some of the programs for example, that United is doing around bundling of services, et cetera, are you starting to see any change as we move into the next year? And we start thinking about planned design changes and changes with the managed care companies around how they pay for oncology. Has there been any noted change this year?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","This discussion has been around for several years and I think it's just really -- it's why our offering is so important. I mean, you look at why we acquired IntrinsiQ and you look at the investments we make in our ION business, our physician services comp",201,"This discussion has been around for several years and I think it's just really -- it's why our offering is so important. I mean, you look at why we acquired IntrinsiQ and you look at the investments we make in our ION business, our physician services company. We really want to enhance the dialogue between managed care companies and our community oncologists then. Our strategy is not to be a principal in those negotiations, but really to assist our customers so they have the information available and they have the sort of data that managed care companies are looking at. And we think are definitely enhancing that dialogue. It's not -- we're stopping that trend. I think as we sit here today -- I was in D.C. last week and often obviously with some of our large oncology practices, people are starting to recognize us. It's very important to keep cancer care in the community setting, not only from a patient point of view, clinical point of view, but also from an economic point of view. And that's obviously a trend that AmerisourceBergen supports and a big part of what our Specialty Group practice -- is able to demonstrate everyday."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","So just to understand it, then you're not seeing anything as far as trends go -- and we think about how would it impact your revenue, you're not seeing any changes to utilization or the way that the product is delivered based on these discussions?",45,"So just to understand it, then you're not seeing anything as far as trends go -- and we think about how would it impact your revenue, you're not seeing any changes to utilization or the way that the product is delivered based on these discussions?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No. And again, we've had that SP formerly -- for over 6 years now. So I think our practitioners are used to it. Everything as we said in the release, everything went very well in our oncology business this quarter.",40,"No. And again, we've had that SP formerly -- for over 6 years now. So I think our practitioners are used to it. Everything as we said in the release, everything went very well in our oncology business this quarter."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of A.J. Rice with Susquehanna.",12,"The next question comes the line of A.J. Rice with Susquehanna."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I guess because there's so much focus on the VA contract, I'd love to get any perspective you'd be willing to offer on sort of the rebidding and the ask for additional information and say taking a second look, what does that imply about what they're tryin",103,"I guess because there's so much focus on the VA contract, I'd love to get any perspective you'd be willing to offer on sort of the rebidding and the ask for additional information and say taking a second look, what does that imply about what they're trying to do there? And I guess, I'll ask you a similar question to the one I asked at the Investor Day. If you guys, with what you now know, if you were to be successful and get the contract, would you consider that to be something that would be additive to your results almost immediately?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, A.J., this is Mike. I'll give a go at it and I'll let Steve add any additional comments. But when we got the additional information from the VA, it essentially clarified that there is a small part of purchases approximately 3% that were off contract",179,"Yes, A.J., this is Mike. I'll give a go at it and I'll let Steve add any additional comments. But when we got the additional information from the VA, it essentially clarified that there is a small part of purchases approximately 3% that were off contract and clarified that fact and asked us to rebid based upon that new information. I would go back to what we said, when we bid this contract back in June, we considered that to be our last and final bid. We took it very seriously. We considered the new information. We made the appropriate modifications, but it did not change our bid material from what we had done at the end of June. Should we get the VA contract? Yes, we think it would add right away. I think our expectations, it's a several billion dollar contract. There's not many of those out there. And typically, the largest contracts in our industry get the best price. And I would expect this to be similar and have the appropriate contribution for a large contract."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. Just maybe then a follow-up on the comments you made in the prepared remarks. I think, maybe Steve made this comment about outpatient in the drug corporation being particularly strong. And I just was wondering -- maybe there's a little more color on",53,"Okay. Just maybe then a follow-up on the comments you made in the prepared remarks. I think, maybe Steve made this comment about outpatient in the drug corporation being particularly strong. And I just was wondering -- maybe there's a little more color on what was exactly going on there in your opinion."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think, A.J., you talked about really our old site? That maybe my accent. That's really our nonhospital institutional business, our mail-order, skilled nursing facility, institutional pharmacy, et cetera. And we did have good revenue trends in that secto",62,"I think, A.J., you talked about really our old site? That maybe my accent. That's really our nonhospital institutional business, our mail-order, skilled nursing facility, institutional pharmacy, et cetera. And we did have good revenue trends in that sector. And we have a couple of new customer wins there, particularly we've talked about the Humana contract where we had good revenue performance."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. Yes, and I understood it was the alternate site. I guess, that's probably my lingo. I was just curious if it was -- if there was underlying pickup in trend or is it new business? So it sounds like it's mostly new business, maybe?",45,"Okay. Yes, and I understood it was the alternate site. I guess, that's probably my lingo. I was just curious if it was -- if there was underlying pickup in trend or is it new business? So it sounds like it's mostly new business, maybe?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Yes, you could say new business. But just good high-growth sector. I mean, benefiting from favorable demographics.",18,"Yes. Yes, you could say new business. But just good high-growth sector. I mean, benefiting from favorable demographics."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes the line of Charles Rhyee with Cowen and Company.",13,"The next question comes the line of Charles Rhyee with Cowen and Company."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","I guess, one real quick follow-up about the VA here. Obviously, investors and analysts are all focused on this contract, but can you tell us essentially when you're in discussions with clients, I mean, is this something that ever comes up? Or is this some",53,"I guess, one real quick follow-up about the VA here. Obviously, investors and analysts are all focused on this contract, but can you tell us essentially when you're in discussions with clients, I mean, is this something that ever comes up? Or is this something that people ever look at and refer to?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I think everyone understands that it's a very, very different contract. The way it works, it's very unique both as in the DOD and it doesn't really come up.",30,"No, I think everyone understands that it's a very, very different contract. The way it works, it's very unique both as in the DOD and it doesn't really come up."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, that's great. And then, Mike, maybe a question for you. And I guess this kind of gets back to your original comments about how you see Lipitor come on. When we look at the LIFO charge in the quarter, obviously down less than a year ago. Should we ex",102,"Okay, that's great. And then, Mike, maybe a question for you. And I guess this kind of gets back to your original comments about how you see Lipitor come on. When we look at the LIFO charge in the quarter, obviously down less than a year ago. Should we expect that to sort of increase as we see more of this -- the rate of adoption on like Lipitor and some of the other generics come on? Is that a good proxy then for us to think about how the pace of generics are coming onto the course of this fiscal year?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. The LIFO charge as expected, Charles, to be significantly below what it was last year and really 2 reasons. Last year was actually much higher than we expected because of how high the brand price appreciation was. And again our expectation is it's st",163,"Yes. The LIFO charge as expected, Charles, to be significantly below what it was last year and really 2 reasons. Last year was actually much higher than we expected because of how high the brand price appreciation was. And again our expectation is it's still going to be strong this year but may moderate a little bit versus last year on the brand side. But certainly, with all the new generic introductions and 34 launches, there's going to be a big impact on the generic price deflation this year from products coming off exclusivity. And that has led to lower overall expectation of what a LIFO charge is going to be. And that's really starting in the beginning of the year and will be pretty consistent the rest of the year as a lot of the launches are pretty well spaced throughout the year. And we'll continue to have launches next quarter and all the way through to the end of the year."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","And so that sequential change, that's a good signal for us? And was this quarter sort of in line with what you had expected?",24,"And so that sequential change, that's a good signal for us? And was this quarter sort of in line with what you had expected?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Yes, very much in line. And again, it's a $15 million annual expectation. We're always a little bit higher in the second quarter because that's where a lot of the brand inflation occurs. But otherwise, very much as we expected.",41,"Yes. Yes, very much in line. And again, it's a $15 million annual expectation. We're always a little bit higher in the second quarter because that's where a lot of the brand inflation occurs. But otherwise, very much as we expected."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes from the line of Ricky Goldwasser with Morgan Stanley.",13,"The next question comes from the line of Ricky Goldwasser with Morgan Stanley."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","So just as a thought to the last question but taking it from a revenue perspective, so you grew revenue at about 2.4% and you're guiding us for flat revenues. So should we assume that second half revenues might decline given the timing of drugs going off",52,"So just as a thought to the last question but taking it from a revenue perspective, so you grew revenue at about 2.4% and you're guiding us for flat revenues. So should we assume that second half revenues might decline given the timing of drugs going off 180s that you just mentioned?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, some of that sequential change, Ricky, has to do obviously with our largest customer who only buys brand-name drugs from us and there's more products, though generic, their revs will moderate some over the rest of the year.",39,"Yes, some of that sequential change, Ricky, has to do obviously with our largest customer who only buys brand-name drugs from us and there's more products, though generic, their revs will moderate some over the rest of the year."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So when we model, I just want to make sure that our model is kind of like accurate, should we assume kind of like a first half kind of like 2%? And then sort of like negative growth in the second half to get to kind of like flat year-over-year? Or i",60,"Okay. So when we model, I just want to make sure that our model is kind of like accurate, should we assume kind of like a first half kind of like 2%? And then sort of like negative growth in the second half to get to kind of like flat year-over-year? Or is it going to be smoother than that?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","I think it's going to be a little bit smoother.",11,"I think it's going to be a little bit smoother."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And then on the generic side, I know we talked a lot about that, but can you quantify kind of like the EPS impact for new generics? Is it back at this quarter? Just to give us a sense of how does it relate to kind of like this $0.05, $0.06 of benefi",61,"Okay. And then on the generic side, I know we talked a lot about that, but can you quantify kind of like the EPS impact for new generics? Is it back at this quarter? Just to give us a sense of how does it relate to kind of like this $0.05, $0.06 of benefit that you're seeing from Gemzar and Taxotere?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Ricky, I don't think we went -- get into a quarter by quantification of the impact of the new generics. And obviously, what happened last year has an impact as well the year-over-year impact. I think again our guidance for the year's, we expect that the c",157,"Ricky, I don't think we went -- get into a quarter by quantification of the impact of the new generics. And obviously, what happened last year has an impact as well the year-over-year impact. I think again our guidance for the year's, we expect that the cumulative impact of the 34 launches will offset the decline on the specialty generics side. From a specialty generic perspective, we had about a $0.06 benefit in the first quarter of last year. And this year was pretty similar down about $0.005 or so. Those comparisons will get more difficult the next couple of quarters as they were very big quarters here for Specialty. But I think the beneficial impact of the oral solids will also increase in those next couple of quarters as well. So we really haven't changed our viewpoint on the year about the offset on the oral solid side to the headwind on the specialty generic side."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Directionally, will Lipitor and Zyprexa combine again directionally, no specific numbers higher or lower than that kind of like $0.05 to $0.06?",22,"Directionally, will Lipitor and Zyprexa combine again directionally, no specific numbers higher or lower than that kind of like $0.05 to $0.06?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Again, Ricky, I don't want to get into the quantification. I think we gave a pretty good view at Investor Day that the top 2 players were a significant part of the year, in the 40% range, I believe we gave. And I think that's the best quantification that",57,"Again, Ricky, I don't want to get into the quantification. I think we gave a pretty good view at Investor Day that the top 2 players were a significant part of the year, in the 40% range, I believe we gave. And I think that's the best quantification that we want to get into at this time."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question goes to the line of George Hill with Citigroup.",12,"The next question goes to the line of George Hill with Citigroup."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Most of my questions have been answered. Mike, I just want to ask another guidance question directionally. I know that you guys don't like to give quarterly guidance but straight expectations for Q2 or for a big number. And as we think about the branded L",168,"Most of my questions have been answered. Mike, I just want to ask another guidance question directionally. I know that you guys don't like to give quarterly guidance but straight expectations for Q2 or for a big number. And as we think about the branded Lipitor to generic conversion, I guess, I'd ask 2 questions, one, do you expect the Pfizer retention rate to stay at the 30-ish percent range? Or how quickly do you guys think that'll continue to fall? And if it hovers at 30%, it would look like the most profitable period for generic Lipitor to kind of be that first month right after May when there's no limit on multisource introductions and the whack probably won't catch up with the falling rate at which you guys can acquire the price. I guess, is it your sense that we might be -- I guess, is the consensus maybe seem too ambitious for fiscal Q2? And maybe should be a little more optimistic on fiscal Q3?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I'd say, again we do not -- let me make clear, we do not give quarterly guidance. And directionally, the March quarter has always been our strongest quarter because of the timing and the impact of manufacturer, our brand price increases and the impact",272,"No, I'd say, again we do not -- let me make clear, we do not give quarterly guidance. And directionally, the March quarter has always been our strongest quarter because of the timing and the impact of manufacturer, our brand price increases and the impact that has on some of our fee-for-service agreements, that trend is -- continues to be our expectation this year. Certainly, the second quarter is a big quarter for the oral solid generics as well. Keep in mind, the first quarter, we only had a month of the Lipitor, 2 months of the Zyprexa generics. In the second quarter, we have a full quarter benefit from those plus some new introductions. So certainly, we think the year-over-year benefit from oral solids is going to increase in the next quarter from the first quarter. So the trending, I think is, again, very similar to where it's been historically. The second quarter continues to be our peak. The number of suppliers that come on board after the exclusionary period for Lipitor can impact our numbers somewhat. But again, we're expecting a handful of people there, and we're expecting a pretty significant price drop after exclusivity is over. As far as the 70:30, that's in line with our expectations. If it's a little bit more generic, it helps us. It helps us. But again, I think the historical trending, as far as quarterly progression is still intact, and as I've mentioned, we've got tough comparisons of 2 and 3 on the specialty side, but good performance on the oral solid side. And the fourth quarter continues to be our easiest comparison."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And maybe just a quick follow-up to Tom's question that's actually where investors worry about clients' trend being unusually high given what's going on in the M&A space. A lot of the big clients tend to see their relationships with the wholesalers",63,"Okay. And maybe just a quick follow-up to Tom's question that's actually where investors worry about clients' trend being unusually high given what's going on in the M&A space. A lot of the big clients tend to see their relationships with the wholesalers as pretty transactional with low switch in costs. What can AmeriSource do, I guess, to make these relationships more sticky?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think obviously, with the smaller customers, we have different services. But in the larger customers, I think we've proven time and again that our relationship to our largest customer is very valuable to them. We were happy to receive the VIP awar",169,"Well, I think obviously, with the smaller customers, we have different services. But in the larger customers, I think we've proven time and again that our relationship to our largest customer is very valuable to them. We were happy to receive the VIP award the last 2 years in a row. And I think we can do different services especially around logistics, cash flow, joint negotiations, even look at some generic lines with large customers. I think there's lots of opportunities in the industry to work together. And then, of course, I just -- I'd be remiss if I didn't mention our specialty franchise, which I think is of great interest to almost anybody in the healthcare space. Specialty is really where the innovation, action's going to be in the years ahead. And definitely our expertise, our physician connectivity, our understanding of the trends there, some of the contracting we do with manufacturers is definitely of interest to all large participants from mail-order to retail to hospital, et cetera."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes from the line of Steven Valiquette with UBS.",12,"The next question comes from the line of Steven Valiquette with UBS."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","So just to confirm, it sounds like there's no change to the $0.14 to $0.15 EPS expected from the -- in fiscal '12 from the big specialty generics. And then, is the reintroduction of generic Oxaliplatin in August, does that account for any material portion",65,"So just to confirm, it sounds like there's no change to the $0.14 to $0.15 EPS expected from the -- in fiscal '12 from the big specialty generics. And then, is the reintroduction of generic Oxaliplatin in August, does that account for any material portion of that? Or is that going to be basically a rounding error at the end of today within fiscal '12?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","It's included in the $0.14 to $0.15. But as you said, it's only a little bit more than a month of inclusion in our fiscal '12. But it is in there.",32,"It's included in the $0.14 to $0.15. But as you said, it's only a little bit more than a month of inclusion in our fiscal '12. But it is in there."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","Next question comes from the line of Matthew Coffina with Morningstar.",11,"Next question comes from the line of Matthew Coffina with Morningstar."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Two quick questions. So you said before that Medco is only about 5% of earnings. Maybe to help us get a better understanding of the flexibility in the cost structure here, what, from a specific standpoint -- what, from a practical standpoint, can you do i",58,"Two quick questions. So you said before that Medco is only about 5% of earnings. Maybe to help us get a better understanding of the flexibility in the cost structure here, what, from a specific standpoint -- what, from a practical standpoint, can you do in terms of reducing SG&A when you lose a large customer like that?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think you look at our year and we always do a good job. I think ABC's got a history of always continuing to look for new efficiencies. And we continue that trend I think I highlighted in my remarks. Medco is unusual because we really had very few",123,"Well, I think you look at our year and we always do a good job. I think ABC's got a history of always continuing to look for new efficiencies. And we continue that trend I think I highlighted in my remarks. Medco is unusual because we really had very few sites, it's a concentrated delivery, they actually work primarily with our large greenfields, so highly automated facilities. So I think that, that's why we pointed to a 5% contribution that also did contemplate the operating expense increase. But in that particular case, it's unlikely we would shut down any distribution centers or anything like that because of the way the business is currently contracted for and operates. Want to say anything else, Mike?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","No, I think that's right. I mean, most of that impact is on the gross profit side. Our expense to serve is very low in that contract as it is with high-volume concentrated location type customers as Steve mentioned.",39,"No, I think that's right. I mean, most of that impact is on the gross profit side. Our expense to serve is very low in that contract as it is with high-volume concentrated location type customers as Steve mentioned."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And how do we think about Express Scripts in there, a CuraScript subsidiary? And would that be seen as a competitor to you? And how do you think they'll be thinking about that?",35,"Okay, great. And how do we think about Express Scripts in there, a CuraScript subsidiary? And would that be seen as a competitor to you? And how do you think they'll be thinking about that?"
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think CuraScript does have the physician distribution business. They also have, I believe, a large amount of order specialty pharmacy business. But nothing extraordinary. We work with all channel participants. We do have some business relationship",59,"Well, I think CuraScript does have the physician distribution business. They also have, I believe, a large amount of order specialty pharmacy business. But nothing extraordinary. We work with all channel participants. We do have some business relationships already with Express Scripts. And obviously, we think that there will be a subject for discussion should the merger be approved."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","There are no further questions. I turn the call back over to Barbara Brungess.",14,"There are no further questions. I turn the call back over to Barbara Brungess."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Cara. And now, I think Steve would just like to make a few closing remarks.",17,"Thank you, Cara. And now, I think Steve would just like to make a few closing remarks."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Thank you, everyone, for your interest and for joining the call today. We -- Mark and Barbara and I certainly do enjoy the exchanges. Our take away message that you should all receive from ABC today is that we're off to a solid start with our results",85,"Yes. Thank you, everyone, for your interest and for joining the call today. We -- Mark and Barbara and I certainly do enjoy the exchanges. Our take away message that you should all receive from ABC today is that we're off to a solid start with our results for this first quarter. And we are well-positioned to meet our objectives for the year. And we also hope to see you at one of the upcoming conferences that we'll be presenting at. Thanks for your attention."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steven. Before we go, I'll just highlight a couple of our upcoming events. On February 8, we'll be attending the UBS Healthcare Conference in New York. On February 28, we'll be attending the Citi Healthcare Conference, also in New York. And finall",65,"Thanks, Steven. Before we go, I'll just highlight a couple of our upcoming events. On February 8, we'll be attending the UBS Healthcare Conference in New York. On February 28, we'll be attending the Citi Healthcare Conference, also in New York. And finally on March 14, we'll be attending the Barclays Healthcare Conference in Miami. So thank you, all, very much for joining us today."
24809,145552360,211921,"AmerisourceBergen Corporation, Q1 2012 Earnings Call, Jan 26, 2012",2012-01-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, this conference will be available for replay today after 1:00 p.m. through February 2, 2012 at midnight. You may access the AT&T Teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering the access code 231917.",72,"Ladies and gentlemen, this conference will be available for replay today after 1:00 p.m. through February 2, 2012 at midnight. You may access the AT&T Teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering the access code 231917. International participants, please dial (320) 365-3844, access code 231917. That does conclude our conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by and welcome to the ABC's Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Ms. Barba",46,"Ladies and gentlemen, thank you for standing by and welcome to the ABC's Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Ms. Barbara Brungess. Please go ahead."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you. Good morning, everyone and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 second quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve Collis",164,"Thank you. Good morning, everyone and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 second quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve Collis, AmerisourceBergen's President and CEO; and Tim Guttman, Vice President, Controller and acting CFO.
During the call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011.
Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by phone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, and good morning, everyone. I am pleased to report that AmerisourceBergen once again delivered solid quarterly results and our performance for the first half of our fiscal year 2012 positions us well to meet our objectives for the full year. In",2087,"Thank you, and good morning, everyone. I am pleased to report that AmerisourceBergen once again delivered solid quarterly results and our performance for the first half of our fiscal year 2012 positions us well to meet our objectives for the full year. In the March quarter, our revenues were up 2% to $20.1 billion. Earnings per share were up 5% to $0.81, and that's on top of a 22% increase in the prior year. We generated $236 million in operating cash flow, and we repurchased $200 million of our shares. I'm especially proud that we overcame a challenging comp 2 this quarter last year and exceeded our internal profit goal for each decision it. 
During that quarter, we also made excellent progress integrating recent acquisitions and working towards the closing of our World Courier acquisition. Our strong cash generation and high-quality balance sheet continue to provide us with outstanding financial flexibility and give us the ability to fund our strategic initiatives, grow our business and return funds to shareholders. 
AmerisourceBergen is fortunate to be an important part of a growing industry. Demographics and initiatives aimed at expanding access to healthcare and coverage -- and healthcare coverage, should continue to drive organic growth in our industry over the next several years. In addition, launches of new pharmaceuticals, as well as new indications for existing drugs should also drive sales growth over the next several years. Whether the new therapies are traditional or medications with complex biotech pharmaceuticals, AmerisourceBergen is well positioned to not only benefit from the distribution of new products, but also to offer prelaunched and commercialization services to manufacturers and to support patient access and reimbursement programs to help ensure that patients have access to large saving therapies and that the products achieve their potential in the marketplace. 
At our revenue base positions us well organic growth driven by demographics, and our customer mix puts us in a favorable position to continue to benefit from the historic influx of generics. As you know, generics mitigate the topline dollar growth in our industry that drive tremendous value for wholesalers, healthcare providers and patients alike. In addition, close scrutiny of healthcare expenses and cost-containment efforts underway by the federal government and other payers also drives demand for our services, most notably in our Consulting Services group. Over the last several years, we have significantly strengthened our relationship with pharmaceutical manufacturers and we continue to look for meaningful ways to provide additional services across the supply channel to help them ensure that they need the challenges of today's changing healthcare landscape. As our provider customer face similar charges regarding cost-containment and reimbursement for services provided to patients, they increasingly turn to AmerisourceBergen. We're helping in making their healthcare practices run as efficiently and effectively as possible. 
I'll provide our customers work hard everyday to provide world-class patient care, and we believe they deserve fair reimbursement for the professional services they provide. AmerisourceBergen is an active participant participating in policy discussions in Washington, D.C. with objective of helping legislative understand our industry and our importance to our healthcare systems. 
Our associates are focused on meeting objectives for the year both in terms of providing outstanding service to customers and in our financial performance. They continue to see creative ways to meet the challenges in the diverse markets we serve and identify new opportunities to add value through collaborative innovation and by maximizing efficiency. I take great proud and enthusiasm and dedication and it is my honor to work beside them. 
Turning now to our business units. AmerisourceBergen Drug Corporation as expected had flat revenue for the quarter as strong performance in the institutional segments was offset by the previously disclosed loss of a large retail customer. Topline growth was also mitigated by the impact of generic convergence including decreased sales to our largest customer. Our ABDC associate did a stellar job managing several generic launches including 5 different generic products that launched within 1 week. Year-to-date, the generic launches have performed as planned and we, of course, look forward to several more launches due to come in the second half of the year. With over 4,600 members, our Good Neighbor Pharmacy network, the third largest network of pharmacies in the U.S. continues to play a crucial role in providing pharmacy care nationwide. Patients preferred choice determining prescriptions and our retail customers are very adept at fulfilling unique patient needs and is adapting to the changing needs is at the marketplace. 
Our ASP implementation continues to run smoothly with 8 distribution centers conversions, 8 distribution conversions complete, 2 additional conversions occurring tomorrow, and the remainder plans at the beginning of 2013. As we have gained expense with the new system, particularly without corporate and back-office functions, we have a ready began to realize some operational savings, which is reflected in part in a good performance we had on the expense line this quarter. Our investments in our Canadian operations to support significant new business wins continued in the March quarter. Our associates have done a tremendous job setting up 4 new distribution centers in 6 months in order to support this new business. There is still much work to be done, but we are confident that our expansion efforts will meaningful increased the value would bring to both independent pharmacies and especially provided in the Canadian market. 
As we noted in the press release, following the closing of the merger with Express Scripts and Medco in early April, we amended our existing Medco agreement to provide for the contract to end upon award and implementation of one or more new Pharmaceutical Distribution agreement with the newly combined business. Express Scripts has issued an RFP for the combined business and anticipate that the new contract or contracts will begin on October 1, 2012. We are participating fully in the competitive RFP process and we intend to pursue this opportunity to retain or grow the business under a new contract. We have had an excellent working relationship with Medco where for over 2 decades and we are excited about the opportunity to demonstrate the value we can bring to the newly combined entity. 
AmerisourceBergen Specialty Group had another strong quarter with revenues up 6% with particularly strong performance in third quarter logistics and in our vaccine and physician business. Our oncology business performed well while facing a very difficult comparison due to the strong performance of the 3 large specialty generic products last year. While our Specialty Group is based for our oncology franchise, we are an instrumental part of the commercialization strategy for any infusible product launched into the physician marketplace. We continue to execute very well on the launch of a new brand of product establishing significant market share in what was the first folk quarter of the introduction. Our Specialty Group often collaborates with our Consulting Services group to help ensure patients have access to products by utilizing the full suite of capabilities of our physician networks, as well as our reimbursement and patient support program expertise. For example, we recently held a manufacture launch a new biotech product. And during the March quarter, we were able to not only achieve the leading market share for the distribution of the product, but also to provide third-party logistics, contract packaging and all of the reimbursement and patient support programs for the product across the market. We are very proud that these combined service offerings provide unmatched value to manufacturers and distinguish AmerisourceBergen in the marketplace. As we look at the products in development pipelines today, we believe that we will win even more of these opportunities in the future, which will be an important driver of our growth in the years ahead. 
Our Consulting Services group delivered a very strong quarter, while making excellent progress in the integration of TheraCom and Premier Source, which are both performing very well. The last group had the strongest quarter in the history even without the contributions from TheraCom. While the group only represents about 2% of our revenues, we believe our packaging and consulting services provide essential expertise to pharmaceutical manufacturers to help ensure that their products are brought to market as safely, quickly and efficiently as possible. In addition, our reimbursement expertise helps ensure that patients who can benefit from growth new and matured therapies have access to the products. 
We continue to make good progress towards closing our most recent acquisition World Courier. As we deepen our knowledge and understanding of their business, I am more convinced than ever that World Courier affords us the opportunity not only to acquire the market leader in premium niche clinical trial logistics services but also to begin to build out a framework to expand our consulting and commercialization services beyond North America. 
In this current quarter, we will begin operating in 50 new international markets and employ about 1,500 new associates outside North America. This is significant expansion for ABC and we are tremendously excited about welcoming the World Courier team to ABC. 
In addition, we are storing ways to potentially our niche Specialty Distribution service into select markets as well. We expect to close the acquisition next week at the end of April, and I'm very excited about the potential we see in the World Courier platform in the years ahead. 
Given the continued strength of our balance sheet, we continue to look for acquisitions that meet the criteria we've had in place for quite some time. They should increase our value offering to existing customers both up and down the channel. They should be within our established core competency and they should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions and we continue to be interested in opportunities in pharmaceutical and Specialty Distribution and Services, as well as consulting and packaging services. While we historically have been very comfortable in the $200 million to $300 million range, we will consider selling larger as we did with World Courier if it made a good strategic sense and will deliver value to our company on our shareholders. 
Looking ahead, the results we've had in the first half of our year have positioned us well to meet our objectives for the full fiscal year. We have a difficult comparison to overcome in 2012, but we continue to expect GAAP earnings per share to be within the range of 2.74 to 2.84, and we are tracking towards the midpoint of that range. Tim will provide the details in our assumptions for the remainder of the year, but I want to highlight that we continue to remain disciplined on expenses, our cash flows are strong and we have increased our share repurchases assumption for the year. Looking further ahead to 2013, we should have a carryover from some of the launches that occurred late in our fiscal 2012 including the relaunch of Oxaliplatin and we should begin to benefit from the completion of our ASP implementation. In fiscal 2014, we should begin to see this 30 million to 40 million uninsured patients enter the healthcare market, driving demand for pharmaceuticals that should carryover into 2015 and beyond. In addition, 2014 and 2015 are expected to be good years for generic conversions. And, of course, there's a chance that may also come to market in a timeframe. 
Before turn it over to Tim, I want to reiterate the confidence that I have in our business and in our future. The modest product is strong for the products we distribute and we play essential role in pharmaceutical supply channel. We have positioned ourselves well to continue to benefit from the 2 key growth drivers, generics and specialty products, and we'll continue to invest in our distribution and in our services businesses. Over the last year, we were summating 4 investment in other areas of our business with an eye to the future. We expect demand in the specialty products to consider grow not only the U.S. but throughout the world and the commercialization and reimbursement support services we provide to manufacturers will help support that growth. As cost containment, if it continues to cross the healthcare landscape, our customers increasingly turn to us for help in meeting the challenges of the marketplace without sacrificing patient care. Finally, the vision and innovative ideas that our associates brings to market everyday help support in our industry, and I am proud to be their leader. Here is Tim."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Steve, and good morning, everyone. It's my pleasure to be participating in my first earnings call as acting CFO. And I am pleased to report another solid ABC quarter, and most importantly, that our Q2 results are on track with our internal plan",1505,"Thank you, Steve, and good morning, everyone. It's my pleasure to be participating in my first earnings call as acting CFO. And I am pleased to report another solid ABC quarter, and most importantly, that our Q2 results are on track with our internal plan. The highlights this quarter: Excellent topline growth at our Specialty and Consulting businesses, very good execution on new generic launches and continued focus on expense management across the organization. And finally, another quarter of strong cash generation. 
Now let's turn to the quarterly details and starting with the topline. Revenues were $20.1 billion, a 1.6% increase over last year's quarter. Drug company revenues were essentially flat, as we guided. We had strong performance in our alternate site and health system segments, offset by the loss of a large chain customer last year, as well as the impact from brand to generic conversions. 
The Specialty Group revenues increased 6% led by 2 of our businesses with above market growth. ICS, our third-party logistics business and Besse Medical, our vaccine and position office distribution business, which benefited from a full quarter impact of sales of a new ophthalmology drug. 
The Consulting group, though small to the overall topline, continues to perform well. Excluding their TheraCom acquisition, they had over 20% topline growth. TheraCom contributed just under 1% of our overall revenue growth in the quarter. 
Moving to gross profit. Gross profit was $695 million in the quarter, up 1.1% from last March with a gross margin of 3.46% in the quarter, down about 2 basis points from last year. As we have discussed in the past, our second quarter was a very top comp due to the significant contribution in the prior-year from oncology generics. In the second quarter of 2011, these oncology drugs contributed about $0.16 of EPS to our results. Our gross margin expanded 31 basis points in the March 2011 quarter. This year, we are able to effectively offset this headwind with contributions from the new Oral Solid generics. As well as the lower contribution from oncology generics, and gross profit contributions from our acquired companies. Additionally, our LIFO charge was approximately $4 million in the quarter, down $10 million from last year. We continue to expect our LIFO charge will be approximately $15 million, down significantly from last year. Our annual LIFO forecast is based on our expectation that brand price inflation will be somewhat less this year. And more importantly, we will see significant generic price deflation in the second half of our fiscal year related to key brand to generic conversions coming off exclusivity. 
Finally, the benefit we received from the new generic launches and also price appreciation was in line with our expectations. This quarter, we did an excellent job controlling our operating expenses. Operating expenses were approximately $327 million, up 1.5%. However, this amount includes the operating expenses of about $11 million from our recently acquired companies. Additionally, we had $9 million of executive severance and acquisition-related transaction costs. Operating expenses would've been down, excluding the impact of our acquisitions, due to lower compensation costs including benefits. 
Additionally, our SAP implementation is progressing well at the corporate level. The system has reached a level of stability faster than we expected enabling us to realize some early savings, especially with external consultants. 
Last quarter, our guidance was an annual expense increase of about 3% due to our acquisitions. As an organization, we continue to exercise discipline and focus on managing expenses. We now expect our total operating expenses for our base business before adding World Courier to be essentially flat for the year. 
Operating income of $368 million in the quarter increased, about 1%, while operating margin was down 2 basis points compared to last March. Our current quarter was slowed by the $9 million of executive severance and acquisition transaction costs. Excluding these non-recurring expenses, our operating income margin would've expanded 3 basis points to 1.88%. 
Moving below the operating income line, interest expense of nearly $24 million in the March quarter increased 25% compared to last year, primarily as a result of our $500 million bonds we issued back in November. The proceeds helped to fund the TheraCom acquisition and will also contribute to the retirement of our 2012 bonds that mature in mid-September. Our effective income tax rate of 38.4% was slightly higher than last year's 38.1%, and is right in line with our expected annualized rate of 38.4%. 
Our diluted GAAP earnings per share in the quarter of $0.81 increased by $0.04, or 5%, over the same quarter last year. And again, overcoming a $0.16 headwind from the contribution from specialty generics in the March 2011 quarter. Our EPS benefited from a reduction in our average diluted shares related to our ongoing share repurchase program. Average diluted shares for the quarter were approximately 262 million, down just over 6% from last March. 
Now let's turn to our balance sheet and cash flows, where trends continue to be very favorable. We generated $236 million of cash from operations in the quarter, bringing our 6-month total to $668 million compared to generating $577 million for the first 6 months last year. We continue to manage AR and inventory level very closely and this has benefited our working capital this year. With our daily revenue volume exceeding $300 million per business day, our quarter end working capital snapshots are subject to volatility. Therefore, our 6-month cash results cannot be extrapolated to determine a full-year cash flow estimate. 
Capital expenditures were $40 million in the quarter and $88 million for the 6 months. During the last 2 years, we put a number of capital projects on hold as we focused on SAP. We have a pipeline of attractive internal projects that we have begun to pursue as our SAP deployment moves along. Additionally, we have CapEx associated with our recent TheraCom acquisition. Because of this, we will exceed our previous target of $150 million for CapEx, and we will be closer to $200 million for the year. Even with this additional CapEx, we expect that our free cash flow will now be in the $800 million to $900 million range. 
During the quarter, we brought back $200 million of our shares. For 6 months, we've purchased $320 million of shares. At March 31, we have approximately $180 million left on our current share repurchase authorization. In terms of key financial metrics that we track, our average day sales in inventory for the quarter remained at 14 days, consistent with fiscal '11. Average DSOs of 18 days in the March quarter were up slightly from 17.3 days last year. And favorable payables timing helped raise average quarterly DPOs by over 3 days compared to Fiscal '11. 
With our recent debt offering, our gross debt to total debt in capital ratio at the end of March was 39%, above our target range of 30% to 35%. And it will remain above the range until we pay off our $400 million of debt in September. Our cash balance at March 31, was $2.3 billion. Keep in mind that we will be funding our World Courier acquisition from cash and we will be paying down debt in September, as previously mentioned. After these 2 large cash outlays, we will still have financial flexibility to fund CapEx and strategic initiatives and return to capital -- and return capital to our shareholders. 
Now let's turn to updated fiscal 2012 guidance. We expect our diluted GAAP EPS to track to the middle of the range we previously provided, $2.74 to $2.84. Our assumption for revenue growth remains unchanged, flat-to-modest revenue growth. We expect our operating margin expansion to be in the high single-digit basis points. Free cash flow will now be in the $800 million to $900 million range. And we are raising our guidance for share repurchases for the year to $500 million, which will complete our current share repurchase authorization. 
Looking ahead, I would like to remind everyone that Q3 is another challenging comparison for us because of the $0.17 EPS contribution from oncology generics last year. Also in Q3 2012, we have 2 of the large generics coming off exclusivity. When looking out to the second half of the year, we believe Q4 will be somewhat of an easier comparison with the return of Oxaliplatin for half a quarter, a few favorable year end generic launches for our drug company and favorable expense comparisons year-over-year. 
So before I turn it back to Barbara, let me reiterate that 6 months into the fiscal year we are performing well in our key areas of the business and we are well positioned to meet our financial targets for fiscal 2012. One final point, I'd like to take a moment and thank our ABC associates, especially those in the finance and accounting areas that have stepped up the largest 2 months and help support the organization and me in particular during our CFO transition period. Thanks, everyone. Here's Barbara to start our Q&A."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","[Operator Instructions] Operator, we are now ready to open the line for questions. [ Go ahead, operator.",17,"[Operator Instructions] Operator, we are now ready to open the line for questions. [ Go ahead, operator."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Glen Santangelo from Credit Suisse.",15,"[Operator Instructions] Our first question comes from the line of Glen Santangelo from Credit Suisse."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I just wanted to quickly follow up, Tim, with respect to some of your comments on the operating margin expansion goals for the year. Previously the company had expected operating margin expansion in the high single-digit, kind of low double-digit range, n",93,"I just wanted to quickly follow up, Tim, with respect to some of your comments on the operating margin expansion goals for the year. Previously the company had expected operating margin expansion in the high single-digit, kind of low double-digit range, now it seems like you're suggesting high single-digit. I guess, could just give me a sense for maybe what has changed in that thinking? And I know there were some onetime costs that you're now embedding in your estimates, and I'm curious if there's anything else that I should be thinking about?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, we changed our guidance to high single digit. In terms of looking out, we did an assessment of the full year, and looking out, we had some deal costs in Q2 and some onetime items, non-recurring items. And as we look out, we're going to have some simil",90,"No, we changed our guidance to high single digit. In terms of looking out, we did an assessment of the full year, and looking out, we had some deal costs in Q2 and some onetime items, non-recurring items. And as we look out, we're going to have some similar costs in Q3 with the World Courier transaction. So when we look out and do a reassessment, we felt more comfortable that high single-digit was a realistic target for us for the year, and there's really nothing else factored into that."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And, Tim, maybe if I could just ask a follow up on the World Courier group, you originally sort of guided $0.06 to $0.10 worth of accretion and I'm kind curious is there anything embedded from an accretion standpoint in your fiscal '12 guidance as it rela",83,"And, Tim, maybe if I could just ask a follow up on the World Courier group, you originally sort of guided $0.06 to $0.10 worth of accretion and I'm kind curious is there anything embedded from an accretion standpoint in your fiscal '12 guidance as it relates to World Courier? It kind of sounds like you're going to be taking down some integration costs or acquisition related costs next quarter. I don't know if you do the size of it at this point?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Glen, no. You will have some transaction related acquisition costs in Q3. Probably not more than the number that we had for Q2. And there is no accretion in our numbers for this fiscal year. We expect it to be neutral. And in terms of next year for fiscal",60,"Glen, no. You will have some transaction related acquisition costs in Q3. Probably not more than the number that we had for Q2. And there is no accretion in our numbers for this fiscal year. We expect it to be neutral. And in terms of next year for fiscal '13, we're still confident with that guidance of $0.06 to $0.10."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Larry Marsh with Barclays Capital.",10,"Our next question comes from Larry Marsh with Barclays Capital."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","So my question is as follows. And Medco, here you're communicating -- I guess, is it fair to say that you voluntarily to move out the termination date of your Medco relationship by 6 months? And if so, is there any benefit for doing so. And possibly for g",94,"So my question is as follows. And Medco, here you're communicating -- I guess, is it fair to say that you voluntarily to move out the termination date of your Medco relationship by 6 months? And if so, is there any benefit for doing so. And possibly for going that profit stream? And then just around the topic, I wanted to confirm, you said you already have a relationship with Express Scripts how long have you had that? And then have you disclosed the comment about the mix of the contract under the RFP."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","First of all, obviously, we are part of a very active process here and we wanted to be respectful of that and some of the questions should really be directed to the buyer. But I think ABC, as you know, has been very proud of the services to Medco and now",187,"First of all, obviously, we are part of a very active process here and we wanted to be respectful of that and some of the questions should really be directed to the buyer. But I think ABC, as you know, has been very proud of the services to Medco and now you could on the shape we are in coming here because we've had such a long relationship. So we wanted to demonstrate the flexibility. We wanted to recognize that this is a new entity that has requirements and we'll have a different dynamics to relationship. And now would just made sense for us to be concurrent with the current requirements. So we demonstrated flexibility. We demonstrated that ABC is a good partner and listened to our customers and I think that, that will hopefully put us in a good position throughout the contracted process but it will be competitive. I guess the only internal benefit I can point is that it is concurrent with our fiscal year, whatever happens we'll be in a good position to plan for it and to communicate that to our investors."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","It sounds like you're coming to me that the length of the contract is proposed in the RFP at this point?",22,"It sounds like you're coming to me that the length of the contract is proposed in the RFP at this point?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","As far as we know, as far as we can say, it's pretty standard on top of contract term.",19,"As far as we know, as far as we can say, it's pretty standard on top of contract term."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Maybe 3 years, and I guess just a follow-up to you and Tim around ASP of implementation, I appreciate the update there. If the cup and remember some of the bigger expenses of this seemed to be fiscal '10 and '11, $40 million to $50 million a year, you've",78,"Maybe 3 years, and I guess just a follow-up to you and Tim around ASP of implementation, I appreciate the update there. If the cup and remember some of the bigger expenses of this seemed to be fiscal '10 and '11, $40 million to $50 million a year, you've mentioned, Tim, stability sooner than you thought. Can you ballpark kind of expenses around SAP for this year and how do we think about that comparable to next year?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Larry, our guidance has been that we'll see some benefits for SAP next year. 6 months after our last DC deployment so we expect that to be in Q4. It guided to $10 million, we expect the full benefit of about $40 million to be in '14. And so far the benefi",101,"Larry, our guidance has been that we'll see some benefits for SAP next year. 6 months after our last DC deployment so we expect that to be in Q4. It guided to $10 million, we expect the full benefit of about $40 million to be in '14. And so far the benefit that we had this year for SAP is really incremental for that. I mean, this is just expense that we've been able to take out of our operating budget, which is probably be in a few million dollars. So again, there a separate, one's not part of the other."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And I got it, expenses associated with consultants and such, but your $10 million incremental next year $40 million for '14, and then just to clarify, I think it's an important point, the guidance confirming the range but you're suggesting the $0.02, whic",73,"And I got it, expenses associated with consultants and such, but your $10 million incremental next year $40 million for '14, and then just to clarify, I think it's an important point, the guidance confirming the range but you're suggesting the $0.02, which was a severance and transaction cost this quarter and the $0.02 which ballpark of transaction cost next quarter are included in that range, and not breaking that out at all?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, absolutely, Larry, we're GAAP and we include than in.",10,"No, absolutely, Larry, we're GAAP and we include than in."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And again using you're saying that's a big reason why you're top line the operating margin expansion has been put down?",22,"And again using you're saying that's a big reason why you're top line the operating margin expansion has been put down?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Absolutely.",1,"Absolutely."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Robert Jones with Goldman Sachs.",10,"Our next question comes from Robert Jones with Goldman Sachs."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Just to go back to the Express Scripts contract. Steve, it sounds like you mentioned contract or contracts so I'm assuming there are some suggestion that it could be broken out. And insight into this of you were maybe more importantly, what benefit that w",53,"Just to go back to the Express Scripts contract. Steve, it sounds like you mentioned contract or contracts so I'm assuming there are some suggestion that it could be broken out. And insight into this of you were maybe more importantly, what benefit that would create for Express to have this contract separated?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think in terms of processing, there's not much differentiation between $10 billion contract or $15 billion, or $20 billion contract, it's just that is the way these large contracts tend to go. And it could be some geographical, regional benefit ba",96,"Well, I think in terms of processing, there's not much differentiation between $10 billion contract or $15 billion, or $20 billion contract, it's just that is the way these large contracts tend to go. And it could be some geographical, regional benefit based on where they're planning to their large mail order stocks, they could be a way to separate the specialty business with the core mail-order business. So we have 2 big specialty units, so, but again, these are questions that we'd probably, are not comfortable commenting on the quality, be directed to Express Scripts."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I definitely appreciate that. And I guess a follow-up, Steve. Given the somewhat more inquisitive nature of the company as of late, and I know you've gotten this question before, and I imagine as you continue to do acquisition you might get it more in a f",72,"I definitely appreciate that. And I guess a follow-up, Steve. Given the somewhat more inquisitive nature of the company as of late, and I know you've gotten this question before, and I imagine as you continue to do acquisition you might get it more in a future, relative to your peers. any thoughts or discussions between you and Tim moving to a cash EPS or at least breaking out a cash EPS?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, we haven't. We think we report not only good earnings, but very hard quality earnings. And at the moment, that hasn't been under consideration.",25,"No, we haven't. We think we report not only good earnings, but very hard quality earnings. And at the moment, that hasn't been under consideration."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","And we, in our public company filings, we feel we give pretty good disclosure on some of those differences especially around intangibles. And the reader of those documents can go ahead and do that calculation.",35,"And we, in our public company filings, we feel we give pretty good disclosure on some of those differences especially around intangibles. And the reader of those documents can go ahead and do that calculation."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Tom Gallucci with Lazard Capital.",10,"Our next question comes from Tom Gallucci with Lazard Capital."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I was wondering if you could expand on some of your prepared remarks around sort of international and how you see the opportunity may be there? Not the near-term necessarily but the next few to 5 years, it sounds like maybe World Courier is a bit o",66,"Steve, I was wondering if you could expand on some of your prepared remarks around sort of international and how you see the opportunity may be there? Not the near-term necessarily but the next few to 5 years, it sounds like maybe World Courier is a bit of a platform that you could grow from it in different ways, so any thoughts it would be appreciated."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well there's a couple of things. First of all, again, we do $300 million in revenue a day as ABC, but one of the things we've been very happy with this our specialty performance in Canada. This is this market works differently than it does in the U.S., bu",359,"Well there's a couple of things. First of all, again, we do $300 million in revenue a day as ABC, but one of the things we've been very happy with this our specialty performance in Canada. This is this market works differently than it does in the U.S., but we've been able to do some joint programs, we've been able to help with more complex, environment there including a very robust product market that is not generally known. At least here in the U.S. we think about it as single-payer market, that hasn't been the case. We've been able to help, we have a very strong presence with new infusible products. So what we've seen is a manufacturer environment that ABC is very comfortable in contracting with that is looking for us to get into more countries. So we've been prompted to look into international opportunities by manufacturers. Then comes World Courier we're in 50 new countries as of next week, hopefully. We have 1,500 associates that are very tenured. We've been actually impressed with the quality of the World Courier associates. As you know, healthcare is very local. So we think that we have an opportunity to understand healthcare markets both organic and inquisitive opportunities with people on the ground there who speak the language, and know the trends, know who's the rock players, the ethical players, the hard quality players in that environment, and we think that, that's going to give us good opportunity. Also think that as of the product at that World Courier is managing are commercialized, as more and more of those products are commercialized and come to market as middle classes is growing in some countries that we haven't traditionally thought about as being sort of specialty consumers and products, we think we're going to have an opportunity to participate in those commercialization strategies. think about it, World Courier has handled those products, they know that treatment, they know the environment, we think that we have to recharacterize part of the business but we think we can do this. So long answer, but as you can tell, I'm very enthusiastic about this."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Sure, that's clear. And maybe just one housekeeping item. On the CapEx, can you sort of breakdown your maintenance CapEx versus maybe what's additional and some of those projects that you highlighted earlier. Did they say next year, should we assume it co",56,"Sure, that's clear. And maybe just one housekeeping item. On the CapEx, can you sort of breakdown your maintenance CapEx versus maybe what's additional and some of those projects that you highlighted earlier. Did they say next year, should we assume it come back down a little bit, or how should we be thinking about that?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Good question. When we look at maintenance CapEx, we think it's to be between $100 million and $120 million. We have big projects this year supporting our expansion up in Canada. We're looking at another DC project in the U.S. in terms of expansion and au",85,"Good question. When we look at maintenance CapEx, we think it's to be between $100 million and $120 million. We have big projects this year supporting our expansion up in Canada. We're looking at another DC project in the U.S. in terms of expansion and automation, renovation and our TheraCom acquisition. So I would say that the $200 million is probably a peak and it definitely should come down next year probably about half of the maintenance CapEx is probably a good, kind of, range."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from the line of Robert Willoughby from Bank of America Merrill Lynch.",16,"Our next question comes from the line of Robert Willoughby from Bank of America Merrill Lynch."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, what kind of clarity do you actually have on -- this RFP provide for you. I mean I assume you would have sized the potential contract, the mail footprint you'd be serving whether or not specialty would be there. I mean, there are some things you I",63,"Steve, what kind of clarity do you actually have on -- this RFP provide for you. I mean I assume you would have sized the potential contract, the mail footprint you'd be serving whether or not specialty would be there. I mean, there are some things you I mean, there are some things you could disclose there that would be helpful for us."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","I think we partly said, Bob, I appreciate your interest in this and believe me, I am really interested in this and the ABC team is very interested in this. We're just participating fully in the RFP process, it has just begun. So I could tell you we really",119,"I think we partly said, Bob, I appreciate your interest in this and believe me, I am really interested in this and the ABC team is very interested in this. We're just participating fully in the RFP process, it has just begun. So I could tell you we really don't -- we think it's in the range of about $20 billion contract. So I will tell you that make our peak with ABC at about 19% of our revenues in fiscal year 2011 and it has come off of a few percent from that, kind of run rate is more in the mid-teens, 16% range. So we could potentially gain some couple of billion dollars in new revenue here."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And any sense on how you're time and when a decision will ultimately be made, obviously, before October 1, but how much time would you need and anticipate, if you win this, is that investment you need to make or in an unfortunate event you don't win",63,"Okay. And any sense on how you're time and when a decision will ultimately be made, obviously, before October 1, but how much time would you need and anticipate, if you win this, is that investment you need to make or in an unfortunate event you don't win, what kind of offsets we might see to your cost structure, some initiatives you pursue?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, we're mainly servicing the current businesses in 3 DCs and we certainly would start giving consideration to what it could mean if we lose. But from a more exciting basis, I think we do have the capacity to service this business without matching them",70,"Well, we're mainly servicing the current businesses in 3 DCs and we certainly would start giving consideration to what it could mean if we lose. But from a more exciting basis, I think we do have the capacity to service this business without matching them from investments. And we look forward to talking about the different capabilities that ABC brings to the table. And we're participating fully in this contract."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And, Steve, anything.",3,"And, Steve, anything."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, I just think you cover Express Scripts, you know they move quickly, I so can tell you that the feet. So we expect you to have a very active and quick and decisive process unlike this other very public contract that we went through very recently. So th",67,"No, I just think you cover Express Scripts, you know they move quickly, I so can tell you that the feet. So we expect you to have a very active and quick and decisive process unlike this other very public contract that we went through very recently. So that should make everyone happy, at least, but we don't know where we said very quickly, we believe so."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Ricky Goldwasser with Morgan Stanley.",10,"Our next question comes from Ricky Goldwasser with Morgan Stanley."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Just quick wrap-up of the Medco Express side, what I want to understand specialty is included with your relationship with Medco. Should we assume that the services that you provided to Medco on a specialty side are more of wholesale type services or deals",57,"Just quick wrap-up of the Medco Express side, what I want to understand specialty is included with your relationship with Medco. Should we assume that the services that you provided to Medco on a specialty side are more of wholesale type services or deals that provide them added value services that's associated with your specialty business?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","We are both the wholesaler to the former division of Medco Express Scripts. We have, obviously, work very collaboratively with them in many areas including the hospital, pharmacy area and the specialty area. So I'm more can comment on any particular progr",85,"We are both the wholesaler to the former division of Medco Express Scripts. We have, obviously, work very collaboratively with them in many areas including the hospital, pharmacy area and the specialty area. So I'm more can comment on any particular program, but certainly it's our largest customer, we spend a lot of time working on common approaches to the marketplace and we would expect to bring that expertise and that market knowledge, and the manufacturer relationships that we have to the combined entity now."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And then. A couple of just questions from for modeling purposes. For the SG&A level for the remainder of the year, should we assume same level as we saw in the March quarter or should we see a step up, and if so, can you quantify for us and is it related",55,"And then. A couple of just questions from for modeling purposes. For the SG&A level for the remainder of the year, should we assume same level as we saw in the March quarter or should we see a step up, and if so, can you quantify for us and is it related to World Courier."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","We, at this point Ricky, we don't have World Courier finished yet, completed. But definitely with World Courier coming in 2 months in quarter 3 and we'll have the entire Q4. They will add extra expense. And when I gave the guidance today this morning, aga",91,"We, at this point Ricky, we don't have World Courier finished yet, completed. But definitely with World Courier coming in 2 months in quarter 3 and we'll have the entire Q4. They will add extra expense. And when I gave the guidance today this morning, again, I was talking about the core business being that for the core business, we will see a little bit of a step up in Q3, but probably not dramatic. And again, we will have some non-recurring acquisition related cost in Q3, probably not in Q4."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And then can you just clarify to us the income from a basis point perspective of the acquisitions on the margins for this quarter?",25,"Okay. And then can you just clarify to us the income from a basis point perspective of the acquisitions on the margins for this quarter?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","In terms of SG&A.",5,"In terms of SG&A."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","SG&A or operating margin.",5,"SG&A or operating margin."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well again, we commented that we had about $11 million of SG&A expense in the quarter from our acquisitions primarily TheraCom. So again, it's probably 4, 3, 4 basis points.",30,"Well again, we commented that we had about $11 million of SG&A expense in the quarter from our acquisitions primarily TheraCom. So again, it's probably 4, 3, 4 basis points."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Eric Coldwell with Robert W. Baird.",11,"Our next question comes from Eric Coldwell with Robert W. Baird."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I think a lot of the timely questions have been answered, so I'll shift gears a bit. Health systems and alternate site in your drug company sounds like another good quarter there, above market growth perhaps. I'm curious if you can define what's leading t",120,"I think a lot of the timely questions have been answered, so I'll shift gears a bit. Health systems and alternate site in your drug company sounds like another good quarter there, above market growth perhaps. I'm curious if you can define what's leading to this growth. It must be share capture, I don't want to lead you too much, but the market's clearly not growing at a rapid pace. You're doing pharmaceuticals and not the other broad and service lines or other services to the health systems. So could you just give us a better sense on what's driving that growth in health systems and alternate sites and perhaps if you could frame it, that will be helpful to."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well with health systems, we think we have the market share that is at least comparable, maybe in the largest in the U.S. And we believe we're with the right customers, we believe that we'll be growing with them. We believe that we have some hospital serv",253,"Well with health systems, we think we have the market share that is at least comparable, maybe in the largest in the U.S. And we believe we're with the right customers, we believe that we'll be growing with them. We believe that we have some hospital services that we provide that maybe don't get the headlines but they are all additive to their business like helping them with 340B consulting, helping them with pharmacies. So we have ever good practice in health systems and we believe we're with the company's and other leaders in that space and I think obviously some of our. Likewise with alternate care, I think ABC has been a leader there. Certainly our knowledge of specialty and our ability to offer an integrated solution on the specialty and drug wholesale side and our knowledge of the manufacturing environment and the patient environment and the reimbursement environment has been very, very helpful. And the Humana contract we think was a direct result of that knowledge and that's a very fast grower. a lot of the companies that are growing faster than the market and when we discussed potential RFP responses, we look at whether we think will be the winners at a certain space and we like to really target them and try to get them into the ABC portfolio. So I think you could look at it as they mutter of happenstance it's a matter of strategically planning the accounts that we believe will be winners in this space."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Great answer, Steve. Could you put a frame around the growth rates in those 2 segments?",16,"Great answer, Steve. Could you put a frame around the growth rates in those 2 segments?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","I think we can maybe look at that and invest it out.  I think we've gotten some of that in the past. But we don't have a framework that we can share right now.",34,"I think we can maybe look at that and invest it out.  I think we've gotten some of that in the past. But we don't have a framework that we can share right now."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Lisa Gill with JPMorgan.",9,"Our next question comes from Lisa Gill with JPMorgan."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I think that you made a comment earlier around your expertise for LIFO this year and within that comment, Tim, I think you talked about branded price inflation being last and more deflation on the generic side. Can you maybe just talk about what actually",103,"I think that you made a comment earlier around your expertise for LIFO this year and within that comment, Tim, I think you talked about branded price inflation being last and more deflation on the generic side. Can you maybe just talk about what actually saw in this quarter and then what you are seeing in the marketplace around an increase in competition as far as the number of generic manufacturers to spend a nice steady state at the last couple of years, are you seeing a trend that's perhaps changing a little bit if we go through the next couple of months?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","In terms of, when I speak of LIFO, just let me say that we look at it at our portfolio of drugs, which in our mix, and in terms of brand, last year we had pretty healthy price increases for brands, slightly above 8%. This year, we're tracking slightly bel",151,"In terms of, when I speak of LIFO, just let me say that we look at it at our portfolio of drugs, which in our mix, and in terms of brand, last year we had pretty healthy price increases for brands, slightly above 8%. This year, we're tracking slightly below 8% again for our mix of inventory. so a little bit different, a little bit lower. But on the generic side, we really expect that we'll see some deflation second half of the especially in Lipitor and Oxaliplatin generics when they come off exclusivity which will help then get us a LIFO benefit. In terms of your second question about suppliers. I mean, last year we also had a pretty good price appreciation on the generic side. It's still pretty good but that's probably off a little bit this year, it softened a little bit this year, but still pretty healthy."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","okay, great about that Steve, just one quick question for you on the oncology side of the business. I know we do a number of these pilot programs that have shared United around the way they're paying their physician and trying to take the drive cost out o",100,"okay, great about that Steve, just one quick question for you on the oncology side of the business. I know we do a number of these pilot programs that have shared United around the way they're paying their physician and trying to take the drive cost out of the question, are you seeing that impact your business at all? And what are the physicians say ended the stakeholder, what does that need of return? would that change the relationship we have in the physician, we now have relationship with one of the managed-care companies, how should we think about that?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, our strategy with the large payers is really 2 help them understand how important community oncology is. We believe that it's not only important from a clinical perspective but we believe that the patient is best served being in the community and ev",136,"Well, our strategy with the large payers is really 2 help them understand how important community oncology is. We believe that it's not only important from a clinical perspective but we believe that the patient is best served being in the community and even the payer is best served by your those patients being in the community. Our big effort over there is really to help bring the 2 sides together. We have taken a lot of infinite hard on physician services company, primarily focused on the oncology, to help the 2 sides communicate. to have a transparent relationship. And we don't anticipate having a direct relationship with the payer but we tend job our customers contract more effectively and more transparently with the payers and I think we are making a lot of progress there."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Your next question comes from David Larsen with Leerink Swann.",10,"Your next question comes from David Larsen with Leerink Swann."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","A question for, Tim. It looks like, put into my model, your SG&A costs on a year-over-year basis declined by about $12 million. Can you describe sort of the cost control process you go through on a quarterly basis?",39,"A question for, Tim. It looks like, put into my model, your SG&A costs on a year-over-year basis declined by about $12 million. Can you describe sort of the cost control process you go through on a quarterly basis?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Sure, David, I mean, when we looked at the year, we knew and we guided that Q2 and Q3 will be very tough comparisons, I mean, we knew it going on in to the year. and we put word out to our business is to really manage expenses this year. And we knew we ha",124,"Sure, David, I mean, when we looked at the year, we knew and we guided that Q2 and Q3 will be very tough comparisons, I mean, we knew it going on in to the year. and we put word out to our business is to really manage expenses this year. And we knew we had to focus in this area. So I mean, we looked hard at managing labor and payroll expense. We look at outside consulting and services and this year too, we've had some good discipline and credit collections and our bad debts are down. So really, it's all of our businesses focusing on headcount, on making sure they spend money prudently and that's been a carryforward into quarters 3 and 4."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And if I were to look at, like say 3% of SG&A in fiscal '11, I'm coming off with like $35 million. So for the incremental acquisition cost like World Courier group and these other ones, all in, that would be $35 million. And that's why they will be -- at",62,"And if I were to look at, like say 3% of SG&A in fiscal '11, I'm coming off with like $35 million. So for the incremental acquisition cost like World Courier group and these other ones, all in, that would be $35 million. And that's why they will be -- at least slight reduction the operating margin reduction guidance, is that correct?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, in terms of your question, the $35 million, no, I don't think the all in -- I mean, we should be under that number. So hopefully that helps you in terms of some guidance but, again, we think we're managing expenses well. We also had the benefit this",100,"Well, in terms of your question, the $35 million, no, I don't think the all in -- I mean, we should be under that number. So hopefully that helps you in terms of some guidance but, again, we think we're managing expenses well. We also had the benefit this quarter and we'll have for the rest of the year in terms of SAP being stable and we're seeing the benefits there. So all in all come I mean, I think what we're saying here is that expense management is offsetting the increases from the special charges and the non-recurring charges."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Great, and your merchandise inventory looked like it declined nicely on a sequential basis. Maybe an increase in cash flow guidance?",21,"Great, and your merchandise inventory looked like it declined nicely on a sequential basis. Maybe an increase in cash flow guidance?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Definitely, like David in my comments I've mentioned that we really focus on working capital. All of our businesses are focused on it. Managing AR, managing inventories, so we are seeing some really good reductions in those area, especially at our ABSG bu",43,"Definitely, like David in my comments I've mentioned that we really focus on working capital. All of our businesses are focused on it. Managing AR, managing inventories, so we are seeing some really good reductions in those area, especially at our ABSG businesses."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Operator, given we're approaching noon we'll have time for one more question.",12,"Operator, given we're approaching noon we'll have time for one more question."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Okay, our last question comes from the line of Steven Valiquette with UBS.",13,"Okay, our last question comes from the line of Steven Valiquette with UBS."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I guess, just one more question on ExpressNet, and here with the -- I think you mentioned in your comments in some ways you view yourselves of the primary incumbent on the Express Medco contracts. I guess my question is, are you now happy this is going to",101,"I guess, just one more question on ExpressNet, and here with the -- I think you mentioned in your comments in some ways you view yourselves of the primary incumbent on the Express Medco contracts. I guess my question is, are you now happy this is going to an official RFP versus your previous thought pattern over the past 9 months got announced, so are you disappointed because you thought you were the primary incumbent or are you just indifferent, just trying to get more color sort of your view now the new information versus kind of what you thought previously?"
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","I actually at NCDS conference and I had one legal trying to spend about election, incumbency is a 4-point advantage of the so it just trying to get that incumbent advantage in there. But that's just my view, I mean I don't know if anyone else have viewed,",131,"I actually at NCDS conference and I had one legal trying to spend about election, incumbency is a 4-point advantage of the so it just trying to get that incumbent advantage in there. But that's just my view, I mean I don't know if anyone else have viewed, we did, of course, to more business with Medco than the current wholesaler did with the SR, so you could look at as incumbency, but I think it's just really my view. We are all pleased that this has been decided relatively early in the process. Very helpful from a planning perspective and, again, it's helped us have a very interesting discussion with BSR. We think that it's a positive for the industry and we think it's potentially could be positive from AmerisourceBergen."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve. Now, Steve Collins would like to make some final comments before we go.",15,"Thanks, Steve. Now, Steve Collins would like to make some final comments before we go."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","We know it's a very busy day, so we really do appreciate everyone's interest and attention with AmerisourceBergen. I would like to commend my colleague and our acting CFO, Tim Guttman, for his leadership and contribution during this transition period. as",96,"We know it's a very busy day, so we really do appreciate everyone's interest and attention with AmerisourceBergen. I would like to commend my colleague and our acting CFO, Tim Guttman, for his leadership and contribution during this transition period. as you could see, Tim's really done a great job. So to wrap up, ABC thinks this is a really good order for us and especially given our tough comps. And we are proud to report good momentum on all fronts as a halfway point of fiscal year 2012. Thank you again for your attention."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve. And before we go, I just like to read me highlight our upcoming events. On May 17, we'll be presenting at the Bank of America Merrill Lynch 2012 Healthcare Conference in Las Vegas. And on June 6, we will be presenting at the Goldman Sachs 3",68,"Thanks, Steve. And before we go, I just like to read me highlight our upcoming events. On May 17, we'll be presenting at the Bank of America Merrill Lynch 2012 Healthcare Conference in Las Vegas. And on June 6, we will be presenting at the Goldman Sachs 33rd Annual Global Healthcare Conference. That concludes our call for today. And now I will turn it back to the operator."
24809,183660881,289784,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Thank you. Ladies and gentlemen, this conference will be available for replay after 1:00 p.m. today through midnight, May 3, 2012. You may access the replay service by dialing 1 (800) 475-6701 and entering access code 243852. International participants di",61,"Thank you. Ladies and gentlemen, this conference will be available for replay after 1:00 p.m. today through midnight, May 3, 2012. You may access the replay service by dialing 1 (800) 475-6701 and entering access code 243852. International participants dial (320) 365-3844. This concludes our conference for today. And thank you for using AT&T executive teleconference services. You may now disconnect."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by and welcome to the ABC Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Ms. Barbara",46,"Ladies and gentlemen, thank you for standing by and welcome to the ABC Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Ms. Barbara Brungess. Please go ahead."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 second quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve Colli",164,"Thank you. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 second quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve Collis, AmerisourceBergen's President and CEO; and Tim Guttman, Vice President, Controller and acting CFO.
During the call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011.
Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by telephone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, and good morning, everyone. I am pleased to report that AmerisourceBergen once again delivered solid quarterly results and our performance for the first half of our fiscal year 2012 positions us well to meet our objectives for the full year. In",2108,"Thank you, and good morning, everyone. I am pleased to report that AmerisourceBergen once again delivered solid quarterly results and our performance for the first half of our fiscal year 2012 positions us well to meet our objectives for the full year. In the March quarter, our revenues were up 2% to $20.1 billion. Earnings per share were up 5% to $0.81, and that's on top of a 22% increase in the prior year. 
We generated $236 million in operating cash flow and we repurchased $200 million of our shares. I'm especially proud that we overcame a challenging comp to this quarter, last year, and exceeded our internal profit goals for each business unit. 
During the quarter, we also made excellent progress integrating recent acquisitions and working towards the closing of our World Courier acquisition. Our strong cash generation and high-quality balance sheet continue to provide us with outstanding financial flexibility and give us the ability to fund our strategic initiatives, grow our business and return funds to shareholders. 
AmerisourceBergen is fortunate to be an important part of a growing industry. Demographics and initiatives aimed at expanding access to health care and coverage -- and healthcare coverage, should continue to drive organic growth in our industry over the next several years. In addition, launches of new pharmaceuticals, as well as new indications for existing drugs should also drive sales growth over the next several years. Whether the new therapies are traditional oral medications or complex biotech pharmaceuticals, AmerisourceBergen is well-positioned to not only benefit from the distribution of new products, but also to offer pre-launch and commercialization services to manufacturers and to support patient access and reimbursement programs to help ensure that patients have access to life-saving therapies, and that the products achieve their full potential in the marketplace. 
At our verse [ph] revenue base positions us well to benefit from organic growth driven by demographics, and our customer mix puts us in a favorable position to continue to benefit from the historic influx of generics. As you know, generics mitigate the topline dollar growth in our industry but drive tremendous value for wholesalers, health care providers and patients alike. In addition, close scrutiny of health care expenses and cost-containment efforts underway by the federal government and other payers also drives demand for our services, most notably in our Consulting Services group. 
Over the last several years, we have significantly strengthened our relationship with pharmaceutical manufacturers and we continue to look for meaningful ways to provide additional services across the supply channel to help them ensure they meet the challenges of today's changing health care landscape. As our provider customers face similar challenges regarding cost -containment and reimbursement for services provided to patients, they increasingly turn to AmerisourceBergen. We help in making their health care practices run as efficiently and effectively as possible.  
Our provider customers work hard everyday to provide world-class patient care, and we believe they deserve fair reimbursement for the professional services they provide. AmerisourceBergen is an active participant participating in policy discussions in Washington, D.C. with the objective of helping legislators understand our industry and our importance to the health care systems. 
Our associates are focused on meeting our objectives for the year, both in terms of providing outstanding service to customers and in our financial performance. They continue to seek creative ways to meet the challenges in the diverse markets we serve and identify new opportunities to add value through collaborative innovation and by maximizing efficiency. I take great pride in their enthusiasm and dedication, and it is my honor to work beside them. 
Turning now to our business units. AmerisourceBergen Drug Corporation, as expected, had flat revenue in the quarter as strong performance in the institutional segment was offset by the previously disclosed loss of a large retail customer. Topline growth was also mitigated by the impact of generic convergence, including decreased sales to our largest customer. 
Our ABDC associates did a stellar job managing several generic launches including 5 different generic products that launched within one week. Year-to-date, the generic launches have performed as planned and we, of course, look forward to several more launches still to come in the second half of the year. 
With over 4,600 members, our Good Neighbor Pharmacy network, the third largest network of pharmacies in the U.S. continues to play a crucial role in providing pharmacy care nationwide. Patients' preferred choice when determining where to fill their prescriptions and our retail customers are very adept at fulfilling unique patient needs, and is adapting to the changing needs of the marketplace. 
Our ASP implementation continues to run smoothly with 8 distribution centers conversions complete, 2 additional conversions occurring tomorrow, and the remainder plans with the beginning of 2013. As we have gained experience with the new system, particularly with the corporate and back-office functions, we have already begun to realize some operational savings, which is reflected, in part, in a good performance we had on the expense line this quarter. 
Our investments in our Canadian operations to support significant new business wins continued in the March quarter. Our associates have done a tremendous job setting up 4 new distribution centers in 6 months, in order to support this new business. There is still much work to be done, but we are confident that our expansion efforts will meaningfully increase the value we bring to both independent pharmacies and especially providers in Canadian market -- 
As we noted in the press release, following the closing of the merger with Express Scripts and Medco in early April, we amended our existing Medco agreement to provide for the contract to end upon the award and implementation of one or more new pharmaceutical distribution agreements for the newly combined business. Express Scripts has issued an RFP for the combined business, and anticipate that the new contract, or contracts, will begin on October 1, 2012. We are participating fully in the competitive RFP process and we intend to pursue this opportunity to retain or grow the business under a new contract. We have had an excellent working relationship with Medco for over 2 decades and we are excited about the opportunity to demonstrate the value we can bring to the newly combined entity. 
AmerisourceBergen Specialty Group had another strong quarter with revenues up 6% with particularly strong performance in third quarter logistics, and in our vaccine and physician distribution business. Our oncology business performed well, while facing a very difficult comparison due to the strong performance of the 3 large Besse generic products last year. While our Specialty Group is best known for our oncology franchise, we are an instrumental part of the commercialization strategy for any infusible product launched into the physician marketplace. We continue to execute very well on the launch of a new brand of ophthalmology product establishing significant market share in what was the first full quarter of the introduction. 
Our Specialty Group often collaborates with our Consulting Services group to help ensure patients have access to products by utilizing the full suite of capabilities of our physician networks, as well as our reimbursement and patient support program expertise. For example, we recently helped a manufacturer launch a new biotech product. And during the March quarter, we were able to not only achieve the leading market share for the distribution of the product, but also to provide third-party logistics, contract packaging and all of the reimbursement and patient support programs for the product across the market. We are very proud that these combined service offerings provide unmatched value to manufacturers and distinguish AmerisourceBergen in the marketplace. As we look at the products in development pipelines today, we believe that we will win even more of these opportunities in the future, which will be an important driver of our growth in the years ahead. 
Our Consulting Services group delivered a very strong quarter, while making excellent progress in the integration of TheraCom and Premier Source, which are both performing very well. The last group had the strongest quarter in its history even without the contributions from TheraCom. While the group only represents about 2% of our revenues, we believe our packaging and consulting services provide essential expertise to pharmaceutical manufacturers to help ensure that their products are brought to market as safely, quickly and efficiently as possible. In addition, our reimbursement expertise helps ensure that patients who can benefit from growth new and matured therapies have access to the products. 
We continue to make good progress towards closing our most recent acquisition, World Courier. As we deepen our knowledge and understanding of their business, I am more convinced than ever that World Courier affords us the opportunity, not only to acquire the market leader in premium niche clinical trial logistics services, but also to begin to build out a framework to expand our consulting and commercialization services beyond North America. 
In this current quarter, we will begin operating in 50 new international markets and employ about 1,500 new associates outside North America. This is significant expansion for ABC and we are tremendously excited about welcoming the World Courier team to ABC. 
In addition, we are storing ways to potentially expand some of our niche Specialty Distribution service into select markets as well. We expect to close the acquisition next week, at the end of April, and I'm very excited about the potential we see in the World Courier platform in the years ahead. 
Given the continued strength of our balance sheet, we continue to look for acquisitions that meet the criteria we've had in place for quite some time. They should increase our value offering to existing customers both up and down the channel. They should be within our established core competency and they should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions and we continue to be interested in opportunities in pharmaceutical and Specialty Distribution and Services, as well as consulting and packaging services. While we, historically, have been very comfortable in the $200 million to $300 million range, we will consider selling larger, as we did with World Courier, if it made a good strategic sense and will deliver value to our company and our shareholders. 
Looking ahead, the results we've had in the first half of our year have positioned us well to meet our objectives for the full fiscal year. We have a difficult comparison to overcome in 2012, but we continue to expect GAAP earnings per share to be within the range of 2.74 to 2.84, and we are tracking towards the midpoint of that range. Tim will provide the details in our assumptions for the remainder of the year, but I want to highlight that we continue to remain disciplined on expenses, our cash flows are strong and we have increased our share repurchases assumption for the year. 
Looking further ahead to 2013, we should have a carryover from some of the launches that occurred late in our fiscal 2012, including the relaunch of Oxaliplatin, and we should begin to benefit from the completion of our ASP implementation. In fiscal 2014, we should begin to see this 30 million to 40 million uninsured patients enter the health care market, driving demand for pharmaceuticals that should carryover into 2015 and beyond. In addition, 2014 and 2015 are expected to be good years for generic conversions. And, of course, there's a chance that biosimilars may also come to market in that timeframe. 
Before turn it over to Tim, I want to reiterate the confidence that I have in our business and in our future. Demand is strong for the products we distribute and we play an essential role in pharmaceutical supply channel. We've positioned ourselves well to continue to benefit from the 2 key growth drivers, generics and specialty products, and we have continued to invest in our distribution and in our services businesses. 
Over the last year, we were summating important investment in other areas of our business with an eye to the future. We expect demand for specialty products to continue to grow, not only the U.S. but throughout the world, and the commercialization and reimbursement support services we provide to manufacturers will help support that growth. As cost containment efforts continue to cross the health care landscape, our customers increasingly turn to us for help in meeting the challenges of the marketplace without sacrificing patient care. Finally, the vision and innovative ideas that our associates bring to market everyday set our support in our industry, and I am proud to be their leader. Here is Tim."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and good morning, everyone. It's my pleasure to be participating in my first earnings call as acting CFO. And I am pleased to report another solid ABC quarter and, most importantly, that our Q2 results are on track with our internal plan.",1501,"Thanks, Steve, and good morning, everyone. It's my pleasure to be participating in my first earnings call as acting CFO. And I am pleased to report another solid ABC quarter and, most importantly, that our Q2 results are on track with our internal plan. 
The highlights this quarter: excellent topline growth at our Specialty and Consulting businesses; very good execution on new generic launches and continued focus on expense management across the organization; and finally, another quarter of strong cash generation. 
Now let's turn to the quarterly details and starting with the topline. Revenues were $20.1 billion, a 1.6% increase over last year's quarter. Drug company revenues were essentially flat, as we guided. We had strong performance in our alternate site and health system segments, offset by the loss of a large chain customer last year, as well as the impact from brand to generic conversions. 
The Specialty Group revenues increased 6%, led by 2 of our businesses with above market growth. ICS, our third-party logistics business and BesseMedical, our vaccine and physician office distribution business, which benefited from a full quarter impact of sales of a new ophthalmology drug. 
The Consulting group, though small to the overall topline, continues to perform well. Excluding their TheraCom acquisition, they had over 20% topline growth. TheraCom contributed just under 1% of our overall revenue growth in the quarter. 
Moving to gross profit. Gross profit was $695 million in the quarter, up 1.1% from last March, with a gross margin of 3.46% in the quarter, down about 2 basis points from last year. As we have discussed in the past, our second quarter was a very tough comp, due to the significant contribution in the prior year from oncology generics. In the second quarter of 2011, these oncology drugs contributed about $0.16 of EPS to our results. Our gross margin expanded 31 basis points in the March 2011 quarter. This year, we are able to effectively offset this headwind with contributions from the new Oral Solid generics, as well as the lower contribution from oncology generics and gross profit contributions from our acquired companies. 
Additionally, our LIFO charge was approximately $4 million in the quarter, down $10 million from last year. We continue to expect our LIFO charge will be approximately $15 million, down significantly from last year. Our annual LIFO forecast is based on our expectation that brand price inflation will be somewhat less this year. And more importantly, we will see significant generic price deflation in the second half of our fiscal year related to key brand to generic conversions coming off exclusivity. 
Finally, the benefit we received from the new generic launches, and also price appreciation, was in line with our expectations. This quarter, we did an excellent job controlling our operating expenses. Operating expenses were approximately $327 million, up 1.5%. However, this amount includes the operating expenses of about $11 million from our recently acquired companies. Additionally, we had $9 million of executive severance and acquisition-related transaction costs. Operating expenses would've been down, excluding the impact of our acquisitions, due to lower compensation costs including benefits. 
Additionally, our SAP implementation is progressing well at the corporate level. The system has reached a level of stability faster than we expected, enabling us to realize some early savings, especially with external consultants. 
Last quarter, our guidance was an annual expense increase of about 3%, due to our acquisitions. As an organization, we continue to exercise discipline and focus on managing expenses. We now expect our total operating expenses for our base business, before adding World Courier, to be essentially flat for the year. 
Operating income of $368 million in the quarter increased about 1%, while operating margin was down 2 basis points compared to last March. Our current quarter was slowed by the $9 million of executive severance and acquisition transaction costs. Excluding these non-recurring expenses, our operating income margin would've expanded 3 basis points to 1.88%. 
Moving below the operating income line, interest expense of nearly $24 million in the March quarter increased 25% compared to last year, primarily, as a result of our $500 million bonds we issued back in November. The proceeds help to fund the TheraCom acquisition and will also contribute to the retirement of our 2012 bonds that mature in mid-September. Our effective income tax rate of 38.j4% was slightly higher than last year's 38.1%, and is right in line with our expected annualized rate of 38.4%. 
Our diluted GAAP earnings per share in the quarter of $0.81 increased by $0.04, or 5%, over the same quarter last year. And again, overcoming a $0.16 headwind from the contribution from specialty generics in the March 2011 quarter. Our EPS benefited from a reduction in our average diluted shares related to our ongoing share repurchase program. Average diluted shares for the quarter were approximately 262 million, down just over 6% from last March. 
Now let's turn to our balance sheet and cash flows, where trends continue to be very favorable. We generated $236 million of cash from operations in the quarter, bringing our 6-month total to $668 million, compared to generating $577 million for the first 6 months last year. We continue to manage AR and inventory levels very closely and this has benefited our working capital this year. With our daily revenue volume exceeding $300 million per business day, our quarter- end working capital snapshots are subject to volatility. Therefore, our 6-month cash results cannot be extrapolated to determine a full-year cash flow estimate. 
Capital expenditures were $40 million in the quarter and $88 million for the 6 months. During the last 2 years, we put a number of capital projects on hold as we focused on SAP. We have a pipeline of attractive internal projects that we have begun to pursue as our SAP deployment moves along. 
Additionally, we have CapEx associated with our recent TheraCom acquisition. Because of this, we will exceed our previous target of $150 million for CapEx, and we will be closer to $200 million for the year. Even with this additional CapEx, we expect that our free cash flow will now be in the $800 million to $900 million range. 
During the quarter, we brought back $200 million of our shares. For 6 months, we've purchased $320 million of shares. At March 31, we have approximately $180 million left on our current share repurchase authorization. In terms of key financial metrics that we track, our average day sales in inventory for the quarter remained at 14 days, consistent with fiscal '11. Average DSOs of 18 days in the March quarter were up slightly from 17.3 days last year. And favorable payables timing helped raise average quarterly DPOs by over 3 days compared to Fiscal '11. 
With our recent debt offering, our gross debt, the total debt and capital ratio, at the end of March, was 39%, above our target range of 30% to 35%. And it will remain above the range until we pay off our $400 million of debt in September. Our cash balance at March 31, was $2.3 billion. Keep in mind, that we will be funding our World Courier acquisition from cash and we will be paying down debt in September, as previously mentioned. After these 2 large cash outlays, we will still have financial flexibility to fund CapEx and strategic initiatives and return to capital -- and return capital to our shareholders. 
Now let's turn to updated fiscal 2012 guidance. We expect our diluted GAAP EPS to track to the middle of the range we previously provided, $2.74 to $2.84. Our assumption for revenue growth remains unchanged, flat-to-modest revenue growth. We expect our operating margin expansion to be in the high-single-digit basis points. Free cash flow will now be in the $800 million to $900 million range. And we are raising our guidance for share repurchases for the year to $500 million, which will complete our current share repurchase authorization. 
Looking ahead, I would like to remind everyone that Q3 is another challenging comparison for us because of the $0.17 EPS contribution from oncology generics last year. Also in Q3 2012, we have 2 of the large generics coming off exclusivity. When looking out to the second half of the year, we believe Q4 will be somewhat of an easier comparison. With the return of Oxaliplatin for half a quarter, a few favorable year-end generic launches for our drug company and favorable expense comparisons year-over-year. 
So before I turn it back to Barbara, let me reiterate, that 6 months into the fiscal year, we are performing well in our key areas of the business and we are well-positioned to meet our financial targets for fiscal 2012. One final point, I'd like to take a moment and thank our ABC associates, especially those in the finance and accounting areas that have stepped up the last 2 months and helped support the organization and me, in particular, during our CFO transition period. Thanks, everyone. Here's Barbara to start our Q&A."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives",".Thank you, Tim. Operator, we'll now open the call to questions. [Operator Instructions] Go ahead, operator.",16,".
Thank you, Tim. Operator, we'll now open the call to questions. [Operator Instructions] Go ahead, operator."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Glen Santangelo from Credit Suisse.",15,"[Operator Instructions] Our first question comes from the line of Glen Santangelo from Credit Suisse."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I just want to quickly follow up, Tim, with respect to some of your comments on the operating margin expansion goals for the year. Previously the company had expected operating margin expansion in the high single-digit, kind of low double-digit range and",95,"I just want to quickly follow up, Tim, with respect to some of your comments on the operating margin expansion goals for the year. Previously the company had expected operating margin expansion in the high single-digit, kind of low double-digit range and now, it seems like you're suggesting high single-digit. I guess -- could just give me a sense for maybe what has changed in that thinking? And I know there were some onetime costs that you're now embedding in your estimates and I'm curious if there's anything else that I should be thinking about?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, we changed our guidance to high single digit. In terms of looking out, we did an assessment of the full year, and looking out, we had some deal costs in Q2 and some onetime items, non-recurring items. And as we look out, we're going to have some simil",91,"No, we changed our guidance to high single digit. In terms of looking out, we did an assessment of the full year, and looking out, we had some deal costs in Q2 and some onetime items, non-recurring items. And as we look out, we're going to have some similar costs in Q3 with the World Courier transaction. So when we look out and do a reassessment, we felt more comfortable that high single digit was a realistic target for us for the year, and there's really nothing else factored into that."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And, Tim, maybe if I could just ask a follow up on the World Courier group. You originally sort of guided $0.06 to $0.10 worth of accretion and I'm kind curious, is there anything embedded from an accretion standpoint in your fiscal '12 guidance as it rel",82,"And, Tim, maybe if I could just ask a follow up on the World Courier group. You originally sort of guided $0.06 to $0.10 worth of accretion and I'm kind curious, is there anything embedded from an accretion standpoint in your fiscal '12 guidance as it relates to World Courier? And it kind of sounds like you're going to be taking down some integration costs or acquisition-related costs next quarter. I don't know if you care to size those at this point?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Glen, no. We will have some transaction-related acquisition costs in Q3. Probably not more than the number that we had for Q2. And there is no accretion in our numbers for this fiscal year. We expect it to be neutral. And in terms of next year, for fiscal",59,"Glen, no. We will have some transaction-related acquisition costs in Q3. Probably not more than the number that we had for Q2. And there is no accretion in our numbers for this fiscal year. We expect it to be neutral. And in terms of next year, for fiscal '13, we're still confident with that guidance of $0.06 to $0.10."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Larry Marsh with Barclays Capital.",10,"Our next question comes from Larry Marsh with Barclays Capital."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","So my question is as follows. Steve, around Medco. Here you're communicating -- I guess, is it fair to say that you voluntarily agreed to move up the termination date of your Medco relationship by 6 months? And if so, is there any benefit for doing so? An",104,"So my question is as follows. Steve, around Medco. Here you're communicating -- I guess, is it fair to say that you voluntarily agreed to move up the termination date of your Medco relationship by 6 months? And if so, is there any benefit for doing so? And possibly for going that profit stream? And then just around the topic, I wanted to confirm, you said you already have a relationship with Express Scripts. How long have you had that? And then have you disclosed, or are in a position to comment the about the links of the suggest new contract under the RFP?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","First of all, obviously, we are part of a very active process here and we want to be very respectful of that and some of the questions should really be directed to the buyer. But I think ABC, as you know, has been very proud of over 2 decades of service t",192,"First of all, obviously, we are part of a very active process here and we want to be very respectful of that and some of the questions should really be directed to the buyer. But I think ABC, as you know, has been very proud of over 2 decades of service to Medco and now, you could almost say we are the incumbent here because we've had such a long relationship. So we wanted to demonstrate flexibility. We wanted to recognize that this is a new entity that has requirements and we'll have a different dynamics to relationship. And now it just made sense for us to be concurrent with the current requirements. So we demonstrated flexibility. We demonstrated that ABC is a good partner and listens to our customers and I think that, that will hopefully put us in a good position throughout the contracting process but it will be competitive. And, I guess, the only internal benefit I can point to is that, it is this concurrent with our fiscal year, whatever happens we'll be in a good position to plan for it and to communicate that to our investors."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So it sounds like you're uncomfortable commenting about the lengths of the contract as proposed in the RFP at this point.",22,"Okay. So it sounds like you're uncomfortable commenting about the lengths of the contract as proposed in the RFP at this point."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","As far as we know, as far as we could take -- it's pretty standard on top of contract term.",20,"As far as we know, as far as we could take -- it's pretty standard on top of contract term."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Right. So we assume, maybe 3 years, but again, not commenting. And I guess just a follow-up to you and Tim around SAP implementation, we appreciate the update there. If you let it to go back or remember some of the bigger expenses for this, seem to be fis",90,"Right. So we assume, maybe 3 years, but again, not commenting. And I guess just a follow-up to you and Tim around SAP implementation, we appreciate the update there. If you let it to go back or remember some of the bigger expenses for this, seem to be fiscal '10 and '11, $40 million to $50 million a year, you've mentioned, Tim, stability sooner than you thought. Can you ballpark kind of expenses around SAP for you this year and how do we think about that comparable to next year?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Larry, our guidance has been that -- we'll see some benefit for SAP next year, 6 months after our last DC deployment, so we expect that to be in Q4. It guided to $10 million, we expect the full benefit of about $40 million to be in '14. And so far, t",102,"Yes. Larry, our guidance has been that -- we'll see some benefit for SAP next year, 6 months after our last DC deployment, so we expect that to be in Q4. It guided to $10 million, we expect the full benefit of about $40 million to be in '14. And so far, the benefit that we had this year for SAP is really incremental for that. I mean, this is just expense that we've been able to take out of our operating budget, which is probably been a few million dollars. So again, they're separate. One's not a part of the other."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I got it. Right. Expenses associated with consultants and such, but again, $10 million incremental next year, $40 million for '14. And then just to clarify, I think it's an important point, the guidance confirming the range but you're suggesting the $0.02",75,"I got it. Right. Expenses associated with consultants and such, but again, $10 million incremental next year, $40 million for '14. And then just to clarify, I think it's an important point, the guidance confirming the range but you're suggesting the $0.02, which was the severance and transaction cost this quarter and the $0.02 which -- ballpark of transaction cost next quarter, are included now in that range. You're not breaking that out at all?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, absolutely, Larry. We're GAAP and we include that in.",10,"No, absolutely, Larry. We're GAAP and we include that in."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And again, you're saying that's a big reason why you're top and the -- your operating margin expansion has been pulled down?",22,"And again, you're saying that's a big reason why you're top and the -- your operating margin expansion has been pulled down?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Absolutely.",1,"Absolutely."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Robert Jones with Goldman Sachs.",10,"Our next question comes from Robert Jones with Goldman Sachs."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Just to go back to the Express Scripts contract. Steve, it sounds like -- you mentioned contract, or contracts, so I'm assuming there's some suggestion that it could be broken out. Any insight into this view or maybe, more importantly, what benefit that w",52,"Just to go back to the Express Scripts contract. Steve, it sounds like -- you mentioned contract, or contracts, so I'm assuming there's some suggestion that it could be broken out. Any insight into this view or maybe, more importantly, what benefit that would create for Express to have this contract separated?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think, in terms of processing, there's not much differentiation between s $10 billion contract, or a $15 billion, or $20 billion contract, it's just that, that is the way these large contracts tend to go. And there could be some geographical, regi",104,"Well, I think, in terms of processing, there's not much differentiation between s $10 billion contract, or a $15 billion, or $20 billion contract, it's just that, that is the way these large contracts tend to go. And there could be some geographical, regional benefit, based on where they're planning to have their large mail-order stocks, there could be a way to separate the specialty business with the core mail-order business. So we have 2 big specialty units so -- but again, these are questions that we probably are not comfortable commenting on and could probably be pissed, be directed to Express Scripts, so..."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","No, I definitely appreciate that. And I guess just one follow-up, Steve. Given the somewhat more acquisitive nature of the company as of late, and I know you've gotten this question before and I imagine as you continue to do acquisitions you might get it",75,"No, I definitely appreciate that. And I guess just one follow-up, Steve. Given the somewhat more acquisitive nature of the company as of late, and I know you've gotten this question before and I imagine as you continue to do acquisitions you might get it more in the future, relative to your peers. Any thoughts or discussion between you and Tim about moving to a cash EPS, or at least breaking out a cash EPS?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, we haven't. We lack -- we think we report not only good earnings, but very hot, quality earnings and, at the moment, that hasn't been under consideration.",28,"No, we haven't. We lack -- we think we report not only good earnings, but very hot, quality earnings and, at the moment, that hasn't been under consideration."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","And we, in our public company filings, we feel we give pretty good disclosure on some of those differences, especially around intangibles. And the reader of those documents can go ahead and do that calculation.",35,"And we, in our public company filings, we feel we give pretty good disclosure on some of those differences, especially around intangibles. And the reader of those documents can go ahead and do that calculation."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Tom Gallucci with Lazard.",9,"Our next question comes from Tom Gallucci with Lazard."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I was wondering if you could expand on some of your prepared remarks around sort of international? And how you see the opportunity may be there overnight? Not the near-term necessarily but the next few to 5 years, it sounds like maybe World Courier",70,"Steve, I was wondering if you could expand on some of your prepared remarks around sort of international? And how you see the opportunity may be there overnight? Not the near-term necessarily but the next few to 5 years, it sounds like maybe World Courier is a bit of a platform that you. could grow from in different ways, so if you have any thoughts there, it would be appreciated."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well there's a couple of things. First of all, again, we do $300 million in revenue a day, as ABC, but one of the things we've been very happy with is our specialty performance in Canada. This is -- this market works differently than it does in the U.S.,",376,"Well there's a couple of things. First of all, again, we do $300 million in revenue a day, as ABC, but one of the things we've been very happy with is our specialty performance in Canada. This is -- this market works differently than it does in the U.S., but we've been able to do some joint programs, we've been able to help with more complex reimbursement environment there, including a pretty robust product market that we -- that is not generally known. At least here, in the U.S., we think about it as single-payer market, that hasn't been the case. We've been able to help, we have a very strong presence with new infusible drugs. So what we've seen is a manufacturer environment that ABC is very comfortable in contracting with, that is looking for us to get into more countries. So we've been prompted to look at international opportunities by manufacturers. Then comes World Courier, we're in 50 new countries as of next week, hopefully. We have 1,500 associates that are very tenured. We've been extremely impressed with the quality of the World Courier associates. As you know, health care is very local. So we think that we have an opportunity to understand health care markets, both organic and acquisitive opportunities, with people on the ground there who speak the language, and know the trends, know who's the rock players, the ethical players, the hard quality players in that environment. And we think that, that's going to give us a good opportunity. We also think that as the products that World Courier is managing or commercialized, as more and more of those products are commercialized and come to market as -- middle class is growing in some countries that we haven't traditionally thought about as being big Baltic and have sort of -- and especially consumers of products, we think we're going to have an opportunity to participate in those commercialization strategies. Think about it, World Courier has handled those products, they know the treatment centers, they know the environment. So we think that we have to recharacterize part of the business, but we think we can do that, so... . Long answer but, as you can tell, I'm very enthusiastic about this."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Sure, that's clear. And then maybe just one housekeeping item. On the CapEx, can you sort of breakdown your maintenance CapEx versus maybe what's additional and some of those projects that you highlighted earlier, did they ssep in to next year? Should we",59,"Sure, that's clear. And then maybe just one housekeeping item. On the CapEx, can you sort of breakdown your maintenance CapEx versus maybe what's additional and some of those projects that you highlighted earlier, did they ssep in to next year? Should we assume that it comes back down a little bit, or how are you thinking about that?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Good question. No, we -- when we look at maintenance CapEx, we think it's typically between about $100 million and $120 million. We have some big projects this year supporting our expansion up in Canada. We're looking at another DC project in the U.S. in",90,"Good question. No, we -- when we look at maintenance CapEx, we think it's typically between about $100 million and $120 million. We have some big projects this year supporting our expansion up in Canada. We're looking at another DC project in the U.S. in terms of expansion, automation, renovation and our TheraCom acquisition. So I would say that the $200 million is probably a peak and it definitely should come down next year, probably about half of the maintenance CapEx is probably a good, kind of a good range."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from the line of Robert Willoughby with Bank of America Merrill Lynch.",16,"Our next question comes from the line of Robert Willoughby with Bank of America Merrill Lynch."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, what kind of clarity do you actually have on -- does the RFP provide for you? I mean, I assume you would have size of the potential contract, the mail footprint you'd be serving, whether or not specialty would be there. I mean, are there some thing",58,"Steve, what kind of clarity do you actually have on -- does the RFP provide for you? I mean, I assume you would have size of the potential contract, the mail footprint you'd be serving, whether or not specialty would be there. I mean, are there some things you could disclose there that would be helpful for us?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","I think, we partly said, Bob, I appreciate your interest in this and, believe you me, I am really interested in this and the ABC team is very interested in this. We're just participating fully in the RFP process, it has just begun. So I could tell you we",119,"I think, we partly said, Bob, I appreciate your interest in this and, believe you me, I am really interested in this and the ABC team is very interested in this. We're just participating fully in the RFP process, it has just begun. So I could tell you we really don't -- we think it's in the range of about a $20 billion contract. So I will tell you that Medco may compete with ABC at about 19% of our revenues in fiscal year 2011 and it's come off a few percent from that, kind of run rate is more in the mid-teens, 16% range. So we could potentially gain some couple of billion dollars in new revenue here."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And any sense on timing, when a decision will ultimately be made, obviously, before October 1. But how much time would you need and do you anticipate if you win, is there investment you need to make or in the unfortunate event you don't win, what ki",61,"Okay. And any sense on timing, when a decision will ultimately be made, obviously, before October 1. But how much time would you need and do you anticipate if you win, is there investment you need to make or in the unfortunate event you don't win, what kind of offsets we might see to your cost structure, some initiatives you'd pursue?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, we're mainly servicing the current business out of 3 DCs and we certainly would start giving consideration to what it could mean if we lose. But from a more exciting basis, I think we do have the capacity to service this business without matching cr",71,"Well, we're mainly servicing the current business out of 3 DCs and we certainly would start giving consideration to what it could mean if we lose. But from a more exciting basis, I think we do have the capacity to service this business without matching criminal [ph] investment. And we look forward to talking about the different capabilities that ABC brings to the table. And we're participating fully in this contract."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And timing, Steve? Anything?",4,"And timing, Steve? Anything?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, I just think you know -- I think you know -- you cover Express Scripts. You know they move quickly, so that's all I can tell you they -- they run if the grass grow under their feet. So we expect them to have a very active and quick and decisive proces",84,"No, I just think you know -- I think you know -- you cover Express Scripts. You know they move quickly, so that's all I can tell you they -- they run if the grass grow under their feet. So we expect them to have a very active and quick and decisive process unlike this other very public contract that we went through very recently. So that should make everyone happy, at least, we'd all know where we stand very quickly. We believe so."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Ricky Goldwasser with Morgan Stanley.",10,"Our next question comes from Ricky Goldwasser with Morgan Stanley."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Just a quick wrap-up of the Medco Express side, what I want to understand specialty is included in your relationship with legacy Medco. Should we assume that the services that you provided to Medco on the specialty side are more of wholesale-type services",63,"Just a quick wrap-up of the Medco Express side, what I want to understand specialty is included in your relationship with legacy Medco. Should we assume that the services that you provided to Medco on the specialty side are more of wholesale-type services or do you also provide them kind of like the added value services that's associated with your specialty business?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","We are both the wholesaler to the former [indiscernible] division of Medco, and now will be Express Scripts. We have, obviously, worked very collaboratively with them in many areas including the hospital, pharmacy area and the specialty area. So I'm more",92,"We are both the wholesaler to the former [indiscernible] division of Medco, and now will be Express Scripts. We have, obviously, worked very collaboratively with them in many areas including the hospital, pharmacy area and the specialty area. So I'm more -- can't point to any particular program, but certainly as our largest customer, we had spent a lot of time working on common approaches to the marketplace and we would expect to bring that expertise and that market knowledge, and the manufacturer relationships that we have to the combined entity now."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And then. I have a couple of just questions from, from modeling purposes. For the SG&A level for the remainder of the year, should we assume same level as we saw in the March quarter or should we see a step up, and if so, can you quantify for us and is it",57,"And then. I have a couple of just questions from, from modeling purposes. For the SG&A level for the remainder of the year, should we assume same level as we saw in the March quarter or should we see a step up, and if so, can you quantify for us and is it related to World Courier."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","We, at this point, Ricky, we don't have World Courier finished yet, completed. But definitely with World Courier coming in 2 months and quarter 3 and we'll have them for the entire Q4. They will add extra expense. And when I gave the guidance today this m",92,"We, at this point, Ricky, we don't have World Courier finished yet, completed. But definitely with World Courier coming in 2 months and quarter 3 and we'll have them for the entire Q4. They will add extra expense. And when I gave the guidance today this morning, again, I was talking about the core business being flat. For the core business, we will see a little bit of a step up in Q3, but probably not dramatic. And again, we will have some non-recurring acquisition-related cost in Q3, probably not in Q4."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And then can you just qualify to us the income from a basis point perspective of the acquisitions on the margins for this quarter?",25,"Okay. And then can you just qualify to us the income from a basis point perspective of the acquisitions on the margins for this quarter?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","In terms of SG&A.",5,"In terms of SG&A."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","SG&A or operating margin.",5,"SG&A or operating margin."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well again, we commented that we had about $11 million of SG&A expense in the quarter from our acquisitions, primarily TheraCom. So again, it's probably 4, 3, 4 basis points.",30,"Well again, we commented that we had about $11 million of SG&A expense in the quarter from our acquisitions, primarily TheraCom. So again, it's probably 4, 3, 4 basis points."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Eric Coldwell with Robert W. Baird.",11,"Our next question comes from Eric Coldwell with Robert W. Baird."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I think a lot of the timely questions have been answered, so I'll shift gears a bit. Health systems and alternate site in your drug company sounds like another good quarter there, above market growth, perhaps. I'm curious if you can define what's leading",119,"I think a lot of the timely questions have been answered, so I'll shift gears a bit. Health systems and alternate site in your drug company sounds like another good quarter there, above market growth, perhaps. I'm curious if you can define what's leading to this growth. It must be share capture, I don't want to lead you too much, but the market's clearly not growing at a rapid pace. You're doing pharmaceuticals and not the other broad and service lines or other services to the health systems. So could you just give us a better sense on what's driving that growth in health systems and alternate sites and perhaps if you could frame it, would be helpful, too."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well with health systems, we think we have a market share that is, at least comparable, maybe even the largest fit in the U.S. We believe we're with the right customers, we believe that we'll be growing with them. We believe that we have some hospital ser",264,"Well with health systems, we think we have a market share that is, at least comparable, maybe even the largest fit in the U.S. We believe we're with the right customers, we believe that we'll be growing with them. We believe that we have some hospital services that we provide that maybe don't get the headlines, but they are all additive to their business like helping them with 340B consulting, helping them with pharmacies. So we have ever good practice in health systems and we believe we're with the companies and all the leaders in that space and I think obviously some of our. Likewise with alternate care, I think ABC has been a leader there. Certainly our knowledge of specialty and our ability to offer an integrated solution on the specialty and drug wholesale side and our knowledge of the manufacturing environment and the patient environment and the reimbursement environment has been very, very helpful. And the Humana contract we think was a direct result of that knowledge and that's a very fast grower. We're with a lot of the companies that are growing faster than the market and when we discussed potential RFP responses, we look at who do we think will be the winners: whether we think will be the winners at a certain space and we like to really target them and try to get them into the ABC portfolio. So I think you could look at it as a matter of happenstance it's a matter of strategically planning the accounts that we believe will be winners in the space."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Great answer, Steve. Could you put a frame around the growth rates in those 2 segments?",16,"Great answer, Steve. Could you put a frame around the growth rates in those 2 segments?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","I think we can maybe look at that and invest it out.  I think we've gotten some of that in the past. But we don't have a framework that we can share right now.",34,"I think we can maybe look at that and invest it out.  I think we've gotten some of that in the past. But we don't have a framework that we can share right now."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Lisa Gill with JPMorgan.",9,"Our next question comes from Lisa Gill with JPMorgan."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I think that you made a comment earlier around your expertise is LIFO this year and within that comment, Tim, I think you talked about branded price inflation being last and more deflation on the generic side. Can you maybe just talk about what actually s",103,"I think that you made a comment earlier around your expertise is LIFO this year and within that comment, Tim, I think you talked about branded price inflation being last and more deflation on the generic side. Can you maybe just talk about what actually saw in this quarter and then what you are seeing in the marketplace around an increase in competition, as far as the number of generic manufacturers that spend a nice steady state at the last couple of years, are you seeing a trend that's perhaps changing a little bit, if we go through the next couple of months?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","In terms of, and when I speak of LIFO, just let me say that we look at it at our portfolio of drugs, which in our mix and in terms of brand, last year we had pretty healthy price increases for brands, slightly above 8%. This year, we're tracking slightly",153,"In terms of, and when I speak of LIFO, just let me say that we look at it at our portfolio of drugs, which in our mix and in terms of brand, last year we had pretty healthy price increases for brands, slightly above 8%. This year, we're tracking slightly below 8% again for our mix of inventory. So a little bit different, a little bit lower. But on the generic side, we really expect that we'll see some deflation, second half of the year, especially on Lipitor and Zyprexa, the generics when they come off exclusivity, which will help and give us a LIFO benefit. In terms of your second question about suppliers. I mean, last year we also had pretty good price appreciation on the generic side. It's still pretty good but that's probably off a little bit this year, it softened a little bit this year, but still pretty healthy."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And then, Steve, just one quick question for you on the oncology side of your business. We know of a number of these pilot programs have been started by Aetna and united around the way they're paying their physician in trying to take the driv",107,"Okay, great. And then, Steve, just one quick question for you on the oncology side of your business. We know of a number of these pilot programs have been started by Aetna and united around the way they're paying their physician in trying to take the drive cost out of the equation, are you seeing that impact your business at all? And what are the physicians saying and it does take hold, what does that mean in longer term, will that change the relationship you have with the physician? Where you'll now have a relationship with one of the managed-care companies, how should we think about that?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, our strategy with the large payers is really to help him understand how important community oncology is. We believe that it's not only important from a clinical perspective but we believe that the patient is best served being in the community, and e",140,"Well, our strategy with the large payers is really to help him understand how important community oncology is. We believe that it's not only important from a clinical perspective but we believe that the patient is best served being in the community, and even the payer is best served by those patients being in the community. So our big effort over there is really to help bring the 2 sides together. We have taken a lot of if in it at ION, our physician services company, primarily focused on the oncology, to help the 2 sides communicate better, have a transparent relationship. And we don't anticipate having a direct relationship with the payer but we intend to help our customers contract more effectively and more transparently with the payers and I think we are making a lot of progress there."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Your next question comes from David Larsen with Leerink Swann.",10,"Your next question comes from David Larsen with Leerink Swann."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","A question for Tim. It looks like, according to my model, your SG&A costs, on a year-over-year basis, declined by about $12 million. Can you describe sort of the cost control process you go through on a quarterly basis? And if that's sustainable?",43,"A question for Tim. It looks like, according to my model, your SG&A costs, on a year-over-year basis, declined by about $12 million. Can you describe sort of the cost control process you go through on a quarterly basis? And if that's sustainable?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Sure, David. I mean, when we looked at the year, I mean, we knew and we guided that Q2 and Q3 will be very tough comparisons, I mean, we knew it going in to the year. And we put word out through our businesses to really manage expenses this year. And we k",125,"Sure, David. I mean, when we looked at the year, I mean, we knew and we guided that Q2 and Q3 will be very tough comparisons, I mean, we knew it going in to the year. And we put word out through our businesses to really manage expenses this year. And we knew we had to focus in this area. So I mean, we looked hard at managing labor and payroll expense. We looked at outside consulting and services and then this year, too, we've had some good discipline and credit collections, and our bad debts are down. So really, it's all of our businesses focusing on headcount, on making sure they spend money prudently and that's going to carryforward into quarters 3 and 4."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And then if I were to look at like, say, 3% of SG&A in fiscal '11, I'm coming up with like $35 million. So for the incremental acquisition cost with like World Courier group and these other ones, will all-in, that would be more than $35 million? And that'",69,"And then if I were to look at like, say, 3% of SG&A in fiscal '11, I'm coming up with like $35 million. So for the incremental acquisition cost with like World Courier group and these other ones, will all-in, that would be more than $35 million? And that's why they'll be -- that's why there's a slight reduction on the operating margin reduction expansion guidance, is that correct?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, in terms of your question, the $35 million, no, I don't think the  all-in -- I mean, we should be under that number. So hopefully that helps you in terms of some guidance but, again, we think we're managing expenses well. We also had the benefit thi",98,"Well, in terms of your question, the $35 million, no, I don't think the  all-in -- I mean, we should be under that number. So hopefully that helps you in terms of some guidance but, again, we think we're managing expenses well. We also had the benefit this quarter and we'll have for the rest of the year in terms of SAP being stable and we're seeing the benefits there. So all in all, I mean, I think what we're saying here is that expense management is offsetting the increases from the special charges and the non-recurring charges."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Great.  And then your merchandise inventory looked like it declined nicely on a sequential basis. Maybe leading to an increase in cash flow guidance? That'll look nice.",27,"Great.  And then your merchandise inventory looked like it declined nicely on a sequential basis. Maybe leading to an increase in cash flow guidance? That'll look nice."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, definitely. Like, David, in my comments, I've mentioned that we've really focused on working capital. All of our businesses are focused on it. Managing AR, managing inventories. So we are seeing some really good reductions in those areas, especially",44,"Yes, definitely. Like, David, in my comments, I've mentioned that we've really focused on working capital. All of our businesses are focused on it. Managing AR, managing inventories. So we are seeing some really good reductions in those areas, especially at our ABSG businesses."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Operator, given we're approaching noon we'll have time for one more question.",12,"Operator, given we're approaching noon we'll have time for one more question."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Okay, our last question comes from the line of Steven Valiquette with UBS.",13,"Okay, our last question comes from the line of Steven Valiquette with UBS."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","So I guess, just one more question on the Express Medco, I'm obligated and at the end here with the -- I think you mentioned in your comments that in some ways you viewed yourself as the primary incumbent on the Express Medco contracts. I guess my questio",115,"So I guess, just one more question on the Express Medco, I'm obligated and at the end here with the -- I think you mentioned in your comments that in some ways you viewed yourself as the primary incumbent on the Express Medco contracts. I guess my question is, are you now happy this is going to an official RFP versus your previous thought pattern over the past 9 months since this deal got announced? Or are you disappointed? Is it because you thought you were the primary incumbent, or are you just indifferent? Just trying to get more color sort of your view now, the new information versus kind of what you thought previously?"
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","I was actually at a NACDS conference and I heard one political pundit speak about the election, and I said incumbency is a 4-point advantage, so... I was just trying to get that incumbent advantage in there. But that's just my view, I mean, I don't know i",140,"I was actually at a NACDS conference and I heard one political pundit speak about the election, and I said incumbency is a 4-point advantage, so... I was just trying to get that incumbent advantage in there. But that's just my view, I mean, I don't know if anyone else has that view. We did, of course, do more business with Medco than the current wholeseller did with ESR so, you could look at it as an incumbency but, I think, that's just really my view, but we are all pleased that this has been decided relatively early in the process. That's very helpful from a planning perspective and, again, it's helped us have a very interesting discussion with ESR. We think that it's a positive for the industry and we think that, potentially, it could be positive for AmerisourceBergen."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve. Now, Steve Collins would like to make some final comments before we go.",15,"Thanks, Steve. Now, Steve Collins would like to make some final comments before we go."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","We know that it's a very busy day, so we really do appreciate everyone's interest and attention with AmerisourceBergen. I would like to commend my colleague and our acting CFO, Tim Guttman, for his leadership and contribution during this transition period",98,"We know that it's a very busy day, so we really do appreciate everyone's interest and attention with AmerisourceBergen. I would like to commend my colleague and our acting CFO, Tim Guttman, for his leadership and contribution during this transition period. As you could see, Tim's really done a great job. So to wrap up, ABC thinks this is a really good quarter for us and especially given our tough comps, and we are proud to report good momentum on all fronts as this halfway point in our fiscal year 2012. Thank you again for your attention."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and before we go, I just like to quickly highlight our upcoming events. On May 17, we'll be presenting at the Bank of America Merrill Lynch 2012 Health Care Conference, in Las Vegas. And on June 6, we will be presenting at the Goldman Sachs",69,"Thanks, Steve, and before we go, I just like to quickly highlight our upcoming events. On May 17, we'll be presenting at the Bank of America Merrill Lynch 2012 Health Care Conference, in Las Vegas. And on June 6, we will be presenting at the Goldman Sachs 33rd Annual Global Health Care Conference. That concludes our call for today. And now I will turn it back to the operator."
24809,183660881,290264,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Thank you. Ladies and gentlemen. This conference will be available for replay after 1:00 p.m. today through midnight, May 3, 2012. You may access the replay service by dialing 1 (800) 475-6701 and entering access code 243852. International participants di",61,"Thank you. Ladies and gentlemen. This conference will be available for replay after 1:00 p.m. today through midnight, May 3, 2012. You may access the replay service by dialing 1 (800) 475-6701 and entering access code 243852. International participants dial (320) 365-3844. This concludes our conference for today. And thank you for using AT&T executive teleconference services. You may now disconnect."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the ABC Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Ms. Barbar",46,"Ladies and gentlemen, thank you for standing by, and welcome to the ABC Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Ms. Barbara Brungess. Please go ahead."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 second quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve Colli",164,"Thank you. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 second quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve Collis, AmerisourceBergen's President and CEO; and Tim Guttman, Vice President, Controller and acting CFO.
During the call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011.
Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by telephone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, and good morning, everyone. I am pleased to report that AmerisourceBergen once again delivered solid quarterly results, and our performance for the first half of our fiscal year 2012 positions us well to meet our objectives for the full year. I",2113,"Thank you, and good morning, everyone. I am pleased to report that AmerisourceBergen once again delivered solid quarterly results, and our performance for the first half of our fiscal year 2012 positions us well to meet our objectives for the full year. In the March quarter, our revenues were up 2% to $20.1 billion. Earnings per share were up 5% to $0.81, and that's on top of a 22% increase in the prior year. 
We generated $236 million in operating cash flow and we repurchased $200 million of our shares. I'm especially proud that we overcame a challenging comp to this quarter, last year, and exceeded our internal profit goals for each business unit. 
During the quarter, we also made excellent progress integrating recent acquisitions and working towards the closing of our World Courier acquisition. Our strong cash generation and high-quality balance sheet continue to provide us with outstanding financial flexibility and give us the ability to fund our strategic initiatives, grow our business and return funds to shareholders. 
AmerisourceBergen is fortunate to be an important part of a growing industry. Demographics and initiatives aimed at expanding access to health care and coverage -- and health care coverage, should continue to drive organic growth in our industry over the next several years. In addition, launches of new pharmaceuticals, as well as new indications for existing drugs should also drive sales growth over the next several years. Whether the new therapies are traditional oral medications or complex biotech pharmaceuticals, AmerisourceBergen is well positioned to not only benefit from the distribution of new products, but also to offer pre-launch and commercialization services to manufacturers and to support patient access and reimbursement programs to help ensure that patients have access to life-saving therapies and that the products achieve their full potential in the marketplace. 
At our verse [ph] revenue base positions us well to benefit from organic growth driven by demographics, and our customer mix puts us in a favorable position to continue to benefit from the historic influx of generics. As you know, generics mitigate the topline dollar growth in our industry but drive tremendous value for wholesalers, health care providers and patients alike. In addition, close scrutiny of health care expenses and cost-containment efforts underway by the federal government and other payers also drives demand for our services, most notably in our Consulting Services group. 
Over the last several years, we have significantly strengthened our relationship with pharmaceutical manufacturers, and we continue to look for meaningful ways to provide additional services across the supply channel to help them ensure they meet the challenges of today's changing health care landscape. As our provider customers face similar challenges regarding cost-containment and reimbursement for services provided to patients, they increasingly turn to AmerisourceBergen. We help in making their health care practices run as efficiently and effectively as possible.  
Our provider customers work hard every day to provide world-class patient care, and we believe they deserve fair reimbursement for the professional services they provide. AmerisourceBergen is an active participant participating in policy discussions in Washington, D.C. with the objective of helping legislators understand our industry and our importance to the health care system. 
Our associates are focused on meeting our objectives for the year, both in terms of providing outstanding service to customers and in our financial performance. They continue to seek creative ways to meet the challenges in the diverse markets we serve and identify new opportunities to add value through collaborative innovation and by maximizing efficiency. I take great pride in their enthusiasm and dedication, and it is my honor to work beside them. 
Turning now to our business units. AmerisourceBergen Drug Corporation, as expected, had flat revenue in the quarter as strong performance in the institutional segment was offset by the previously disclosed loss of a large retail customer. Topline growth was also mitigated by the impact of generic convergence, including decreased sales to our largest customer. 
Our ABDC associates did a stellar job this quarter managing several generic launches, including 5 different generic products that launched within one week. Year-to-date, the generic launches have performed as planned and we, of course, look forward to several more launches still to come in the second half of the year. 
With over 4,600 members, our Good Neighbor Pharmacy network, the third largest network of pharmacies in the U.S., continues to play a crucial role in providing pharmacy care nationwide. Patients prefer choice when determining where to fill their prescriptions, and our retail customers are very adept at fulfilling unique patient needs and at adapting to the changing needs of the marketplace. 
Our ASHP implementation continues to run smoothly with 8 distribution centers conversions complete, 2 additional conversions occurring tomorrow, and the remainder planned for the beginning of 2013. As we have gained experience with the new system, particularly with the corporate and back-office functions, we have already begun to realize some operational savings, which is reflected, in part, in the good performance we had on the expense line this quarter. 
Our investments in our Canadian operations to support significant new business wins continued in the March quarter. Our associates have done a tremendous job setting up 4 new distribution centers in 6 months, in order to support this new business. There is still much work to be done, but we are confident that our expansion efforts will meaningfully increase the value we bring to both independent pharmacies and especially providers in the Canadian market.
As we noted in the press release, following the closing of the merger of Express Scripts and Medco in early April, we amended our existing Medco agreement to provide for the contract to end upon the award and implementation of one or more new pharmaceutical distribution agreements for the newly combined business. Express Scripts has issued an RFP for the combined business, and anticipate that the new contract, or contracts, will begin on October 1, 2012. We are participating fully in the competitive RFP process, and we intend to pursue this opportunity to retain or grow the business under a new contract. We have had an excellent working relationship with Medco for over 2 decades, and we are excited about the opportunity to demonstrate the value we can bring to the newly combined entity. 
AmerisourceBergen Specialty Group had another strong quarter with revenues up 6% with particularly strong performance in third-party logistics and in our vaccine and physician distribution business. Our oncology business performed well, while facing a very difficult comparison due to the strong performance of the 3 large Besse generic products last year. While our Specialty Group is best known for our oncology franchise, we are an instrumental part of the commercialization strategy for any infusible product launched into the physician marketplace. We continue to execute very well on the launch of a new brand of ophthalmology product establishing significant market share in what was the first full quarter of the introduction. 
Our Specialty Group often collaborates with our Consulting Services group to help ensure patients have access to products by utilizing the full suite of capabilities of our physician networks, as well as our reimbursement and patient support program expertise. For example, we recently helped a manufacturer launch a new biotech product. And during the March quarter, we were able to not only achieve the leading market share for the distribution of the product, but also to provide third-party logistics, contract packaging and all of the reimbursement and patient support programs for the product across the market. We are very proud that these combined service offerings provide unmatched value to manufacturers and distinguish AmerisourceBergen in the marketplace. As we look at the products in development pipelines today, we believe that we will win even more of these opportunities in the future, which will be an important driver of our growth in the years ahead. 
Our Consulting Services group delivered a very strong quarter, while making excellent progress in the integration of TheraCom and Premier Source, which are both performing very well. The last group had the strongest quarter in its history, even without the contributions from TheraCom. While the group only represents about 2% of our revenues, we believe our packaging and consulting services provide essential expertise to pharmaceutical manufacturers to help ensure that their products are brought to market as safely, quickly and efficiently as possible. In addition, our reimbursement expertise helps ensure that patients who can benefit from both new and mature therapies have access to the products. 
We continue to make good progress towards closing our most recent acquisition, World Courier. As we deepen our knowledge and understanding of their business, I am more convinced than ever that World Courier affords us the opportunity, not only to acquire the market leader in premium niche clinical trial logistics services, but also to begin to build out a framework to expand our consulting and commercialization services beyond North America. 
In this current quarter, we will begin operating in 50 new international markets and employ about 1,500 new associates outside North America. This is significant expansion for ABC, and we are tremendously excited about welcoming the World Courier team to ABC. 
In addition, we are exploring ways to potentially expand some of our niche Specialty Distribution services into select markets as well. We expect to close the acquisition next week, at the end of April, and I'm very excited about the potential we see in the World Courier platform in the years ahead. 
Given the continued strength of our balance sheet, we continue to look for acquisitions that meet the criteria we've had in place for quite some time. They should increase our value offering to existing customers both up and down the channel, they should be within our established core competency and they should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions and we continue to be interested in opportunities in pharmaceutical and Specialty Distribution and Services, as well as consulting and packaging services. While we, historically, have been very comfortable in the $200 million to $300 million range, we will consider selling larger, as we did with World Courier, if it made good strategic sense and would deliver value to our company and our shareholders. 
Looking ahead, the results we've had in the first half of our year have positioned us well to meet our objectives for the full fiscal year. We have a difficult comparison to overcome in 2012, but we continue to expect GAAP earnings per share to be within the range of $2.74 to $2.84, and we are tracking towards the midpoint of that range. Tim will provide the details in our assumptions for the remainder of the year, but I want to highlight that we continue to remain disciplined on expenses, our cash flows are strong and we have increased our share repurchase assumption for the year. 
Looking further ahead to 2013, we should have a carryover from some of the launches that occur late in our fiscal 2012, including the relaunch of Oxaliplatin, and we should begin to benefit from the completion of our ASHP implementation. In fiscal 2014, we should begin to see this 30 million to 40 million uninsured patients enter the health care market, driving demand for pharmaceuticals that should carry over into 2015 and beyond. In addition, 2014 and 2015 are expected to be good years for generic conversions. And, of course, there's a chance that biosimilars may also come to market in that time frame. 
Before turn it over to Tim, I want to reiterate the confidence that I have in our business and in our future. Demand is strong for the products we distribute, and we play an essential role in pharmaceutical supply channel. We've positioned ourselves well to continue to benefit from the 2 key growth drivers, generics and specialty products, and we have continued to invest in our distribution and in our services businesses. 
Over the last year, we were summating important investment in other areas of our business with an eye to the future. We expect demand for specialty products to continue to grow, not only the U.S. but throughout the world, and the commercialization and reimbursement support services we provide to manufacturers will help support that growth. As cost containment efforts continue to cross the health care landscape, our customers increasingly turn to us for help in meeting the challenges of the marketplace without sacrificing patient care. Finally, the vision and innovative ideas that our associates bring to market every day set us apart in our industry, and I am proud to be their leader. Here is Tim."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and good morning, everyone. It's my pleasure to be participating in my first earnings call as acting CFO. And I am pleased to report another solid ABC quarter and, most importantly, that our Q2 results are on track with our internal plan.",1502,"Thanks, Steve, and good morning, everyone. It's my pleasure to be participating in my first earnings call as acting CFO. And I am pleased to report another solid ABC quarter and, most importantly, that our Q2 results are on track with our internal plan. 
The highlights this quarter: excellent topline growth at our Specialty and Consulting businesses; very good execution on new generic launches and continued focus on expense management across the organization; and finally, another quarter of strong cash generation. 
Now let's turn to the quarterly details. And starting with the topline, revenues were $20.1 billion, a 1.6% increase over last year's quarter. Drug company revenues were essentially flat, as we guided. We had strong performance in our alternate site and health system segments, offset by the loss of a large chain customer last year, as well as the impact from brand to generic conversions. 
The Specialty Group revenues increased 6%, led by 2 of our businesses with above market growth. ICS, our third-party logistics business and Besse Medical, our vaccine and physician office distribution business, which benefited from a full quarter impact of sales of a new ophthalmology drug. 
The Consulting group, though small to the overall topline, continues to perform well. Excluding their TheraCom acquisition, they had over 20% topline growth. TheraCom contributed just under 1% of our overall revenue growth in the quarter. 
Moving to gross profit. Gross profit was $695 million in the quarter, up 1.1% from last March, with a gross margin of 3.46% in the quarter, down about 2 basis points from last year. As we have discussed in the past, our second quarter was a very tough comp, due to the significant contribution in the prior year from oncology generics. In the second quarter 2011, these oncology drugs contributed about $0.16 of EPS to our results. Our gross margin expanded 31 basis points in the March 2011 quarter. This year, we are able to effectively offset this headwind with contributions from the new oral solid generics, as well as the lower contribution from oncology generics and gross profit contributions from our acquired companies. 
Additionally, our LIFO charge was approximately $4 million in the quarter, down $10 million from last year. We continue to expect our LIFO charge will be approximately $15 million, down significantly from last year. Our annual LIFO forecast is based on our expectation that brand price inflation will be somewhat less this year. And more importantly, we will see significant generic price deflation in the second half of our fiscal year related to key brand to generic conversions coming off exclusivity. 
Finally, the benefit we received from the new generic launches, and also price appreciation, was in line with our expectations. This quarter, we did an excellent job controlling our operating expenses. Operating expenses were approximately $327 million, up 1.5%. However, this amount includes the operating expenses of about $11 million from our recently acquired companies. Additionally, we had $9 million of executive severance and acquisition-related transaction costs. Operating expenses would've been down, excluding the impact of our acquisitions, due to lower compensation costs, including benefits. 
Additionally, our SAP implementation is progressing well at the corporate level. The system has reached a level of stability faster than we expected, enabling us to realize some early savings, especially with external consultants. 
Last quarter, our guidance was an annual expense increase of about 3%, due to our acquisitions. As an organization, we continue to exercise discipline and focus on managing expenses. We now expect our total operating expenses for our base business, before adding World Courier, to be essentially flat for the year. 
Operating income of $368 million in the quarter increased about 1%, while operating margin was down 2 basis points compared to last March. Our current quarter was slowed by the $9 million of executive severance and acquisition transaction costs. Excluding these nonrecurring expenses, our operating income margin would've expanded 3 basis points to 1.88%. 
Moving below the operating income line, interest expense of nearly $24 million in the March quarter increased 25% compared to last year, primarily as a result of our $500 million bonds we issued back in November. The proceeds help to fund the TheraCom acquisition and will also contribute to the retirement of our 2012 bonds that mature in mid-September. Our effective income tax rate of 38.4% was slightly higher than last year's 38.1% and is right in line with our expected annualized rate of 38.4%. 
Our diluted GAAP earnings per share in the quarter of $0.81 increased by $0.04, or 5%, over the same quarter last year. And again, overcoming a $0.16 headwind from the contribution from specialty generics in the March 2011 quarter. Our EPS benefited from a reduction in our average diluted shares related to our ongoing share repurchase program. Average diluted shares for the quarter were approximately 262 million, down just over 6% from last March. 
Now let's turn to our balance sheet and cash flows, where trends continue to be very favorable. We generated $236 million of cash from operations in the quarter, bringing our 6-month total to $668 million, compared to generating $577 million for the first 6 months last year. We continue to manage AR and inventory levels very closely, and this has benefited our working capital this year. With our daily revenue volume exceeding $300 million per business day, our quarter-end working capital snapshots are subject to volatility. Therefore, our 6-month cash results cannot be extrapolated to determine a full year cash flow estimate. 
Capital expenditures were $40 million in the quarter and $88 million for the 6 months. During the last 2 years, we put a number of capital projects on hold as we focused on SAP. We have a pipeline of attractive internal projects that we have begun to pursue as our SAP deployment moves along. 
Additionally, we have CapEx associated with our recent TheraCom acquisition. Because of this, we will exceed our previous target of $150 million for CapEx, and we will be closer to $200 million for the year. Even with this additional CapEx, we expect that our free cash flow will now be in the $800 million to $900 million range. 
During the quarter, we bought back $200 million of our shares. For 6 months, we've purchased $320 million of shares. At March 31, we have approximately $180 million left on our current share repurchase authorization. In terms of key financial metrics that we track, our average day sales in inventory for the quarter remained at 14 days, consistent with fiscal '11. Average DSOs of 18 days in the March quarter were up slightly from 17.3 days last year. And favorable payables timing helped raise average quarterly DPOs by over 3 days compared to fiscal '11. 
With our recent debt offering, our gross debt, the total debt and capital ratio, at the end of March, was 39%, above our target range of 30% to 35%. And it will remain above the range until we pay off our $400 million of debt in September. Our cash balance at March 31 was $2.3 billion. Keep in mind that we will be funding our World Courier acquisition from cash and we will be paying down debt in September, as previously mentioned. After these 2 large cash outlays, we will still have financial flexibility to fund CapEx and strategic initiatives and return to capital -- and return capital to our shareholders. 
Now let's turn to updated fiscal 2012 guidance. We expect our diluted GAAP EPS to track to the middle of the range we previously provided, $2.74 to $2.84. Our assumption for revenue growth remains unchanged, flat-to-modest revenue growth. We expect our operating margin expansion to be in the high-single-digit basis points. Free cash flow will now be in the $800 million to $900 million range. And we are raising our guidance for share repurchases for the year to $500 million, which will complete our current share repurchase authorization. 
Looking ahead, I would like to remind everyone that Q3 is another challenging comparison for us because of the $0.17 EPS contribution from oncology generics last year. Also in Q3 2012, we have 2 of the large generics coming off exclusivity. When looking out to the second half of the year, we believe Q4 will be somewhat of an easier comparison. With the return of Oxaliplatin for half a quarter, a few favorable year-end generic launches for the Drug Company and favorable expense comparisons year-over-year. 
So before I turn it back to Barbara, let me reiterate, that 6 months into the fiscal year, we are performing well in our key areas of the business, and we are well positioned to meet our financial targets for fiscal 2012. 
One final point, I'd like to take a moment and thank our ABC associates, especially those in the finance and accounting areas that have stepped up the last 2 months and helped support the organization and me, in particular, during our CFO transition period. Thanks, everyone. Here's Barbara to start our Q&A."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives",".Thank you, Tim. Operator, we'll now open the call to questions. [Operator Instructions] Go ahead, operator.",16,".
Thank you, Tim. Operator, we'll now open the call to questions. [Operator Instructions] Go ahead, operator."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Glen Santangelo with Crdit Suisse.",15,"[Operator Instructions] Our first question comes from the line of Glen Santangelo with Crdit Suisse."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I just want to quickly follow up, Tim, with respect to some of your comments on the operating margin expansion goals for the year. Previously the company had expected operating margin expansion in the high single-digit, kind of low double-digit range and",95,"I just want to quickly follow up, Tim, with respect to some of your comments on the operating margin expansion goals for the year. Previously the company had expected operating margin expansion in the high single-digit, kind of low double-digit range and now, it seems like you're suggesting high single-digit. I guess -- could just give me a sense for maybe what has changed in that thinking? And I know there were some onetime costs that you're now embedding in your estimates, and I'm curious if there's anything else that I should be thinking about."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, we changed our guidance to high single-digit. In terms of looking out, we did an assessment of the full year, and looking out, we had some deal costs in Q2 and some onetime items, nonrecurring items. And as we look out, we're going to have some simila",89,"No, we changed our guidance to high single-digit. In terms of looking out, we did an assessment of the full year, and looking out, we had some deal costs in Q2 and some onetime items, nonrecurring items. And as we look out, we're going to have some similar costs in Q3 with the World Courier transaction. So when we look out and do a reassessment, we felt more comfortable that high single-digit was a realistic target for us for the year, and there's really nothing else factored into that."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And, Tim, maybe if I could just ask a follow up on the World Courier group. You originally sort of guided $0.06 to $0.10 worth of accretion and I'm kind curious, is there anything embedded from an accretion standpoint in your fiscal '12 guidance as it rel",82,"And, Tim, maybe if I could just ask a follow up on the World Courier group. You originally sort of guided $0.06 to $0.10 worth of accretion and I'm kind curious, is there anything embedded from an accretion standpoint in your fiscal '12 guidance as it relates to World Courier? And it kind of sounds like you're going to be taking down some integration costs or acquisition-related costs next quarter. I don't know if you care to size those at this point."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Glen, no. We will have some transaction-related acquisition costs in Q3. Probably not more than the number that we had for Q2. And there is no accretion in our numbers for this fiscal year. We expect it to be neutral. And in terms of next year, for fiscal",59,"Glen, no. We will have some transaction-related acquisition costs in Q3. Probably not more than the number that we had for Q2. And there is no accretion in our numbers for this fiscal year. We expect it to be neutral. And in terms of next year, for fiscal '13, we're still confident with that guidance of $0.06 to $0.10."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Larry Marsh with Barclays.",9,"Our next question comes from Larry Marsh with Barclays."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","So my question is as follows, Steve, around Medco. Here you're communicating -- I guess, is it fair to say that you voluntarily agreed to move up the termination date of your Medco relationship by 6 months? And if so, is there any benefit for doing so, an",101,"So my question is as follows, Steve, around Medco. Here you're communicating -- I guess, is it fair to say that you voluntarily agreed to move up the termination date of your Medco relationship by 6 months? And if so, is there any benefit for doing so, and possibly foregoing that profit stream? And then just around the topic, I wanted to confirm, you said you've already have a relationship with Express Scripts. How long have you had that? And then have you disclosed or in a position to comment about the length of the suggested new contract under the RFP?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","First of all, obviously, we are part of a very active process here and we want to be very respectful of that and some of the questions should really be directed to the buyer. But I think ABC, as you know, has been very proud of over 2 decades of service t",194,"First of all, obviously, we are part of a very active process here and we want to be very respectful of that and some of the questions should really be directed to the buyer. But I think ABC, as you know, has been very proud of over 2 decades of service to Medco and now, you could almost say we are the incumbent here because we've had such a long relationship. So we wanted to demonstrate flexibility. We wanted to recognize that this is a new entity that has their own requirements and will have a different dynamics to relationship. And now it just made sense for us to be concurrent with the current requirements. So we demonstrated flexibility. We demonstrated that ABC is a good partner and listens to our customers and I think that, that will hopefully put us in a good position throughout the contracting process, but it will be competitive. And, I guess, the only internal benefit I can point to is that this is concurrent with our fiscal year, and whatever happens, we'll be in a good position to plan for it and to communicate that to our investors."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So it sounds like you're uncomfortable commenting about the length of the contract as proposed in the RFP at this point.",22,"Okay. So it sounds like you're uncomfortable commenting about the length of the contract as proposed in the RFP at this point."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","As far as we know, as far as we could say, it's pretty standard type of contract term.",18,"As far as we know, as far as we could say, it's pretty standard type of contract term."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Right. So we assume, maybe 3 years, but again, not commenting. And I guess just a follow-up to you and Tim around SAP implementation, we appreciate the update there. If you let it to go back or remember some of the bigger expenses for this, seemed to be f",90,"Right. So we assume, maybe 3 years, but again, not commenting. And I guess just a follow-up to you and Tim around SAP implementation, we appreciate the update there. If you let it to go back or remember some of the bigger expenses for this, seemed to be fiscal '10 and '11, $40 million to $50 million a year, you've mentioned, Tim, stability sooner than you thought. Can you ballpark kind of expenses around SAP for you this year? And how do we think about that comparable to next year?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Larry, our guidance has been that we'll see some benefit for SAP next year, 6 months after our last DC deployment, so we expect that to be in Q4, and we've guided to $10 million. And we expect the full benefit of about $40 million to be in '14. And s",103,"Yes. Larry, our guidance has been that we'll see some benefit for SAP next year, 6 months after our last DC deployment, so we expect that to be in Q4, and we've guided to $10 million. And we expect the full benefit of about $40 million to be in '14. And so far, the benefit that we've had this year for SAP is really incremental for that. I mean, this is just expense that we've been able to take out of our operating budget, which has probably been a few million dollars. So again, they're separate. One's not a part of the other."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I got it. Right. Expenses associated with consultants and such, but again, $10 million incremental next year, $40 million for '14. And then just to clarify, I think it's an important point, the guidance confirming the range, but you're suggesting the $0.0",75,"I got it. Right. Expenses associated with consultants and such, but again, $10 million incremental next year, $40 million for '14. And then just to clarify, I think it's an important point, the guidance confirming the range, but you're suggesting the $0.02, which was the severance and transaction cost this quarter and the $0.02 which -- ballpark of transaction cost next quarter, are included now in that range. You're not breaking that out at all?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, absolutely, Larry. We're GAAP, and we include that in.",10,"No, absolutely, Larry. We're GAAP, and we include that in."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And again, you're saying that's a big reason why you're top and the operating margin expansion has been pulled down?",20,"And again, you're saying that's a big reason why you're top and the operating margin expansion has been pulled down?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Absolutely.",1,"Absolutely."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Robert Jones with Goldman Sachs.",10,"Our next question comes from Robert Jones with Goldman Sachs."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Just to go back to the Express Scripts contract. Steve, it sounds like -- you mentioned contract, or contracts, so I'm assuming there's some suggestion that it could be broken up. Any insight into this view or maybe, more importantly, what benefit that wo",52,"Just to go back to the Express Scripts contract. Steve, it sounds like -- you mentioned contract, or contracts, so I'm assuming there's some suggestion that it could be broken up. Any insight into this view or maybe, more importantly, what benefit that would create for Express to have this contract separated?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think, in terms of processing, there's not much differentiation between s $10 billion contract, or a $15 billion, or $20 billion contract, it's just that, that is the way these large contracts tend to go. And there could be some geographical, regi",105,"Well, I think, in terms of processing, there's not much differentiation between s $10 billion contract, or a $15 billion, or $20 billion contract, it's just that, that is the way these large contracts tend to go. And there could be some geographical, regional benefit, based on where they're planning to have their large mail-order sites, there could be a way to separate the specialty business with the core mail-order business. So we have 2 big specialty units so -- but again, these are questions that we probably are not that comfortable commenting on and could probably be best be directed to Express Scripts, sir."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","No, I definitely appreciate that. And I guess just one follow-up, Steve. Given the somewhat more acquisitive nature of the company as of late, and I know you've gotten this question before and I imagine as you continue to do acquisitions, you might get it",75,"No, I definitely appreciate that. And I guess just one follow-up, Steve. Given the somewhat more acquisitive nature of the company as of late, and I know you've gotten this question before and I imagine as you continue to do acquisitions, you might get it more in the future, relative to your peers. Any thoughts or discussion between you and Tim about moving to a cash EPS, or at least breaking out a cash EPS?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, we haven't. We lack -- we think we report not only good earnings, but very high quality earnings and, at the moment, that hasn't been under consideration.",28,"No, we haven't. We lack -- we think we report not only good earnings, but very high quality earnings and, at the moment, that hasn't been under consideration."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","And we, in our public company filings, we feel we give pretty good disclosure on some of those differences, especially around intangibles. And the reader of those documents can go ahead and do that calculation.",35,"And we, in our public company filings, we feel we give pretty good disclosure on some of those differences, especially around intangibles. And the reader of those documents can go ahead and do that calculation."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Tom Gallucci with Lazard.",9,"Our next question comes from Tom Gallucci with Lazard."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I was wondering if you could expand on some of your prepared remarks around sort of international and how you see the opportunity may be there over -- not the near-term necessarily but the next few to 5 years, it sounds like maybe World Courier is",71,"Steve, I was wondering if you could expand on some of your prepared remarks around sort of international and how you see the opportunity may be there over -- not the near-term necessarily but the next few to 5 years, it sounds like maybe World Courier is a bit of a platform that you could grow from in different ways, so if you have any thoughts there, it would be appreciated."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well there's a couple of things. First of all, again, we do $300 million in revenue a day, as ABC, but one of the things we've been very, very happy with is our specialty performance in Canada. This is -- this market works differently than it does in the",375,"Well there's a couple of things. First of all, again, we do $300 million in revenue a day, as ABC, but one of the things we've been very, very happy with is our specialty performance in Canada. This is -- this market works differently than it does in the U.S., but we've been able to do some joint programs, we've been able to help with a more complex reimbursement environment there, including a pretty robust product market that we -- that is not generally known. At least here, in the U.S., we think about it as single-payer market, that hasn't been the case. We've been able to help, we have a very strong presence with new infusible drugs. So what we've seen is a manufacturer environment that ABC is very comfortable in contracting with, that is looking for us to get into more countries. So we've been prompted to look at international opportunities by manufacturers. Then comes World Courier, we're in 50 new countries as of next week, hopefully. We have 1,500 associates that are very tenured. We've been extremely impressed with the quality of the World Courier associates. As you know, health care is very local. So we think that we have an opportunity to understand health care markets, both organic and acquisitive opportunities, with people on the ground there who speak the language and know the trends, know who's the right players, the ethical players, the high quality players in that environment. And we think that, that's going to give us a good opportunity. We also think that as the products that World Courier is managing are commercialized, as more and more of those products are commercialized and come to market as -- middle class is growing in some countries that we haven't traditionally thought about as being big [indiscernible] sort of -- and especially consumers of products, we think we're going to have an opportunity to participate in those commercialization strategies. Think about it, World Courier has handled those products, they know the treatment centers, they know the environment. So we think that we have to recharacterize part of the business, but we think we can do that, so long answer, but as you can tell, I'm very enthusiastic about this."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Sure, that's clear. And then maybe just one housekeeping item. On the CapEx, can you sort of breakdown your maintenance CapEx versus maybe what's additional and some of those projects that you highlighted earlier, do they seep into next year? Should we as",58,"Sure, that's clear. And then maybe just one housekeeping item. On the CapEx, can you sort of breakdown your maintenance CapEx versus maybe what's additional and some of those projects that you highlighted earlier, do they seep into next year? Should we assume that it comes back down a little bit, or how are you thinking about that?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Good question. No, we -- when we look at maintenance CapEx, we think it's typically between about $100 million and $120 million. We have some big projects this year supporting our expansion up in Canada. We're looking at another DC project in the U.S. in",91,"Good question. No, we -- when we look at maintenance CapEx, we think it's typically between about $100 million and $120 million. We have some big projects this year supporting our expansion up in Canada. We're looking at another DC project in the U.S. in terms of expansion, automation, renovation and our TheraCom acquisition. So I would say that the $200 million is probably a peak, and it definitely should come down next year. Probably about half of the maintenance CapEx is probably a good -- kind of a good range."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from the line of Robert Willoughby with Bank of America Merrill Lynch.",16,"Our next question comes from the line of Robert Willoughby with Bank of America Merrill Lynch."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, what kind of clarity do you actually have on -- does the RFP provide for you? I mean, I assume you would have size of the potential contract, the mail footprint you'd be serving, whether or not specialty would be there. I mean, are there some thing",58,"Steve, what kind of clarity do you actually have on -- does the RFP provide for you? I mean, I assume you would have size of the potential contract, the mail footprint you'd be serving, whether or not specialty would be there. I mean, are there some things you could disclose there that would be helpful for us?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","I think, we partly said, Bob, I appreciate your interest in this and, believe you me, I am really interested in this and the ABC team is very interested in this. We're just participating fully in the RFP process, it has just begun. So I could tell you we",118,"I think, we partly said, Bob, I appreciate your interest in this and, believe you me, I am really interested in this and the ABC team is very interested in this. We're just participating fully in the RFP process, it has just begun. So I could tell you we really don't -- we think it's in the range of about a $20 billion contract. So I will tell you that Medco peaked with ABC at about 19% of our revenues in fiscal year 2011, and it's come off a few percent from that, and our current run rate is more in the mid-teens, 16% range. So we could potentially gain some couple billion dollars in new revenue here."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And any sense on timing, when a decision will ultimately be made, obviously, before October 1. But how much time would you need? And do you anticipate if you win, is there investment you need to make or in the unfortunate event you don't win, what k",61,"Okay. And any sense on timing, when a decision will ultimately be made, obviously, before October 1. But how much time would you need? And do you anticipate if you win, is there investment you need to make or in the unfortunate event you don't win, what kind of offsets we might see to your cost structure, some initiatives you'd pursue?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, we're mainly servicing the current business out of 3 DCs, and we certainly would start giving consideration to what it could mean if we lose. But from a more exciting basis, I think we do have the capacity to service this business without much incre",70,"Well, we're mainly servicing the current business out of 3 DCs, and we certainly would start giving consideration to what it could mean if we lose. But from a more exciting basis, I think we do have the capacity to service this business without much incremental investment. And we look forward to talking about the different capabilities that ABC brings to the table. And we're participating fully in this contract."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And timing, Steve? Anything?",4,"And timing, Steve? Anything?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, I just think you know -- I think you know -- you cover Express Scripts. You know they move quickly, so that's all I can tell you. They don't let the grass grow under their feet. So we expect them to have a very active and quick and decisive process un",82,"No, I just think you know -- I think you know -- you cover Express Scripts. You know they move quickly, so that's all I can tell you. They don't let the grass grow under their feet. So we expect them to have a very active and quick and decisive process unlike this other very public contract that we went through very recently. So that should make everyone happy, at least, we'd all know where we stand very quickly. We believe so."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Ricky Goldwasser with Morgan Stanley.",10,"Our next question comes from Ricky Goldwasser with Morgan Stanley."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Just a quick follow-up [ph] on the Medco Express side, from what we understand, specialty is included in your relationship with legacy Medco. Should we assume that the services that you provided to Medco on the specialty side are more of wholesale-type se",63,"Just a quick follow-up [ph] on the Medco Express side, from what we understand, specialty is included in your relationship with legacy Medco. Should we assume that the services that you provided to Medco on the specialty side are more of wholesale-type services, or do you also provide them kind of like the added value services that's associated with your specialty business?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","We are both the wholesaler to the former Accredo division, the Accredo division of Medco, and now will be Express Scripts. And we have, obviously, worked very collaboratively with them in many areas including the hospital, pharmacy area and the specialty",97,"We are both the wholesaler to the former Accredo division, the Accredo division of Medco, and now will be Express Scripts. And we have, obviously, worked very collaboratively with them in many areas including the hospital, pharmacy area and the specialty area. So I can't -- I'm not comfortable pointing to any particular program, but certainly as our largest customer, we spend a lot of time working on common approaches to the marketplace, and we would expect to bring that expertise and that market knowledge and the manufacturer relationships that we have to the combined entity now."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, and then I have a couple of just questions from modeling purposes. For the SG&A level for the remainder of the year, should we assume same level as we saw in the March quarter or should we see a step up, and if so, can you quantify for us? And is it",57,"Okay, and then I have a couple of just questions from modeling purposes. For the SG&A level for the remainder of the year, should we assume same level as we saw in the March quarter or should we see a step up, and if so, can you quantify for us? And is it related to World Courier?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","We, at this point, Ricky, we don't have World Courier finished yet, completed. But definitely with World Courier coming in 2 months in quarter 3 and we'll have them for the entire Q4, they will add extra expense. When I gave the guidance today this mornin",91,"We, at this point, Ricky, we don't have World Courier finished yet, completed. But definitely with World Courier coming in 2 months in quarter 3 and we'll have them for the entire Q4, they will add extra expense. When I gave the guidance today this morning, again, I was talking about the core business being flat. For the core business, we will see a little bit of a step up in 3, but probably not dramatic. And again, we will have some nonrecurring acquisition-related cost in Q3, probably not in Q4."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And then can you just qualify to us the impact from a basis point perspective of the acquisitions on the margins for this quarter?",25,"Okay. And then can you just qualify to us the impact from a basis point perspective of the acquisitions on the margins for this quarter?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","In terms of SG&A?",5,"In terms of SG&A?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","SG&A or operating margin.",5,"SG&A or operating margin."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well again, we commented that we had about $11 million of SG&A expense in the quarter from our acquisitions, primarily TheraCom. So again, it's probably 4, 3, 4 basis points.",30,"Well again, we commented that we had about $11 million of SG&A expense in the quarter from our acquisitions, primarily TheraCom. So again, it's probably 4, 3, 4 basis points."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Eric Coldwell with Robert W. Baird.",11,"Our next question comes from Eric Coldwell with Robert W. Baird."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I think a lot of the timely questions have been answered, so I'll shift gears a bit. Health systems and alternate site in your drug company, sound like another good quarter there, above market growth, perhaps. I'm curious if you can define what's leading",121,"I think a lot of the timely questions have been answered, so I'll shift gears a bit. Health systems and alternate site in your drug company, sound like another good quarter there, above market growth, perhaps. I'm curious if you can define what's leading to this growth. It must be share capture, I don't want to lead you too much, but the market's clearly not growing at a rapid pace. You're primarily doing pharmaceuticals and not the other broad med service lines or other services into the health systems. So could you just give us some better sense on what's driving that growth in health systems and alternate site and then perhaps if you could frame it, would be helpful, too."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well with health systems, we think we have a market share that is, at least comparable, maybe even the largest in the U.S. We believe we're with the right customers, we believe that we're growing with them. We believe that we have some nice little service",261,"Well with health systems, we think we have a market share that is, at least comparable, maybe even the largest in the U.S. We believe we're with the right customers, we believe that we're growing with them. We believe that we have some nice little services that we provide that maybe don't get the headlines, but they are additive to their business, like helping them with 340B consulting, helping them with price pharmacy. So we have a very good practice in health systems, and we believe we're with the companies that are the leaders in that space, and I think some of our customers are there. Likewise with alternate care, I think ABC has been a leader there. Certainly our knowledge of specialty and our ability to offer an integrated solution on the specialty and drug wholesale side and our knowledge of the manufacturing environment and the patient environment and the reimbursement environment has been very, very helpful. And the Humana contract, we think ,was a direct result of that knowledge, and that's a very fast grower. We're with a lot of the companies that are growing faster than the market and when we discuss potential RFP responses, we look at who do we think will be the winners in a certain space, and we like to really target them and try to get them into the ABC portfolio. So I think you could look at it as it's not a matter of happenstance, it's a matter of strategically planning the accounts that we believe will be winners in the space."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Great answer, Steve. Could you put a frame around the growth rates in those 2 segments?",16,"Great answer, Steve. Could you put a frame around the growth rates in those 2 segments?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","I think we can maybe look at that and invest it out.  I think we've done some of that in the past. But we don't have a framework that we can share right now.",34,"I think we can maybe look at that and invest it out.  I think we've done some of that in the past. But we don't have a framework that we can share right now."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Lisa Gill with JPMorgan.",9,"Our next question comes from Lisa Gill with JPMorgan."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I think that you made a comment earlier around your expectations for LIFO this year and within that comment, Tim, I think you talked about branded price inflation being less and more deflation on the generic side. Can you maybe just talk about what you ac",103,"I think that you made a comment earlier around your expectations for LIFO this year and within that comment, Tim, I think you talked about branded price inflation being less and more deflation on the generic side. Can you maybe just talk about what you actually saw in this quarter and then what you are seeing in the marketplace around an increase in competition, as far as the number of generic manufacturers that spend a nice steady state the last couple of years, are you seeing a trend that's perhaps changing a little bit, as we go through the next couple of months?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","In terms of -- and when I speak of LIFO, just let me say that we look at our portfolio of drugs which -- in our mix and in terms of brand, last year we had pretty healthy price increases for brands, slightly above 8%. This year, we're tracking slightly be",153,"In terms of -- and when I speak of LIFO, just let me say that we look at our portfolio of drugs which -- in our mix and in terms of brand, last year we had pretty healthy price increases for brands, slightly above 8%. This year, we're tracking slightly below 8% again for our mix of inventory. So a little bit different, a little bit lower. But on the generic side, we really expect that we'll see some deflation, second half of the year, especially on Lipitor and Zyprexa, the generics when they come off exclusivity, which will help and give us a LIFO benefit. In terms of your second question about suppliers. I mean, last year we also had pretty good price appreciation on the generic side. It's still pretty good, but that's probably off a little bit this year, it's softened a little bit this year, but still pretty healthy."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And then, Steve, just one quick question for you on the oncology side of your business. We know of a number of these pilot programs that have been started by Aetna and United around the way they're paying their physician in trying to take the",108,"Okay, great. And then, Steve, just one quick question for you on the oncology side of your business. We know of a number of these pilot programs that have been started by Aetna and United around the way they're paying their physician in trying to take the drug cost out of the equation, are you seeing that impact your business at all? And what are the physicians saying? And if it does take hold, what does that mean longer term, will that change the relationship you have with the physician, where you'll now have a relationship with one of the managed-care companies? How should we think about that?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, our strategy with the large payers is really to help them understand how important community oncology is. We believe that it's not only important from a clinical perspective, but we believe that the patient is best served being in the community, and",136,"Well, our strategy with the large payers is really to help them understand how important community oncology is. We believe that it's not only important from a clinical perspective, but we believe that the patient is best served being in the community, and even the payer is best served by those patients being in the community. So our big effort over there is really to help bring the 2 sides together. We have taken a lot of effort at ION, our physician services company, primarily focused on oncology, to help the 2 sides communicate better, have a transparent relationship. And we don't anticipate having a direct relationship with the payer, but we intend to help our customers contract more effectively and more transparently with the payers, and I think we're making a lot of progress there."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Your next question comes from David Larsen with Leerink Swann.",10,"Your next question comes from David Larsen with Leerink Swann."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","A question for Tim. It looks like, according to my model, your SG&A costs, on a year-over-year basis, declined by about $12 million. Can you describe sort of the cost control process you go through on a quarterly basis and if that's sustainable?",43,"A question for Tim. It looks like, according to my model, your SG&A costs, on a year-over-year basis, declined by about $12 million. Can you describe sort of the cost control process you go through on a quarterly basis and if that's sustainable?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Sure, David. I mean, when we looked at the year, I mean, we knew and we guided that Q2 and Q3 would be very tough comparisons, I mean, we knew it going into the year. And we put word out through our businesses to really manage expenses this year. And we k",125,"Sure, David. I mean, when we looked at the year, I mean, we knew and we guided that Q2 and Q3 would be very tough comparisons, I mean, we knew it going into the year. And we put word out through our businesses to really manage expenses this year. And we knew we had to focus in this area. So I mean, we looked hard at managing labor and payroll expense. We looked at outside consulting and services and then this year, too, we've had some good discipline and credit collections, and our bad debts are down. So really, it's all of our businesses focusing on headcount, on making sure they spend money prudently, and that's going to carry forward into quarters 3 and 4."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And then if I were to look at like, say, 3% of SG&A in fiscal '11, I'm coming up with like $35 million. So for the incremental acquisition cost with like World Courier group and these other ones, will all-in, that will be more than $35 million? And that's",69,"And then if I were to look at like, say, 3% of SG&A in fiscal '11, I'm coming up with like $35 million. So for the incremental acquisition cost with like World Courier group and these other ones, will all-in, that will be more than $35 million? And that's why they'll be -- that's why there was a slight reduction on the operating margin expansion guidance, is that correct?"
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, in terms of your question, the $35 million, no, I don't think the  all-in -- I mean, we should be under that number. So hopefully that helps you in terms of some guidance but, again, we think we're managing expenses well. We also had the benefit thi",98,"Well, in terms of your question, the $35 million, no, I don't think the  all-in -- I mean, we should be under that number. So hopefully that helps you in terms of some guidance but, again, we think we're managing expenses well. We also had the benefit this quarter and we'll have for the rest of the year in terms of SAP being stable, and we're seeing the benefits there. So all in all, I mean, I think what we're saying here is that expense management is offsetting the increases from the special charges and the nonrecurring charges."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Great. And then your merchandise inventory looked like it declined nicely on a sequential basis, maybe leading to an increase in cash flow guidance. That looked nice.",27,"Great. And then your merchandise inventory looked like it declined nicely on a sequential basis, maybe leading to an increase in cash flow guidance. That looked nice."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, definitely. Like, David, in my comments, I've mentioned that we've really focused on working capital. All of our businesses are focused on it. Managing AR, managing inventories. So we are seeing some really good reductions in those areas, especially",44,"Yes, definitely. Like, David, in my comments, I've mentioned that we've really focused on working capital. All of our businesses are focused on it. Managing AR, managing inventories. So we are seeing some really good reductions in those areas, especially at our ABSG businesses."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Okay, our last question comes from the line of Steven Valiquette with UBS.",13,"Okay, our last question comes from the line of Steven Valiquette with UBS."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","So I guess, just one more question on the Express Medco, I'm obligated at the end here with the -- I think you mentioned in your comments that in some ways you viewed yourself as the primary incumbent on the Express Medco contracts. I guess my question is",115,"So I guess, just one more question on the Express Medco, I'm obligated at the end here with the -- I think you mentioned in your comments that in some ways you viewed yourself as the primary incumbent on the Express Medco contracts. I guess my question is, are you now happy this is going to an official RFP versus your previous thought pattern over the past 9 months since this deal got announced? Or are you disappointed? Is it because you thought you were the primary incumbent, or are you just indifferent? Just trying to get more color sort of on your view now, the new information versus kind of what you thought previously."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","I was actually at a NACDS conference, and I heard one political pundit speak about the election, and they said incumbency is a 4-point advantage, so I was just trying to get that incumbent advantage in there. But that's just my view, I mean, I don't know",142,"I was actually at a NACDS conference, and I heard one political pundit speak about the election, and they said incumbency is a 4-point advantage, so I was just trying to get that incumbent advantage in there. But that's just my view, I mean, I don't know if anyone else has that view. We did, of course, do more business with Medco than the current wholesaler did with ESR so, you could look at it as an incumbency but, I think, that's just really my view, but we are pleased that this has been decided relatively early in the process. That's very helpful from a planning perspective and, again, it's helped us have a very quick and interesting discussion with ESR. So we think that it's a positive for the industry and we think that, potentially, it could be positive for AmerisourceBergen."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve. Now, Steve Collis would like to make some final comments before we go.",15,"Thanks, Steve. Now, Steve Collis would like to make some final comments before we go."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","We know that it's a very busy day, so we really do appreciate everyone's interest and attention with AmerisourceBergen. I would like to commend my colleague and our acting CFO, Tim Guttman, for his leadership and contribution during this transition period",98,"We know that it's a very busy day, so we really do appreciate everyone's interest and attention with AmerisourceBergen. I would like to commend my colleague and our acting CFO, Tim Guttman, for his leadership and contribution during this transition period. As you could see, Tim's really done a great job. So to wrap up, ABC thinks this is a really good quarter for us and especially given our tough comps, and we are proud to report good momentum on all fronts at this halfway point in our fiscal year 2012. Thank you again for your attention."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and before we go, I'd just like to quickly highlight our upcoming events. On May 17, we'll be presenting at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas. And on June 6, we will be presenting at the Goldman Sach",68,"Thanks, Steve, and before we go, I'd just like to quickly highlight our upcoming events. On May 17, we'll be presenting at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas. And on June 6, we will be presenting at the Goldman Sachs 33rd Annual Global Healthcare Conference. That concludes our call for today. And now I will turn it back to the operator."
24809,183660881,290514,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Thank you. Ladies and gentlemen, this conference will be available for replay after 1:00 p.m. today through midnight, May 3, 2012. You may access the replay service by dialing 1 (800) 475-6701 and entering access code 243852. International participants, d",61,"Thank you. Ladies and gentlemen, this conference will be available for replay after 1:00 p.m. today through midnight, May 3, 2012. You may access the replay service by dialing 1 (800) 475-6701 and entering access code 243852. International participants, dial (320) 365-3844. This concludes our conference for today, and thank you for using AT&T executive teleconference services. You may now disconnect."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the ABC Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Ms. Barbar",46,"Ladies and gentlemen, thank you for standing by, and welcome to the ABC Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Ms. Barbara Brungess. Please go ahead."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 second quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve Colli",164,"Thank you. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fiscal 2012 second quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve Collis, AmerisourceBergen's President and CEO; and Tim Guttman, Vice President, Controller and acting CFO.
During the call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011.
Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by telephone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, and good morning, everyone. I am pleased to report that AmerisourceBergen once again delivered solid quarterly results, and our performance for the first half of our fiscal year 2012 positions us well to meet our objectives for the full year. I",2115,"Thank you, and good morning, everyone. I am pleased to report that AmerisourceBergen once again delivered solid quarterly results, and our performance for the first half of our fiscal year 2012 positions us well to meet our objectives for the full year. In the March quarter, our revenues were up 2% to $20.1 billion. Earnings per share were up 5% to $0.81, and that's on top of a 22% increase in the prior year. 
We generated $236 million in operating cash flow and we repurchased $200 million of our shares. I'm especially proud that we overcame a challenging comp to this quarter, last year, and exceeded our internal profit goals for each business unit. 
During the quarter, we also made excellent progress integrating recent acquisitions and working towards the closing of our World Courier acquisition. Our strong cash generation and high-quality balance sheet continue to provide us with outstanding financial flexibility and give us the ability to fund our strategic initiatives, grow our business and return funds to shareholders. 
AmerisourceBergen is fortunate to be an important part of a growing industry. Demographics and initiatives aimed at expanding access to health care and coverage -- and health care coverage, should continue to drive organic growth in our industry over the next several years. In addition, launches of new pharmaceuticals, as well as new indications for existing drugs should also drive sales growth over the next several years. Whether the new therapies are traditional oral medications or complex biotech pharmaceuticals, AmerisourceBergen is well positioned to not only benefit from the distribution of new products, but also to offer pre-launch and commercialization services to manufacturers and to support patient access and reimbursement programs to help ensure that patients have access to life-saving therapies and that the products achieve their full potential in the marketplace. 
At our verse [ph] revenue base positions us well to benefit from organic growth driven by demographics, and our customer mix puts us in a favorable position to continue to benefit from the historic influx of generics. As you know, generics mitigate the top line dollar growth in our industry but drive tremendous value for wholesalers, health care providers and patients alike. In addition, close scrutiny of health care expenses and cost-containment efforts underway by the federal government and other payers also drives demand for our services, most notably in our Consulting Services group. 
Over the last several years, we have significantly strengthened our relationship with pharmaceutical manufacturers, and we continue to look for meaningful ways to provide additional services across the supply channel to help them ensure they meet the challenges of today's changing health care landscape. As our provider customers face similar challenges regarding cost-containment and reimbursement for services provided to patients, they increasingly turn to AmerisourceBergen. We help in making their health care practices run as efficiently and effectively as possible.  
Our provider customers work hard every day to provide world-class patient care, and we believe they deserve fair reimbursement for the professional services they provide. AmerisourceBergen is an active participant participating in policy discussions in Washington, D.C. with the objective of helping legislators understand our industry and our importance to the health care system. 
Our associates are focused on meeting our objectives for the year, both in terms of providing outstanding service to customers and in our financial performance. They continue to seek creative ways to meet the challenges in the diverse markets we serve and identify new opportunities to add value through collaborative innovation and by maximizing efficiency. I take great pride in their enthusiasm and dedication, and it is my honor to work beside them. 
Turning now to our business units. AmerisourceBergen Drug Corporation, as expected, had flat revenue in the quarter as strong performance in the institutional segment was offset by the previously disclosed loss of a large retail customer. Top line growth was also mitigated by the impact of generic convergence, including decreased sales to our largest customer. 
Our ABDC associates did a stellar job this quarter managing several generic launches, including 5 different generic products that launched within one week. Year-to-date, the generic launches have performed as planned and we, of course, look forward to several more launches still to come in the second half of the year. 
With over 4,600 members, our Good Neighbor Pharmacy network, the third largest network of pharmacies in the U.S., continues to play a crucial role in providing pharmacy care nationwide. Patients prefer choice when determining where to fill their prescriptions, and our retail customers are very adept at fulfilling unique patient needs and at adapting to the changing needs of the marketplace. 
Our ASHP implementation continues to run smoothly with 8 distribution centers conversions complete, 2 additional conversions occurring tomorrow, and the remainder planned for the beginning of 2013. As we have gained experience with the new system, particularly with the corporate and back-office functions, we have already begun to realize some operational savings, which is reflected, in part, in the good performance we had on the expense line this quarter. 
Our investments in our Canadian operations to support significant new business wins continued in the March quarter. Our associates have done a tremendous job setting up 4 new distribution centers in 6 months, in order to support this new business. There is still much work to be done, but we are confident that our expansion efforts will meaningfully increase the value we bring to both independent pharmacies and especially providers in the Canadian market.
As we noted in the press release, following the closing of the merger of Express Scripts and Medco in early April, we amended our existing Medco agreement to provide for the contract to end upon the award and implementation of one or more new pharmaceutical distribution agreements for the newly combined business. Express Scripts has issued an RFP for the combined business, and anticipate that the new contract, or contracts, will begin on October 1, 2012. We are participating fully in the competitive RFP process, and we intend to pursue this opportunity to retain or grow the business under a new contract. We have had an excellent working relationship with Medco for over 2 decades, and we are excited about the opportunity to demonstrate the value we can bring to the newly combined entity. 
AmerisourceBergen Specialty Group had another strong quarter with revenues up 6% with particularly strong performance in third-party logistics and in our vaccine and physician distribution business. Our oncology business performed well, while facing a very difficult comparison due to the strong performance of the 3 large Besse generic products last year. While our Specialty Group is best known for our oncology franchise, we are an instrumental part of the commercialization strategy for any infusible product launched into the physician marketplace. We continue to execute very well on the launch of a new brand of ophthalmology product establishing significant market share in what was the first full quarter of the introduction. 
Our Specialty Group often collaborates with our Consulting Services group to help ensure patients have access to products by utilizing the full suite of capabilities of our physician networks, as well as our reimbursement and patient support program expertise. For example, we recently helped a manufacturer launch a new biotech product. And during the March quarter, we were able to not only achieve the leading market share for the distribution of the product, but also to provide third-party logistics, contract packaging and all of the reimbursement and patient support programs for the product across the market. We are very proud that these combined service offerings provide unmatched value to manufacturers and distinguish AmerisourceBergen in the marketplace. As we look at the products in development pipelines today, we believe that we will win even more of these opportunities in the future, which will be an important driver of our growth in the years ahead. 
Our Consulting Services group delivered a very strong quarter, while making excellent progress in the integration of TheraCom and Premier Source, which are both performing very well. The last group had the strongest quarter in its history, even without the contributions from TheraCom. While the group only represents about 2% of our revenues, we believe our packaging and consulting services provide essential expertise to pharmaceutical manufacturers to help ensure that their products are brought to market as safely, quickly and efficiently as possible. In addition, our reimbursement expertise helps ensure that patients who can benefit from both new and mature therapies have access to the products. 
We continue to make good progress towards closing our most recent acquisition, World Courier. As we deepen our knowledge and understanding of their business, I am more convinced than ever that World Courier affords us the opportunity, not only to acquire the market leader in premium niche clinical trial logistics services, but also to begin to build out a framework to expand our consulting and commercialization services beyond North America. 
In this current quarter, we will begin operating in 50 new international markets and employ about 1,500 new associates outside North America. This is significant expansion for ABC, and we are tremendously excited about welcoming the World Courier team to ABC. 
In addition, we are exploring ways to potentially expand some of our niche Specialty Distribution services into select markets as well. We expect to close the acquisition next week, at the end of April, and I'm very excited about the potential we see in the World Courier platform in the years ahead. 
Given the continued strength of our balance sheet, we continue to look for acquisitions that meet the criteria we've had in place for quite some time. They should increase our value offering to existing customers both up and down the channel, they should be within our established core competency and they should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions and we continue to be interested in opportunities in pharmaceutical and Specialty Distribution and Services, as well as consulting and packaging services. While we, historically, have been very comfortable in the $200 million to $300 million range, we will consider selling larger, as we did with World Courier, if it made good strategic sense and would deliver value to our company and our shareholders. 
Looking ahead, the results we've had in the first half of our year have positioned us well to meet our objectives for the full fiscal year. We have a difficult comparison to overcome in 2012, but we continue to expect GAAP earnings per share to be within the range of $2.74 to $2.84, and we are tracking towards the midpoint of that range. Tim will provide the details in our assumptions for the remainder of the year, but I want to highlight that we continue to remain disciplined on expenses, our cash flows are strong and we have increased our share repurchase assumption for the year. 
Looking further ahead to 2013, we should have a carryover from some of the launches that occur late in our fiscal 2012, including the relaunch of Oxaliplatin, and we should begin to benefit from the completion of our ASHP implementation. In fiscal 2014, we should begin to see this 30 million to 40 million uninsured patients enter the health care market, driving demand for pharmaceuticals that should carry over into 2015 and beyond. In addition, 2014 and 2015 are expected to be good years for generic conversions. And, of course, there's a chance that biosimilars may also come to market in that time frame. 
Before turn it over to Tim, I want to reiterate the confidence that I have in our business and in our future. Demand is strong for the products we distribute, and we play an essential role in pharmaceutical supply channel. We've positioned ourselves well to continue to benefit from the 2 key growth drivers, generics and specialty products, and we have continued to invest in our distribution and in our services businesses. 
Over the last year, we were summating important investment in other areas of our business with an eye to the future. We expect demand for specialty products to continue to grow, not only the U.S. but throughout the world, and the commercialization and reimbursement support services we provide to manufacturers will help support that growth. As cost containment efforts continue to cross the health care landscape, our customers increasingly turn to us for help in meeting the challenges of the marketplace without sacrificing patient care. Finally, the vision and innovative ideas that our associates bring to market every day set us apart in our industry, and I am proud to be their leader. Here is Tim."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and good morning, everyone. It's my pleasure to be participating in my first earnings call as acting CFO. And I am pleased to report another solid ABC quarter and, most importantly, that our Q2 results are on track with our internal plan.",1506,"Thanks, Steve, and good morning, everyone. It's my pleasure to be participating in my first earnings call as acting CFO. And I am pleased to report another solid ABC quarter and, most importantly, that our Q2 results are on track with our internal plan. 
The highlights this quarter: excellent top line growth at our Specialty and Consulting businesses; very good execution on new generic launches and continued focus on expense management across the organization; and finally, another quarter of strong cash generation. 
Now let's turn to the quarterly details. And starting with the top line, revenues were $20.1 billion, a 1.6% increase over last year's quarter. Drug company revenues were essentially flat, as we guided. We had strong performance in our alternate site and health system segments, offset by the loss of a large chain customer last year, as well as the impact from brand to generic conversions. 
The Specialty Group revenues increased 6%, led by 2 of our businesses with above market growth. ICS, our third-party logistics business and Besse Medical, our vaccine and physician office distribution business, which benefited from a full quarter impact of sales of a new ophthalmology drug. 
The Consulting group, though small to the overall top line, continues to perform well. Excluding their TheraCom acquisition, they had over 20% top line growth. TheraCom contributed just under 1% of our overall revenue growth in the quarter. 
Moving to gross profit. Gross profit was $695 million in the quarter, up 1.1% from last March, with a gross margin of 3.46% in the quarter, down about 2 basis points from last year. As we have discussed in the past, our second quarter was a very tough comp, due to the significant contribution in the prior year from oncology generics. In the second quarter 2011, these oncology drugs contributed about $0.16 of EPS to our results. Our gross margin expanded 31 basis points in the March 2011 quarter. This year, we are able to effectively offset this headwind with contributions from the new oral solid generics, as well as the lower contribution from oncology generics and gross profit contributions from our acquired companies. 
Additionally, our LIFO charge was approximately $4 million in the quarter, down $10 million from last year. We continue to expect our LIFO charge will be approximately $15 million, down significantly from last year. Our annual LIFO forecast is based on our expectation that brand price inflation will be somewhat less this year. And more importantly, we will see significant generic price deflation in the second half of our fiscal year related to key brand to generic conversions coming off exclusivity. 
Finally, the benefit we received from the new generic launches, and also price appreciation, was in line with our expectations. This quarter, we did an excellent job controlling our operating expenses. Operating expenses were approximately $327 million, up 1.5%. However, this amount includes the operating expenses of about $11 million from our recently acquired companies. Additionally, we had $9 million of executive severance and acquisition-related transaction costs. Operating expenses would've been down, excluding the impact of our acquisitions, due to lower compensation costs, including benefits. 
Additionally, our SAP implementation is progressing well at the corporate level. The system has reached a level of stability faster than we expected, enabling us to realize some early savings, especially with external consultants. 
Last quarter, our guidance was an annual expense increase of about 3%, due to our acquisitions. As an organization, we continue to exercise discipline and focus on managing expenses. We now expect our total operating expenses for our base business, before adding World Courier, to be essentially flat for the year. 
Operating income of $368 million in the quarter increased about 1%, while operating margin was down 2 basis points compared to last March. Our current quarter was slowed by the $9 million of executive severance and acquisition transaction costs. Excluding these nonrecurring expenses, our operating income margin would've expanded 3 basis points to 1.88%. 
Moving below the operating income line, interest expense of nearly $24 million in the March quarter increased 25% compared to last year, primarily as a result of our $500 million bonds we issued back in November. The proceeds help to fund the TheraCom acquisition and will also contribute to the retirement of our 2012 bonds that mature in mid-September. Our effective income tax rate of 38.4% was slightly higher than last year's 38.1% and is right in line with our expected annualized rate of 38.4%. 
Our diluted GAAP earnings per share in the quarter of $0.81 increased by $0.04, or 5%, over the same quarter last year. And again, overcoming a $0.16 headwind from the contribution from specialty generics in the March 2011 quarter. Our EPS benefited from a reduction in our average diluted shares related to our ongoing share repurchase program. Average diluted shares for the quarter were approximately 262 million, down just over 6% from last March. 
Now let's turn to our balance sheet and cash flows, where trends continue to be very favorable. We generated $236 million of cash from operations in the quarter, bringing our 6-month total to $668 million, compared to generating $577 million for the first 6 months last year. We continue to manage AR and inventory levels very closely, and this has benefited our working capital this year. With our daily revenue volume exceeding $300 million per business day, our quarter-end working capital snapshots are subject to volatility. Therefore, our 6-month cash results cannot be extrapolated to determine a full year cash flow estimate. 
Capital expenditures were $40 million in the quarter and $88 million for the 6 months. During the last 2 years, we put a number of capital projects on hold as we focused on SAP. We have a pipeline of attractive internal projects that we have begun to pursue as our SAP deployment moves along. 
Additionally, we have CapEx associated with our recent TheraCom acquisition. Because of this, we will exceed our previous target of $150 million for CapEx, and we will be closer to $200 million for the year. Even with this additional CapEx, we expect that our free cash flow will now be in the $800 million to $900 million range. 
During the quarter, we bought back $200 million of our shares. For 6 months, we've purchased $320 million of shares. At March 31, we have approximately $180 million left on our current share repurchase authorization. In terms of key financial metrics that we track, our average day sales in inventory for the quarter remained at 14 days, consistent with fiscal '11. Average DSOs of 18 days in the March quarter were up slightly from 17.3 days last year. And favorable payables timing helped raise average quarterly DPOs by over 3 days compared to fiscal '11. 
With our recent debt offering, our gross debt, the total debt and capital ratio, at the end of March, was 39%, above our target range of 30% to 35%. And it will remain above the range until we pay off our $400 million of debt in September. Our cash balance at March 31 was $2.3 billion. Keep in mind that we will be funding our World Courier acquisition from cash and we will be paying down debt in September, as previously mentioned. After these 2 large cash outlays, we will still have financial flexibility to fund CapEx and strategic initiatives and return to capital -- and return capital to our shareholders. 
Now let's turn to updated fiscal 2012 guidance. We expect our diluted GAAP EPS to track to the middle of the range we previously provided, $2.74 to $2.84. Our assumption for revenue growth remains unchanged, flat-to-modest revenue growth. We expect our operating margin expansion to be in the high-single-digit basis points. Free cash flow will now be in the $800 million to $900 million range. And we are raising our guidance for share repurchases for the year to $500 million, which will complete our current share repurchase authorization. 
Looking ahead, I would like to remind everyone that Q3 is another challenging comparison for us because of the $0.17 EPS contribution from oncology generics last year. Also in Q3 2012, we have 2 of the large generics coming off exclusivity. When looking out to the second half of the year, we believe Q4 will be somewhat of an easier comparison. With the return of Oxaliplatin for half a quarter, a few favorable year-end generic launches for the Drug Company and favorable expense comparisons year-over-year. 
So before I turn it back to Barbara, let me reiterate, that 6 months into the fiscal year, we are performing well in our key areas of the business, and we are well positioned to meet our financial targets for fiscal 2012. 
One final point, I'd like to take a moment and thank our ABC associates, especially those in the finance and accounting areas that have stepped up the last 2 months and helped support the organization and me, in particular, during our CFO transition period. Thanks, everyone. Here's Barbara to start our Q&A."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives",".Thank you, Tim. Operator, we'll now open the call to questions. [Operator Instructions] Go ahead, operator.",16,".
Thank you, Tim. Operator, we'll now open the call to questions. [Operator Instructions] Go ahead, operator."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Glen Santangelo with Crdit Suisse.",15,"[Operator Instructions] Our first question comes from the line of Glen Santangelo with Crdit Suisse."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I just want to quickly follow up, Tim, with respect to some of your comments on the operating margin expansion goals for the year. Previously the company had expected operating margin expansion in the high single-digit, kind of low double-digit range and",95,"I just want to quickly follow up, Tim, with respect to some of your comments on the operating margin expansion goals for the year. Previously the company had expected operating margin expansion in the high single-digit, kind of low double-digit range and now, it seems like you're suggesting high single-digit. I guess -- could just give me a sense for maybe what has changed in that thinking? And I know there were some onetime costs that you're now embedding in your estimates, and I'm curious if there's anything else that I should be thinking about."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, we changed our guidance to high single-digit. In terms of looking out, we did an assessment of the full year, and looking out, we had some deal costs in Q2 and some onetime items, nonrecurring items. And as we look out, we're going to have some simila",89,"No, we changed our guidance to high single-digit. In terms of looking out, we did an assessment of the full year, and looking out, we had some deal costs in Q2 and some onetime items, nonrecurring items. And as we look out, we're going to have some similar costs in Q3 with the World Courier transaction. So when we look out and do a reassessment, we felt more comfortable that high single-digit was a realistic target for us for the year, and there's really nothing else factored into that."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And, Tim, maybe if I could just ask a follow up on the World Courier group. You originally sort of guided $0.06 to $0.10 worth of accretion and I'm kind curious, is there anything embedded from an accretion standpoint in your fiscal '12 guidance as it rel",82,"And, Tim, maybe if I could just ask a follow up on the World Courier group. You originally sort of guided $0.06 to $0.10 worth of accretion and I'm kind curious, is there anything embedded from an accretion standpoint in your fiscal '12 guidance as it relates to World Courier? And it kind of sounds like you're going to be taking down some integration costs or acquisition-related costs next quarter. I don't know if you care to size those at this point."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Glen, no. We will have some transaction-related acquisition costs in Q3. Probably not more than the number that we had for Q2. And there is no accretion in our numbers for this fiscal year. We expect it to be neutral. And in terms of next year, for fiscal",59,"Glen, no. We will have some transaction-related acquisition costs in Q3. Probably not more than the number that we had for Q2. And there is no accretion in our numbers for this fiscal year. We expect it to be neutral. And in terms of next year, for fiscal '13, we're still confident with that guidance of $0.06 to $0.10."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Larry Marsh with Barclays.",9,"Our next question comes from Larry Marsh with Barclays."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","So my question is as follows, Steve, around Medco. Here you're communicating -- I guess, is it fair to say that you voluntarily agreed to move up the termination date of your Medco relationship by 6 months? And if so, is there any benefit for doing so, an",101,"So my question is as follows, Steve, around Medco. Here you're communicating -- I guess, is it fair to say that you voluntarily agreed to move up the termination date of your Medco relationship by 6 months? And if so, is there any benefit for doing so, and possibly foregoing that profit stream? And then just around the topic, I wanted to confirm, you said you've already have a relationship with Express Scripts. How long have you had that? And then have you disclosed or in a position to comment about the length of the suggested new contract under the RFP?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","First of all, obviously, we are part of a very active process here and we want to be very respectful of that and some of the questions should really be directed to the buyer. But I think ABC, as you know, has been very proud of over 2 decades of service t",194,"First of all, obviously, we are part of a very active process here and we want to be very respectful of that and some of the questions should really be directed to the buyer. But I think ABC, as you know, has been very proud of over 2 decades of service to Medco and now, you could almost say we are the incumbent here because we've had such a long relationship. So we wanted to demonstrate flexibility. We wanted to recognize that this is a new entity that has their own requirements and will have a different dynamics to relationship. And now it just made sense for us to be concurrent with the current requirements. So we demonstrated flexibility. We demonstrated that ABC is a good partner and listens to our customers and I think that, that will hopefully put us in a good position throughout the contracting process, but it will be competitive. And, I guess, the only internal benefit I can point to is that this is concurrent with our fiscal year, and whatever happens, we'll be in a good position to plan for it and to communicate that to our investors."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So it sounds like you're uncomfortable commenting about the length of the contract as proposed in the RFP at this point.",22,"Okay. So it sounds like you're uncomfortable commenting about the length of the contract as proposed in the RFP at this point."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","As far as we know, as far as we could say, it's pretty standard type of contract term.",18,"As far as we know, as far as we could say, it's pretty standard type of contract term."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Right. So we assume, maybe 3 years, but again, not commenting. And I guess just a follow-up to you and Tim around SAP implementation, we appreciate the update there. If you let it to go back or remember some of the bigger expenses for this, seemed to be f",90,"Right. So we assume, maybe 3 years, but again, not commenting. And I guess just a follow-up to you and Tim around SAP implementation, we appreciate the update there. If you let it to go back or remember some of the bigger expenses for this, seemed to be fiscal '10 and '11, $40 million to $50 million a year, you've mentioned, Tim, stability sooner than you thought. Can you ballpark kind of expenses around SAP for you this year? And how do we think about that comparable to next year?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Yes. Larry, our guidance has been that we'll see some benefit for SAP next year, 6 months after our last DC deployment, so we expect that to be in Q4, and we've guided to $10 million. And we expect the full benefit of about $40 million to be in '14. And s",103,"Yes. Larry, our guidance has been that we'll see some benefit for SAP next year, 6 months after our last DC deployment, so we expect that to be in Q4, and we've guided to $10 million. And we expect the full benefit of about $40 million to be in '14. And so far, the benefit that we've had this year for SAP is really incremental for that. I mean, this is just expense that we've been able to take out of our operating budget, which has probably been a few million dollars. So again, they're separate. One's not a part of the other."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I got it. Right. Expenses associated with consultants and such, but again, $10 million incremental next year, $40 million for '14. And then just to clarify, I think it's an important point, the guidance confirming the range, but you're suggesting the $0.0",75,"I got it. Right. Expenses associated with consultants and such, but again, $10 million incremental next year, $40 million for '14. And then just to clarify, I think it's an important point, the guidance confirming the range, but you're suggesting the $0.02, which was the severance and transaction cost this quarter and the $0.02 which -- ballpark of transaction cost next quarter, are included now in that range. You're not breaking that out at all?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, absolutely, Larry. We're GAAP, and we include that in.",10,"No, absolutely, Larry. We're GAAP, and we include that in."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And again, you're saying that's a big reason why you're top and the operating margin expansion has been pulled down?",20,"And again, you're saying that's a big reason why you're top and the operating margin expansion has been pulled down?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Absolutely.",1,"Absolutely."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Robert Jones with Goldman Sachs.",10,"Our next question comes from Robert Jones with Goldman Sachs."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Just to go back to the Express Scripts contract. Steve, it sounds like -- you mentioned contract, or contracts, so I'm assuming there's some suggestion that it could be broken up. Any insight into this view or maybe, more importantly, what benefit that wo",52,"Just to go back to the Express Scripts contract. Steve, it sounds like -- you mentioned contract, or contracts, so I'm assuming there's some suggestion that it could be broken up. Any insight into this view or maybe, more importantly, what benefit that would create for Express to have this contract separated?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, I think, in terms of processing, there's not much differentiation between s $10 billion contract, or a $15 billion, or $20 billion contract, it's just that, that is the way these large contracts tend to go. And there could be some geographical, regi",105,"Well, I think, in terms of processing, there's not much differentiation between s $10 billion contract, or a $15 billion, or $20 billion contract, it's just that, that is the way these large contracts tend to go. And there could be some geographical, regional benefit, based on where they're planning to have their large mail-order sites, there could be a way to separate the specialty business with the core mail-order business. So we have 2 big specialty units so -- but again, these are questions that we probably are not that comfortable commenting on and could probably be best be directed to Express Scripts, sir."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","No, I definitely appreciate that. And I guess just one follow-up, Steve. Given the somewhat more acquisitive nature of the company as of late, and I know you've gotten this question before and I imagine as you continue to do acquisitions, you might get it",75,"No, I definitely appreciate that. And I guess just one follow-up, Steve. Given the somewhat more acquisitive nature of the company as of late, and I know you've gotten this question before and I imagine as you continue to do acquisitions, you might get it more in the future, relative to your peers. Any thoughts or discussion between you and Tim about moving to a cash EPS, or at least breaking out a cash EPS?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, we haven't. We lack -- we think we report not only good earnings, but very high quality earnings and, at the moment, that hasn't been under consideration.",28,"No, we haven't. We lack -- we think we report not only good earnings, but very high quality earnings and, at the moment, that hasn't been under consideration."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","And we, in our public company filings, we feel we give pretty good disclosure on some of those differences, especially around intangibles. And the reader of those documents can go ahead and do that calculation.",35,"And we, in our public company filings, we feel we give pretty good disclosure on some of those differences, especially around intangibles. And the reader of those documents can go ahead and do that calculation."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Tom Gallucci with Lazard.",9,"Our next question comes from Tom Gallucci with Lazard."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I was wondering if you could expand on some of your prepared remarks around sort of international and how you see the opportunity may be there over -- not the near-term necessarily but the next few to 5 years, it sounds like maybe World Courier is",71,"Steve, I was wondering if you could expand on some of your prepared remarks around sort of international and how you see the opportunity may be there over -- not the near-term necessarily but the next few to 5 years, it sounds like maybe World Courier is a bit of a platform that you could grow from in different ways, so if you have any thoughts there, it would be appreciated."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well there's a couple of things. First of all, again, we do $300 million in revenue a day, as ABC, but one of the things we've been very, very happy with is our specialty performance in Canada. This is -- this market works differently than it does in the",375,"Well there's a couple of things. First of all, again, we do $300 million in revenue a day, as ABC, but one of the things we've been very, very happy with is our specialty performance in Canada. This is -- this market works differently than it does in the U.S., but we've been able to do some joint programs, we've been able to help with a more complex reimbursement environment there, including a pretty robust product market that we -- that is not generally known. At least here, in the U.S., we think about it as single-payer market, that hasn't been the case. We've been able to help, we have a very strong presence with new infusible drugs. So what we've seen is a manufacturer environment that ABC is very comfortable in contracting with, that is looking for us to get into more countries. So we've been prompted to look at international opportunities by manufacturers. Then comes World Courier, we're in 50 new countries as of next week, hopefully. We have 1,500 associates that are very tenured. We've been extremely impressed with the quality of the World Courier associates. As you know, health care is very local. So we think that we have an opportunity to understand health care markets, both organic and acquisitive opportunities, with people on the ground there who speak the language and know the trends, know who's the right players, the ethical players, the high quality players in that environment. And we think that, that's going to give us a good opportunity. We also think that as the products that World Courier is managing are commercialized, as more and more of those products are commercialized and come to market as -- middle class is growing in some countries that we haven't traditionally thought about as being big [indiscernible] sort of -- and especially consumers of products, we think we're going to have an opportunity to participate in those commercialization strategies. Think about it, World Courier has handled those products, they know the treatment centers, they know the environment. So we think that we have to recharacterize part of the business, but we think we can do that, so long answer, but as you can tell, I'm very enthusiastic about this."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Sure, that's clear. And then maybe just one housekeeping item. On the CapEx, can you sort of breakdown your maintenance CapEx versus maybe what's additional and some of those projects that you highlighted earlier, do they seep into next year? Should we as",58,"Sure, that's clear. And then maybe just one housekeeping item. On the CapEx, can you sort of breakdown your maintenance CapEx versus maybe what's additional and some of those projects that you highlighted earlier, do they seep into next year? Should we assume that it comes back down a little bit, or how are you thinking about that?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Good question. No, we -- when we look at maintenance CapEx, we think it's typically between about $100 million and $120 million. We have some big projects this year supporting our expansion up in Canada. We're looking at another DC project in the U.S. in",91,"Good question. No, we -- when we look at maintenance CapEx, we think it's typically between about $100 million and $120 million. We have some big projects this year supporting our expansion up in Canada. We're looking at another DC project in the U.S. in terms of expansion, automation, renovation and our TheraCom acquisition. So I would say that the $200 million is probably a peak, and it definitely should come down next year. Probably about half of the maintenance CapEx is probably a good -- kind of a good range."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from the line of Robert Willoughby with Bank of America Merrill Lynch.",16,"Our next question comes from the line of Robert Willoughby with Bank of America Merrill Lynch."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, what kind of clarity do you actually have on -- does the RFP provide for you? I mean, I assume you would have size of the potential contract, the mail footprint you'd be serving, whether or not specialty would be there. I mean, are there some thing",58,"Steve, what kind of clarity do you actually have on -- does the RFP provide for you? I mean, I assume you would have size of the potential contract, the mail footprint you'd be serving, whether or not specialty would be there. I mean, are there some things you could disclose there that would be helpful for us?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","I think, we partly said, Bob, I appreciate your interest in this and, believe you me, I am really interested in this and the ABC team is very interested in this. We're just participating fully in the RFP process, it has just begun. So I could tell you we",118,"I think, we partly said, Bob, I appreciate your interest in this and, believe you me, I am really interested in this and the ABC team is very interested in this. We're just participating fully in the RFP process, it has just begun. So I could tell you we really don't -- we think it's in the range of about a $20 billion contract. So I will tell you that Medco peaked with ABC at about 19% of our revenues in fiscal year 2011, and it's come off a few percent from that, and our current run rate is more in the mid-teens, 16% range. So we could potentially gain some couple billion dollars in new revenue here."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And any sense on timing, when a decision will ultimately be made, obviously, before October 1. But how much time would you need? And do you anticipate if you win, is there investment you need to make or in the unfortunate event you don't win, what k",61,"Okay. And any sense on timing, when a decision will ultimately be made, obviously, before October 1. But how much time would you need? And do you anticipate if you win, is there investment you need to make or in the unfortunate event you don't win, what kind of offsets we might see to your cost structure, some initiatives you'd pursue?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, we're mainly servicing the current business out of 3 DCs, and we certainly would start giving consideration to what it could mean if we lose. But from a more exciting basis, I think we do have the capacity to service this business without much incre",70,"Well, we're mainly servicing the current business out of 3 DCs, and we certainly would start giving consideration to what it could mean if we lose. But from a more exciting basis, I think we do have the capacity to service this business without much incremental investment. And we look forward to talking about the different capabilities that ABC brings to the table. And we're participating fully in this contract."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And timing, Steve? Anything?",4,"And timing, Steve? Anything?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","No, I just think you know -- I think you know -- you cover Express Scripts. You know they move quickly, so that's all I can tell you. They don't let the grass grow under their feet. So we expect them to have a very active and quick and decisive process un",82,"No, I just think you know -- I think you know -- you cover Express Scripts. You know they move quickly, so that's all I can tell you. They don't let the grass grow under their feet. So we expect them to have a very active and quick and decisive process unlike this other very public contract that we went through very recently. So that should make everyone happy, at least, we'd all know where we stand very quickly. We believe so."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Ricky Goldwasser with Morgan Stanley.",10,"Our next question comes from Ricky Goldwasser with Morgan Stanley."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Just a quick follow-up [ph] on the Medco Express side, from what we understand, specialty is included in your relationship with legacy Medco. Should we assume that the services that you provided to Medco on the specialty side are more of wholesale-type se",63,"Just a quick follow-up [ph] on the Medco Express side, from what we understand, specialty is included in your relationship with legacy Medco. Should we assume that the services that you provided to Medco on the specialty side are more of wholesale-type services, or do you also provide them kind of like the added value services that's associated with your specialty business?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","We are both the wholesaler to the former Accredo division, the Accredo division of Medco, and now will be Express Scripts. And we have, obviously, worked very collaboratively with them in many areas including the hospital, pharmacy area and the specialty",97,"We are both the wholesaler to the former Accredo division, the Accredo division of Medco, and now will be Express Scripts. And we have, obviously, worked very collaboratively with them in many areas including the hospital, pharmacy area and the specialty area. So I can't -- I'm not comfortable pointing to any particular program, but certainly as our largest customer, we spend a lot of time working on common approaches to the marketplace, and we would expect to bring that expertise and that market knowledge and the manufacturer relationships that we have to the combined entity now."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, and then I have a couple of just questions from modeling purposes. For the SG&A level for the remainder of the year, should we assume same level as we saw in the March quarter or should we see a step up, and if so, can you quantify for us? And is it",57,"Okay, and then I have a couple of just questions from modeling purposes. For the SG&A level for the remainder of the year, should we assume same level as we saw in the March quarter or should we see a step up, and if so, can you quantify for us? And is it related to World Courier?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","We, at this point, Ricky, we don't have World Courier finished yet, completed. But definitely with World Courier coming in 2 months in quarter 3 and we'll have them for the entire Q4, they will add extra expense. When I gave the guidance today this mornin",91,"We, at this point, Ricky, we don't have World Courier finished yet, completed. But definitely with World Courier coming in 2 months in quarter 3 and we'll have them for the entire Q4, they will add extra expense. When I gave the guidance today this morning, again, I was talking about the core business being flat. For the core business, we will see a little bit of a step up in 3, but probably not dramatic. And again, we will have some nonrecurring acquisition-related cost in Q3, probably not in Q4."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And then can you just qualify to us the impact from a basis point perspective of the acquisitions on the margins for this quarter?",25,"Okay. And then can you just qualify to us the impact from a basis point perspective of the acquisitions on the margins for this quarter?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","In terms of SG&A?",5,"In terms of SG&A?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","SG&A or operating margin.",5,"SG&A or operating margin."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well again, we commented that we had about $11 million of SG&A expense in the quarter from our acquisitions, primarily TheraCom. So again, it's probably 4, 3, 4 basis points.",30,"Well again, we commented that we had about $11 million of SG&A expense in the quarter from our acquisitions, primarily TheraCom. So again, it's probably 4, 3, 4 basis points."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Eric Coldwell with Robert W. Baird.",11,"Our next question comes from Eric Coldwell with Robert W. Baird."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I think a lot of the timely questions have been answered, so I'll shift gears a bit. Health systems and alternate site in your drug company, sound like another good quarter there, above market growth, perhaps. I'm curious if you can define what's leading",121,"I think a lot of the timely questions have been answered, so I'll shift gears a bit. Health systems and alternate site in your drug company, sound like another good quarter there, above market growth, perhaps. I'm curious if you can define what's leading to this growth. It must be share capture, I don't want to lead you too much, but the market's clearly not growing at a rapid pace. You're primarily doing pharmaceuticals and not the other broad med service lines or other services into the health systems. So could you just give us some better sense on what's driving that growth in health systems and alternate site and then perhaps if you could frame it, would be helpful, too."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well with health systems, we think we have a market share that is, at least comparable, maybe even the largest in the U.S. We believe we're with the right customers, we believe that we're growing with them. We believe that we have some nice little service",261,"Well with health systems, we think we have a market share that is, at least comparable, maybe even the largest in the U.S. We believe we're with the right customers, we believe that we're growing with them. We believe that we have some nice little services that we provide that maybe don't get the headlines, but they are additive to their business, like helping them with 340B consulting, helping them with price pharmacy. So we have a very good practice in health systems, and we believe we're with the companies that are the leaders in that space, and I think some of our customers are there. Likewise with alternate care, I think ABC has been a leader there. Certainly our knowledge of specialty and our ability to offer an integrated solution on the specialty and drug wholesale side and our knowledge of the manufacturing environment and the patient environment and the reimbursement environment has been very, very helpful. And the Humana contract, we think ,was a direct result of that knowledge, and that's a very fast grower. We're with a lot of the companies that are growing faster than the market and when we discuss potential RFP responses, we look at who do we think will be the winners in a certain space, and we like to really target them and try to get them into the ABC portfolio. So I think you could look at it as it's not a matter of happenstance, it's a matter of strategically planning the accounts that we believe will be winners in the space."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Great answer, Steve. Could you put a frame around the growth rates in those 2 segments?",16,"Great answer, Steve. Could you put a frame around the growth rates in those 2 segments?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","I think we can maybe look at that and invest it out.  I think we've done some of that in the past. But we don't have a framework that we can share right now.",34,"I think we can maybe look at that and invest it out.  I think we've done some of that in the past. But we don't have a framework that we can share right now."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from Lisa Gill with JPMorgan.",9,"Our next question comes from Lisa Gill with JPMorgan."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","I think that you made a comment earlier around your expectations for LIFO this year and within that comment, Tim, I think you talked about branded price inflation being less and more deflation on the generic side. Can you maybe just talk about what you ac",103,"I think that you made a comment earlier around your expectations for LIFO this year and within that comment, Tim, I think you talked about branded price inflation being less and more deflation on the generic side. Can you maybe just talk about what you actually saw in this quarter and then what you are seeing in the marketplace around an increase in competition, as far as the number of generic manufacturers that spend a nice steady state the last couple of years, are you seeing a trend that's perhaps changing a little bit, as we go through the next couple of months?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","In terms of -- and when I speak of LIFO, just let me say that we look at our portfolio of drugs which -- in our mix and in terms of brand, last year we had pretty healthy price increases for brands, slightly above 8%. This year, we're tracking slightly be",153,"In terms of -- and when I speak of LIFO, just let me say that we look at our portfolio of drugs which -- in our mix and in terms of brand, last year we had pretty healthy price increases for brands, slightly above 8%. This year, we're tracking slightly below 8% again for our mix of inventory. So a little bit different, a little bit lower. But on the generic side, we really expect that we'll see some deflation, second half of the year, especially on Lipitor and Zyprexa, the generics when they come off exclusivity, which will help and give us a LIFO benefit. In terms of your second question about suppliers. I mean, last year we also had pretty good price appreciation on the generic side. It's still pretty good, but that's probably off a little bit this year, it's softened a little bit this year, but still pretty healthy."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And then, Steve, just one quick question for you on the oncology side of your business. We know of a number of these pilot programs that have been started by Aetna and United around the way they're paying their physician in trying to take the",108,"Okay, great. And then, Steve, just one quick question for you on the oncology side of your business. We know of a number of these pilot programs that have been started by Aetna and United around the way they're paying their physician in trying to take the drug cost out of the equation, are you seeing that impact your business at all? And what are the physicians saying? And if it does take hold, what does that mean longer term, will that change the relationship you have with the physician, where you'll now have a relationship with one of the managed-care companies? How should we think about that?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, our strategy with the large payers is really to help them understand how important community oncology is. We believe that it's not only important from a clinical perspective, but we believe that the patient is best served being in the community, and",136,"Well, our strategy with the large payers is really to help them understand how important community oncology is. We believe that it's not only important from a clinical perspective, but we believe that the patient is best served being in the community, and even the payer is best served by those patients being in the community. So our big effort over there is really to help bring the 2 sides together. We have taken a lot of effort at ION, our physician services company, primarily focused on oncology, to help the 2 sides communicate better, have a transparent relationship. And we don't anticipate having a direct relationship with the payer, but we intend to help our customers contract more effectively and more transparently with the payers, and I think we're making a lot of progress there."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Your next question comes from David Larsen with Leerink Swann.",10,"Your next question comes from David Larsen with Leerink Swann."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","A question for Tim. It looks like, according to my model, your SG&A costs, on a year-over-year basis, declined by about $12 million. Can you describe sort of the cost control process you go through on a quarterly basis and if that's sustainable?",43,"A question for Tim. It looks like, according to my model, your SG&A costs, on a year-over-year basis, declined by about $12 million. Can you describe sort of the cost control process you go through on a quarterly basis and if that's sustainable?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Sure, David. I mean, when we looked at the year, I mean, we knew and we guided that Q2 and Q3 would be very tough comparisons, I mean, we knew it going into the year. And we put word out through our businesses to really manage expenses this year. And we k",125,"Sure, David. I mean, when we looked at the year, I mean, we knew and we guided that Q2 and Q3 would be very tough comparisons, I mean, we knew it going into the year. And we put word out through our businesses to really manage expenses this year. And we knew we had to focus in this area. So I mean, we looked hard at managing labor and payroll expense. We looked at outside consulting and services and then this year, too, we've had some good discipline and credit collections, and our bad debts are down. So really, it's all of our businesses focusing on headcount, on making sure they spend money prudently, and that's going to carry forward into quarters 3 and 4."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","And then if I were to look at like, say, 3% of SG&A in fiscal '11, I'm coming up with like $35 million. So for the incremental acquisition cost with like World Courier group and these other ones, will all-in, that will be more than $35 million? And that's",69,"And then if I were to look at like, say, 3% of SG&A in fiscal '11, I'm coming up with like $35 million. So for the incremental acquisition cost with like World Courier group and these other ones, will all-in, that will be more than $35 million? And that's why they'll be -- that's why there was a slight reduction on the operating margin expansion guidance, is that correct?"
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Well, in terms of your question, the $35 million, no, I don't think the  all-in -- I mean, we should be under that number. So hopefully that helps you in terms of some guidance but, again, we think we're managing expenses well. We also had the benefit thi",98,"Well, in terms of your question, the $35 million, no, I don't think the  all-in -- I mean, we should be under that number. So hopefully that helps you in terms of some guidance but, again, we think we're managing expenses well. We also had the benefit this quarter and we'll have for the rest of the year in terms of SAP being stable, and we're seeing the benefits there. So all in all, I mean, I think what we're saying here is that expense management is offsetting the increases from the special charges and the nonrecurring charges."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","Great. And then your merchandise inventory looked like it declined nicely on a sequential basis, maybe leading to an increase in cash flow guidance. That looked nice.",27,"Great. And then your merchandise inventory looked like it declined nicely on a sequential basis, maybe leading to an increase in cash flow guidance. That looked nice."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, definitely. Like, David, in my comments, I've mentioned that we've really focused on working capital. All of our businesses are focused on it. Managing AR, managing inventories. So we are seeing some really good reductions in those areas, especially",44,"Yes, definitely. Like, David, in my comments, I've mentioned that we've really focused on working capital. All of our businesses are focused on it. Managing AR, managing inventories. So we are seeing some really good reductions in those areas, especially at our ABSG businesses."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Okay, our last question comes from the line of Steven Valiquette with UBS.",13,"Okay, our last question comes from the line of Steven Valiquette with UBS."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Analysts","So I guess, just one more question on the Express Medco, I'm obligated at the end here with the -- I think you mentioned in your comments that in some ways you viewed yourself as the primary incumbent on the Express Medco contracts. I guess my question is",115,"So I guess, just one more question on the Express Medco, I'm obligated at the end here with the -- I think you mentioned in your comments that in some ways you viewed yourself as the primary incumbent on the Express Medco contracts. I guess my question is, are you now happy this is going to an official RFP versus your previous thought pattern over the past 9 months since this deal got announced? Or are you disappointed? Is it because you thought you were the primary incumbent, or are you just indifferent? Just trying to get more color sort of on your view now, the new information versus kind of what you thought previously."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","I was actually at a NACDS conference, and I heard one political pundit speak about the election, and they said incumbency is a 4-point advantage, so I was just trying to get that incumbent advantage in there. But that's just my view, I mean, I don't know",142,"I was actually at a NACDS conference, and I heard one political pundit speak about the election, and they said incumbency is a 4-point advantage, so I was just trying to get that incumbent advantage in there. But that's just my view, I mean, I don't know if anyone else has that view. We did, of course, do more business with Medco than the current wholesaler did with ESR so, you could look at it as an incumbency but, I think, that's just really my view, but we are pleased that this has been decided relatively early in the process. That's very helpful from a planning perspective and, again, it's helped us have a very quick and interesting discussion with ESR. So we think that it's a positive for the industry and we think that, potentially, it could be positive for AmerisourceBergen."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve. Now, Steve Collis would like to make some final comments before we go.",15,"Thanks, Steve. Now, Steve Collis would like to make some final comments before we go."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","We know that it's a very busy day, so we really do appreciate everyone's interest and attention with AmerisourceBergen. I would like to commend my colleague and our acting CFO, Tim Guttman, for his leadership and contribution during this transition period",98,"We know that it's a very busy day, so we really do appreciate everyone's interest and attention with AmerisourceBergen. I would like to commend my colleague and our acting CFO, Tim Guttman, for his leadership and contribution during this transition period. As you could see, Tim's really done a great job. So to wrap up, ABC thinks this is a really good quarter for us and especially given our tough comps, and we are proud to report good momentum on all fronts at this halfway point in our fiscal year 2012. Thank you again for your attention."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and before we go, I'd just like to quickly highlight our upcoming events. On May 17, we'll be presenting at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas. And on June 6, we will be presenting at the Goldman Sach",68,"Thanks, Steve, and before we go, I'd just like to quickly highlight our upcoming events. On May 17, we'll be presenting at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas. And on June 6, we will be presenting at the Goldman Sachs 33rd Annual Global Healthcare Conference. That concludes our call for today. And now I will turn it back to the operator."
24809,183660881,290684,"AmerisourceBergen Corporation, Q2 2012 Earnings Call, Apr 26, 2012",2012-04-26,"Earnings Calls","Cencora, Inc.","Operator","Thank you. Ladies and gentlemen, this conference will be available for replay after 1:00 p.m. today through midnight, May 3, 2012. You may access the replay service by dialing 1 (800) 475-6701 and entering access code 243852. International participants, d",61,"Thank you. Ladies and gentlemen, this conference will be available for replay after 1:00 p.m. today through midnight, May 3, 2012. You may access the replay service by dialing 1 (800) 475-6701 and entering access code 243852. International participants, dial (320) 365-3844. This concludes our conference for today, and thank you for using AT&T executive teleconference services. You may now disconnect."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the ABC Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to our host, Barbara Brungess. Ple",44,"Ladies and gentlemen, thank you for standing by. Welcome to the ABC Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to our host, Barbara Brungess. Please go ahead."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Merit. Good morning, everyone, and welcome to AmerisourceBergen's Earnings Conference Call covering our fiscal 2012 third quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve",164,"Thank you, Merit. Good morning, everyone, and welcome to AmerisourceBergen's Earnings Conference Call covering our fiscal 2012 third quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve Collis, AmerisourceBergen's President and CEO; and Tim Guttman, Senior Vice President and CFO. During the call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011. Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by telephone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen once again overcame a challenging year-over-year comparison and delivered solid quarterly results. In the June quarter, our revenues were down 2% to $19.8 billio",2115,"Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen once again overcame a challenging year-over-year comparison and delivered solid quarterly results. In the June quarter, our revenues were down 2% to $19.8 billion, but our GAAP earnings per share were up 8% to $0.71. We made excellent progress integrating recent acquisitions including World Courier, which closed in early May. Our strong cash generation and high-quality balance sheet continue to provide us with an outstanding financial flexibility and give us the ability to fund our strategic initiatives, grow our business, and return funds to shareholders. Through the 9 months we are well positioned to meet objectives for the full year. 
Our diverse revenue base continues to position us well to benefit from organic growth across the entire spectrum of pharmaceutical care and our customer mix helps drive benefits from the historic influx of generics. Even as generics mitigate the top line dollar growth in our industry, IMS' healthy compounded sales growth in the U.S. in the range of 1% to 4%, and 4% to 6% worldwide through 2016. In addition, continued scrutiny of health care expenses and cost-containment efforts underway by the U.S. Federal government and commercial payers, demand continues improvement in efficiency, productivity and effectiveness across all aspects of health care. 
One of the hallmarks of the U.S. market in particular is the quality of the relationship wholesalers have with pharmaceutical manufacturers. Over the last several years, AmerisourceBergen has significantly strengthened our relationship with pharmaceutical manufacturers and we continue to put an emphasis on looking for meaningful ways to provide additional services across the supply channel in order to help manufacture and meet the challenges of today's changing health care landscape. This is the strategic rationale for the material acquisitions we have made in the past 12 months. As we sit here today, we believe that both the TheraCom and World Courier acquisitions have significantly enhanced our spectrum of services at the supply channel. Moreover, they have brought a array of valuable new customers, employees and capabilities which have exceeded our pre-closing expectations. 
As our provided customer face similar challenges regarding cost containment and reimbursement for services provided to patients and new challenges such as accountable care organization, they also increasingly turn to AmerisourceBergen for help in making their health care practices run as efficiently and effectively as possible. Our provided customers deliver world-class patient care on navigating a complex wave of reimbursement. And we believe they deserve fair compensation for the professional services they provide. AmerisourceBergen continues to be an active participant in policy discussions in Washington with the objective of helping legislators understand our industry and our importance to the health care system. 
AmerisourceBergen associates remain focus on meeting objectives for the year both in terms of our financial performance and in delivering outstanding service to our customers. I take great pride in the enthusiasm and dedication of our team and I'm honored to work beside them everyday. They meet challenges with creativity and determination and they tirelessly seek new ways to meet the need of the diverse markets we serve through collaborative innovation and by maximizing efficiency. 
As we noted in our press release, we believe it was prudent to separate our manufacture services business from pharmaceuticals distribution for financial reporting purposes. We believe that disclosing this additional level of detail will increase and best understanding of our business and further improve the overall transparency of our financial reporting. Tim will cover the financials for the 2 segments, and I will now cover some of the key trends in our business units during the quarter. 
AmerisourceBergen Drug Corporation revenue declined 5% due in large part to a decline in sales to our largest customer, as well as the previously reported loss of a large retail customer beginning last September. In addition, we anniversaried last years' addition of a new alternate customers in May, and top line growth continues to be mitigated the impact of generic conversions. Year-to-date, the drug company revenues are only down slightly as anticipated. Over the course of the year, the wave of generic launches has progressed as planned and the Drug Company saw significant gross margin expansion in the quarter even as in the 2 largest generics of Zyprexa and Lipitor came off exclusivity. We look forward to a few more launches still to come in our fourth quarter. 
Back in June, we held our annual tradeshow for our independent retail customers and we continue to be impressed with their resilience and their ingenuity in providing personalized patient care in the community they serve. Our Good Neighbor Pharmacy members participate actively in the largest independent network of community pharmacies in the U.S. AmerisourceBergen and our independent customers strongly believe that they play a critical role in health care throughout the country by offering a compelling value proposition to patients and payers alike. ABDC is focused on ensuring that our network, Good Neighbor Pharmacy, remains dynamic by continuous investment in programs and services to meet the challenges of community pharmacy today and in the future. The implementation of our SAP platform continues on schedule with 14 distribution center conversions complete representing over half of our distribution centers and 2/3 of our revenues. We've made excellent progress and we expect additional conversions occurring in our fourth quarter and the remainder plan through the beginning of the fiscal year 2013. 
We also continue to strengthen our Canadian operations in support of previously reported the business wins in that market. We are confident that these and other investments will meaningfully increase the value we bring to all of our customers in the U.S. and Canada. 
As were noted in the press release, we continue to participate in negotiations for the distribution contract to serve the newly combined business of Express Scripts and a former Medco. We believe we are nearing the end of the process and while we don't have the from date for an announcement, we do hope that the decision will be made within the next few weeks. We continue to be optimistic about our chances to win the business. However, it is a competitive process and we believe Express Scripts will ultimately choose the partner that they believe provides the best overall value. 
AmerisourceBergen's Specialty Group had another strong quarter with revenues up 8% driven by another particularly strong performance in third-party logistics and in our vaccine and physician distribution business. Our oncology business performed well, while facing another very difficult comparison due to the strong performance of the 3 large Specialty generic products in the June quarter last year. The comparison would ease in the September quarter as Oxaliplatin returns to the market. ABSG continues to benefit from the launch of a branded ophthalmology product earlier this year, continuing to help establish significant market share for the manufacturers. I experienced their product demonstrates the potent value of our Specialty franchise. While our undisputed strength in specialty is oncology business, we have expanded those capabilities to become an instrumental part of the commercialization strategy for any infusible product launched into the physician marketplace. As I previously discussed, we now have a keen interest going forward in further expanding those capabilities into select global markets. The acquisition of World Courier has given us not only a premium quality clinical trial logistics services provider, but also an international framework upon which to further capitalize on our strengths by driving our specialty logistics, consulting, commercialization and reimbursement services into other geographic markets. The integration of World Courier is going very well and we are very excited about the new insights and opportunities that are being discovered as we bring these 2 great organizations together and gain operational exposure to international markets. 
Our Consulting Services group continues to have a strong year as demand for commercialization, reimbursement and patient support services continues to be robust. We believe these combined services offerings distinguish AmerisourceBergen in the marketplace, provide unmatched value to manufacturers and begun important driver of our growth going forward. As manufacturers seek to bring new products to market or expand sales of existing products in a challenging health care environment, we believe that demand for the services would only increase. 
In terms of financial performance, the Consulting Services group delivered a solid quarter while making excellent progress into the further integration of TheraCom, which is performing very well. Even setting aside the contribution from TheraCom, the last group alone had outstanding results. As Tim will detail, the solid performance across our business contributed to excellent cash flow in the quarter. Given the strength of our balance sheet, we continue to explore opportunities to deploy our capital in order to increase shareholder value, including searching for acquisitions that meet the criteria we have in place for quite some time. They should increase our value offering to existing customers both up and down the channel. They should be within our established core competency and that should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions and we continue to be investing and pharmaceutical and the specialty distribution services, as well as consulting services. We also remain committed to returning a minimum of 30% of our free cash flow disorders in the form of dividends and share repurchases. A hurdle that we have exceeded over the last several years. 
Looking ahead, the results we've had in the first 9 months of our fiscal year put us well on our way to meeting our objectives for the full fiscal year. As we stated in our press release, we have narrowed the range of our diluted EPS expectations for the full year to $2.80 to $2.84. Tim will provide the details on our assumptions for the remainder of the year, but I want to highlight that as a result of that tremendous financial flexibility, we have repurchased $540 million of our shares in the year when we spent over $800 million in acquisitions and we'll pay down about $400 million in debt in September. This speaks to the enormous strength and resilience of our business in a year of significant change for AmerisourceBergen, and indeed for the health care industry more broadly, as well as the quality of our financial planning and financial stewardship. 
As you know, we are deeply engaged in our business planning process for our fiscal 2013 and we do not yet know the future status of the business we do with our largest customer. As we noted in our press release, however, we do expect that new generic launches in both ABDC and ABSG, as well as contributions from our recent acquisitions and other favorable items will help drive earnings growth next fiscal year. They impact of customer consolidation and competitive market dynamics on our margins is expected to offset some of that growth. As our provided customers across the health landscape prepare for the full implementation of the federal government's health-care reform initiatives, we are being challenged to help find ways to reduce cost. Across the industry, big customers are getting bigger, whether they are mail order networks or independents seeking greater strength in number through joining buying groups. Over the longer term this has lead to even more stable and resilient industry. Of course, we will continue to manage our own expenses and working capital. In addition, the strength of our balance sheet afford us additional opportunity to drive shareholder value through acquisitions, share repurchases and dividends. With all that in mind, our preliminary expectation is for high single digits to low double-digit diluted EPS growth in fiscal 2013. 
Over the last year, we made important investments in our business with an eye to the future while we continued to focus on helping our customers and ourselves take advantage of the unprecedented growth in generics and the many opportunities in Specialty. Demand is strong and growing for the core products we distribute and we play a essential role in the pharmaceutical supply chain, ensuring the integrity and security of the distribution of life improving and life-saving therapies. Our manufacturing services help market as efficiently as possible and that patients have access to both traditional medications and the most innovative and complex products. As cost-containment efforts mount across the health care spectrum, our customers increasingly turn to us to help to meet the challenges of the marketplace without sacrificing patient care. I take great pride in the energy and creativity our associates bring to our business. Each day I see the results of their innovative thinking and their dedication to exceeding customer expectations and I'm proud to be their leader. Here is Tim."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve. And good morning, everyone. As you just heard, ABC delivered a solid quarter and through 9 months, our performance is tracking well to our financial targets. The key highlights this quarter was our ability to overcome the oncology generic h",1723,"Thanks, Steve. And good morning, everyone. As you just heard, ABC delivered a solid quarter and through 9 months, our performance is tracking well to our financial targets. The key highlights this quarter was our ability to overcome the oncology generic headwind the mentioned in the past. Going into this fiscal year, we knew that Q3 would be our toughest EPS comparison. We had consistently called out a $0.33 headwind this year from Specialty generics. Of this headwind, we anticipated about half of the $0.33 would negatively impact the third quarter. We're pleased that we are able to successfully overcome this Q3 headwind and show solid EPS growth. 
Two other highlights for the quarter. We continued our discipline in terms of managing expenses across the organization and we integrated World Courier into ABC reporting. Our results include 2 months of their operations. 
Before I start with the quarterly financial details, let me highlight that in our press release, we have expanded our disclosures to include detail for 2 reporting segments in addition to our ABC consolidated results. The pharmaceutical distribution segment includes our drug and Specialty Group operating segments. The Other segment includes our manufacturer services businesses, which consists of the consulting and World Courier operating segments. Upon review of the financial reporting requirements, we determined that there was a need to separate drug distribution and manufacturer services due to the nature of their business operations and different revenue growth rates and operating margins. The disclosure of our 2 reporting segments will improve investor transparency going forward. 
Now back to the quarterly details. I'll cover ABC consolidated results first. Starting with the top line, revenues were $19.8 billion, a 1 .9% decrease over last year's quarter. Drug Company revenues were down about 5%, offset by higher specialty revenues of nearly 8%. We also had the benefit in our June '12 revenues from 2 of our acquisitions, TheraCom and World Courier. They contributed a combined $300 million of new revenues in the current quarter. 
Moving along, gross profit was $689 million in the quarter, up 5.4% from last June with the gross margin of 3.49%. Just to remind everyone, World Courier is included in our financial results and they have a fairly high gross profit margin due to their best-in-class service model. World Courier and our other acquisitions contributed nearly $60 million to our gross profit in the current quarter. 
Our LIFO charge was $4.7 million in the quarter, down $6.7 million from last year. We expect the LIFO charge of between $12 million and $15 million for the full year, down significantly from last year. Finally, the generic benefit we received in the current June quarter from new generic launches and price appreciation was in line with our expectations. Let's move to operating expenses. 
This quarter, operating expenses were $375 million, up 11.6%. But this amount includes approximately $50 million of operating expenses related to our recent acquisitions, as well as approximately $5 million of non-recurring charges related to the World Courier transaction. Excluding the impact of acquisitions, our operating expenses would have decreased about $10 million quarter-over-quarter. Our businesses continue to do an excellent job at managing their expenses. 
Operating income of $314 million in the quarter decreased about 1%, while operating margin was up by 2 basis points compared to last June. Our third quarter was slowed by the World Courier transaction cost. And more importantly, the difficult comparison versus the prior year. 
Moving below the operating income line and other income, we had income of $4.8 million primarily related to an increase in evaluation of a note that was due to ABC from the October 2008 sale of our prior PMIS business. Interest expense of approximately $25 million in the June quarter increased 33% compared to last year. As a result of our $500 million senior notes that we issued back in November. Our effective income tax rate of 38.3% was slightly higher than last year's 38.2%, and is in line with our expected annualized rate of 38.4%. 
Our GAAP diluted earnings per share in the quarter of $0.71 increased by $0.05 or just under 8%, over the last quarter -- over the same quarter last year. Our EPS benefited from a reduction in our average diluted shares outstanding due to our ongoing share repurchase programs. Average diluted shares for the quarter were approximately $256 million, down just over 8% from last June. At June 30, 2012, we have 251 million outstanding shares. 
Let's take a few minutes discussing our some results for the June quarter. Starting with pharmaceutical distribution, total revenues were $19.4 billion, down about 3.3% over last year's quarter. Drug Company revenues were down about 5% due primarily to lower sales with former Medco, and the impact from the loss of a large chain customer last year to former Longs Drugs. Slightly over half of the decline came from lower sales to former Medco driven by generic conversions and changes in their book of business. Without these 2 negative impacts, our drug business would have had growth of 2%. Also during the quarter, the Drug Company anniversaried a large customer win from the prior June quarter. 
Specialty Group's revenue increased nearly 8% led by strong performance in 2 of its businesses with growth significantly above market rates. ICS, our third party logistics business, and Besse Medical, our vaccine and physician office distribution business. From a segment standpoint, gross profit if decreased about $25 million and our gross profit margins slipped somewhat. Most of the dollar decrease is due to the oncology generics headwind, a high-margin contributor last June quarter offset by the contribution from generic Lipitor and Zyprexa, both of exclusivity periods end during the June '12 quarter. We did have other generic launches during the quarter and also gross profit contributions from our specialty businesses. These positives were offset by the decrease in our revenues and margin pressure. It should be noted that Drug Company is viewed on its own had gross profit margin expansion of 20 basis points in the June 2012 quarter. This segment managed operating expenses very effectively especially payroll and benefit expenses, as well as external consulting expenses which enabled us to offset some of the gross profit dollars we lost with the oncology generic headwind. Overall, we're very pleased with the operating results for this segment. 
Moving to the other reporting segment, which again is consulting which includes our packaging business and World Courier. As mentioned previously, our 2 large acquisitions accounted for nearly $300 million of new revenues in the third quarter. World Courier revenues are tracking well against our expectations, which we provided back in our press release that announced the acquisition. Operating income from the Other segment increased $11 million from last year's quarter. Of this increase, about $8 million is related to our fiscal '12 acquisitions. The remaining increase is related to our legacy businesses. I'd like to highlight that our non-recurring charge of about $5 million is not included in our segment level reporting. For the June quarter, the impact of our World Courier acquisition was essentially breakeven due to the transaction costs. 
Now let's turn to our consolidated balance sheet and cash flows where trends continue to be favorable. We generated $92 million of cash from operations in the quarter, bringing our 9 month's total to $760 million. Our businesses continue to focus on working capital. In fact, our cash conversion cycle based on a rolling 4-quarter average improved by 1 day to 1.7 days based in the current June quarter, from 2.7 days in the June 2011 quarter. 
Capital expenditures were $39 million in the quarter and $128 million for the 9 months. For the full year, we are still tracking to our guidance for CapEx of $200 million. During the quarter, we bought back $186 million of our shares. For the 9 months, we purchased $514 million of shares and is slightly exceeds our March quarter guidance of $500 million. At June 30, we have $744 million left on our May 2012 share repurchase authorization. 
Our cash balance at June 30 was $1.7 billion. As we have discussed in the past, we need approximately $500 million in available cash to account for swings in working capital and to run the business. As a reminder, in mid-September, we will be using cash to retire our $400 million 5 5/8 notes. 
Now let's turn to updated fiscal 2012 guidance. We now expect our GAAP diluted EPS to be in the range of $2.80 to $2.84. This includes an estimated $20 million of non-recurring cost related primarily to transaction and severance expenses. With narrowing our EPS range, this means that we will have EPS growth of 10% to 12% this year after absorbing the $0.05 negative impact from non-recurring charges. 
Revenue. We continue to expect revenue growth to be flat or up modestly for the full year. We expect our operating margin expansion to be in the high single digits. As previously communicated, Q4 is our easiest operating income comparable for the year. Because of this, we expect most of our operating margin expansion to be achieved in the fourth quarter. Free cash flow is still tracking to finish in the $800 million to $900 million range. 
Looking ahead. We are deeply engaged in our business planning process for fiscal 2013 and are still many moving parts including, of course, the Express Scripts RFP. As Steve outlined, as large customers consolidate they are seeking better pricing which includes generic pricing. And as recent contract discussions have demonstrated, our customers want us to be part of a solution in helping them meet the economic demands of a new health care landscape. Our highs double-digit to low double-digit EPS growth great is based on the assumptions on several moving parts, and includes possible outcomes on the Express Scripts contract. Our EPS range is preliminary and we still have quite a bit of work to complete in our planning process. But it does incorporate the best information we have right now. So before I turn it back to Barbara, let me reiterate that 9 months into our fiscal year, we are well positioned to meet our financial targets for fiscal '12 and we are hard at work on our fiscal '13 plan. Here is Barbara to start our Q&A."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Tim. We will now open the call to questions. [Operator Instructions] Please go ahead, Mary.",17,"Thank you, Tim. We will now open the call to questions. [Operator Instructions] Please go ahead, Mary."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Tom Gallucci with Lazard Capital Markets.",17,"[Operator Instructions] And our first question comes from the line of Tom Gallucci with Lazard Capital Markets."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","I guess my first question was, on some of the commentary that you had in the press release and I think you echo it a bit on your prepared remarks, when you sort of talk about the competitive pricing pressures and sort of the competitive landscape. Can you",81,"I guess my first question was, on some of the commentary that you had in the press release and I think you echo it a bit on your prepared remarks, when you sort of talk about the competitive pricing pressures and sort of the competitive landscape. Can you expand a little bit on what you mean there? Is it sure that something we always see in the part of the business or are there really do dynamics that you're referring to?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","No. I think, what we're seeing is the larger customers are getting large and we always in the larger customers get the best deal and we're seeing some of that. I think in addition, we've got much more generics as a percentage of sales. Don't forget, we ha",134,"No. I think, what we're seeing is the larger customers are getting large and we always in the larger customers get the best deal and we're seeing some of that. I think in addition, we've got much more generics as a percentage of sales. Don't forget, we have a very diverse customer base, almost all of them by generics from us. So generics as a percentage of overall portfolio have increased. So I think people are looking at their businesses and their potential financial impacts from Health Care Reform and reimbursement pressure. And they're expecting us to participate with them in a much tougher future. So tougher future, we always have to be more efficient and I think we just got immune from some of that. That is what I would point out now."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And then just to clarify your comments on guidance. I guess asked you specifically, it sounds like it's ready conservatism because there are so many moving parts. On Express specifically, we all know that's a pretty big moving parts, would you be ab",63,"Okay. And then just to clarify your comments on guidance. I guess asked you specifically, it sounds like it's ready conservatism because there are so many moving parts. On Express specifically, we all know that's a pretty big moving parts, would you be able to meet these guidance range if tomorrow you found out you did retain the Medco, the legacy Medco business?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Tom, this is Tim, I'll answer your question this way. I mean our guidance includes, like you said, different assumptions on moving parts. One of which is Express Scripts and it contemplates both scenarios. Winning it and losing it. Again, it's Express Scr",52,"Tom, this is Tim, I'll answer your question this way. I mean our guidance includes, like you said, different assumptions on moving parts. One of which is Express Scripts and it contemplates both scenarios. Winning it and losing it. Again, it's Express Scripts and other factors looking out over the next years."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","And our next question comes from the line of Larry Marsh with Barclays.",13,"And our next question comes from the line of Larry Marsh with Barclays."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Just my question is elaboration around Tom's around next year. So I appreciate in providing some clarity here with, perhaps, a tone of trying to be prudent here. But I guess, Steve, as if we think about scenario where your largest customers chooses not to",124,"Just my question is elaboration around Tom's around next year. So I appreciate in providing some clarity here with, perhaps, a tone of trying to be prudent here. But I guess, Steve, as if we think about scenario where your largest customers chooses not to continue to do business with you or splits the business. Can you remind some of the factors that you would, could, go through to help mitigate some of those lost revenues from the cost side that would keep you still in the range of guidance? And along with that, could there be a situation where they might be a quarter or 2 timing mismatch between revenues and costs that could cause you to vary around your guidance range?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","We really are deep in this. In fact, we're going -- the team's is going to visit all over our drug regions next weak work which is really the start for us a detailed process. We had information that we have information that we think is material that we fe",253,"We really are deep in this. In fact, we're going -- the team's is going to visit all over our drug regions next weak work which is really the start for us a detailed process. We had information that we have information that we think is material that we felt was incumbent on us to share with all of you and that's the way AmerisourceBergen is run. We're proud of that, we are not backing off that. So absolutely, if we lose Express Scripts, don't forget our current business is really, a lot of the Greenfields that we set up during the mergers really set out to handle big matter business that we have done with Medco, traditionally for as long as I can remember. I've been with the company 8.5 years before the Medco. But it's very little expense. In fact, many of the characteristics of this business are what we used to call dock to dock to business. Of course, you remember that very well. There's not too much expense there. And coincidently, a lot of the facilities that we are service to Medco or our most highly efficient modern facilities, but we absolutely have opportunities to cut down our cost and like I've said, this current thinking, while it's early, really contemplates all the way from us entirely losing this business to winning it including winning the part that we currently do not service based on our base understanding of what the economic can be. But it honestly is early."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, appreciate the reflection there. And I guess my follow-up is around your LIFO charge. So, Tim, you're communicating a reduction in your range of LIFO expectations versus what you would suggest to back in April by, I say, a couple of million dollars.",108,"Okay, appreciate the reflection there. And I guess my follow-up is around your LIFO charge. So, Tim, you're communicating a reduction in your range of LIFO expectations versus what you would suggest to back in April by, I say, a couple of million dollars. On the time you said you anticipated big impact last year was the generic introductions and some moderation of brand price inflation. What's causing you to further moderate your views on that inflation based cost and as you think about your guidance to next year, can you give us in a sense of general range of LIFO charges that you're anticipating for fiscal '13?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Larry, it's probably a little bit early to talk about LIFO '13. I mean, we're still looking through that. In terms of LIFO for the June quarter, at the end of the June quarter we saw a pretty good brand pricing increase percentages for our top 75 brands d",120,"Larry, it's probably a little bit early to talk about LIFO '13. I mean, we're still looking through that. In terms of LIFO for the June quarter, at the end of the June quarter we saw a pretty good brand pricing increase percentages for our top 75 brands drugs, a little bit off from last year. I mean, there are some moderation there in terms of brand pricing. And we're seeing a little bit steeper generic deflation especially with generic Lipitor and Zyprexa. So that's driving the change, the slight change in our full year LIFO forecast. But again for next year, we're probably just -- it just depends on where brand price inflation is. It's a little bit early."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","And our next question comes from the line of Robert Jones with Goldman Sachs.",14,"And our next question comes from the line of Robert Jones with Goldman Sachs."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I just wanted to go back, I know you touched on some of the changing market industry dynamics and specifically, Tim mentioned the generic pricing. I was just wondering maybe for perspective, if you could share your thoughts or recent trends on both",77,"Steve, I just wanted to go back, I know you touched on some of the changing market industry dynamics and specifically, Tim mentioned the generic pricing. I was just wondering maybe for perspective, if you could share your thoughts or recent trends on both the buy side margin that you've seen recently and maybe separate out the sell side margin just to give us some perspective on your dealings on both at the manufacturers and the customer?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Many times I'll just talk about the buy side first. Many times on the fee-for-service agreements we are really in our third generation and we dealt with a lot of pharma consolidation and we feel that we've, the industry on the manufacturer side really und",322,"Many times I'll just talk about the buy side first. Many times on the fee-for-service agreements we are really in our third generation and we dealt with a lot of pharma consolidation and we feel that we've, the industry on the manufacturer side really understand the value we represent. And there's no significant erosion there or anything at all. Obviously, the generic mix at AmerisourceBergen has opportunities had an opportunity to sell generics to almost all of our customers. As you know, we believe we have the most diverse customer base. In this really, but driven by this generic wave and we have set out our will portfolio in both drug and specialty to really recognize the strength in generics. Hope you would buy some day and health recapitalized the opportunity that we have for generics and specialty. The sell side, I think, the biggest thing we can point to you is somewhat of an anxiety of compressed reimbursement. And just a lot of consolidation. I mean, read the headline, is not just the particular one, it's on everyone's mind. There's just that there's a lot of consolidation. We have community oncologists, for example, that are constantly getting a lot bigger and our bigger customers get a better deal. We have independent customers joining buying groups. So these are the biggest trends that I can point to. And, of course, there's a lot of marquee customers up for bid. It has been pretty well-publicized, the a process, now definitely the SR process has really kicked up some dust, I could say, from other customers. So without being too specific, we don't like to comment on individual contracts, we have been in this business for long time. We understand how the contract with customers and we believe that our best bet is to maintain our key customers and customers that we believe are going to represent us growth in the years ahead."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","I appreciate that. And just maybe around the preliminary guidance. I was hoping you can maybe talk about the major swing factors. And obviously, I think, we are all well aware of the Express contract but maybe just how you're thinking about other importan",106,"I appreciate that. And just maybe around the preliminary guidance. I was hoping you can maybe talk about the major swing factors. And obviously, I think, we are all well aware of the Express contract but maybe just how you're thinking about other important contracts, I know you don't want to name names, but I think PharMerica is one that's out there and some of the other major contributing factors, what's assumption around buyback, it looks like there's obviously some nice contribution from lower interest expense and clearly World Courier next year. Maybe some of the push and pulls around the guidance range would be helpful."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","This is Tim. In terms of the guidance, I mean, we're not going to talk specifically about other contracts. Certainly, we made an assumption about Express in there. And as we start the plan process, we always look at over the 12 month horizon of what other",166,"This is Tim. In terms of the guidance, I mean, we're not going to talk specifically about other contracts. Certainly, we made an assumption about Express in there. And as we start the plan process, we always look at over the 12 month horizon of what other contracts we may renew and renegotiate. There's an assumption in there about other contracts. And some of the other things too would be our so plan and an assumption how we're going to perform next year. I mean that's a big unknown. We don't know how the pricing will stick in the market. How many suppliers and that's a factor. Certainly, we make an assumption about expenses. And finally, in terms of share repurchases the assumption is I think if you look back what they've done historically the last 2 or 3 years, we've been around about the $500 million range, so that's probably a pretty safe number to be in at -- for the -- that's our thinking."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from the line of Glen Santangelo with Credit Suisse.",13,"Our next question comes from the line of Glen Santangelo with Credit Suisse."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","I just want to follow-up on generics. And I'm not sure exactly how you're thinking about this with respect to your guidance. But, Tim, you mentioned in your prepared remarks right, you went into fiscal '12, with a $0.33 whole. Obviously, everyone's focuse",78,"I just want to follow-up on generics. And I'm not sure exactly how you're thinking about this with respect to your guidance. But, Tim, you mentioned in your prepared remarks right, you went into fiscal '12, with a $0.33 whole. Obviously, everyone's focused on is generic calendar. So as you think about your guidance for fiscal '13, could give us a since for maybe what the contribution you're expecting in '13 versus '12? What that looks like?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Glen, I mean, we're just, again, we are early in the plan process. We don't like get into any specifics. We do have generics, a couple of good ones that launched at the end of our Q4 that carryover into fiscal '13 that will definitely help us. We're encou",112,"Glen, I mean, we're just, again, we are early in the plan process. We don't like get into any specifics. We do have generics, a couple of good ones that launched at the end of our Q4 that carryover into fiscal '13 that will definitely help us. We're encouraged I mentioned before, will be back, we only have it for 6 weeks, we'll get it next year. There's some unknowns about that. But overall are not going to have a generic Lipitor and Zyprexa, but there are some good generics that help us early in the year. But again, we're not ready to kind of dial in any specific EPS impact numbers."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, that's fair. Maybe I could ask Steve one follow-up question. Steve, I just want to talk about a comment you made with respect to acquisitions you said, I think, the company is still receptive to the idea of acquisitions. And it sounds like you're pr",93,"Okay, that's fair. Maybe I could ask Steve one follow-up question. Steve, I just want to talk about a comment you made with respect to acquisitions you said, I think, the company is still receptive to the idea of acquisitions. And it sounds like you're pretty pleased with the progress at both TheraCom and World Courier Group. And as you think about where you are with respect to those integrations, I mean, you feel like the company could handle additional acquisitions in fiscal '13 or kind of get just see how it goes?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","That's a great question. I do think that we are operationally well situated. And I think actually, TheraCom is a very good example. I mean we've had some work to do at the corporate office, yes, what obviously we brought some well-run companies and he's i",267,"That's a great question. I do think that we are operationally well situated. And I think actually, TheraCom is a very good example. I mean we've had some work to do at the corporate office, yes, what obviously we brought some well-run companies and he's in good shape integration work is carried on in our Consulting Services business. So I think they're very well equipped to run that. World Courier was definitely a different expansion for us. We've had a lot of work to do. I think Tim pointed out one of the highlights for this year was really getting World Courier into the financial reporting criteria for a public company and that's gone well but we do think that one of the reasons we're investing in this company was the platform opportunity and now when we go consider anything internationally we have local intelligence which is huge. Local understanding of tax laws, of who the good players are, who the bad players are. So we do think that this opens up some attractive markets to us which we started our release by talking a bit about obviously, the obvious fact that pharmaceutical growth in the rest of the world will be higher in the U.S. So we're not rushing in here. We don't think that it is in any market or anything. But it is important to us to drive our Specialty and Consulting practices throughout the world and we think we have the leading practices in other areas and a lot of good intelligence and methodologies to share with the rest of the world."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","This is, Tim. I'll just say after 100 days, we're really pleased with what we have so far and they're performing right on our expectations. So, like I said, neutral in Q3, and we expect them to contribute $0.01 or $0.02 in Q4. So again, very encouraging t",60,"This is, Tim. I'll just say after 100 days, we're really pleased with what we have so far and they're performing right on our expectations. So, like I said, neutral in Q3, and we expect them to contribute $0.01 or $0.02 in Q4. So again, very encouraging this year and looking forward to what they're going to do in '13."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question goes to the line of Robert Willoughby of Bank of America Merrill Lynch.",16,"Our next question goes to the line of Robert Willoughby of Bank of America Merrill Lynch."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Tim, what's left on your expenses. Will we see much going forward in the numbers. And I think you hit at it, but what was the actual dilution from new generics year-over-year into revenues?",34,"Tim, what's left on your expenses. Will we see much going forward in the numbers. And I think you hit at it, but what was the actual dilution from new generics year-over-year into revenues?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","The actual dilution, in terms of revenues?",7,"The actual dilution, in terms of revenues?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Yes, in terms of revenue growth rate.",7,"Yes, in terms of revenue growth rate."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","What we said in terms of the Medco. I mean, Medco was down probably about half. I mean, it's probably in the $500 million or $600 million range, that's from our largest customer Medco by itself. And not all that is some of that is book of business, right,",126,"What we said in terms of the Medco. I mean, Medco was down probably about half. I mean, it's probably in the $500 million or $600 million range, that's from our largest customer Medco by itself. And not all that is some of that is book of business, right, and some of this is the generic conversions. In terms of your other question, I would say, Robert, that we don't have much left in terms of World Courier. I think we have $17 million in terms of non-recurring cost over Q3. In my comments I said I thought we end at about $20 million. We probably still have some other non-recurring charges that will come through about $3 million, not related to World Courier in Q4."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","And our next question comes from the line of Eric Coldwell with Robert W. Baird.",15,"And our next question comes from the line of Eric Coldwell with Robert W. Baird."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","I'm going to ask you if it's right. Regardless of correlation in the past, we have seen some rather funky behavior from the manufacturers around major U.S. elections, I'm specifically thinking about the September quarter of 2004 where price inflation cont",85,"I'm going to ask you if it's right. Regardless of correlation in the past, we have seen some rather funky behavior from the manufacturers around major U.S. elections, I'm specifically thinking about the September quarter of 2004 where price inflation contracted fairly dramatically. Have you considered the possibility of that hitting this election or do you think it's really not in the limelight here. I guess any signal on pharma behavior on pricing here in the near term. And then I have a follow-up."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","The pharma pricing has been a little bit less than last year price increases but still robust. And as I said we spend more time internationally and everyone's very envious of an environment where we can have price increase. It's an excellent thought, Eric",132,"The pharma pricing has been a little bit less than last year price increases but still robust. And as I said we spend more time internationally and everyone's very envious of an environment where we can have price increase. It's an excellent thought, Eric, I credit to you for thinking of that. We'll have more attention but we haven't really seen anything concerning. I think more of the pricing increases have to do with patent expirations, is what we're seeing a trend there. Some price and pricing strategies ahead of large patent expirations. And as you know, we've got some significant launches in this quarter and less exciting newer brands to generic conversion next year, but still very robust. And we will see some of the impact on brand prices from those."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","And my follow-up is related to business transformation, the ASP program you seem to continue to be ahead of schedule and doing with there. Just curious if you could give us an update on the incremental benefits to OpEx compared to your original thoughts t",85,"And my follow-up is related to business transformation, the ASP program you seem to continue to be ahead of schedule and doing with there. Just curious if you could give us an update on the incremental benefits to OpEx compared to your original thoughts to the implementation. And then whether you might be looking to fiscal '13 and '14 in thinking that there could be some additional juice on that $10 million and $40 million of OpEx savings that you had previously talked about?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","I'll let Tim handle this, but I'll just say that generally we've said, we've done most of our capital spend, then now it's operational spend. So the depreciation is starting to hit us financially. The consulting expenses, the external consultants is defin",75,"I'll let Tim handle this, but I'll just say that generally we've said, we've done most of our capital spend, then now it's operational spend. So the depreciation is starting to hit us financially. The consulting expenses, the external consultants is definitely an opportunity we have to reduce cost. And we've actually done well against our plan for our BD budget for this year, but I'll let Tim give you some color on this."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Eric, actually to Steve's point, I mean, I just want to make sure I stress this. I mean, we're starting to see a little bit of expense savings now. Again when I mentioned external consulting, a chunk of that is from our IT department and the fact that we'",133,"Eric, actually to Steve's point, I mean, I just want to make sure I stress this. I mean, we're starting to see a little bit of expense savings now. Again when I mentioned external consulting, a chunk of that is from our IT department and the fact that we're moving along and deploying SAP really efficiently, effectively. So we're seeing a little bit now. But we're still, we're not -- we're still believing that the $10 million's appropriate. That's one of those when we talked about moving parts in our range, that's one of the assumptions kind of factored in to our range for '13 and we're still on the $40 million for '14. So at this point, we're just not ready to commit any upside or juice as you called out there."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from the line of Lisa Gill from JPMorgan.",12,"Our next question comes from the line of Lisa Gill from JPMorgan."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I just wanted to follow up on a comment that you made around the Express Scripts new contract. You said it would be the best overall value. I'm just wondering if there's any changes to the types of services that they're looking for versus what you'",104,"Steve, I just wanted to follow up on a comment that you made around the Express Scripts new contract. You said it would be the best overall value. I'm just wondering if there's any changes to the types of services that they're looking for versus what you've previously provided for Medco? And then just on the follow-up side for that, I think I read in a Philadelphia paper some comments around specialty and your growth in Specialty and perhaps moving towards the patient. I was wondering if you could also comment on that, as well as potentially competing with a customer like the PVM?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Let me just talk about that. I think our business in Specialty is -- and we're talking about this with a customer that everyone has a different definition of Specialty. With AmerisourceBergen's Specialty we're really talking about physician administrative",249,"Let me just talk about that. I think our business in Specialty is -- and we're talking about this with a customer that everyone has a different definition of Specialty. With AmerisourceBergen's Specialty we're really talking about physician administrative products and related services to manufacturers. I think when a PVM specialty it usually means patient administrative products. And so I think that that's pretty well defined. We actually think there's a lot of opportunities to collaborate in those areas including with our Good Neighbor Pharmacy network and there's an opportunity to do potentially more specialty in the community. And we do take Specialty franchise and expertise very seriously there. And think that we afford a lot of AmerisourceBergen customers in this area an opportunity to gain from our expertise including in the policy area and the manufacturer relations area. The first part of your question had to do with Express Scripts and the overall value that we provide. I think that was more of a comment that the economic deals. I mean, there's a very few companies that are qualified to be the provider to Express Scripts. So it's a small universe and I think economics is part of it, experience is part of it and I don't think, honestly, that any of the qualifications have really materially changed since the start of the process, which has been pretty quick if you think about it compared to some of the other ones that we've seen in the recent past."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","So if I understand that though, so your comments around commercialization of a product and perhaps working in partnership with a PVM, you don't do that is an opportunity with a new potential contract with the new Express Scripts or is that a future opport",52,"So if I understand that though, so your comments around commercialization of a product and perhaps working in partnership with a PVM, you don't do that is an opportunity with a new potential contract with the new Express Scripts or is that a future opportunity, but not part of this RFP process?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","No, we see -- I think that our markets presence and our markets expertise are very complimentary. But the focus on this has really been on the core economics and I think ideas is obviously to win an account and then we can work on an alignment and future",59,"No, we see -- I think that our markets presence and our markets expertise are very complimentary. But the focus on this has really been on the core economics and I think ideas is obviously to win an account and then we can work on an alignment and future opportunities together. So that's really what our strategy is there."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes from John Ransom from Raymond James.",10,"The next question comes from John Ransom from Raymond James."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Just a couple of things just drilling down to your assumptions next year. If Oxaliplatin comes back to Express, is that a fair mover for you?",26,"Just a couple of things just drilling down to your assumptions next year. If Oxaliplatin comes back to Express, is that a fair mover for you?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","We are obviously excited to have Oxaliplatin back and at the end of May we were thrilled that the comp is out now. We enjoyed the ride, but it was a good timing to have the comp out. August we're going to have the product back, but it's going to be very d",192,"We are obviously excited to have Oxaliplatin back and at the end of May we were thrilled that the comp is out now. We enjoyed the ride, but it was a good timing to have the comp out. August we're going to have the product back, but it's going to be very different. The ASP's pretty high so that's a positive. But there's no at risk there's no exclusivity periods. So we're going to have several manufacturers. And we think that the pricing would will be very dynamic. It's probably going to be more  akin to, again, specialty drugs they're different than our solid process never get quite as low, but it's going to be more akin to the expiry of 180-day exclusivity period than it is to a new generic injectable launch is what I'd say. So while we're expecting with our market share that we have, the expertise we have in oncology, we are expect them to do very well here as we did with docetaxel and gemcitabine. We don't expect that you're going to be hearing half of our earnings call will be devoted to Oxaliplatin in the future."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","The said question, if you just look at the totality of all generics, the contribution that you think you're getting next year compared to the contribution, and my specific view is I think from all accounts was just off the charts exclusivity period obviou",61,"The said question, if you just look at the totality of all generics, the contribution that you think you're getting next year compared to the contribution, and my specific view is I think from all accounts was just off the charts exclusivity period obviously you're alluding that. We were just having troubles thinking it's going to be worse, the same next?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","I don't think it's going to be quite as robust, but, Tim, you.",14,"I don't think it's going to be quite as robust, but, Tim, you."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, John, you're breaking up a little bit, but I think what you're asking is what next year looks like. And again, we have a little bit of a benefit from our fiscal year with a couple of large generics lunching at the end of our Q4. But overall, talking",107,"Yes, John, you're breaking up a little bit, but I think what you're asking is what next year looks like. And again, we have a little bit of a benefit from our fiscal year with a couple of large generics lunching at the end of our Q4. But overall, talking to our generics guys. I mean, we think it will be a good year. It's going to probably be a little down compared to this year. It's tough to replace generic Lipitor and Zyprexa. But again there are a couple of other ones out there that we're encouraged about. So down a little bit, but not bad."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","And again, Lipitor, because of the class of customers we serve is who buys generics from us, might not have been as big for us as it was for the other players in the industry. Just keep that in mind.",40,"And again, Lipitor, because of the class of customers we serve is who buys generics from us, might not have been as big for us as it was for the other players in the industry. Just keep that in mind."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","And I guess, I would like, again, going back to that, I mean let's go back and highlight Steve's comment earlier, is a lot of our volume is coming through larger customers on generics. So, again, they get their pricing -- they bring us more volume but the",54,"And I guess, I would like, again, going back to that, I mean let's go back and highlight Steve's comment earlier, is a lot of our volume is coming through larger customers on generics. So, again, they get their pricing -- they bring us more volume but they're pricing's a little bit more favorable."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Our last question comes from the line of Ricky Goldwasser with Morgan Stanley.",13,"Our last question comes from the line of Ricky Goldwasser with Morgan Stanley."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","So just some quick follow-up questions here. So first of all, Steve, I think on your last comment around the volume, a lot of your generic volume coming from larger customers, so can you clarify that a little bit for us because when I think about Amerisou",153,"So just some quick follow-up questions here. So first of all, Steve, I think on your last comment around the volume, a lot of your generic volume coming from larger customers, so can you clarify that a little bit for us because when I think about AmerisourceBergen,  I think it really is going to affect a big portion of your customer base being kind of like the smaller independents. So when you comment about the generic volumes, are you referring to kind of the PVM and the Omnicares of the word, or are you talking about like your specialty segments. So if you could just clarify as to who those large customers are? And then secondly, from data that we have seen recently, it seems like that there have been some good generic price increases taking place. So how are you think of generic inflation in the context of your forward outlook?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Well, 2011 we did very well on generic price inflation. It's been much more moderate this year. And I think we even pointed out the numbers because it was significant to the interpretation. We haven't seen anything as robust as. Ricky, apologies for your",278,"Well, 2011 we did very well on generic price inflation. It's been much more moderate this year. And I think we even pointed out the numbers because it was significant to the interpretation. We haven't seen anything as robust as. Ricky, apologies for your last name, but we do have, we believe the most diverse customer base within our industry. And we are very proud of the strong independent business that we have. We're also doing more business within the health systems on generics, which is a great trend for us given our health systems presence. We also as you know we never use to talk about generics and specialty we talk about a lot. So there are a lot of very good trends for us in generics. But another trend is obviously our large PVM customer doesn't really buy any significant generics from us, which we've talked a lot about. And the larger customers, a lot of them say -- and we're doing our last round of contract negotiations there may be buying 4% to 7% of their purchases, when generics are now it's a lot higher. And those customers are getting bigger. And we have to share more of the economics of generics with them because it's a much bigger part, they're much higher profile product category to them. So those are some of the trends that we've been pointing out. And you're absolutely correct to think of AmerisourceBergen as specialty customers and independent pharmacies and large health system presence and big ultimate start or closed-door pharmacy businesses and that's definitely one of the strengths of us is our diversing up the business that we serve."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","So in that line, just another clarification, when you think about for fiscal year '13 and where you say it might done in little in terms of generic contribution, you're really looking at it which include specialty generic and Oxaliplatin and solid orals r",51,"So in that line, just another clarification, when you think about for fiscal year '13 and where you say it might done in little in terms of generic contribution, you're really looking at it which include specialty generic and Oxaliplatin and solid orals rather than separating the 2, is that fair?"
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","The top line brand to generic conversions and some of it is fall -- it's complicated because we have fourth quarter launches that will impact our fiscal year '13, but it was $13 billion in fiscal year '12, and it's about $11 billion to $12 billion in fisc",305,"The top line brand to generic conversions and some of it is fall -- it's complicated because we have fourth quarter launches that will impact our fiscal year '13, but it was $13 billion in fiscal year '12, and it's about $11 billion to $12 billion in fiscal year '13, and again, the court has moved and earlier in our guidance and we're looking at it. But again $11 billion is a very -- is a good year for us. If you look at our performance over the last 10 years, it's a good year. We look forward to providing more guidance. We just wanted to give you a benefit of our early look at 2013, what we know about some large contract negotiations that are going on. And I hope you appreciate the full stock that we've given you and the approach that we've taken, which is always being as transparent and as communicative with our investors as we can. So I think, with that, we'll wrap up. And, Barb, you want to make some comments. I'm up for a strong close. So my strong close is I recently completed my first full year as CEO of AmerisourceBergen, which I'm very proud to sit in this position. And I unequivocably and very confidently state that ABC's franchise in our place in the industry and our long-term prospects are really outstanding. We have just repeated -- we have just reported an excellent quarter and we are well on our way to completing a successful 2012. And I thank you for your attention today. And I believe that ABC's making the right investments to secure our future and we look forward to seeing some of you in September at various conferences. And, of course, we'll have our full fiscal year '13 earnings in November. Thank you."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve. And just a couple of calendar items, we'll be at the Robert W. Baird Health Care Conference in New York on September 5. And at the Morgan Stanley Conference, also in New York, on September 11. So that concludes our call for today. I'll now",55,"Thanks, Steve. And just a couple of calendar items, we'll be at the Robert W. Baird Health Care Conference in New York on September 5. And at the Morgan Stanley Conference, also in New York, on September 11. So that concludes our call for today. I'll now turn it back to the operator. Thank you."
24809,212451049,331558,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Thank you. Ladies and gentlemen. This conference will be made available for replay today, after 1:00 p.m. Eastern time through August 2 at midnight. You may access the AT&T teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering t",77,"Thank you. Ladies and gentlemen. This conference will be made available for replay today, after 1:00 p.m. Eastern time through August 2 at midnight. You may access the AT&T teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering the access code 253858. International participants may dial (320) 365-3844. The access code is 253585. That concludes our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the ABC Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to our host, Barbara Brungess. Ple",44,"Ladies and gentlemen, thank you for standing by. Welcome to the ABC Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to our host, Barbara Brungess. Please go ahead."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Mary. Good morning, everyone, and welcome to AmerisourceBergen's Earnings Conference Call covering our fiscal 2002 -- 2012 third quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today ar",167,"Thank you, Mary. Good morning, everyone, and welcome to AmerisourceBergen's Earnings Conference Call covering our fiscal 2002 -- 2012 third quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve Collis, AmerisourceBergen's President and CEO; and Tim Guttman, Senior Vice President and CFO. During the conference call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011. Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by telephone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen once again overcame a challenging year-over-year comparison and delivered solid quarterly results. In the June quarter, our revenues were down 2% to $19.8 billio",2131,"Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen once again overcame a challenging year-over-year comparison and delivered solid quarterly results. In the June quarter, our revenues were down 2% to $19.8 billion, but our GAAP earnings per share were up 8% to $0.71. We made excellent progress integrating recent acquisitions including World Courier, which closed in early May. Our strong cash generation and high-quality balance sheet continue to provide us with outstanding financial flexibility, and give us the ability to fund our strategic initiatives, grow our business and return funds to shareholders. Through 9 months, we are well positioned to meet objectives for the full year. 
Our diverse revenue base continues to position us well to benefit from organic growth across the entire spectrum of pharmaceutical care, and our customer mix helps drive benefits from the historic influx of generics. Even as generics mitigate the top line dollar growth in our industry, IMS Health's compounded annual sales growth in the U.S. in the range of 1% to 4%, and 4% to 6% worldwide through 2016. In addition, continued scrutiny of health care expenses and cost-containment efforts underway by the U.S. Federal government and commercial payers demand continues improvement in efficiency, productivity and effectiveness across all aspects of health care. 
One of the hallmarks of the U.S. market in particular is the quality of the relationship wholesalers have with pharmaceutical manufacturers. Over the last several years, AmerisourceBergen has significantly strengthened our relationship with pharmaceutical manufacturers, and we continue to put an emphasis on looking for meaningful ways to provide additional services across the supply channel in order to help manufacturers meet the challenges of today's changing health care landscape. This is the strategic rationale for the material acquisitions we have made in the past 12 months. As we sit here today, we believe that both the TheraCom and World Courier acquisitions have significantly enhanced our spectrum of services at the supply channel. Moreover, they have brought a cadre of valuable new customers, employees and capabilities, which have exceeded our pre-closing expectations. 
As our provider customers face similar challenges regarding cost containment and reimbursement for services provided to patients and new challenges such as accountable care organization, they also increasingly turn to AmerisourceBergen for help in making their health care practices run as efficiently and effectively as possible. Our provided customers deliver world-class patient care on navigating a complex wave of reimbursement. And we believe they deserve fair compensation for the professional services they provide. AmerisourceBergen continues to be an active participant in policy discussions in Washington with the objective of helping legislators understand our industry and our importance to the health care system. 
AmerisourceBergen associates remain focus on meeting objectives for the year both in terms of our financial performance and in delivering outstanding service to our customers. I take great pride in the enthusiasm and dedication of our team, and I'm honored to work besides them everyday. They meet challenges with creativity and determination, and they tirelessly seek new ways to meet the needs of the diverse markets we serve through collaborative innovation and by maximizing efficiency. 
As we noted in our press release, we believe it was prudent to separate our manufacture services business from pharmaceutical distribution for financial reporting purposes. We believe that disclosing this additional level of detail will increase investor understanding of our business and further improve the overall transparency of our financial reporting. Tim will cover the financials for the 2 segments, and I will now cover some of the key trends in our business units during the quarter. 
AmerisourceBergen Drug Corporation revenue declined 5% due in large part to a decline in sales to our largest customer, as well as the previously reported loss of a large retail customer beginning last September. In addition, we anniversaried last year's addition of a new alternate site customer in May, and top line growth continues to be mitigated by the impact of generic conversions. Year-to-date, the drug company revenues are only down slightly as anticipated. Over the course of the year, the wave of generic launches has progressed as planned and the Drug Company saw significant gross margin expansion in the quarter even as the 2 largest generics of Zyprexa and Lipitor came off exclusivity. We look forward to a few more launches still to come in our fourth quarter. 
Back in June, we held our annual trade show for our independent retail customers and we continued to be impressed with their resilience and their ingenuity in providing personalized patient care in the committee -- community they serve. Our Good Neighbor Pharmacy members participate actively in the largest independent network of community pharmacies in the U.S. AmerisourceBergen and our independent customers strongly believe that they play a critical role in health care throughout the country by offering a compelling value proposition to patients and payers alike. ABDC is focused on ensuring that our network, Good Neighbor Pharmacy, remains dynamic by continuous investment in programs and services to meet the challenges of community pharmacy today and in the future. The implementation of our SAP platform continues on schedule with 14 distribution center conversions complete, representing over half of our distribution centers and 2/3 of our revenues. We've made excellent progress and we expect additional conversions occurring in our fourth quarter and the remainder planned through the beginning of fiscal year 2013. 
We also continue to strengthen our Canadian operations in support of previously reported new business wins in that market. We are confident that these and other investments will meaningfully increase the value we bring to all of our customers in the U.S. and Canada. 
As we noted in the press release, we continue to participate in negotiations for the distribution contract to serve the newly combined business of Express Scripts and the former Medco. We believe we are nearing the end of the process, and while we don't have a firm date for an announcement, we do hope that the decision will be made within the next few weeks. We continue to be optimistic about our chances to win the business. However, it is a competitive process and we believe Express Scripts will ultimately choose a partner that they believe provides the best overall value. 
AmerisourceBergen's Specialty Group had another strong quarter with revenues up 8%, driven by another particularly strong performance in third-party logistics and in our vaccine and physician distribution business. Our Oncology business performed well, while facing another very difficult comparison due to the strong performance of the 3 large Specialty generic products in the June quarter last year. The comparison will ease in the September quarter as Oxaliplatin returns to the market. ABSG continues to benefit from the launch of a branded ophthalmology product earlier this year, continuing to help establish significant market share for the manufacturers. Our experience with their product demonstrates the potent value of our Specialty franchise. While our undisputed strength in Specialty is Oncology business, we have expanded those capabilities to become an instrumental part of the commercialization strategy for any infusible product launched into the physician marketplace. As I previously discussed, we now have a keen interest going forward in further expanding those capabilities into select global markets. The acquisition of World Courier has given us not only a premium quality clinical trial logistics services provider, but also an international framework upon which to further capitalize on our strengths by driving our specialty logistics, consulting, commercialization and reimbursement services into other geographic markets. The integration of World Courier is going very well and we are very excited about the new insights and opportunities that are being discovered as we bring these 2 great organizations together and gain operational exposure to international markets. 
Our Consulting Services group continues to have a strong year as demand for commercialization, reimbursement and patient support services continues to be robust. We believe these combined services offerings distinguish AmerisourceBergen in the marketplace, provide unmatched value to manufacturers and will be an important driver of our growth going forward. As manufacturers seek to bring new products to market or expand sales of existing products in a challenging health care environment, we believe that demand for these services will only increase. 
In terms of financial performance, the Consulting Services group delivered a solid quarter while making excellent progress in the further integration of TheraCom, which is performing well. Even setting aside the contribution from TheraCom, the Lash Group alone had outstanding results. As Tim will detail, the solid performance across our business contributed to excellent cash flow in the quarter. Given the strength of our balance sheet, we continue to explore opportunities to deploy our capital in order to increase shareholder value, including searching for acquisitions that meet the criteria we have in place for quite some time. They should increase our value offering to existing customers, both up and down the channel. They should be within our established core competency and they should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions and we continue to be interested in opportunities in pharmaceutical and specialty distribution and services, as well as consulting services. We also remain committed to returning a minimum of 30% of our free cash flow to shareholders in the form of dividends and share repurchases, a hurdle that we have handily exceeded over the last several years. 
Looking ahead, the results we've had in the first 9 months of our fiscal year put us well on our way to meeting our objectives for the full fiscal year. As we stated in our press release, we have narrowed the range of our diluted EPS expectations for the full year to $2.80 to $2.84. Tim will provide the details on our assumptions for the remainder of the year, but I want to highlight that as a result of that tremendous financial flexibility, we have repurchased $540 million of our shares in the year when we spent over $800 million on acquisitions, and we'll pay down about $400 million in debt in September. This speaks to the enormous strength and resilience of our business in a year of significant change for AmerisourceBergen, and indeed for the health care industry more broadly, as well as the quality of our financial planning and financial stewardship. 
As you know, we are deeply engaged in our business planning process for our fiscal 2013, and we do not yet know the future status of the business we do with our largest customer. As we noted in our press release, however, we do expect that new generic launches in both ABDC and ABSG, as well as contributions from our recent acquisitions and other favorable items will help drive earnings growth next fiscal year. The impact of customer consolidation and competitive market dynamics on our margins is expected to offset some of that growth. As our provider customers across the health landscape prepare for the full implementation of the federal government's health care reform initiatives, we are being challenged to help find new ways to reduce costs. Across the industry, big customers are getting bigger, whether they are mail order pharmacies, acute care networks or independents seeking greater strength in number through joining buying groups. Over the longer term, this has lead to an even more stable and resilient industry. Of course, we will continue to manage our own expenses and working capital. In addition, the strength of our balance sheet affords us additional opportunities to drive shareholder value through acquisitions, share repurchases and dividends. With all that in mind, our preliminary expectation is for high single digits to low double-digit diluted EPS growth in fiscal 2013. 
Over the last year, we made important investments in our business with an eye to the future while we continued to focus on helping our customers and ourselves take advantage of the unprecedented growth in generics and the many opportunities in Specialty. Demand is strong and growing for the core products we distribute, and we play an essential role in the pharmaceutical supply chain, ensuring the integrity and security of the distribution of life-improving and life-saving therapies. Our manufacture services businesses help ensure products get to market as efficiently as possible and that patients have access to both traditional medications and the most innovative and complex products. As cost-containment efforts mount across the health care spectrum, our customers increasingly turn to us for help in meeting the challenges of the marketplace without sacrificing patient care. I take great pride in the energy and creativity our associates bring to our business. Each day, I see the results of their innovative thinking and their dedication to exceeding customer expectations, and I'm proud to be their leader. Here is Tim."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve. And good morning, everyone. As you just heard, ABC delivered a solid quarter and through 9 months, our performance is tracking well to our financial targets. The key highlight this quarter was our ability to overcome the oncology generic he",1725,"Thanks, Steve. And good morning, everyone. As you just heard, ABC delivered a solid quarter and through 9 months, our performance is tracking well to our financial targets. The key highlight this quarter was our ability to overcome the oncology generic headwind we've mentioned in the past. Going into this fiscal year, we knew that Q3 would be our toughest EPS comparison. We consistently called out a $0.33 headwind this year from Specialty generics. Of this headwind, we anticipated about half of the $0.33 would negatively impact the third quarter. We're pleased that we are able to successfully overcome this Q3 headwind and show solid EPS growth. 
Two other highlights for the quarter. We continued our discipline in terms of managing expenses across the organization and we integrated World Courier into ABC reporting. Our results include 2 months of their operations. 
Before I start with the quarterly financial details, let me highlight that in our press release, we expanded our disclosures to include detail for 2 reporting segments in addition to our ABC consolidated results. The Pharmaceutical Distribution segment includes our Drug and Specialty Group operating segments. The Other segment includes our manufacturer and services businesses, which consists of the Consulting and World Courier operating segments. Upon review of the financial reporting requirements, we determined that there was a need to separate drug distribution and manufacturer services due to the nature of their business operations and different revenue growth rates and operating margins. The disclosure of our 2 reporting segments will improve investor transparency going forward. 
Now back to the quarterly details. I'll cover ABC consolidated results first. Starting with the top line, revenues were $19.8 billion, a 1 .9% decrease over last year's quarter. Drug Company revenues were down about 5%, offset by higher Specialty revenues of nearly 8%. We also had the benefit in our June '12 revenues from 2 of our acquisitions, TheraCom and World Courier. They contributed a combined $300 million of new revenues in the current quarter. 
Moving along, gross profit was $689 million in the quarter, up 5.4% from last June with a gross margin of 3.49%. Just to remind everyone, World Courier is included in our financial results and they have a fairly high gross profit margin due to their best-in-class service model. World Courier and our other acquisitions contributed nearly $60 million to our gross profit in the current quarter. 
Our LIFO charge was $4.7 million in the quarter, down $6.7 million from last year. We expect a LIFO charge of between $12 million and $15 million for the full year, down significantly from last year. Finally, the generic benefit we received in the current June quarter from new generic launches and price appreciation was in line with our expectations. Let's move to operating expenses. 
This quarter, operating expenses were $375 million, up 11.6%. But this amount includes approximately $50 million of operating expenses related to our recent acquisitions, as well as approximately $5 million of non-recurring charges related to the World Courier transaction. Excluding the impact of acquisitions, our operating expenses would have decreased about $10 million quarter-over-quarter. Our businesses continue to do an excellent job at managing their expenses. 
Operating income of $314 million in the quarter decreased about 1%, while operating margin was up by 2 basis points compared to last June. Our third quarter was slowed by the World Courier transaction cost, and more importantly, the difficult comparison versus the prior year. 
Moving below the operating income line and other income, we had income of $4.8 million primarily related to an increase in evaluation of a note that was due to ABC from the October 2008 sale of our prior PMSI business. Interest expense of approximately $25 million in the June quarter increased 33% compared to last year as a result of our $500 million senior notes that we issued back in November. Our effective income tax rate of 38.3% was slightly higher than last year's 38.2% and is in line with our expected annualized rate of 38.4%. 
Our GAAP diluted earnings per share in the quarter of $0.71 increased by $0.05 or just under 8% over the last quarter -- over the same quarter last year. Our EPS benefited from a reduction in our average diluted shares outstanding due to our ongoing share repurchase programs. Average diluted shares for the quarter were approximately $256 million, down just over 8% from last June. At June 30, 2012, we had 251 million outstanding shares. 
Let's spend a few minutes discussing our segment results for the June quarter. Starting with Pharmaceutical Distribution, total revenues were $19.4 billion, down about 3.3% over last year's quarter. Drug Company revenues were down about 5% due primarily to lower sales with former Medco and the impact from the loss of a large chain customer last year to former Longs Drugs. Slightly over half of the decline came from lower sales to former Medco, driven by generic conversions and changes in their book of business. Without these 2 negative impacts, our Drug business would have had growth of 2%. Also during the quarter, the Drug Company anniversaried a large customer win from the prior June quarter. 
Specialty Group's revenues increased nearly 8%, led by strong performance in 2 of its businesses with growth significantly above market rates, ICS, our third party logistics business, and Besse Medical, our vaccine and physician office distribution business. From a segment standpoint, gross profit decreased about $25 million and our gross profit margins slipped somewhat. Most of the dollar decrease is due to the oncology generics headwind, a high-margin contributor last June quarter, offset by the contribution from generic Lipitor and Zyprexa, both of which had their exclusivity periods end during the June '12 quarter. We did have other generic launches during the quarter and also gross profit contributions from our specialty businesses. These positives were offset by the decrease in our revenues and margin pressure. It should be noted that Drug Company is viewed on its own, had gross profit margin expansion of 20 basis points in the June 2012 quarter. This segment managed operating expenses very effectively, especially payroll and benefit expenses, as well as external consulting expenses, which enabled us to offset some of the gross profit dollars we lost with the oncology generic headwind. Overall, we're very pleased with the operating results for this segment. 
Moving to the Other reporting segment which again is Consulting, which includes our Packaging business and World Courier. As mentioned previously, our 2 large acquisitions accounted for nearly $300 million of new revenues in the third quarter. World Courier revenues are tracking well against our expectations, which we provided back in our press release that announced the acquisition. Operating income from the Other segment increased $11 million from last year's quarter. Of this increase, about $8 million is related to our fiscal '12 acquisitions. The remaining increase is related to our legacy businesses. I'd like to highlight that our non-recurring charge of about $5 million is not included in our segment level reporting. For the June quarter, the impact of our World Courier acquisition was essentially breakeven due to the transaction costs. 
Now let's turn to our consolidated balance sheet and cash flows where trends continue to be favorable. We generated $92 million of cash from operations in the quarter, bringing our 9 month's total to $760 million. Our businesses continue to focus on working capital. In fact, our cash conversion cycle, based on a rolling 4-quarter average, improved by 1 day to 1.7 days based in the current June quarter, from 2.7 days in the June 2011 quarter. 
Capital expenditures were $39 million in the quarter and $128 million for the 9 months. For the full year, we are still tracking to our guidance for CapEx of $200 million. During the quarter, we bought back $186 million of our shares. For the 9 months, we purchased $514 million of shares and this slightly exceeds our March quarter guidance of $500 million. At June 30, we have $744 million left on our May 2012 share repurchase authorization. 
Our cash balance at June 30 was $1.7 billion. As we've discussed in the past, we need approximately $500 million in available cash to account for swings in working capital and to run the business. As a reminder, in mid-September, we will be using cash to retire our $400 million 5 5/8% senior notes. 
Now let's turn to updated fiscal 2012 guidance. We now expect our GAAP diluted EPS to be in the range of $2.80 to $2.84. This includes an estimated $20 million of non-recurring costs related primarily to transaction and severance expenses. With narrowing our EPS range, this means that we will have EPS growth of 10% to 12% this year after absorbing the $0.05 negative impact from non-recurring charges. 
Revenue. We continue to expect revenue growth to be flat or up modestly for the full year. We expect our operating margin expansion to be in the high single digits. As previously communicated, Q4 is our easiest operating income comparable for the year. Because of this, we expect most of our operating margin expansion to be achieved in the fourth quarter. Free cash flow is still tracking to finish in the $800 million to $900 million range. 
Looking ahead. We are deeply engaged in our business planning process for fiscal 2013, and there are still many moving parts including, of course, the Express Scripts RFP. As Steve outlined, as large customers consolidate, they are seeking better pricing which includes generic pricing. And as recent contract discussions have demonstrated, our customers want us to be part of the solution in helping them meet the economic demands of the new health care landscape. Our high single digit to low double-digit EPS growth range is based on assumptions on several moving parts, and includes possible outcomes on the Express Scripts contract. Our EPS range is preliminary and we still have quite a bit of work to complete in our planning process, but it does incorporate the best information we have right now. So before I turn it back to Barbara, let me reiterate that 9 months into our fiscal year, we are well positioned to meet our financial targets for fiscal '12 and we are hard at work on our fiscal '13 plan. Here is Barbara to start our Q&A."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Tim. We will now open the call to questions. [Operator Instructions] Please go ahead, Mary.",17,"Thank you, Tim. We will now open the call to questions. [Operator Instructions] Please go ahead, Mary."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Tom Gallucci with Lazard Capital Markets.",17,"[Operator Instructions] And our first question comes from the line of Tom Gallucci with Lazard Capital Markets."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","I guess my first question was, on some of the commentary that you had in the press release, and I think you echoed it a bit on your prepared remarks when you sort of talked about competitive pricing pressures and sort of the competitive landscape, can you",82,"I guess my first question was, on some of the commentary that you had in the press release, and I think you echoed it a bit on your prepared remarks when you sort of talked about competitive pricing pressures and sort of the competitive landscape, can you expand a little bit on what you mean there? Is it sort of something that we always see as a persistent part in the business or are there really new dynamics that you're referring to?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","No. I think -- thanks for the question, Tom. What we're seeing is that the larger customers are getting larger, and we've always said that the larger customers get the biggest -- the best deal and we're seeing some of that. I think in addition, we've got",153,"No. I think -- thanks for the question, Tom. What we're seeing is that the larger customers are getting larger, and we've always said that the larger customers get the biggest -- the best deal and we're seeing some of that. I think in addition, we've got much more generics as a percentage of sales. Don't forget, we have a very diverse customer base, almost all of them buy generics from us. So generics as a percentage of overall portfolio have increased. So I think we just -- people are looking at their businesses and their potential financial impacts from health care reform and reimbursement pressure, and we -- they're expecting us to participate with them in a much tougher future. So a tougher future where we all have to be more efficient, and I think we're just not immuned from some of that. So those are the trends that I'd point out."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And then just to clarify your comments on guidance, I guess just to ask specifically, it sounds like it's early [indiscernible] conservatism because there are so many moving parts. On Express specifically, we all know that's a pretty big moving part",65,"Okay. And then just to clarify your comments on guidance, I guess just to ask specifically, it sounds like it's early [indiscernible] conservatism because there are so many moving parts. On Express specifically, we all know that's a pretty big moving parts. Would you be able to meet this guidance range if tomorrow you found out you didn't retain the Medco, the legacy Medco business?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Hey, Tom, this is Tim, and I'll answer your question this way. I mean our guidance includes, like you said, different assumptions on moving parts, one of which is Express Scripts, and it contemplates both scenarios, winning it and losing it. Again, it's E",54,"Hey, Tom, this is Tim, and I'll answer your question this way. I mean our guidance includes, like you said, different assumptions on moving parts, one of which is Express Scripts, and it contemplates both scenarios, winning it and losing it. Again, it's Express Scripts and other factors looking out over the next years."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","And our next question comes from the line of Larry Marsh with Barclays.",13,"And our next question comes from the line of Larry Marsh with Barclays."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Just my question is elaboration on comps around next year. So -- and I appreciate providing some clarity here with, perhaps, a tone of trying to be prudent here. But I guess, Steve, if we think about a scenario where your largest customer, Express, choose",131,"Just my question is elaboration on comps around next year. So -- and I appreciate providing some clarity here with, perhaps, a tone of trying to be prudent here. But I guess, Steve, if we think about a scenario where your largest customer, Express, chooses not to continue to do business with you or splits the business, can you remind us of some of the factors that you would, could, go through to help mitigate some of those lost revenues from the cost side that would keep you still in the range of guidance? And along with that, is there -- could there be a situation where they might be a quarter or 2 of timing mismatch between revenues and costs that could cause you to vary around your guidance ranges?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks for the question. We really are deep in this. In fact, we're going -- the team's going out to visit all our drug regions next weak, which is really the start for us in detail, in the detailed planning process. But we had information that -- we have",270,"Thanks for the question. We really are deep in this. In fact, we're going -- the team's going out to visit all our drug regions next weak, which is really the start for us in detail, in the detailed planning process. But we had information that -- we have information that we think is material that want -- that we felt was incumbent on us to share with all of you, and that's the way AmerisourceBergen is run. And we're proud of that. We're not backing off that. So absolutely, if we lose Express Scripts, don't forget our current business is -- really a lot of the greenfield that we set up during the merge is really set up to handle big mail order business that we've done with Medco traditionally for as long as I can remember. I've been with the company 8.5 years. We've always had the count. But it's very little expense. In fact, many of the characteristics of this business are what we used to call dock to dock business and of course, you remember that very well. So there's not too much expense there. And coincidently, a lot of the facilities that we service in Medco are our most highly efficient modern facilities, but we would -- we absolutely have opportunities to cut down our cost. And like Tim said, this current thinking, while it's early, really contemplates all the way from us entirely losing this business to winning it, including winning the part that we currently do not service, based on our basic understanding what the economic can be. But it honestly is early."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. I appreciate the reflection there. And I guess my follow-up is around your LIFO charge. So, Tim, you're communicating a reduction in your range of LIFO expectations versus what you had suggested back in April by, say, a couple of million dollars. I",108,"Okay. I appreciate the reflection there. And I guess my follow-up is around your LIFO charge. So, Tim, you're communicating a reduction in your range of LIFO expectations versus what you had suggested back in April by, say, a couple of million dollars. I know at the time you had said you anticipated big impact relative last year with the generic introductions and some moderation in brand price inflation. What's causing you to further moderate your views on that inflation-based cost? And as you think about your guidance for next year, can you give us any sense of general ranges of LIFO charges you're anticipating for fiscal '13?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, Larry, it's probably a little bit early to talk about LIFO for '13. I mean, we're still looking through that. In terms of LIFO for the June quarter, at the end of the June quarter, we saw a pretty good brand pricing, increased percentages for our top",122,"Yes, Larry, it's probably a little bit early to talk about LIFO for '13. I mean, we're still looking through that. In terms of LIFO for the June quarter, at the end of the June quarter, we saw a pretty good brand pricing, increased percentages for our top 75 brand drugs, a little bit off from last year. So I mean there is some moderation there in terms of brand pricing. And we're seeing a little bit steeper generic deflation especially with generic Lipitor and Zyprexa. So that's driving the change, the slight change in our full year LIFO forecast. But again, for next year, we're probably -- it just depends on where brand price inflation is. It's a little bit early."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","And our next question comes from the line of Robert Jones with Goldman Sachs.",14,"And our next question comes from the line of Robert Jones with Goldman Sachs."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I just wanted to go back, I know you touched on some of the changing market industry dynamics and specifically, Tim mentioned the generic pricing. I was just wondering maybe for perspective, if you could share your thoughts or recent trends on both",78,"Steve, I just wanted to go back, I know you touched on some of the changing market industry dynamics and specifically, Tim mentioned the generic pricing. I was just wondering maybe for perspective, if you could share your thoughts or recent trends on both the buy side margin that you've seen recently and then maybe separate out the sell side margin just to give us some perspective on your dealings on both with the manufacturer and the customer."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Many times -- I'll just talk about the buy side first. Many times on the fee-for-service agreements, we're really in our third generation and we've dealt with a lot of pharma consolidation, and we feel that we've -- the industry on the manufacturer side r",325,"Many times -- I'll just talk about the buy side first. Many times on the fee-for-service agreements, we're really in our third generation and we've dealt with a lot of pharma consolidation, and we feel that we've -- the industry on the manufacturer side really understands the value we represent and there's no significant erosion there or anything at all. Obviously, the generic mix at AmerisourceBergen has opportunities to sell generics to almost all of our customers. As you know, we believe we have the most diverse customer base. It has really been driven by this generic wave, and we have set out our whole portfolio in both Drug and Specialty to really recognize the strength in generics. I hope you would have buy [indiscernible] someday and really capitalize on the opportunity that we have for generics and specialty. The sell side, I think, the biggest things we can point to is somewhat of an anxiety of compressed reimbursement and just a lot of consolidation. I mean, just read the headlines. It's not just that particular one that's on everyone's mind. It's -- there's just a lot of consolidation. We have community oncologists, for example, that are constantly getting a lot bigger, and our bigger customers get a better deal. We have independent customers joining buying groups. So these are the biggest trends that I can point to. And we -- I think also there's a lot of marquee customers up for bid. It's been pretty well-publicized. VA process, definitely the SR process has really kicked up some dust, I could say, from other customers. So those -- without being too specific, and we don't like to comment on individual contracts, we have been in this business a long time. We understand how to contract with customers, and we believe that our best bet is to maintain our key customers and customers that we believe are going to represent us growth in the years ahead."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","I appreciate that. And just maybe around the preliminary guidance, I was hoping maybe you could talk a little bit more about the major swing factors. Obviously, I think, we all are well aware of the Express contract, but maybe just how you're thinking abo",113,"I appreciate that. And just maybe around the preliminary guidance, I was hoping maybe you could talk a little bit more about the major swing factors. Obviously, I think, we all are well aware of the Express contract, but maybe just how you're thinking about other important contracts. I know you don't want to name names, but I think PharMerica is one that's out there. And then just some of the other major contributing factors, what's the assumption around buyback. It looks like there's obviously some nice contribution from lower interest expense and clearly, World Courier next year. Maybe just some of the pushes and pulls around the guidance range would be helpful."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, this is Tim. In terms of the guidance, I mean, we're not going to talk specifically about other contracts. Certainly, we made an assumption about Express in there. And as we start the plan process, we always look out over the 12-month horizon of what",167,"Yes, this is Tim. In terms of the guidance, I mean, we're not going to talk specifically about other contracts. Certainly, we made an assumption about Express in there. And as we start the plan process, we always look out over the 12-month horizon of what other contracts we may renew and renegotiate. So there's an assumption in there about other contracts. And some of the other things, too, would be Oxaliplatin and an assumption about how that's going to perform next year. I mean that's a big unknown. We don't know how the pricing will stick in the market, how many suppliers, and so that's a factor. Certainly, we make an assumption about expenses. And finally, in terms of share repurchases, the assumption is, I think if you look back to what we've done historically, the last 2 or 3 years, we've been around about the $500 million range, so that's probably a pretty safe number to be in at for the -- that's our thinking."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from the line of Glen Santangelo with Credit Suisse.",13,"Our next question comes from the line of Glen Santangelo with Credit Suisse."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","I just want to follow up on generics. And I'm not sure exactly how you're thinking about this with respect to your guidance, but, Tim, you mentioned in your prepared remarks, right? You went into fiscal '12 with a $0.33 hole. Obviously, everyone's focused",79,"I just want to follow up on generics. And I'm not sure exactly how you're thinking about this with respect to your guidance, but, Tim, you mentioned in your prepared remarks, right? You went into fiscal '12 with a $0.33 hole. Obviously, everyone's focused on this generic calendar. And so as you think about your guidance for fiscal '13, could give us a sense for maybe what the contribution you're expecting in '13 versus '12, what that looks like?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Glen, I mean, we're just, again, we're early in the plan process. We don't want to get into specifics. I mean we do have generics, a couple of good ones that launched at the end of our Q4 that carry over into fiscal '13 that will definitely help us. We're",118,"Glen, I mean, we're just, again, we're early in the plan process. We don't want to get into specifics. I mean we do have generics, a couple of good ones that launched at the end of our Q4 that carry over into fiscal '13 that will definitely help us. We're encouraged, I mentioned before, Oxaliplatin will be back. We only have it for 6 weeks, we get it next year. There are some unknowns about that. But overall, it's -- you're not going to have a generic Lipitor and Zyprexa, but there are some good generics that helped us early in the year. But again, we're not ready to kind of dial in any specific EPS impact numbers."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, that's fair. Maybe I could just ask Steve one follow-up question. Steve, I just want to talk about a comment you made with respect to acquisitions. You said, I think, the company is still receptive to the idea of acquisitions. And it sounds like you",96,"Okay, that's fair. Maybe I could just ask Steve one follow-up question. Steve, I just want to talk about a comment you made with respect to acquisitions. You said, I think, the company is still receptive to the idea of acquisitions. And it sounds like you're pretty pleased with the progress at both TheraCom and World Courier Group. And as you think about where you are with respect to those integrations, I mean, you feel like the company could handle additional acquisitions in fiscal '13 or you kind of going to just see how it goes?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Well, Glen, that's a great question. I do think that we are operationally well-situated. And I think actually, TheraCom is a very good example. I mean, we've had some work to do at the corporate office, yes, but obviously, we bought this from a well-run c",273,"Well, Glen, that's a great question. I do think that we are operationally well-situated. And I think actually, TheraCom is a very good example. I mean, we've had some work to do at the corporate office, yes, but obviously, we bought this from a well-run company and it was in good shape. And really, most of the integration work is carrying on in our Consulting Services business. So I think they're very well equipped to run that. And World Courier was definitely a different expansion for us. We've had a lot of work to do. I think Tim pointed out one of the highlights for this year was really getting World Courier into the financial reporting criteria for a public company and that's gone well, but we do think that one of the reasons we're investing in this company was the platform opportunity and now, when we go consider anything internationally, we have local intelligence, which is huge. Local understanding of tax laws, of who the good players are, who the bad players are. So we do think that this opens up some attractive markets to us, which we started out our release by talking about, obviously, the obvious fact that pharmaceutical growth in the rest of the world will be higher than the U.S. So we're not rushing in here. We don't think that there's any nirvana market or anything. But it is important to us to drive our Specialty and Consulting practices throughout the world, and we think we have leading practices in those areas and a lot of good intelligence and methodologies to share with the rest of the world."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Glen, this is Tim. I'll just say, after 100 days, we're really pleased with what we have so far, and they're performing right on our expectations. So, like I said, neutral in Q3, and we expect them to contribute $0.01 or $0.02 in 4. So again, very encoura",61,"Glen, this is Tim. I'll just say, after 100 days, we're really pleased with what we have so far, and they're performing right on our expectations. So, like I said, neutral in Q3, and we expect them to contribute $0.01 or $0.02 in 4. So again, very encouraged this year and looking forward to what they're going to do in '13."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question goes to the line of Robert Willoughby with Bank of America Merrill Lynch.",16,"Our next question goes to the line of Robert Willoughby with Bank of America Merrill Lynch."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Tim, what's left on deal expenses? Will we see much going forward in the numbers? And I think you hinted at it, but what was the actual dilution from new generics year-over-year to revenues?",34,"Tim, what's left on deal expenses? Will we see much going forward in the numbers? And I think you hinted at it, but what was the actual dilution from new generics year-over-year to revenues?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","The actual dilution -- in terms of revenues?",8,"The actual dilution -- in terms of revenues?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Yes, in terms of revenue growth rate.",7,"Yes, in terms of revenue growth rate."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, we -- what we said in terms of the Medco, I mean Medco was down probably about half. I mean, it's probably in the $500 million or $600 million range, that's from our largest customer, Medco by itself. And again, not all that is -- some of that is boo",133,"Yes, we -- what we said in terms of the Medco, I mean Medco was down probably about half. I mean, it's probably in the $500 million or $600 million range, that's from our largest customer, Medco by itself. And again, not all that is -- some of that is book of business, right, and some of it is the generic conversions. In terms of your other question, I would say, Robert, that we don't have much left in terms of World Courier. I mean I think we're at $17 million in terms of non-recurring costs through Q3. In my comments I said I thought we'd end up about $20 million. We probably still have some other non-recurring charges that will come through, about $3 million, not related to World Courier in Q4."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","And our next question comes from the line of Eric Coldwell with Robert W. Baird.",15,"And our next question comes from the line of Eric Coldwell with Robert W. Baird."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, I'm going to ask 2 if it's all right. Regardless of correlation or causation in the past, we have seen some rather funky behavior from the manufacturers around major U.S. elections. I'm specifically thinking about the September quarter of 2004, wher",89,"Okay, I'm going to ask 2 if it's all right. Regardless of correlation or causation in the past, we have seen some rather funky behavior from the manufacturers around major U.S. elections. I'm specifically thinking about the September quarter of 2004, where price inflation contracted fairly dramatically. Have you considered the possibility of that hitting into this election or do you think it's really not in the limelight here? I guess any signal on pharma behavior on pricing here in the near term. And then I have a follow-up."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","The pharma pricing has been a little bit less than last year, the price increases, but still very robust. And as I said, we're spending more time internationally and everyone's very envious of an environment where we can have price increases. So it's an e",136,"The pharma pricing has been a little bit less than last year, the price increases, but still very robust. And as I said, we're spending more time internationally and everyone's very envious of an environment where we can have price increases. So it's an excellent thought, Eric. I credit to you for thinking of that. We'll pay it more attention, but we haven't really seen anything concerning. I think more of the price increases have to do with patent expirations, is what we're seeing a trend there, some price increases and pricing strategies ahead of large patent expirations. But as you know, we've got some significant launches in this quarter and less exciting year in brand to generic conversion next year, but still very robust. And we will see some impact on brand prices from those."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","That's great. And my follow-up is related to business transformation, the ASP program. You seem to continue to be ahead of schedule and doing great there. Just curious if you could give us an update on the incremental benefits to OpEx compared to your ori",87,"That's great. And my follow-up is related to business transformation, the ASP program. You seem to continue to be ahead of schedule and doing great there. Just curious if you could give us an update on the incremental benefits to OpEx compared to your original thoughts for the implementation, and then whether you might be looking to fiscal '13 and '14 and thinking that there could be some additional juice on that $10 million and $40 million of OpEx savings that you had previously talked about."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, I'll let Tim mainly handle this, but I'll just say that generally, we spend -- we've done most of our capital spend, then now, it's really operational spend. So the depreciation is starting to hit us financially. The consulting expenses, the external",78,"Yes, I'll let Tim mainly handle this, but I'll just say that generally, we spend -- we've done most of our capital spend, then now, it's really operational spend. So the depreciation is starting to hit us financially. The consulting expenses, the external consulting is definitely an opportunity we've had to reduce cost. And we've actually done well against our plan for our BT budget for this year, but I'll let Tim give you some color on this."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, thanks, Steve. Yes, Eric, actually, to Steve's point, I mean I just want to make sure I stress this. I mean, we're starting to see a little bit of expense savings now. Again, when I mention external consulting, a chunk of that is from our IT departme",139,"Yes, thanks, Steve. Yes, Eric, actually, to Steve's point, I mean I just want to make sure I stress this. I mean, we're starting to see a little bit of expense savings now. Again, when I mention external consulting, a chunk of that is from our IT department and the fact that we're moving along and deploying SAP really efficiently and effectively. So we're seeing a little bit now, but we're still -- we're not -- we're still believing that the $10 million's appropriate. That's one of those when we talked about moving parts in our range, that's one of the assumptions kind of factored in to our range for '13, and we're still on the $40 million for '14. So at this point, we're just not ready to commit any upside or juice as you called out there."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from the line of Lisa Gill with JPMorgan.",12,"Our next question comes from the line of Lisa Gill with JPMorgan."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I just wanted to follow up on a comment that you made around the Express Scripts new contract. You said it would be the best overall value. I'm just wondering if there's any changes to the types of services that they're looking for versus what you",107,"Steve, I just wanted to follow up on a comment that you made around the Express Scripts new contract. You said it would be the best overall value. I'm just wondering if there's any changes to the types of services that they're looking for versus what you previously provided for Medco? And then just on the follow-up side for that, I think I read in a Philadelphia paper some comments around specialty and your growth in specialty and perhaps, moving more towards the patient. I was wondering if maybe you could just also comment on that, as well as potentially competing with a customer like the PBM."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Let me just talk about that. I think our business in specialty is -- and we're talking about this with a customer the other day that everyone has a different definition of specialty. When AmerisourceBergen says specialty, we're really talking about physic",259,"Let me just talk about that. I think our business in specialty is -- and we're talking about this with a customer the other day that everyone has a different definition of specialty. When AmerisourceBergen says specialty, we're really talking about physician administrative products and related services to manufacturers. I think when a PBM says specialty, it usually means patient self-administrative products. And so I think that, that's pretty well defined. And we actually think that there's a lot of opportunities to collaborate in those areas including with our Good Neighbor Pharmacy network and there's an opportunity to do potentially more specialty in the community. And we do take our specialty franchise and expertise very seriously there, and think that we afford a lot of AmerisourceBergen customers that are interested in this area, an opportunity to gain from our expertise, including in the policy area and the manufacturer relations area. The first part of your question had to do with Express Scripts and the overall value we provide. I think that was more of a comment that the economic deals. I mean, there's a very few companies that are qualified to be the provider to Express Scripts so it's a small universe. And I think economics is part of it, experience is part of it. And I don't think, honestly, that any of the qualifications have really materially changed since the start of this process, which has been pretty quick if you think about it compared to some of the other ones that we've seen in the recent past."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Just so I understand that, Steve, though, so your comments around commercialization of a product and perhaps, working in partnership with a PBM, you don't view that as an opportunity with a new potential contract with the new Express Scripts or is that a",53,"Just so I understand that, Steve, though, so your comments around commercialization of a product and perhaps, working in partnership with a PBM, you don't view that as an opportunity with a new potential contract with the new Express Scripts or is that a future opportunity, but not part of this RFP process?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","No, we see -- I think quite opposite. I said I think that our market presences and our market expertises are very complimentary. But the focus on this has really been on the core economics, and I think our idea is obviously to win an account and then we c",66,"No, we see -- I think quite opposite. I said I think that our market presences and our market expertises are very complimentary. But the focus on this has really been on the core economics, and I think our idea is obviously to win an account and then we can work on an alignment and future opportunities together. So that's really what our strategy is there."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes from John Ransom with Raymond James.",10,"The next question comes from John Ransom with Raymond James."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Just a couple of things, just drilling down to your assumption for next year. Oxaliplatin comes back, Express, is that -- could be a mover for you?",27,"Just a couple of things, just drilling down to your assumption for next year. Oxaliplatin comes back, Express, is that -- could be a mover for you?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","We are obviously excited to have Oxaliplatin back and at the end of May, we were thrilled that the comp is out now. We enjoyed the ride, but it was a good timing to have the comp out. And August, we're going to have the product back, but it's going to be",195,"We are obviously excited to have Oxaliplatin back and at the end of May, we were thrilled that the comp is out now. We enjoyed the ride, but it was a good timing to have the comp out. And August, we're going to have the product back, but it's going to be very different. The ASP's pretty high so that's a positive, but there's no at risk, there's no exclusivity period, so we're going to have several manufacturers and we think that the pricing will be very dynamic. It's probably going to be more akin to, again, the specialty drugs and they're different than all the solids. The prices never get quite as low, but it's going to be more akin to the expiry of 180-day exclusivity period than it is to a new generic injectable launch is what I'd say. So while we're expecting with our market share that we have and the expertise we have in oncology, we expect them to do very well here as we did with docetaxel and gemcitabine. We don't expect that you're going to be hearing half of our earnings call be devoted to Oxaliplatin in the future."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","The said question, if you just look at the totality of your -- for all generics, the contribution that you think you'll get next year compared to the contribution [indiscernible], and my specific view is, I think, from all accounts, Lipitor was just off t",78,"The said question, if you just look at the totality of your -- for all generics, the contribution that you think you'll get next year compared to the contribution [indiscernible], and my specific view is, I think, from all accounts, Lipitor was just off the charts [indiscernible] during the exclusivity period. Obviously, you're losing that. And we were just having more troubles still at the calendar and thinking is it going to better, worse, the same next [indiscernible]?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, I don't think it's going to be quite as robust, but, Tim, you...",14,"Yes, I don't think it's going to be quite as robust, but, Tim, you..."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, John, you were breaking up a little bit, but I think what you're asking is what next year looks like. And again, we have a little bit of a benefit from our fiscal year with a couple of large generics lunching at the end of our Q4. But overall, talkin",108,"Yes, John, you were breaking up a little bit, but I think what you're asking is what next year looks like. And again, we have a little bit of a benefit from our fiscal year with a couple of large generics lunching at the end of our Q4. But overall, talking to our generics guys, I mean, we think it will be a good year. It's going to probably be a little down compared to this year. It's tough to replace generic Lipitor and Zyprexa. But again, there are a couple of other ones out there that we're encouraged about. So down a little bit, but not bad."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","And again, Lipitor, because of the class of customers we service here, who buys generics from us, might not have been as big for us as it was for the other players in the industry. Just keep that in mind.",40,"And again, Lipitor, because of the class of customers we service here, who buys generics from us, might not have been as big for us as it was for the other players in the industry. Just keep that in mind."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","And I guess I would like, again, going back to that, I mean let's go back and highlight Steve's comment earlier, is a lot of our volume is coming through larger customers on generics. So again, they get their pricing -- they bring us more volumes but they",55,"And I guess I would like, again, going back to that, I mean let's go back and highlight Steve's comment earlier, is a lot of our volume is coming through larger customers on generics. So again, they get their pricing -- they bring us more volumes but they're pricing is a little bit more favorable."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Our last question comes from the line of Ricky Goldwasser with Morgan Stanley.",13,"Our last question comes from the line of Ricky Goldwasser with Morgan Stanley."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","So just some quick follow-up questions here. So first of all, Steve, I think on your last comment around the volume, a lot of your generic volume coming from larger customers, so can you clarify that a little bit for us? Because when I think about Ameriso",156,"So just some quick follow-up questions here. So first of all, Steve, I think on your last comment around the volume, a lot of your generic volume coming from larger customers, so can you clarify that a little bit for us? Because when I think about AmerisourceBergen, I think, really, it's going to affect a big portion of your customer base being kind of like the smaller independents. So when you comment about the generic volumes, are you referring to kind of the PBM and the Omnicare of the word? Or is that -- or are you talking about comp like your Specialty segment? So if you can just clarify as to who those large customers are. And then secondly, from data that we've seen recently, it seems like that there have been some good generic price increases taking place. So how are you thinking of generic inflation in the context of your forward outlook?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Well, 2011, we did very well on generic price inflation. It's been much more moderate this year. And I think we even pointed out the numbers because it was significant to the interpretation. We haven't seen anything as robust this year. Ricky, apologies f",282,"Well, 2011, we did very well on generic price inflation. It's been much more moderate this year. And I think we even pointed out the numbers because it was significant to the interpretation. We haven't seen anything as robust this year. Ricky, apologies for your last name, [indiscernible] but we do have, we believe, the most diverse customer base within our industry. And we are very proud of the strong independent business that we have. We're also doing more business within the health systems on generics, which is a great trend for us given our health systems presence. We also, as you know, we never used to talk about generics and specialty, we talk about a lot. So there are a lot of really good trends for us in generics. But another trend is obviously, our large PBM customer doesn't really buy any significant generics from us, which we've talked about a lot. And the larger customers, a lot of them say -- when we do -- during our last round of contract negotiations, they may have been buying 4% to 7% of their purchases when generics are now, it's a lot higher. And those customers are getting bigger. And we have to share more of the economics on generics with them because it's a much bigger part, they're much higher profile product category to them. So those are some of the trends that we've been pointing out. And you're absolutely correct to think of AmerisourceBergen as specialty customers and independent pharmacies and large health system presence and big ultimate start or closed-door pharmacy businesses, and that's definitely one of the strengths of us, is our diversing our business that we serve."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","So in that line, just another clarification, when you think about CapEx fiscal year '13 and when you say that it might be done a little in terms of generic contribution, you're really looking at a basket which include the specialty generic and Oxaliplatin",57,"So in that line, just another clarification, when you think about CapEx fiscal year '13 and when you say that it might be done a little in terms of generic contribution, you're really looking at a basket which include the specialty generic and Oxaliplatin, as well as solid orals rather than separating the 2. Is that fair?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","The top line brand to generic conversions, and some of this fall -- it's complicated because some of it will have fourth quarter launches that would impact our fiscal year '13, but you know it was $13 billion in fiscal year '12, and it's about $11 billion",195,"The top line brand to generic conversions, and some of this fall -- it's complicated because some of it will have fourth quarter launches that would impact our fiscal year '13, but you know it was $13 billion in fiscal year '12, and it's about $11 billion to $12 billion in fiscal year '13. And again, the quarters move and we're early in our guidance and we're really looking at it. But again, $11 billion is a very -- is a good year for us. It's -- if you look at our performance over the last 10 years, it's not -- it's a good year. So yes, we look forward to providing more guidance. We just wanted to give you a benefit of our early look at 2013 and what we know about some large contract negotiations that are going on. And I hope you appreciate the full stock that we've given you and the approach that we've taken, which is always being as transparent and as communicative with our investors as we can. So I think with that, we'll wrap up. Ricky, thanks for your questions. And, Barb, you want to make some comments?"
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Do you have a...",5,"Do you have a..."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Okay, I have -- all right [indiscernible]  Okay. I'm up for the strong close. All right. So my strong close is that I recently completed my first full year as CEO of AmerisourceBergen, which I'm very proud to serve in this position. And I unequivocably an",138,"Okay, I have -- all right [indiscernible]  Okay. I'm up for the strong close. All right. So my strong close is that I recently completed my first full year as CEO of AmerisourceBergen, which I'm very proud to serve in this position. And I unequivocably and very confidently state that ABC's franchise and our place in the industry and our long-term prospects are really outstanding. We have just repeated -- we have just reported an excellent quarter and we are well on our way to completing a successful 2012. And I thank you for your attention today. I believe that ABC's making the right investments to secure our future and we look forward to seeing some of you in September at various conferences. And, of course, we'll have our full fiscal year '13 earnings in November. Thank you."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve. And just a couple of calendar items. We'll be at the Robert W. Baird Health Care Conference in New York on September 5 and at the Morgan Stanley Conferences also in New York on September 11. So that concludes our call for today. I'll now tu",55,"Thanks, Steve. And just a couple of calendar items. We'll be at the Robert W. Baird Health Care Conference in New York on September 5 and at the Morgan Stanley Conferences also in New York on September 11. So that concludes our call for today. I'll now turn it back to the operator. Thank you."
24809,212451049,331884,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Thank you. Ladies and gentlemen, this conference will be made available for replay today after 1:00 p.m. Eastern time through August 2 at midnight. You may access the AT&T teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering th",77,"Thank you. Ladies and gentlemen, this conference will be made available for replay today after 1:00 p.m. Eastern time through August 2 at midnight. You may access the AT&T teleconference replay system at anytime by dialing 1 (800) 475-6701 and entering the access code 253858. International participants may dial (320) 365-3844. The access code is 253585. That concludes our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the ABC Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to our host, Barbara Brungess. Ple",44,"Ladies and gentlemen, thank you for standing by. Welcome to the ABC Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to our host, Barbara Brungess. Please go ahead."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Mary. Good morning, everyone, and welcome to AmerisourceBergen's Earnings Conference Call covering our fiscal 2002 -- 2012 third quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today ar",167,"Thank you, Mary. Good morning, everyone, and welcome to AmerisourceBergen's Earnings Conference Call covering our fiscal 2002 -- 2012 third quarter results. I am Barbara Brungess, Vice President of Corporate and Investor Relations, and joining me today are Steve Collis, AmerisourceBergen's President and CEO; and Tim Guttman, Senior Vice President and CFO. During the conference call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011. Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by telephone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen once again overcame a challenging year-over-year comparison and delivered solid quarterly results. In the June quarter, our revenues were down 2% to $19.8 billio",2131,"Thank you, Barbara, and good morning, everyone. I am pleased to report that AmerisourceBergen once again overcame a challenging year-over-year comparison and delivered solid quarterly results. In the June quarter, our revenues were down 2% to $19.8 billion, but our GAAP earnings per share were up 8% to $0.71. We made excellent progress integrating recent acquisitions including World Courier, which closed in early May. Our strong cash generation and high-quality balance sheet continue to provide us with outstanding financial flexibility, and give us the ability to fund our strategic initiatives, grow our business and return funds to shareholders. Through 9 months, we are well positioned to meet objectives for the full year. 
Our diverse revenue base continues to position us well to benefit from organic growth across the entire spectrum of pharmaceutical care, and our customer mix helps drive benefits from the historic influx of generics. Even as generics mitigate the top line dollar growth in our industry, IMS Health's compounded annual sales growth in the U.S. in the range of 1% to 4%, and 4% to 6% worldwide through 2016. In addition, continued scrutiny of health care expenses and cost-containment efforts underway by the U.S. Federal government and commercial payers demand continues improvement in efficiency, productivity and effectiveness across all aspects of health care. 
One of the hallmarks of the U.S. market in particular is the quality of the relationship wholesalers have with pharmaceutical manufacturers. Over the last several years, AmerisourceBergen has significantly strengthened our relationship with pharmaceutical manufacturers, and we continue to put an emphasis on looking for meaningful ways to provide additional services across the supply channel in order to help manufacturers meet the challenges of today's changing health care landscape. This is the strategic rationale for the material acquisitions we have made in the past 12 months. As we sit here today, we believe that both the TheraCom and World Courier acquisitions have significantly enhanced our spectrum of services at the supply channel. Moreover, they have brought a cadre of valuable new customers, employees and capabilities, which have exceeded our pre-closing expectations. 
As our provider customers face similar challenges regarding cost containment and reimbursement for services provided to patients and new challenges such as accountable care organization, they also increasingly turn to AmerisourceBergen for help in making their health care practices run as efficiently and effectively as possible. Our provider customers deliver world-class patient care on navigating a complex wave of reimbursement. And we believe they deserve fair compensation for the professional services they provide. AmerisourceBergen continues to be an active participant in policy discussions in Washington with the objective of helping legislators understand our industry and our importance to the health care system. 
AmerisourceBergen associates remain focused on meeting objectives for the year both in terms of our financial performance and in delivering outstanding service to our customers. I take great pride in the enthusiasm and dedication of our team, and I'm honored to work beside them everyday. They meet challenges with creativity and determination, and they tirelessly seek new ways to meet the needs of the diverse markets we serve through collaborative innovation and by maximizing efficiency. 
As we noted in our press release, we believe it was prudent to separate our manufacture services business from pharmaceutical distribution for financial reporting purposes. We believe that disclosing this additional level of detail will increase investor understanding of our business and further improve the overall transparency of our financial reporting. Tim will cover the financials for the 2 segments, and I will now cover some of the key trends in our business units during the quarter. 
AmerisourceBergen Drug Corporation revenue declined 5% due in large part to a decline in sales to our largest customer, as well as the previously reported loss of a large retail customer beginning last September. In addition, we anniversaried last year's addition of a new alternate site customer in May, and top line growth continues to be mitigated by the impact of generic conversions. Year-to-date, the drug company revenues are only down slightly as anticipated. Over the course of the year, the wave of generic launches has progressed as planned and the Drug Company saw significant gross margin expansion in the quarter even as the 2 largest generics of Zyprexa and Lipitor came off exclusivity. We look forward to a few more launches still to come in our fourth quarter. 
Back in June, we held our annual trade show for our independent retail customers and we continued to be impressed with their resilience and their ingenuity in providing personalized patient care in the committee -- community they serve. Our Good Neighbor Pharmacy members participate actively in the largest independent network of community pharmacies in the U.S. AmerisourceBergen and our independent customers strongly believe that they play a critical role in health care throughout the country by offering a compelling value proposition to patients and payers alike. ABDC is focused on ensuring that our network, Good Neighbor Pharmacy, remains dynamic by continuous investment in programs and services to meet the challenges of community pharmacy today and in the future. The implementation of our SAP platform continues on schedule with 14 distribution center conversions complete, representing over half of our distribution centers and 2/3 of our revenues. We've made excellent progress and we expect additional conversions occurring in our fourth quarter and the remainder planned through the beginning of fiscal year 2013. 
We also continue to strengthen our Canadian operations in support of previously reported new business wins in that market. We are confident that these and other investments will meaningfully increase the value we bring to all of our customers in the U.S. and Canada. 
As we noted in the press release, we continue to participate in negotiations for the distribution contract to serve the newly combined business of Express Scripts and the former Medco. We believe we are nearing the end of the process, and while we don't have a firm date for an announcement, we do hope that the decision will be made within the next few weeks. We continue to be optimistic about our chances to win the business. However, it is a competitive process and we believe Express Scripts will ultimately choose a partner that they believe provides the best overall value. 
AmerisourceBergen's Specialty Group had another strong quarter with revenues up 8%, driven by another particularly strong performance in third-party logistics and in our vaccine and physician distribution business. Our Oncology business performed well, while facing another very difficult comparison due to the strong performance of the 3 large Specialty generic products in the June quarter last year. The comparison will ease in the September quarter as Oxaliplatin returns to the market. ABSG continues to benefit from the launch of a branded ophthalmology product earlier this year, continuing to help establish significant market share for the manufacturers. Our experience with their product demonstrates the potent value of our Specialty franchise. While our undisputed strength in Specialty is Oncology business, we have expanded those capabilities to become an instrumental part of the commercialization strategy for any infusible product launched into the physician marketplace. As I previously discussed, we now have a keen interest going forward in further expanding those capabilities into select global markets. The acquisition of World Courier has given us not only a premium quality clinical trial logistics services provider, but also an international framework upon which to further capitalize on our strengths by driving our specialty logistics, consulting, commercialization and reimbursement services into other geographic markets. The integration of World Courier is going very well and we are very excited about the new insights and opportunities that are being discovered as we bring these 2 great organizations together and gain operational exposure to international markets. 
Our Consulting Services group continues to have a strong year as demand for commercialization, reimbursement and patient support services continues to be robust. We believe these combined service offerings distinguish AmerisourceBergen in the marketplace, provide unmatched value to manufacturers and will be an important driver of our growth going forward. As manufacturers seek to bring new products to market or expand sales of existing products in a challenging health care environment, we believe that demand for these services will only increase. 
In terms of financial performance, the Consulting Services group delivered a solid quarter while making excellent progress in the further integration of TheraCom, which is performing well. Even setting aside the contribution from TheraCom, the Lash Group alone had outstanding results. As Tim will detail, the solid performance across our business contributed to excellent cash flow in the quarter. Given the strength of our balance sheet, we continue to explore opportunities to deploy our capital in order to increase shareholder value, including searching for acquisitions that meet the criteria we have in place for quite some time. They should increase our value offering to existing customers, both up and down the channel. They should be within our established core competency and they should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions and we continue to be interested in opportunities in pharmaceutical and specialty distribution and services, as well as consulting services. We also remain committed to returning a minimum of 30% of our free cash flow to shareholders in the form of dividends and share repurchases, a hurdle that we have handily exceeded over the last several years. 
Looking ahead, the results we've had in the first 9 months of our fiscal year put us well on our way to meeting our objectives for the full fiscal year. As we said in our press release, we have narrowed the range of our diluted EPS expectations for the full year to $2.80 to $2.84. Tim will provide the details on our assumptions for the remainder of the year, but I want to highlight that as a result of that tremendous financial flexibility, we have repurchased $540 million of our shares in the year when we spent over $800 million on acquisitions, and we'll pay down about $400 million in debt in September. This speaks to the enormous strength and resilience of our business in a year of significant change for AmerisourceBergen, and indeed for the health care industry more broadly, as well as the quality of our financial planning and financial stewardship. 
As you know, we are deeply engaged in our business planning process for our fiscal 2013, and we do not yet know the future status of the business we do with our largest customer. As we noted in our press release, however, we do expect that new generic launches in both ABDC and ABSG, as well as contributions from our recent acquisitions and other favorable items will help drive earnings growth next fiscal year. The impact of customer consolidation and competitive market dynamics on our margins is expected to offset some of that growth. As our provider customers across the health landscape prepare for the full implementation of the federal government's health care reform initiatives, we are being challenged to help find new ways to reduce costs. Across the industry, big customers are getting bigger, whether they are mail order pharmacies, acute care networks or independents seeking greater strength in number through joining buying groups. Over the long term, this should lead to an even more stable and resilient industry. Of course, we will continue to manage our own expenses and working capital. In addition, the strength of our balance sheet affords us additional opportunities to drive shareholder value through acquisitions, share repurchases and dividends. With all that in mind, our preliminary expectation is for high single digits to low double-digit diluted EPS growth in fiscal 2013. 
Over the last year, we made important investments in our business with an eye to the future while we continued to focus on helping our customers and ourselves take advantage of the unprecedented growth in generics and the many opportunities in Specialty. Demand is strong and growing for the core products we distribute, and we play an essential role in the pharmaceutical supply chain, ensuring the integrity and security of the distribution of life-improving and life-saving therapies. Our manufacture services businesses help ensure products get to market as efficiently as possible and that patients have access to both traditional medications and the most innovative and complex products. As cost-containment efforts mount across the health care spectrum, our customers increasingly turn to us for help in meeting the challenges of the marketplace without sacrificing patient care. I take great pride in the energy and creativity our associates bring to our business. Each day, I see the results of their innovative thinking and their dedication to exceeding customer expectations, and I'm proud to be their leader. Here is Tim."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve. And good morning, everyone. As you just heard, ABC delivered a solid quarter and through 9 months, our performance is tracking well to our financial targets. The key highlight this quarter was our ability to overcome the oncology generic he",1726,"Thanks, Steve. And good morning, everyone. As you just heard, ABC delivered a solid quarter and through 9 months, our performance is tracking well to our financial targets. The key highlight this quarter was our ability to overcome the oncology generic headwind we've mentioned in the past. Going into this fiscal year, we knew that Q3 would be our toughest EPS comparison. We consistently called out a $0.33 headwind this year from Specialty generics. Of this headwind, we anticipated about half of the $0.33 would negatively impact the third quarter. We're pleased that we are able to successfully overcome this Q3 headwind and show solid EPS growth. 
Two other highlights for the quarter. We continued our discipline in terms of managing expenses across the organization and we integrated World Courier into ABC reporting. Our results include 2 months of their operations. 
Before I start with the quarterly financial details, let me highlight that in our press release, we expanded our disclosures to include detail for 2 reporting segments in addition to our ABC consolidated results. The Pharmaceutical Distribution segment includes our Drug and Specialty Group operating segments. The Other segment includes our manufacturer and services businesses, which consists of the Consulting and World Courier operating segments. Upon review of the financial reporting requirements, we determined that there was a need to separate drug distribution and manufacturer services due to the nature of their business operations and different revenue growth rates and operating margins. The disclosure of our 2 reporting segments will improve investor transparency going forward. 
Now back to the quarterly details. I'll cover ABC consolidated results first. Starting with the top line, revenues were $19.8 billion, a 1 .9% decrease over last year's quarter. Drug Company revenues were down about 5%, offset by higher Specialty revenues of nearly 8%. We also had the benefit in our June '12 revenues from 2 of our acquisitions, TheraCom and World Courier. They contributed a combined $300 million of new revenues in the current quarter. 
Moving along, gross profit was $689 million in the quarter, up 5.4% from last June with a gross margin of 3.49%. Just to remind everyone, World Courier is included in our financial results and they have a fairly high gross profit margin due to their best-in-class service model. World Courier and our other acquisitions contributed nearly $60 million to our gross profit in the current quarter. 
Our LIFO charge was $4.7 million in the quarter, down $6.7 million from last year. We expect a LIFO charge of between $12 million and $15 million for the full year, down significantly from last year. Finally, the generic benefit we received in the current June quarter from new generic launches and price appreciation was in line with our expectations. Let's move to operating expenses. 
This quarter, operating expenses were $375 million, up 11.6%. But this amount includes approximately $50 million of operating expenses related to our recent acquisitions, as well as approximately $5 million of non-recurring charges related to the World Courier transaction. Excluding the impact of acquisitions, our operating expenses would have decreased about $10 million quarter-over-quarter. Our businesses continue to do an excellent job at managing their expenses. 
Operating income of $314 million in the quarter decreased about 1%, while operating margin was up by 2 basis points compared to last June. Our third quarter was slowed by the World Courier transaction cost, and more importantly, the difficult comparison versus the prior year. 
Moving below the operating income line and other income, we had income of $4.8 million primarily related to an increase in evaluation of a note that was due to ABC from the October 2008 sale of our prior PMSI business. Interest expense of approximately $25 million in the June quarter increased 33% compared to last year as a result of our $500 million senior notes that we issued back in November. Our effective income tax rate of 38.3% was slightly higher than last year's 38.2% and is in line with our expected annualized rate of 38.4%. 
Our GAAP diluted earnings per share in the quarter of $0.71 increased by $0.05 or just under 8% over the last quarter -- over the same quarter last year. Our EPS benefited from a reduction in our average diluted shares outstanding due to our ongoing share repurchase programs. Average diluted shares for the quarter were approximately $256 million, down just over 8% from last June. At June 30, 2012, we had 251 million outstanding shares. 
Let's spend a few minutes discussing our segment results for the June quarter. Starting with Pharmaceutical Distribution, total revenues were $19.4 billion, down about 3.3% over last year's quarter. Drug Company revenues were down about 5% due primarily to lower sales with former Medco and the impact from the loss of a large chain customer last year , the  former Longs Drugs. Slightly over half of the decline came from lower sales to former Medco, driven by generic conversions and changes in their book of business. Without these 2 negative impacts, our Drug business would have had growth of 2%. Also during the quarter, the Drug Company anniversaried a large customer win from the prior June quarter. 
Specialty Group's revenues increased nearly 8%, led by strong performance in 2 of its businesses with growth significantly above market rates, ICS, our third party logistics business, and Besse Medical, our vaccine and physician office distribution business. From a segment standpoint, gross profit decreased about $25 million and our gross profit margins slipped somewhat. Most of the dollar decrease is due to the oncology generics headwind, a high-margin contributor last June quarter, offset by the contribution from generic Lipitor and Zyprexa, both of which had their exclusivity periods end during the June '12 quarter. We did have other generic launches during the quarter and also gross profit contributions from our specialty businesses. These positives were offset by the decrease in our revenues and margin pressure. It should be noted that Drug Company as viewed on its own, had gross profit margin expansion of 20 basis points in the June 2012 quarter. This segment managed operating expenses very effectively, especially payroll and benefit expenses, as well as external consulting expenses, which enabled us to offset some of the gross profit dollars we lost with the oncology generic headwind. Overall, we're very pleased with the operating results for this segment. 
Moving to the Other reporting segment which again is Consulting, which includes our Packaging business and World Courier. As mentioned previously, our 2 large acquisitions accounted for nearly $300 million of new revenues in the third quarter. World Courier revenues are tracking well against our expectations, which we provided back in our press release that announced the acquisition. Operating income from the Other segment increased $11 million from last year's quarter. Of this increase, about $8 million is related to our fiscal '12 acquisitions. The remaining increase is related to our legacy businesses. I'd like to highlight that our non-recurring charge of about $5 million is not included in our segment level reporting. For the June quarter, the impact of our World Courier acquisition was essentially breakeven due to the transaction costs. 
Now let's turn to our consolidated balance sheet and cash flows where trends continue to be favorable. We generated $92 million of cash from operations in the quarter, bringing our 9 month's total to $760 million. Our businesses continue to focus on working capital. In fact, our cash conversion cycle, based on a rolling 4-quarter average, improved by 1 day to 1.7 days based in the current June quarter, from 2.7 days in the June 2011 quarter. 
Capital expenditures were $39 million in the quarter and $128 million for the 9 months. For the full year, we are still tracking to our guidance for CapEx of $200 million. During the quarter, we bought back $186 million of our shares. For the 9 months, we purchased $514 million of shares and this slightly exceeds our March quarter guidance of $500 million. At June 30, we have $744 million left on our May 2012 share repurchase authorization. 
Our cash balance at June 30 was $1.7 billion. As we've discussed in the past, we need approximately $500 million in available cash to account for swings in working capital and to run the business. As a reminder, in mid-September, we will be using cash to retire our $400 million 5 5/8% senior notes. 
Now let's turn to updated fiscal 2012 guidance. We now expect our GAAP diluted EPS to be in the range of $2.80 to $2.84. This includes an estimated $20 million of non-recurring costs related primarily to transaction and severance expenses. With narrowing our EPS range, this means that we will have EPS growth of 10% to 12% this year after absorbing the $0.05 negative impact from non-recurring charges. 
Revenue. We continue to expect revenue growth to be flat or up modestly for the full year. We expect our operating margin expansion to be in the high single digits. As previously communicated, Q4 is our easiest operating income comparable for the year. Because of this, we expect most of our operating margin expansion to be achieved in the fourth quarter. Free cash flow is still tracking to finish in the $800 million to $900 million range. 
Looking ahead. We are deeply engaged in our business planning process for fiscal 2013, and there are still many moving parts including, of course, the Express Scripts RFP. As Steve outlined, as large customers consolidate, they are seeking better pricing which includes generic pricing. And as recent contract discussions have demonstrated, our customers want us to be part of the solution in helping them meet the economic demands of the new health care landscape. Our high single digit to low double-digit EPS growth range is based on assumptions on several moving parts, and includes possible outcomes on the Express Scripts contract. Our EPS range is preliminary and we still have quite a bit of work to complete in our planning process, but it does incorporate the best information we have right now. So before I turn it back to Barbara, let me reiterate that 9 months into our fiscal year, we are well positioned to meet our financial targets for fiscal '12 and we are hard at work on our fiscal '13 plan. Here is Barbara to start our Q&A."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Tim. We will now open the call to questions. [Operator Instructions] Please go ahead, Mary.",17,"Thank you, Tim. We will now open the call to questions. [Operator Instructions] Please go ahead, Mary."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Tom Gallucci with Lazard Capital Markets.",17,"[Operator Instructions] And our first question comes from the line of Tom Gallucci with Lazard Capital Markets."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","I guess my first question was, on some of the commentary that you had in the press release, and I think you echoed it a bit on your prepared remarks where you sort of talked about competitive pricing pressures and sort of the competitive landscape, can yo",82,"I guess my first question was, on some of the commentary that you had in the press release, and I think you echoed it a bit on your prepared remarks where you sort of talked about competitive pricing pressures and sort of the competitive landscape, can you expand a little bit on what you mean there? Is it sort of something that we always see as a persistent part in the business or are there really new dynamics that you're referring to?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","No. I think -- thanks for the question, Tom. What we're seeing is that the larger customers are getting larger, and we've always said that the larger customers get the biggest -- the best deal and we're seeing some of that. I think in addition, we've got",153,"No. I think -- thanks for the question, Tom. What we're seeing is that the larger customers are getting larger, and we've always said that the larger customers get the biggest -- the best deal and we're seeing some of that. I think in addition, we've got much more generics as a percentage of sales. Don't forget, we have a very diverse customer base, almost all of them buy generics from us. So generics as a percentage of overall portfolio have increased. So I think we just -- people are looking at their businesses and their potential financial impacts from health care reform and reimbursement pressure, and we -- they're expecting us to participate with them in a much tougher future. So a tougher future where we all have to be more efficient, and I think we're just not immune from some of that. So those are the trends that I'd point out."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And then just to clarify your comments on guidance, I guess just to ask specifically, it sounds like it's early, maybe there;s some conservatism because there are so many moving parts. On Express specifically, we all know that's a pretty big moving",67,"Okay. And then just to clarify your comments on guidance, I guess just to ask specifically, it sounds like it's early, maybe there;s some conservatism because there are so many moving parts. On Express specifically, we all know that's a pretty big moving parts. Would you be able to meet this guidance range if tomorrow you found out you didn't retain the Medco, the legacy Medco business?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Hey, Tom, this is Tim, and I'll answer your question this way. I mean our guidance includes, like you said, different assumptions on moving parts, one of which is Express Scripts, and it contemplates both scenarios, winning it and losing it. Again, it's E",54,"Hey, Tom, this is Tim, and I'll answer your question this way. I mean our guidance includes, like you said, different assumptions on moving parts, one of which is Express Scripts, and it contemplates both scenarios, winning it and losing it. Again, it's Express Scripts and other factors looking out over the next years."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","And our next question comes from the line of Larry Marsh with Barclays.",13,"And our next question comes from the line of Larry Marsh with Barclays."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Just my question is elaboration on comps around next year. So -- and I appreciate providing some clarity here with, perhaps, a tone of trying to be prudent here. But I guess, Steve, if we think about a scenario where your largest customer, Express, choose",131,"Just my question is elaboration on comps around next year. So -- and I appreciate providing some clarity here with, perhaps, a tone of trying to be prudent here. But I guess, Steve, if we think about a scenario where your largest customer, Express, chooses not to continue to do business with you or splits the business, can you remind us of some of the factors that you would, could, go through to help mitigate some of those lost revenues from the cost side that would keep you still in the range of guidance? And along with that, is there -- could there be a situation where they might be a quarter or 2 of timing mismatch between revenues and costs that could cause you to vary around your guidance ranges?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks for the question. We really are deep in this. In fact, we're going -- the team's going out to visit all our drug regions next weak, which really is the start for us in detail, in the detailed planning process. But we had information that -- we have",270,"Thanks for the question. We really are deep in this. In fact, we're going -- the team's going out to visit all our drug regions next weak, which really is the start for us in detail, in the detailed planning process. But we had information that -- we have information that we think is material that want -- that we felt was incumbent on us to share with all of you, and that's the way AmerisourceBergen is run. And we're proud of that. We're not backing off that. So absolutely, if we lose Express Scripts, don't forget our current business is -- really a lot of the greenfield that we set up during the merge is really set up to handle big mail order business that we've done with Medco traditionally for as long as I can remember. I've been with the company 8.5 years. We've always had the count. But it's very little expense. In fact, many of the characteristics of this business are what we used to call dock to dock business and of course, you remember that very well. So there's not too much expense there. And coincidently, a lot of the facilities that we service in Medco are our most highly efficient modern facilities, but we would -- we absolutely have opportunities to cut down our cost. And like Tim said, this current thinking, while it's early, really contemplates all the way from us entirely losing this business to winning it, including winning the part that we currently do not service, based on our basic understanding what the economics can be. But it honestly is early."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay. I appreciate the reflection there. And I guess my follow-up is around your LIFO charge. So, Tim, you're communicating a reduction in your range of LIFO expectations versus what you had suggested back in April by, say, a couple of million dollars. I",108,"Okay. I appreciate the reflection there. And I guess my follow-up is around your LIFO charge. So, Tim, you're communicating a reduction in your range of LIFO expectations versus what you had suggested back in April by, say, a couple of million dollars. I know at the time you had said you anticipated big impact relative last year with the generic introductions and some moderation in brand price inflation. What's causing you to further moderate your views on that inflation-based cost? And as you think about your guidance for next year, can you give us any sense of general ranges of LIFO charges you're anticipating for fiscal '13?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, Larry, it's probably a little bit early to talk about LIFO for '13. I mean, we're still looking through that. In terms of LIFO for the June quarter, at the end of the June quarter, we saw a pretty good brand pricing, increased percentages for our top",122,"Yes, Larry, it's probably a little bit early to talk about LIFO for '13. I mean, we're still looking through that. In terms of LIFO for the June quarter, at the end of the June quarter, we saw a pretty good brand pricing, increased percentages for our top 75 brand drugs, a little bit off from last year. So I mean there is some moderation there in terms of brand pricing. And we're seeing a little bit steeper generic deflation especially with generic Lipitor and Zyprexa. So that's driving the change, the slight change in our full year LIFO forecast. But again, for next year, we're probably -- it just depends on where brand price inflation is. It's a little bit early."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","And our next question comes from the line of Robert Jones with Goldman Sachs.",14,"And our next question comes from the line of Robert Jones with Goldman Sachs."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I just wanted to go back, I know you touched on some of the changing market industry dynamics and specifically, Tim mentioned the generic pricing. I was just wondering maybe for perspective, if you could share your thoughts or recent trends on both",78,"Steve, I just wanted to go back, I know you touched on some of the changing market industry dynamics and specifically, Tim mentioned the generic pricing. I was just wondering maybe for perspective, if you could share your thoughts or recent trends on both the buy side margin that you've seen recently and then maybe separate out the sell side margin just to give us some perspective on your dealings on both with the manufacturer and the customer."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Many times -- I'll just talk about the buy side first. Many times on the fee-for-service agreements, we're really in our third generation and we've dealt with a lot of pharma consolidation, and we feel that we've -- the industry on the manufacturer side r",325,"Many times -- I'll just talk about the buy side first. Many times on the fee-for-service agreements, we're really in our third generation and we've dealt with a lot of pharma consolidation, and we feel that we've -- the industry on the manufacturer side really understands the value we represent and there's no significant erosion there or anything at all. Obviously, the generic mix at AmerisourceBergen has opportunities to sell generics to almost all of our customers. As you know, we believe we have the most diverse customer base. It has really been driven by this generic wave, and we have set out our whole portfolio in both Drug and Specialty to really recognize the strength in generics. I hope you would have buy [indiscernible] someday and really capitalize on the opportunity that we have for generics and specialty. The sell side, I think, the biggest things we can point to is somewhat of an anxiety of compressed reimbursement and just a lot of consolidation. I mean, just read the headlines. It's not just that particular one that's on everyone's mind. It's -- there's just a lot of consolidation. We have community oncologists, for example, that are constantly getting a lot bigger, and our bigger customers get a better deal. We have independent customers joining buying groups. So these are the biggest trends that I can point to. And we -- I think also there's a lot of marquee customers up for bid. It's been pretty well-publicized. VA process, definitely the SR process has really kicked up some dust, I could say, from other customers. So those -- without being too specific, and we don't like to comment on individual contracts, we have been in this business a long time. We understand how to contract with customers, and we believe that our best bet is to maintain our key customers and customers that we believe are going to represent us growth in the years ahead."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","I appreciate that. And just maybe around the preliminary guidance, I was hoping maybe you could talk a little bit more about the major swing factors. Obviously, I think, we all are well aware of the Express contract, but maybe just how you're thinking abo",113,"I appreciate that. And just maybe around the preliminary guidance, I was hoping maybe you could talk a little bit more about the major swing factors. Obviously, I think, we all are well aware of the Express contract, but maybe just how you're thinking about other important contracts. I know you don't want to name names, but I think PharMerica is one that's out there. And then just some of the other major contributing factors, what's the assumption around buyback. It looks like there's obviously some nice contribution from lower interest expense and clearly, World Courier next year. Maybe just some of the pushes and pulls around the guidance range would be helpful."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, this is Tim. In terms of the guidance, I mean, we're not going to talk specifically about other contracts. Certainly, we made an assumption about Express in there. And as we start the plan process, we always look out over the 12-month horizon of what",167,"Yes, this is Tim. In terms of the guidance, I mean, we're not going to talk specifically about other contracts. Certainly, we made an assumption about Express in there. And as we start the plan process, we always look out over the 12-month horizon of what other contracts we may renew and renegotiate. So there's an assumption in there about other contracts. And some of the other things, too, would be Oxaliplatin and an assumption about how that's going to perform next year. I mean that's a big unknown. We don't know how the pricing will stick in the market, how many suppliers, and so that's a factor. Certainly, we make an assumption about expenses. And finally, in terms of share repurchases, the assumption is, I think if you look back to what we've done historically, the last 2 or 3 years, we've been around about the $500 million range, so that's probably a pretty safe number to be in at for the -- that's our thinking."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from the line of Glen Santangelo with Credit Suisse.",13,"Our next question comes from the line of Glen Santangelo with Credit Suisse."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","I just want to follow up on generics. And I'm not sure exactly how you're thinking about this with respect to your guidance, but, Tim, you mentioned in your prepared remarks, right? You went into fiscal '12 with a $0.33 hole. Obviously, everyone's focused",79,"I just want to follow up on generics. And I'm not sure exactly how you're thinking about this with respect to your guidance, but, Tim, you mentioned in your prepared remarks, right? You went into fiscal '12 with a $0.33 hole. Obviously, everyone's focused on this generic calendar. And so as you think about your guidance for fiscal '13, could give us a sense for maybe what the contribution you're expecting in '13 versus '12, what that looks like?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Glen, I mean, we're just, again, we're early in the plan process. We don't want to get into specifics. I mean we do have generics, a couple of good ones that launched at the end of our Q4 that carry over into fiscal '13 that will definitely help us. We're",118,"Glen, I mean, we're just, again, we're early in the plan process. We don't want to get into specifics. I mean we do have generics, a couple of good ones that launched at the end of our Q4 that carry over into fiscal '13 that will definitely help us. We're encouraged, I mentioned before, Oxaliplatin will be back. We only have it for 6 weeks, we get it next year. There are some unknowns about that. But overall, it's -- you're not going to have a generic Lipitor and Zyprexa, but there are some good generics that helped us early in the year. But again, we're not ready to kind of dial in any specific EPS impact numbers."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, that's fair. Maybe I could just ask Steve one follow-up question. Steve, I just want to talk about a comment you made with respect to acquisitions. You said, I think, the company is still receptive to the idea of acquisitions. And it sounds like you",96,"Okay, that's fair. Maybe I could just ask Steve one follow-up question. Steve, I just want to talk about a comment you made with respect to acquisitions. You said, I think, the company is still receptive to the idea of acquisitions. And it sounds like you're pretty pleased with the progress at both TheraCom and World Courier Group. And as you think about where you are with respect to those integrations, I mean, you feel like the company could handle additional acquisitions in fiscal '13 or you kind of going to just see how it goes?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Well, Glen, that's a great question. I do think that we are operationally well-situated. And I think actually, TheraCom is a very good example. I mean, we've had some work to do at the corporate office, yes, but obviously, we bought this from a well-run c",273,"Well, Glen, that's a great question. I do think that we are operationally well-situated. And I think actually, TheraCom is a very good example. I mean, we've had some work to do at the corporate office, yes, but obviously, we bought this from a well-run company and it was in good shape. And really, most of the integration work is carrying on in our Consulting Services business. So I think they're very well equipped to run that. And World Courier was definitely a different expansion for us. We've had a lot of work to do. I think Tim pointed out one of the highlights for this year was really getting World Courier into the financial reporting criteria for a public company and that's gone well, but we do think that one of the reasons we're investing in this company was the platform opportunity and now, when we go consider anything internationally, we have local intelligence, which is huge. Local understanding of tax laws, of who the good players are, who the bad players are. So we do think that this opens up some attractive markets to us, which we started out our release by talking about, obviously, the obvious fact that pharmaceutical growth in the rest of the world will be higher than the U.S. So we're not rushing in here. We don't think that there's any nirvana market or anything. But it is important to us to drive our Specialty and Consulting practices throughout the world, and we think we have leading practices in those areas and a lot of good intelligence and methodologies to share with the rest of the world."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Glen, this is Tim. I'll just say, after 100 days, we're really pleased with what we have so far, and they're performing right on our expectations. So, like I said, neutral in Q3, and we expect them to contribute $0.01 or $0.02 in 4. So again, very encoura",61,"Glen, this is Tim. I'll just say, after 100 days, we're really pleased with what we have so far, and they're performing right on our expectations. So, like I said, neutral in Q3, and we expect them to contribute $0.01 or $0.02 in 4. So again, very encouraged this year and looking forward to what they're going to do in '13."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question goes to the line of Robert Willoughby with Bank of America Merrill Lynch.",16,"Our next question goes to the line of Robert Willoughby with Bank of America Merrill Lynch."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Tim, what's left on deal expenses? Will we see much going forward in the numbers? And I think you hinted at it, but what was the actual dilution from new generics year-over-year to revenues?",34,"Tim, what's left on deal expenses? Will we see much going forward in the numbers? And I think you hinted at it, but what was the actual dilution from new generics year-over-year to revenues?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","The actual dilution -- in terms of revenues?",8,"The actual dilution -- in terms of revenues?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Yes, in terms of revenue growth rate.",7,"Yes, in terms of revenue growth rate."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, we -- what we said in terms of the Medco, I mean Medco was down probably about half. I mean, it's probably in the $500 million or $600 million range, that's from our largest customer, Medco by itself. And again, not all that is -- some of that is boo",133,"Yes, we -- what we said in terms of the Medco, I mean Medco was down probably about half. I mean, it's probably in the $500 million or $600 million range, that's from our largest customer, Medco by itself. And again, not all that is -- some of that is book of business, right, and some of it is the generic conversions. In terms of your other question, I would say, Robert, that we don't have much left in terms of World Courier. I mean I think we're at $17 million in terms of non-recurring costs through Q3. In my comments I said I thought we'd end up about $20 million. We probably still have some other non-recurring charges that will come through, about $3 million, not related to World Courier in Q4."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","And our next question comes from the line of Eric Coldwell with Robert W. Baird.",15,"And our next question comes from the line of Eric Coldwell with Robert W. Baird."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Okay, I'm going to ask 2 if it's all right. Regardless of correlation or causation in the past, we have seen some rather funky behavior from the manufacturers around major U.S. elections. I'm specifically thinking about the September quarter of 2004, wher",89,"Okay, I'm going to ask 2 if it's all right. Regardless of correlation or causation in the past, we have seen some rather funky behavior from the manufacturers around major U.S. elections. I'm specifically thinking about the September quarter of 2004, where price inflation contracted fairly dramatically. Have you considered the possibility of that hitting into this election or do you think it's really not in the limelight here? I guess any signal on pharma behavior on pricing here in the near term. And then I have a follow-up."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","The pharma pricing has been a little bit less than last year, the price increases, but still very robust. And as I said, we're spending more time internationally and everyone's very envious of an environment where we can have price increases. So it's an e",136,"The pharma pricing has been a little bit less than last year, the price increases, but still very robust. And as I said, we're spending more time internationally and everyone's very envious of an environment where we can have price increases. So it's an excellent thought, Eric. I credit to you for thinking of that. We'll pay it more attention, but we haven't really seen anything concerning. I think more of the price increases have to do with patent expirations, is what we're seeing a trend there, some price increases and pricing strategies ahead of large patent expirations. But as you know, we've got some significant launches in this quarter and less exciting year in brand to generic conversion next year, but still very robust. And we will see some impact on brand prices from those."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","That's great. And my follow-up is related to business transformation, the ASP program. You seem to continue to be ahead of schedule and doing great there. Just curious if you could give us an update on the incremental benefits to OpEx compared to your ori",87,"That's great. And my follow-up is related to business transformation, the ASP program. You seem to continue to be ahead of schedule and doing great there. Just curious if you could give us an update on the incremental benefits to OpEx compared to your original thoughts for the implementation, and then whether you might be looking to fiscal '13 and '14 and thinking that there could be some additional juice on that $10 million and $40 million of OpEx savings that you had previously talked about."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, I'll let Tim mainly handle this, but I'll just say that generally, we spend -- we've done most of our capital spend, then now, it's really operational spend. So the depreciation is starting to hit us financially. The consulting expenses, the external",78,"Yes, I'll let Tim mainly handle this, but I'll just say that generally, we spend -- we've done most of our capital spend, then now, it's really operational spend. So the depreciation is starting to hit us financially. The consulting expenses, the external consulting is definitely an opportunity we've had to reduce cost. And we've actually done well against our plan for our BT budget for this year, but I'll let Tim give you some color on this."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, thanks, Steve. Yes, Eric, actually, to Steve's point, I mean I just want to make sure I stress this. I mean, we're starting to see a little bit of expense savings now. Again, when I mention external consulting, a chunk of that is from our IT departme",139,"Yes, thanks, Steve. Yes, Eric, actually, to Steve's point, I mean I just want to make sure I stress this. I mean, we're starting to see a little bit of expense savings now. Again, when I mention external consulting, a chunk of that is from our IT department and the fact that we're moving along and deploying SAP really efficiently and effectively. So we're seeing a little bit now, but we're still -- we're not -- we're still believing that the $10 million's appropriate. That's one of those when we talked about moving parts in our range, that's one of the assumptions kind of factored in to our range for '13, and we're still on the $40 million for '14. So at this point, we're just not ready to commit any upside or juice as you called out there."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Our next question comes from the line of Lisa Gill with JPMorgan.",12,"Our next question comes from the line of Lisa Gill with JPMorgan."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I just wanted to follow up on a comment that you made around the Express Scripts new contract. You said it would be the best overall value. I'm just wondering if there's any changes to the types of services that they're looking for versus what you",107,"Steve, I just wanted to follow up on a comment that you made around the Express Scripts new contract. You said it would be the best overall value. I'm just wondering if there's any changes to the types of services that they're looking for versus what you previously provided for Medco? And then just on the follow-up side for that, I think I read in a Philadelphia paper some comments around specialty and your growth in specialty and perhaps, moving more towards the patient. I was wondering if maybe you could just also comment on that, as well as potentially competing with a customer like the PBM."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Let me just talk about that. I think our business in specialty is -- and we're talking about this with a customer the other day that everyone has a different definition of specialty. When AmerisourceBergen says specialty, we're really talking about physic",259,"Let me just talk about that. I think our business in specialty is -- and we're talking about this with a customer the other day that everyone has a different definition of specialty. When AmerisourceBergen says specialty, we're really talking about physician administrative products and related services to manufacturers. I think when a PBM says specialty, it usually means patient self-administrative products. And so I think that, that's pretty well defined. And we actually think that there's a lot of opportunities to collaborate in those areas including with our Good Neighbor Pharmacy network and there's an opportunity to do potentially more specialty in the community. And we do take our specialty franchise and expertise very seriously there, and think that we afford a lot of AmerisourceBergen customers that are interested in this area, an opportunity to gain from our expertise, including in the policy area and the manufacturer relations area. The first part of your question had to do with Express Scripts and the overall value we provide. I think that was more of a comment that the economic deals. I mean, there's a very few companies that are qualified to be the provider to Express Scripts so it's a small universe. And I think economics is part of it, experience is part of it. And I don't think, honestly, that any of the qualifications have really materially changed since the start of this process, which has been pretty quick if you think about it compared to some of the other ones that we've seen in the recent past."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Just so I understand that, Steve, though, so your comments around commercialization of a product and perhaps, working in partnership with a PBM, you don't view that as an opportunity with a new potential contract with the new Express Scripts or is that a",53,"Just so I understand that, Steve, though, so your comments around commercialization of a product and perhaps, working in partnership with a PBM, you don't view that as an opportunity with a new potential contract with the new Express Scripts or is that a future opportunity, but not part of this RFP process?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","No, we see -- I think quite the opposite. I said I think that our market presences and our market expertises are very complimentary. But the focus on this has really been on the core economics, and I think our idea is obviously to win an account and then",67,"No, we see -- I think quite the opposite. I said I think that our market presences and our market expertises are very complimentary. But the focus on this has really been on the core economics, and I think our idea is obviously to win an account and then we can work on an alignment and future opportunities together. So that's really what our strategy is there."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","The next question comes from John Ransom with Raymond James.",10,"The next question comes from John Ransom with Raymond James."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","Just a couple of things, just drilling down to your assumption for next year. Oxaliplatin comes back, Express, is that -- could be a mover for you?",27,"Just a couple of things, just drilling down to your assumption for next year. Oxaliplatin comes back, Express, is that -- could be a mover for you?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","We are obviously excited to have Oxaliplatin back and at the end of May, we were thrilled that the comp is out now. We enjoyed the ride, but it was good timing to have the comp out. And August, we're going to have the product back, but it's going to be ve",194,"We are obviously excited to have Oxaliplatin back and at the end of May, we were thrilled that the comp is out now. We enjoyed the ride, but it was good timing to have the comp out. And August, we're going to have the product back, but it's going to be very different. The ASP's pretty high so that's a positive, but there's no at risk, there's no exclusivity period, so we're going to have several manufacturers and we think that the pricing will be very dynamic. It's probably going to be more akin to, again, the specialty drugs and they're different than all the solids. The prices never get quite as low, but it's going to be more akin to the expiry of 180-day exclusivity period than it is to a new generic injectable launch is what I'd say. So while we're expecting with our market share that we have and the expertise we have in oncology, we expect them to do very well here as we did with docetaxel and gemcitabine. We don't expect that you're going to be hearing half of our earnings call be devoted to Oxaliplatin in the future."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","The said question, if you just look at the totality of your -- for all generics, the contribution that you think you'll get next year compared to the contribution [indiscernible], and my specific view is, I think, from all accounts, Lipitor was just off t",78,"The said question, if you just look at the totality of your -- for all generics, the contribution that you think you'll get next year compared to the contribution [indiscernible], and my specific view is, I think, from all accounts, Lipitor was just off the charts [indiscernible] during the exclusivity period. Obviously, you're losing that. And we were just having more troubles still at the calendar and thinking is it going to better, worse, the same next [indiscernible]?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, I don't think it's going to be quite as robust, but, Tim, you...",14,"Yes, I don't think it's going to be quite as robust, but, Tim, you..."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Yes, John, you were breaking up a little bit, but I think what you're asking is what next year looks like. And again, we have a little bit of a benefit from our fiscal year with a couple of large generics launching at the end of our Q4. But overall, talki",108,"Yes, John, you were breaking up a little bit, but I think what you're asking is what next year looks like. And again, we have a little bit of a benefit from our fiscal year with a couple of large generics launching at the end of our Q4. But overall, talking to our generics guys, I mean, we think it will be a good year. It's going to probably be a little down compared to this year. It's tough to replace generic Lipitor and Zyprexa. But again, there are a couple of other ones out there that we're encouraged about. So down a little bit, but not bad."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","And again, Lipitor, because of the class of customers we service here, who buys generics from us, might not have been as big for us as it was for the other players in the industry. Just keep that in mind.",40,"And again, Lipitor, because of the class of customers we service here, who buys generics from us, might not have been as big for us as it was for the other players in the industry. Just keep that in mind."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","And I guess I would like, again, going back to that, I mean let's go back and highlight Steve's comment earlier, is a lot of our volume is coming through larger customers on generics. So again, they get their pricing -- they bring us more volumes but they",55,"And I guess I would like, again, going back to that, I mean let's go back and highlight Steve's comment earlier, is a lot of our volume is coming through larger customers on generics. So again, they get their pricing -- they bring us more volumes but they're pricing is a little bit more favorable."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Our last question comes from the line of Ricky Goldwasser with Morgan Stanley.",13,"Our last question comes from the line of Ricky Goldwasser with Morgan Stanley."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","So just some quick follow-up questions here. So first of all, Steve, I think on your last comment around the volume, a lot of your generic volume coming from larger customers, so can you clarify that a little bit for us? Because when I think about Ameriso",156,"So just some quick follow-up questions here. So first of all, Steve, I think on your last comment around the volume, a lot of your generic volume coming from larger customers, so can you clarify that a little bit for us? Because when I think about AmerisourceBergen, I think, really, it's going to affect a big portion of your customer base being kind of like the smaller independents. So when you comment about the generic volumes, are you referring to kind of the PBM and the Omnicare of the word? Or is that -- or are you talking about comp like your Specialty segment? So if you can just clarify as to who those large customers are. And then secondly, from data that we've seen recently, it seems like that there have been some good generic price increases taking place. So how are you thinking of generic inflation in the context of your forward outlook?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Well, 2011, we did very well on generic price inflation. It's been much more moderate this year. And I think we even pointed out the numbers because it was significant to the interpretation. We haven't seen anything as robust this year. Ricky, apologies f",283,"Well, 2011, we did very well on generic price inflation. It's been much more moderate this year. And I think we even pointed out the numbers because it was significant to the interpretation. We haven't seen anything as robust this year. Ricky, apologies for your last name, [indiscernible] but we do have, we believe, the most diverse customer base within our industry. And we are very proud of the strong independent business that we have. We're also doing more business within the health systems on generics, which is a great trend for us given our health systems presence. We also, as you know, we never used to talk about generics and specialty, we talk about a lot. So there are a lot of really good trends for us in generics. But another trend is obviously, our large PBM customer doesn't really buy any significant generics from us, which we've talked about a lot. And the larger customers, a lot of them say -- when we do -- during our last round of contract negotiations, they may have been buying 4% to 7% of their purchases were generics and now, it's a lot higher. And those customers are getting bigger. And we have to share more of the economics on generics with them because it's a much bigger part, they're much higher profile product category to them. So those are some of the trends that we've been pointing out. And you're absolutely correct to think of AmerisourceBergen as specialty customers and independent pharmacies and large health system presence and big ultimate start or closed-door pharmacy businesses, and that's definitely one of the strengths of us, is our diversity in our business that we serve."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Analysts","So in that line, just another clarification, when you think about CapEx fiscal year '13 and when you say that it might be done a little in terms of generic contribution, you're really looking at a basket which includes a specialty generic and Oxaliplatin,",57,"So in that line, just another clarification, when you think about CapEx fiscal year '13 and when you say that it might be done a little in terms of generic contribution, you're really looking at a basket which includes a specialty generic and Oxaliplatin, as well as solid orals rather than separating the 2. Is that fair?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","The top line brand to generic conversions, and some of this fall -- it's complicated because some of it will have fourth quarter launches that would impact our fiscal year '13, but you know it was $13 billion in fiscal year '12, and it's about $11 billion",194,"The top line brand to generic conversions, and some of this fall -- it's complicated because some of it will have fourth quarter launches that would impact our fiscal year '13, but you know it was $13 billion in fiscal year '12, and it's about $11 billion to $12 billion in fiscal year '13. And again, the quarters move and we're early in our guidance and we're busy looking at it. But again, $11 billion is a very -- is a good year for us. It's -- if you look at our performance over the last 10 years, it's not -- it's a good year. So yes, we look forward to providing more guidance. We just wanted to give you a benefit of our early look at 2013 and what we know about some large contract negotiations that are going on. And I hope you appreciate the foresight that we've given you and the approach that we've taken, which is always being as transparent and as communicative with our investors as we can. So I think with that, we'll wrap up. Ricky, thanks for your questions. And, Barb, you want to make some comments?"
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Do you have a...",5,"Do you have a..."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Okay, I have -- all right [indiscernible]  Okay. I'm up for the strong close. All right. So my strong close is that I recently completed my first full year as CEO of AmerisourceBergen, which I'm very proud to serve in this position. And I unequivocably an",138,"Okay, I have -- all right [indiscernible]  Okay. I'm up for the strong close. All right. So my strong close is that I recently completed my first full year as CEO of AmerisourceBergen, which I'm very proud to serve in this position. And I unequivocably and very confidently state that ABC's franchise and our place in the industry and our long-term prospects are really outstanding. We have just repeated -- we have just reported an excellent quarter and we are well on our way to completing a successful 2012. And I thank you for your attention today. I believe that ABC's making the right investments to secure our future and we look forward to seeing some of you in September at various conferences. And, of course, we'll have our full fiscal year '13 earnings in November. Thank you."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve. And just a couple of calendar items. We'll be at the Robert W. Baird Health Care Conference in New York on September 5 and at the Morgan Stanley Conferences also in New York on September 11. So that concludes our call for today. I'll now tu",55,"Thanks, Steve. And just a couple of calendar items. We'll be at the Robert W. Baird Health Care Conference in New York on September 5 and at the Morgan Stanley Conferences also in New York on September 11. So that concludes our call for today. I'll now turn it back to the operator. Thank you."
24809,212451049,332207,"AmerisourceBergen Corporation, Q3 2012 Earnings Call, Jul 26, 2012",2012-07-26,"Earnings Calls","Cencora, Inc.","Operator","Thank you. Ladies and gentlemen, this conference will be made available for replay today after 1:00 p.m. Eastern time through August 2 at midnight. You may access the AT&T teleconference replay system at any time by dialing 1 (800) 475-6701 and entering t",78,"Thank you. Ladies and gentlemen, this conference will be made available for replay today after 1:00 p.m. Eastern time through August 2 at midnight. You may access the AT&T teleconference replay system at any time by dialing 1 (800) 475-6701 and entering the access code 253858. International participants may dial (320) 365-3844. The access code is 253585. That concludes our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to ABC Fourth Quarter Earnings Conference Call. [Operator Instructions] And also as a reminder, today's teleconference is being recorded. At this time, we will turn the conference over to your h",47,"Ladies and gentlemen, thank you for standing by, and welcome to ABC Fourth Quarter Earnings Conference Call. [Operator Instructions] And also as a reminder, today's teleconference is being recorded. At this time, we will turn the conference over to your host, Ms. Barbara Brungess. Please go ahead."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Tony. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fourth quarter and fiscal year 2012 results. I am Barbara Brungess, Vice President, Corporate and Investor Relations, and joining me today ar",166,"Thank you, Tony. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fourth quarter and fiscal year 2012 results. I am Barbara Brungess, Vice President, Corporate and Investor Relations, and joining me today are Steve Collis, AmerisourceBergen President and CEO; and Tim Guttman, Senior Vice President and CFO. 
During the conference call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011. 
Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by telephone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Barbara, and good morning, everyone. Before we begin, I just want to say a few words about the storm we have all experienced over the last few days. Our thoughts are with all of those who have lost loved ones, those their homes and have otherwi",2502,"Thank you, Barbara, and good morning, everyone. Before we begin, I just want to say a few words about the storm we have all experienced over the last few days. Our thoughts are with all of those who have lost loved ones, those their homes and have otherwise been severely impacted by the storm. I want to thank our ABC associates who have worked highly to ensure that we would continue to be able to meet the needs of our customers and the patients we all ultimately serve throughout this difficult week. 
Turning now to our results. I'm delighted to report solid results for our fourth quarter and our fiscal year 2012. In my first full fiscal year as CEO, we overcame a challenging year-over-year comparison while executing very well on generic conversions. We renewed and expanded our contract with our largest customer, we integrate our 4 acquisitions and we returned funds in excess of free cash flow to shareholders. 
In the September quarter, our revenues were down 4% to $19.5 billion, but our GAAP earnings per share from continuing operations were up 23% to $0.65. For the fiscal year, our revenues were down about 0.5% to $79.5 million, and our earnings per share were up 10% to $2.76, which excludes $0.04 driven by Anderson. I Am very pleased with the performance that AmerisourceBergen associates delivered in fiscal 2012. We executed extremely well against our key strategies of generics and specialty and we are well positioned heading into fiscal 2013. 
In addition, we made important investments in our forward-looking strategies of expanding our manufacture services business and beginning to build out our international platform for growth. 
This morning, we also announced that our Board of Directors approved a 62% increase in our annual dividend and authorized a new $750 million share repurchase program. We completed a $650 million accelerated share repurchase program during this quarter, bringing our repurchases for the fiscal year to nearly $1.2 billion. We are confident to undertaking this capital deployment initiatives due to the tremendous underlying strength and resilience of our business. Since the merger that created AmerisourceBergen, we have generated free cash flow of $8.8 billion. Of this amount, we have returned $6.6 million to investors by share repurchases and $600 million through dividends. In total, we returned 82% of our 11-year free cash flow to our shareholders. Truly outstanding performance for our business.
I am very proud that in fiscal 2012, we generated $1.1 billion in free cash flow, repaid $450 million in debt, completed nearly $800 million in acquisitions and repurchased over $1 billion of our stop. And heading into next year, we continue to have excellent financial flexibility. Our high-quality balance sheet, combined with our ability to generate cash affords us the opportunity to continue to invest in our business, find our strategic initiatives and return value to shareholders. Our legacy of outstanding financial stewardship is one of the bed rocks in the foundation of AmerisourceBergen program and one which gives us a firm footing upon which to grow our business in the years ahead. 
Another important aspect of our financial stewardship has been our careful management of our existing assets, investing in care for receptive to acquisitions and divesting of assets that do not serve our long-term objectives. This morning, we announced that we are pursuing the sale of Anderson, our contract pharmaceutical Packaging business. While Anderson Bracken is a market leader, had excellent customer relationships, talented and dedicated enough associates, has performed well and is on a growth trajectory, we have not realized significant synergies between Alison Bracken and our other larger business. We remain committed to expanding our remaining manufacturer services businesses with a particular focus on expanding our Consulting Services and specialty third-party logistics business in the U.S. and in select global markets. 
The acquisitions we made this year support those efforts and we've made excellent progress on the integrations and all 4 are performing as expected. 
The 2 largest acquisitions, TheraCom and World Courier, made modest contributions to our earnings in fiscal 2012 and are expected to contribute more meaningfully in fiscal 2013. TheraCom's part of whatever fastest growing business to Consulting group, and we expected demand for the services this group provides will increase as manufacturers seek to bring products to market as efficiently as possible and to demonstrate the value of the products in the marketplace. 
The integration of World Courier is also progressing very well and we are pleased with the performance of its core business as it has transitioned to becoming part of AmerisourceBergen. As these 2 businesses have comp together, our cultures and our vision for the future have aligned seamlessly. And I'm more excited than ever about the potential we now have to begin to expand our marketing specialty, 3PL consulting and other manufacture services outside the U.S. 
After a year of substantial change, I believe we are very well positioned to continue to add to our legacy of success and innovation in the years ahead. Our diverse revenue base continues to position us well to benefit from organic growth across the entire spectrum of pharmaceutical care. While overall, pharmaceutical market growth will likely continue to be slowing in calendar 2013, IMS Health sees compounded annual sales growth in the U.S. in the range of 1% to 4% and 4% to 6% worldwide through 2016. We are part of a strong and stable industry and we have demonstrated both resilience and solid performance in a variety of economic and market situations. 
As changes continue to roll across the U.S. health care markets for both our manufacture and health care provider customers, the opportunity for us to provide value should continue to increase. One of the hallmarks of the U.S. market is the quality of our relationships, wholesalers we have with pharmaceutical manufacturers. And we continue to put an emphasis on looking for meaningful ways to provide additional services across the supply channel in order to help them meet the challenges in today's changing health care landscape. 
Just last week, I served on an international wholesale panel at the ISW, International Federation of Pharmaceutical Wholesalers biannual meeting. I was again reminded by listening to the comments of others on the panel about the robust and transparent relationship we are privileged to enjoy with both our provider and manufacturer customers here in the U.S. 
Turning now to our 2 operating segments. Tim will provide the details can see results but I would like to highlight a few key trends. In the pharmaceutical distribution segment, AmerisourceBergen Drug Corporation had a truly stellar year, delivering strong performance on generics and a historic year for new launches. That drug companies performance helped overcome a $0.33 headwind in EPS due to a difficult comparison with specialty generic performance in the prior year. In addition, strong results in our U.S.-based business offset disappointing results in a much more Canadian distribution business. With reimbursement changes challenge the market and further unforeseen reimbursement cuts are on the horizon. 
In addition, we continue to work out some issues with the implementation of our large retail contract. While the distribution marketing candidate is challenged, the small but growing specialty business in Canada continues to gain traction. 
Drug Company revenues in the September quarter declined 8% due in large part to a larger-than-expected decline in sales, our largest customers, as well as the previously reported loss of a large retail customer beginning last September. 
For fiscal year 2012, the drug companies revenues are down 2%, somewhat lower than anticipated. However, when adjusting for non-recurring items, the Drug Company demonstrated disciplined expense management, gross margin expansion and she can't operating margin expansion. In addition we renewed and expanded the contract with our largest customer and began to serve a significantly higher volume with their customer beginning on October 1. As you would expect with ABC, the conversion has proceeded very well and we are excited about the relationship we are developing with our largest customer. 
Given the difficult generic comparison we will have in the Drug Company in fiscal year 2013, we are optimizing our resources to ensure that they are deployed and utilized in a most efficient manner possible. Some of those efforts resulted in a severance charge as we reported in our fourth quarter. One example is that we are leveraging some of the efficiencies gained through the ASP implementation particularly in back-office and adversative areas, which has allowed us to reduce the number of our Drug Company operating regions from 4 to 3 regions. As you would expect, we continue to look at ways to streamline our operations but we never sacrifice our ability to provide world-class service to our customers. 
Another example of where we continue to invade is in our Good Neighbor Pharmacy program, which is the largest independent network of community pharmacies in the U.S. We believe our pharmacy customers play a critical role in the health care throughout the company country by offering a compelling value position to patients and payers alike. We negotiate on behalf of GFP members to ensure that they continue to have access to third-party networks. Looking ahead, we are working with GFP number shortstop them ensure they are able to take full advantage of the expansion of health care under the health reform legislation. The Drug Company has performed admirably over the last few years while the overall market is inflected down. 
The implementation of our SAP platform continues on schedule with 20 distribution center conversions complete and 6 remaining. We have made excellent progress and we expect the remaining conversions to be completed by the end of the March quarter in 2013. We are confident that these and other investments will continue to meaningfully increase the value we bring to all of our customers. 
The Drug Company is, and always will be, the foundation of AmerisourceBergen Corporation. The excellent consistent financial operative performance it has achieved over the years and the resilience it has demonstrated are hallmarks of the value we provide. Furthermore, the Drug Company is the key driver in our ability to generate tremendous cash flow and as such, enables us to fund our growth initiatives. We take deep pride in this business and while it's performance in fiscal 2013 would be quite as strong as it has been historically, we expect it to return to its normal growth rate in fiscal 2014 and beyond. 
AmerisourceBergen's Specialty Group had another strong quarter with revenues up 6% in the quarter, which led to record revenue for the full fiscal year 2012. Revenue growth was driven by another particularly strong performance in third-party logistics and our vaccine and physician distribution business. Our oncology business performed well at a difficult comparison. We were, however, somewhat disappointed in the processing of our in release in mid-August. ABSG to continue to benefit, however, from the launch of a branded ophthalmology product earlier this year, continuing to help establish significant market share for the manufacturer. Our success in ophthalmology market demonstrates the unique value proposition of our specialty franchise. While our undisputed strength in specialties and oncology business, we have expanded those capabilities to become an instrumental part of the commercialization strategy for any complex products launch into the physician marketplace and beyond. 
Our Consulting Services group achieved strong results for the fiscal year, as demand for commercialization, reimbursement and patient support services continues to be robust. We believe this compound service offerings distinguished AmerisourceBergen in the marketplace and will be an important driver of our growth going forward. As manufacturers seek to bring new products to market, we expect sales of existing products in a challenging health care environment, we believe demand for these services will only increase. 
In terms of financial performance, the Consulting group delivered a solid quarter while making excellent progress in the integration of TheraCom, which is performing well. Even setting aside the contribution from TheraCom, the last group alone had outstanding results. 
As Tim will detail, the solid performance across our business once again contributed to excellent cash flow in the quarter. Given the strength of our balance sheet, we continue to explore opportunities to deploy our capital in order to increase shareholder value, including searching for acquisitions that meet the criteria we've had in place for quite some time. That should increase our value offering to existing customers both up and down the channel. That should be within our established core competency and that should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions and we continue to be interested in opportunities in pharmaceutical and Specialty Distribution and Services, as well as Consulting Services. 
We also remain committed to returning a minimum of 30% of our free cash flow to shareholders in the form of dividends and share repurchases. A hurdle that we have exceeded over the last several years. 
Looking ahead, our performance in fiscal 2012 sets us up very well for continued success in fiscal 2013. As we stated in our press release, our guidance for GAAP EPS growth from continued operations in fiscal 2013 is to be in the range of $3.06 $3.16, an 11% to 14% increase over the $2.76 that we earned in fiscal 2012, excluding, of course, the contribution from Anderson bracken. Tim will provide the details in our assumptions for next year but I would like to hide it but we continue to tremendous financial flexibility. We are undertaking initiatives across our business to help ensure that we are efficient and effective as we can possibly be. 
The enormous strength and resilience of our business and that year's significant change at AmerisourceBergen and for the health care industry more broadly, reinforces my confidence in the long-term prospects for our business. 
Demand is strong and growing for the core products we distribute and we play an essential role in the pharmaceutical supply chain, ensuring the integrity and security of the distribution of life-improving and life-saving therapies. Over the last year, we've made important investments in our future while we continued to focus on helping our customers and ourselves take advantage of the unprecedented growth in generics and the many opportunities in specialty. 
Our distribution business is not only a cornerstone of AmerisourceBergen, but it's a cornerstone in a stable and growing industry. Our manufacturer service businesses help ensure products get to market as efficiently as possible and that patient have access to both traditional medications in the most innovative and complex products. 
Lastly, I believe that we both have an exceptional management team with a diverse background and deep experience that is excited about the opportunities we have in front of us. The knowledge, passion and creativity our associates bring to the market each day set us apart from our peers. I think them all for the work they do to continue to drive innovative solutions in a dynamic environment. I am proud to be their leader. Here is Tim."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and thanks, everyone, for joining us today. We had a solid finish to what has been a good year. We're pleased with our financial results and we have momentum entering our new fiscal year. So let's start with our review of fiscal 2012. We wi",2400,"Thanks, Steve, and thanks, everyone, for joining us today. We had a solid finish to what has been a good year. We're pleased with our financial results and we have momentum entering our new fiscal year. So let's start with our review of fiscal 2012. We will compare our performance against the guidance we gave back in July when we discussed Q3 results. 
Our revenue expectation for fiscal 2012 was flat to modest growth. We were off a little bit. We finished down about 0.5%. This was due primarily to sales to our largest customer being lower than what we estimated. This decrease was offset by revenues from our 2 large acquisitions, TheraCom and World Courier. 
In fiscal 2012, our operating margin expanded by 10 basis points, which was slightly above our expectation. This is the seventh consecutive year of expanded our operating margins. 
Free cash flow, we have $1.1 billion in free cash flow for the year, and this exceeded our expectation of $800 million to $900 million. Finally, our GAAP diluted EPS entered a $2.80, a 10% increase over our GAAP EPS from fiscal 2011. This EPS amount includes $0.04 from Anderson Bracken, which we classified as a discontinued operation. As Steve mentioned, we plan to divest the business within the next 6 months. 
You may recall that our guidance assume $20 million of nonrecurring charges for the fiscal year. Our $2.80 GAAP EPS includes $31 million of nonrecurring charges. That's $11 million higher than we expected in the equivalent of $0.03. Excluding this $0.03 negative impact, our EPS results for the fiscal year would have been $2.83. 
One more important item, cash deployment. As Steve mentioned, our board approved a 62% increase in our annual dividend per share, $0.84. Why do we increase our diluted now? Three reasons. One, the long-term financial outlook for our core distribution business continues to be very positive; two, we expect growing contributions from our recent acquisition; and three, we continue to generate consistent, significant, free cash flow. 
We were pleased that we can provide added value to shareholders. Looking ahead, we expect to grow our annual dividend approximately in line with our earnings growth. We believe that our business will generate enough excess capital to continue with meaningful share repurchases and, at the same time, to have flexibility to complete acquisitions in the strategic areas that we've discussed in the past. 
We also announced that we completed an accelerated share repurchase for nearly $650 million, about 17 million shares. Additionally, our board approved a new share repurchase authorization of $750 million. We still have about $97 million remaining on our May 2012 authorization. In total, we had approximately $850 million remaining on share repurchase authorizations. 
Now let's move to our fourth quarter results, starting with the top line. Revenues were $19.5 billion, down 4.4% compared to last year's quarter. Drug Company revenues were down about 8% and were partially offset by and specialty revenues that were up nearly 6%. Our acquisitions contributed a combined $335 million of new revenues. 
Gross profit was approximately $720 million in the quarter, up 19% from last September with a gross margin of 3.70%. Our acquisitions, primarily World Courier, contributed $76 million in the current quarter. We also benefited from a $15 million of antitrust settlements. We consider this income nonrecurring. 
Finally, in the quarter, we have a LIFO credit of $11 million. This credit reduced our fiscal year LIFO charge to about $1 million less than we expected. Two factors contributed to our fourth quarter LIFO credit: One, our sales of brand inventory were especially high at the end of the quarter due to the purchasing patterns of a few large customers; and two, our mix of inventory was weighted heavily towards generic inventory at our LIFO calculation date. 
Let's move to operating expenses. This quarter, operating expenses were $423 million, up 15%. This amount includes $65 million related to the operating expenses of our acquired companies. Also included is $29 million of nonrecurring charges related to optimizing our field operations and corporate organization. As you come to expect from ABC, we continue to manage our expenses tightly. Excluding acquisitions and non-recurring costs, our comparable operating expenses would have decreased about $10 million or 3% compared to the same quarter last year. 
Operating income of $296 million in the quarter increased about 25%. Our operating margin was 1.52%, up by 35 basis points compared to last September quarter. When excluding the nonrecurring items from both the fourth quarter 2012 and 2011, our operating income is up $44 million or 16%. This growth demonstrates our strong performance in our core drug business, as well is contributions from our acquisitions. 
Moving below the operating income line. Interest expense of approximately $24 million in the September quarter increased 22% compared to last year. This is a result of issuing new Senior Notes back in mid-November. As a reminder, we repaid $400 million of debt in September 2012. 
Moving to income taxes. We had an increase in our effective income tax rate in the current quarter to 41.6%. This rate is higher than our normal tax rate of 38.6%. The primary reason for the increase is that we recorded a tax valuation allowance against our Canadian drug distribution business due to their operating loss. Going forward, we expect our ABC annualized tax rate to be about 39%. 
Our GAAP diluted earnings per share in the quarter of $0.66 increased by $0.12 or 22% over the same quarter last year. In the current quarter, again, the negative impact of non-recurring items was $0.03. Our EPS benefited from a 9% reduction in average diluted shares outstanding. At September 30, 2012, we had 235 million outstanding shares. 
Let's spend a few minutes discussing our segment results for the September quarter. Starting with pharmaceutical distribution. Total revenues were $19.1 billion, down just under 6% versus the same quarter last year. Drug Company revenues were down about 8%. The decrease was due to 3 primary drivers: One, branded generic conversions offset by very strong brand price appreciation; two, lower sales to our largest customers; and three, the negative impact from the loss of the pharma long-lost drugs last year about $400 million. 
Specialty Group's revenues increased 6%, led by strong performance in 3 of its businesses with growth significantly above market rates especially medical, ESD and ICS. Pharmaceutical distribution gross profit increased about $33 million when comparing the fourth quarter of 2012 to the same quarter last year. And our growth gross profit margin increased 35 basis points to 3.23%. Most of the increase is due to our Drug Company business where we had strong generic revenue percentage growth in the low teens, due in part to 3 meaningful launches in the quarter. This segment also benefited from the LIFO credit. 
As expected, we did see gross profit dollars associated with specialty oncology generic drugs decreased substantially specifically docetaxel, a negative impact of $0.06. We did have a minimal positive impact from the relaunch of Oxaliplatin, below expectations due to market pricing. This segment managed operating expenses very effectively. Overall, expense has decreased approximately $11 million or 3%. We continue to review spending in our distribution businesses to ensure we're at appropriate levels. 
Pharmaceutical distribution operating income grew 16% or nearly $44 million to $308 million in the fourth quarter of 2012. The increase was primarily the result of strong performance in our Drug Company business, which offset disappointing results in our Canadian distribution business. Overall, we're very pleased with the operating results for this segment. 
Moving to the other reporting segment. As a reminder, this segment is comprised of Consulting Services and World Courier. TheraCom, our November 2011 acquisition, is included in Consulting Services. As discussed previously, our Anderson Bracken Packaging business has been excluded since this business is reported now as a discontinued operation. Segment revenues increased nearly $350 million to $422 million in the fourth quarter 2012. As mentioned previously, World Courier and TheraCom accounted for nearly $335 million of this increase. The revenues are tracking well against our expectations. 
Operating income increased $21 million for the same quarter. About $6.5 million of the increase is related to an intangible impairment expense we incurred in the fourth quarter 2011 in one of our consulting businesses. Our acquisitions contributed about $0.02 to our Q4 2012 EPS. 
Let's switch to our fiscal year performance. I'll highlight a few key points. Back at Investor Day, we discussed the large negative headwind from Oxaliplatin that we've had this fiscal year, about $100 million of loss gross profit. Our Drug Company business more than offset this headwind. This year, they launched over 30 generic drugs, negotiated a number of sizable contracts, managed expenses tightly and implemented SAP in 16 DCs. On a fiscal year basis, Drug Company, excluding Canada, grew their operating margin a very strong 18 basis points. And finally, it was a record revenue year for our Specialty business, $16.4 billion of total revenues, a lot to be pleased about. 
Now let's turn to our balance sheet and cash flows. Capital expenditures were $164 million for the year, lower than expectations as a large DC automation project is shifting to fiscal 2013. Free cash flow was $1.1 billion, better than expected. This is our ninth straight year where free cash flow exceeded our net income from continuing operations. The increase was primarily due to improved committed capital at our specialty business where certain manufacturers provide extended payment terms. 
Our gross debt to total debt in capital ratio at the end of September was 37%, which is slightly higher than our target range of 30% to 35%. This is due to accelerating our share repurchases. This percentage will gradually decrease during the year. During this fiscal year, we bought back just under $1.2 billion of our shares. This amount far exceeds our original guidance of $400 million for the year. Our philosophy has consistently been to gives upsize return to shareholders if we haven't otherwise deployed our capital and when market conditions permit. We're pleased that we have continued with this practice in fiscal 2012. Our cash balance of about $1.1 billion at September 30 leaves us with financial flexibility as we move forward. 
Now let's turn to expectations for 2013, EPS. We expect GAAP diluted EPS from continuing operations to be in the range of $3.06 to $3.16. This translates to EPS growth of 11% to 14%. We're using $2.76 as our base EPS. This number excludes the $0.04 from the AndersonBrecon discontinued operations. 
Revenues. We expect revenue growth to be in the 6% to 9% range driven primarily by our new Express Scripts contract. This customer will represent just over 20% of our revenues. As a comparison, the Pharma Medco represented nearly 17% of our revenues in fiscal 2012. 
Operating income. As discussed in the past, our Express Scripts business is for brand drugs and is bolt like in nature, meaning that the business very low operating income margin. Our operating margin assumption also includes the loss of a large food drug combo retail buying group during the year. And most importantly, fewer oral solid generic launches. 
In terms of operating expenses, excluding nonrecurring expenses, we expect operating expenses to increase 12% to 14% in fiscal 2013. However, most of these increase is related to the full year impact of World Courier. Excluding this impact, our growth in OpEx is primarily due to cost to service our large customer and general wage and benefit inflation, offset by cost savings from our network and corporate optimization efforts. Again, our current assumptions do not include any meaningful nonrecurring expenses for fiscal 2013. 
The items that I just covered all impact our operating impact and margin. For fiscal 2013, we expect our operating impact dollars to grow 3% to 5% while our operating income margin will decrease in the low double-digit basis point range, probably in the low teens. 
Free cash flow. We expect that our free cash flow will be in the $750 million to $850 million range. Capital expenditures should be in the $180 million range with less ERP spend but new spending on a number of business initiatives. 
Share repurchases. We are assuming at least $200 million in share repurchases. The lower amount is due to ABC completing an ASR in Q4 2012. 
Let's transition and cover high-level expectations on our segment. We can start with pharmaceutical distribution. For the Drug Company, we expect revenues to grow in the 6% to 9% range, again, due primarily to the new Express Scripts contract. On the Specialty side, we expect to grow in the 7% to 9% range, which is considerably above market growth. This includes solid growth in our oncology drug business. 
Our segment operating income margin will decline in the mid double-digit basis point range. Again, this decrease is due to our new Express Scripts contract that significantly increases our mix of lower margin brand business, the impact of previously discussed customer contract renewals and fewer generics lunching year-over-year. It is important to note that after we anniversary the impact of the Express Scripts contract, we expect to return to our normal pace of annual operating income margin expansion. 
Moving to the Other segment. Revenues will increase significantly as we have World Courier for the full year versus the 5 months in fiscal year 2012. This should benefit the Other segment by about $300 million. Combined, the Consulting group and World Courier are expected to contribute 8% to 10% of our total operating income in fiscal 2013. As a reminder, we do not give quarterly guidance but I will say that directionally, our EPS growth will be higher in quarters 3 and 4. As you know, Q2 is traditionally our strongest EPS quarter but we will have a tough comparative against Q2 2012 due to the contributions from generic, Lipitor and Zyprexa. 
I know that our comments today were longer than usual due to all the moving parts, so thanks for your attention. And let me finish by reiterating we're pleased with our results for the quarter and the year. We expect solid performance in fiscal 2013 and a challenging year for generic launches. And we're working on a number of internal initiatives to streamline and strengthen our business. The future continues to look very bright for AmerisourceBergen. 
Now here's Barbara for Q&A."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Tim. We'll now open the call to questions. [Operator Instructions] Go ahead, please, Tony.",16,"Thank you, Tim. We'll now open the call to questions. [Operator Instructions] Go ahead, please, Tony."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] We'll take our first question in queue from Bob Willoughby with Bank of America Merrill Lynch.",18,"[Operator Instructions] We'll take our first question in queue from Bob Willoughby with Bank of America Merrill Lynch."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","I heard somebody say that the larger purchase of branded drugs by a particularly large customer as the reason for the LIFO charges, I guess. And I'm just kind of curious if it's bulk customer predominantly, does that purchases buyback customer impact your",49,"I heard somebody say that the larger purchase of branded drugs by a particularly large customer as the reason for the LIFO charges, I guess. And I'm just kind of curious if it's bulk customer predominantly, does that purchases buyback customer impact your LIFO assumptions on any particular year?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Bob, this is Tim. No, I sited 2 reasons, the larger brand purchases by certain customers, a few of our government customers in particular and then also just a mix of inventory between brand and generic, generic being a little bit the heavier. That impacte",62,"Bob, this is Tim. No, I sited 2 reasons, the larger brand purchases by certain customers, a few of our government customers in particular and then also just a mix of inventory between brand and generic, generic being a little bit the heavier. That impacted. And then in terms of next year, we expect to get back to a modest LIFO charge."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So it didn't sound like that in itself was a particular.",12,"Okay. So it didn't sound like that in itself was a particular."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","No, it wasn't.",3,"No, it wasn't."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And just broadly speaking maybe for Steve, what kind of competition are you seeing from a business model perspective given your share on the oncology market, what kind of new entrants or challenges are you seeing in that business?",40,"Okay. And just broadly speaking maybe for Steve, what kind of competition are you seeing from a business model perspective given your share on the oncology market, what kind of new entrants or challenges are you seeing in that business?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, we've been the leader in oncology for several years and we still retain that position. I think we have really bolt up some unique drivers for value with our physician services organization. I think we've built up on non-oncology businesses, very pro",149,"Well, we've been the leader in oncology for several years and we still retain that position. I think we have really bolt up some unique drivers for value with our physician services organization. I think we've built up on non-oncology businesses, very proud on what be built up to not oncology businesses and that we've integrated a lot of the services, say, from last year and extend and increasing World Courier. And the formative businesses we do with new manufacturers in our, and a lot of the work we do with. And so we got a great franchise and we intend to support it. Just quickly on oncology, I'll tell you one of the things we're focusing on is what we called in hybrid models, which is more oncology taking place within a larger health system and we believe we've got a dynamic role to play there as well."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Other's making any type of inroads or different models you know?",12,"Other's making any type of inroads or different models you know?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","I think obviously we got one company that's trying to get a foothold in specialty, don't want to comment about this but there strategy that we likely we believe we've got the largest community-based oncology, customers that have been loyal customers for a",63,"I think obviously we got one company that's trying to get a foothold in specialty, don't want to comment about this but there strategy that we likely we believe we've got the largest community-based oncology, customers that have been loyal customers for a long time and those discussions tend to be very promising and a lot of commitment to remaining within AmerisourceBergen."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Tom Gallucci with Lazard Capital Markets.",10,"That will come from Tom Gallucci with Lazard Capital Markets."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","This is Colleen Lang on for Tim. Generics are clearly strong in the quarter. Can you talk about the performance generics in Q4 relative to your expectations and what went better?",31,"This is Colleen Lang on for Tim. Generics are clearly strong in the quarter. Can you talk about the performance generics in Q4 relative to your expectations and what went better?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, we really do -- we do focus on our generic offering, I mean, we have really 2 generic offerings approach in, which is our preferred formulary. And we have many customers that take advantage of that and then we also have our non-approach in generic c",69,"Well, we really do -- we do focus on our generic offering, I mean, we have really 2 generic offerings approach in, which is our preferred formulary. And we have many customers that take advantage of that and then we also have our non-approach in generic customers and both segments were very robust. We executed as expected. I don't know, Tim, if you have any color you'd add there."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","We have a couple of generics that launched in the third quarter that rolled in the fourth quarter, plus we had some launches in Q4 that really helped us. And then let's not forget, we had a good base of our generics where we saw expansion that provides be",93,"We have a couple of generics that launched in the third quarter that rolled in the fourth quarter, plus we had some launches in Q4 that really helped us. And then let's not forget, we had a good base of our generics where we saw expansion that provides benefits. And utilization is also up. So I think really all those 4 things together help grow our generic top line. In my comments I said in the low teens, we saw revenue increase. So it was a really good quarter for generics Drug Company."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And then on the branded side, it seems like branded inflation was particularly strong throughout your fiscal 2012. What's your expectations for '13?",25,"Okay, great. And then on the branded side, it seems like branded inflation was particularly strong throughout your fiscal 2012. What's your expectations for '13?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Colleen. It was a strong year. In fact, with our mix inventory, it was a record year for brand inflation and we expect that to continue. Our assumption next year is in the brand inflation in the 8% to 9% range.",42,"Thanks, Colleen. It was a strong year. In fact, with our mix inventory, it was a record year for brand inflation and we expect that to continue. Our assumption next year is in the brand inflation in the 8% to 9% range."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","The next question in queue will come from Robert Jones with Goldman Sachs.",13,"The next question in queue will come from Robert Jones with Goldman Sachs."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Steve, decisions to divest the Packaging business, I was hoping you could share your thoughts in a little bit more detail there. I always understood that a pretty steady high-margin business. I know it's not quarters Specialty Distribution but just wonder",53,"Steve, decisions to divest the Packaging business, I was hoping you could share your thoughts in a little bit more detail there. I always understood that a pretty steady high-margin business. I know it's not quarters Specialty Distribution but just wondering if you could share your thoughts on divesting in this business now?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Bob, you're actually right. The contract Packaging business has been successful and has grown significantly since we established it really about in quite several years ago. The business has always operated as a separate entity while under the ABC umbrella",160,"Bob, you're actually right. The contract Packaging business has been successful and has grown significantly since we established it really about in quite several years ago. The business has always operated as a separate entity while under the ABC umbrella. And while we have been pleased with this performance, we've not really realized that many synergy opportunity between contract packaging and our other lines of business. The way that we've been running the company since I've been CEO, I think we really do look at the company holistically even more so as we react to the marketplace. So I think as we've done some deep analysis, there aren't really enough touch points on the overall business development with manufacturers to warrant pertaining this is a separate entity going forward. And also the business is growing and I think the capital needs there are going to increase and we just see that for better opportunities to invest our capital going forward."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","On the capital deployment going forward actually, is there any change in strategy as we think about the lower buybacks that's baked in for next year? It looks like the free cash flow, $750 million to $800 million, you have $400 million from the buyback an",61,"On the capital deployment going forward actually, is there any change in strategy as we think about the lower buybacks that's baked in for next year? It looks like the free cash flow, $750 million to $800 million, you have $400 million from the buyback and the dividend, any comments on the use of the rest of that cash going forward?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, I'll just tell you. Look at what we have done this year, I could not be more proud. I mean, $800 million in acquisitions I think we're performing more of those acquisitions. If we did well over $1 billion in share buybacks, we're increasing our divi",90,"Well, I'll just tell you. Look at what we have done this year, I could not be more proud. I mean, $800 million in acquisitions I think we're performing more of those acquisitions. If we did well over $1 billion in share buybacks, we're increasing our dividends. So there's not just to like about how ABC uses our capital. I think we are -- among the base of capital that you find an array out there. we will continue to contain our flexibility and use our balance sheet appropriately. Tim?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Yes, I would just echo what Steve said. I think -- I don't think you could regressing on that, as I mentioned in my comments, Bob, we're very consistent. When we have excess cash, we return it some form or fashion. So that's our guidance for now and we th",73,"Yes, I would just echo what Steve said. I think -- I don't think you could regressing on that, as I mentioned in my comments, Bob, we're very consistent. When we have excess cash, we return it some form or fashion. So that's our guidance for now and we think it's pretty reasonable compared with in relation to the ASR. And as we go through the year, we'll just see how we're tracking."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Glen Santangelo with Crdit Suisse.",9,"That will come from Glen Santangelo with Crdit Suisse."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I just want to talk to you a little bit about the pricing environment. Sort of last quarter, you gave us some of the candid assessment of how you view the sell side pricing environment. And I'm just kind of curious now that you've had another quart",74,"Steve, I just want to talk to you a little bit about the pricing environment. Sort of last quarter, you gave us some of the candid assessment of how you view the sell side pricing environment. And I'm just kind of curious now that you've had another quarter under your belt, we've seen some contracts come and go, I'm just kind of curious if you could give us maybe an update or an assessment?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, a couple of things. I mean, we typically about 25% to 30% of our business is up for renewal each year. And last quarter was really unique because eventually the next week, we were able to announce exciting new contract with Express Scripts. And that",128,"Well, a couple of things. I mean, we typically about 25% to 30% of our business is up for renewal each year. And last quarter was really unique because eventually the next week, we were able to announce exciting new contract with Express Scripts. And that was truly unique if you look at the timing of what we were facing tnen. So in that 3 months since we've launched by on the call with you, we've been through several contract negotiations and honestly they've all gone very much as expected. There's just one exception which is a shared customer but I would say that things have really stabilized and that the industry really remains very competitive, stable with more most large customers not really showing to change wholesalers."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","If I could just ask one follow-up on the specialty pharmacy side, as well as sort of the Other segment. Steve, can you maybe give us your view on kind of how we should think about that portion of your business from a growth rate perspective? And as a look",83,"If I could just ask one follow-up on the specialty pharmacy side, as well as sort of the Other segment. Steve, can you maybe give us your view on kind of how we should think about that portion of your business from a growth rate perspective? And as a look out through 2013 and 2014, sort of any potential generic launches on the specialty side that can even come close to sort of rivaling what we saw on Hoxie Gemzar and Taxotere?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, you said specialty pharmacy, so we more are characterized by Specialty Distribution. There is a distinction and specialty pharmacy, of course, is largely carried out by some of the retail change but most notably, the PBMs. And those offer customers",191,"Well, you said specialty pharmacy, so we more are characterized by Specialty Distribution. There is a distinction and specialty pharmacy, of course, is largely carried out by some of the retail change but most notably, the PBMs. And those offer customers for us particularly with AmerisourceBergen Drug Company. But there is more and more the specialty product management taking place within large health systems, within mail order infusion centers. So our specialty pharmacy franchise, specialty distribution franchises a very important character for AmerisourceBergen. I think the way we understand this business both in the community and health systems settings and what we call our open care setting is really a unique characteristics and differentiates us for AmerisourceBergen and I think it leads to some upside performance in areas that you don't traditionally expect us to benefit from specialty, like in our health systems area where we've done very well. And I think you see more and more specialty therapies being administered in health system setting. So, again, we keep on adding to this franchise. We've got excellent leadership year and you'll continue to see us investing and maintaining market leadership there."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Lisa Gill with JPMorgan.",8,"That will come from Lisa Gill with JPMorgan."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Tim, I had a question around your free cash flow guidance. If I look back to last year, the initial guidance was $800 million to $900 million, and you clearly did $1.1 billion. Can you maybe just talk about the $750 million to $850 million this year? Is t",73,"Tim, I had a question around your free cash flow guidance. If I look back to last year, the initial guidance was $800 million to $900 million, and you clearly did $1.1 billion. Can you maybe just talk about the $750 million to $850 million this year? Is there any impact because of the relationship with Express Scripts and inventory? Or is there anything else that's a onetime items for free cash flow?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Liisa. Yes, we do have a slight impact. I mean, on the new contract, our terms, our AR terms are slightly lower than what we had with the former Medco. So that's probably a 1 to 2-day impact. So that's part of the reason why you see that cash a li",71,"Thanks, Liisa. Yes, we do have a slight impact. I mean, on the new contract, our terms, our AR terms are slightly lower than what we had with the former Medco. So that's probably a 1 to 2-day impact. So that's part of the reason why you see that cash a little bit lower. But as always, we're going to work hard to pick that up, but that's in the recent."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","And then just as a follow-on to that just trying understand 2 things. One, is there anything else relationship with Express Scripts. And then second, Steve, charges have a question for you this year hybrid model with the hospitals. Is there any change in",71,"And then just as a follow-on to that just trying understand 2 things. One, is there anything else relationship with Express Scripts. And then second, Steve, charges have a question for you this year hybrid model with the hospitals. Is there any change in that the way that you are being reimbursed or any different level of risk or anything else you are taking on in your specialty distribution business?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Tim, you go first and then I'll...",7,"Tim, you go first and then I'll..."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Right. In terms of, I don't think there's anything else. In terms of the Express Scripts, your first question about nothing else on the Express Scripts contract, no, I don't think there's anything else really to call out. I mean I think we've hit the high",66,"Right. In terms of, I don't think there's anything else. In terms of the Express Scripts, your first question about nothing else on the Express Scripts contract, no, I don't think there's anything else really to call out. I mean I think we've hit the highlights again. That it's pretty much all brand virtually brand and it's a little bit over 20% of our expected revenues."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Look, we had a great relationship with Medco and I think we've made a very profound transition to now servicing the overall Express Scripts contract, which we're pleased to be the wholesale and we continue to work on the strategic relationship. Of course",219,"Look, we had a great relationship with Medco and I think we've made a very profound transition to now servicing the overall Express Scripts contract, which we're pleased to be the wholesale and we continue to work on the strategic relationship. Of course I think the priority for both organizations is being really working on implementing the contract and now we can look forward to broadening and strengthening the relationship over the next couple of quarters. The hybrid model was the second part of your question. And now I think it's just really taking advantage of a lot of the services that we offer to community oncologists, and allowing those services to transition into more of a hospital settings. And think it is also getting some of the manufacturer some of the information that they lack on the patient side and the protocol and formerly management side that we've been able to give them in a community settings. So you're seeing us making investment there but we think that will preserve some of the unique financial, as well as therapeutic characteristics of our oncology business. So very important for us to continue to move with the markets. And again, a great example of how we're looking at the company very holistically and less hard lines between specialty and drug."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Eric Coldwell with Robert W. Baird.",10,"That will come from Eric Coldwell with Robert W. Baird."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","On the loss account that you knowledged on the call today, the regional food pharmacy combo GPO business, I guess. I'm curious if you could help us understand the ultimate revenue impact compared to your -- what your expectations would have been had year",121,"On the loss account that you knowledged on the call today, the regional food pharmacy combo GPO business, I guess. I'm curious if you could help us understand the ultimate revenue impact compared to your -- what your expectations would have been had year retained that? And you did mention that's one of the contributors to the operating margin compression, so should we assume that, that's a higher operating margin contract and perhaps your overall book. And then finally, still sticking with that contract. In terms of the phasing of that loss centers, sometimes with GPO contracts, you don't lose all of the business on day 1. Can you give us some sense on the phasing of the revenue rolling off?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Sure, Eric. I think that is -- if I'm going to right, that's a 3-part question. I mean really the  first one, were not prepared to size that contract. I mean, it was a -- it's a large contract, it's got a nice mix of branded generics business so again, yo",103,"Sure, Eric. I think that is -- if I'm going to right, that's a 3-part question. I mean really the  first one, were not prepared to size that contract. I mean, it was a -- it's a large contract, it's got a nice mix of branded generics business so again, you could definitely say it's more profitable with that brand mix. Part of it will have for about half a year in total. So it doesn't entirely roll off in Q1. We have it through about March quarters so -- but, yes, it definitely impacts -- it's definitely an impact to our margin."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","So, Tim, I'm sorry I guess we'll go to part 4 here, when you say that you have the contract through March, the total contract or a piece of it?",30,"So, Tim, I'm sorry I guess we'll go to part 4 here, when you say that you have the contract through March, the total contract or a piece of it?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","We'll have a piece of it. We'll have a piece of it. There's a piece that comes off in November and the remaining piece will come off in March, I think it's about 60-40.",35,"We'll have a piece of it. We'll have a piece of it. There's a piece that comes off in November and the remaining piece will come off in March, I think it's about 60-40."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Ricky Goldwasser with Morgan Stanley.",9,"That will come from Ricky Goldwasser with Morgan Stanley."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Can you just provide us a more color around fiscal year '13 guidance? And what I'm basically trying to understand is what the contribution of acquisitions? I think you mentioned that operating income in fiscal year '13 is going to growth 3% to 5% but the",70,"Can you just provide us a more color around fiscal year '13 guidance? And what I'm basically trying to understand is what the contribution of acquisitions? I think you mentioned that operating income in fiscal year '13 is going to growth 3% to 5% but the 8% to 10% is going to come from acquisition, so I just wanted to clarify that comment. And then I have one follow-up question."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Let me answer your question this way. Between World Courier and TheraCom, we'll have World Courier for the full year so that. [Technical Difficulty]",24,"Let me answer your question this way. Between World Courier and TheraCom, we'll have World Courier for the full year so that. 
[Technical Difficulty]"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, please standby as we reestablish the phone line.",11,"Ladies and gentlemen, please standby as we reestablish the phone line."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, the phone line has been reestablished [Operator Instructions]",11,"Ladies and gentlemen, the phone line has been reestablished [Operator Instructions]"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay, thanks for your patience, everyone [indiscernible]",7,"Okay, thanks for your patience, everyone [indiscernible]"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","We lost power, our building went down, so apologies, everyone. Getting back to your first question, Ricky, I think you're asking about impact of acquisitions. I'll answer it this way, World Courier and TheraCom should be about 4% to 5% of our EPS in terms",48,"We lost power, our building went down, so apologies, everyone. Getting back to your first question, Ricky, I think you're asking about impact of acquisitions. I'll answer it this way, World Courier and TheraCom should be about 4% to 5% of our EPS in terms of fiscal '13."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So 4% to 5% of EPS is from the acquisition and I think that you provided a comment on the EPS, it was around 3% of 5% from EBIT?",30,"Okay. So 4% to 5% of EPS is from the acquisition and I think that you provided a comment on the EPS, it was around 3% of 5% from EBIT?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","That was correct.",3,"That was correct."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. That is helpful. And then on the -- on your margin expansion guidance and just kind of if I could have made better understand the numbers because as I think about your revenue guidance and you're in the guidance, get to EBIT margin contraction in th",75,"Okay. That is helpful. And then on the -- on your margin expansion guidance and just kind of if I could have made better understand the numbers because as I think about your revenue guidance and you're in the guidance, get to EBIT margin contraction in the mid single digits versus your comments around low double digits, so if you could just help me reconcile the difference, maybe you should just corporate versus drug distribution?"
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Ricky, I guess the best thing I could say on that one is as we get closer to Investor Day, we'll give more specific information my business in terms of margins. But again, let me just say that there is a big impact from the new contract with Express Scrip",110,"Ricky, I guess the best thing I could say on that one is as we get closer to Investor Day, we'll give more specific information my business in terms of margins. But again, let me just say that there is a big impact from the new contract with Express Scripts. We talked just before Eric about we gave some comments Tapco contract, which again the generics, I mean that's a big impact to our margin. And then, clearly, the generic launch is being down. So those 3 items clearly impact our operating income margin. And in fact, cause it to be down like we said in the low double-digit range."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","I think in light of everyone's time, we'll wrap up the call here. Steve has some final closing remarks.",20,"I think in light of everyone's time, we'll wrap up the call here. Steve has some final closing remarks."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Again, sorry for this. And we want really to thank you, Gord attention for today. I hope you find the call helpful and informative. There was a lot of detail provided and we really appreciate your attention, especially with the strong close we have, thank",87,"Again, sorry for this. And we want really to thank you, Gord attention for today. I hope you find the call helpful and informative. There was a lot of detail provided and we really appreciate your attention, especially with the strong close we have, thanks to Sandy. I hope Tim and I conveyed to you our excitement and confidence in our company and I hope you share our firm belief that AmerisourceBergen is a great company to invest in. Thank you, all, and have a great day."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","I just have a couple of closing comments. We'll be holding our Investor Day on December 12 in New York City, there'll be more information about that on our website next week. And the next conference we'll be attending will be the J.P. Morgan Healthcare Co",72,"I just have a couple of closing comments. We'll be holding our Investor Day on December 12 in New York City, there'll be more information about that on our website next week. And the next conference we'll be attending will be the J.P. Morgan Healthcare Conference on January 9 at San Francisco, so thanks very much. And thank you for your attention today. Turn it back to the operator for replay information."
24809,222419523,375167,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","Thank you, and ladies and gentlemen, this conference will be available for replay after 1:00 p.m. today, running through November 8 at midnight. You may access the AT&T executive playback service at anytime by dialing (320) 365-3844, use the access code o",62,"Thank you, and ladies and gentlemen, this conference will be available for replay after 1:00 p.m. today, running through November 8 at midnight. You may access the AT&T executive playback service at anytime by dialing (320) 365-3844, use the access code of 266794. That does conclude your conference call for today. We do thank you for your participation. You may now disconnect."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to ABC Fourth Quarter Earnings Conference Call. [Operator Instructions] And also as a reminder, today's teleconference is being recorded. At this time, we will turn the conference over to your h",47,"Ladies and gentlemen, thank you for standing by, and welcome to ABC Fourth Quarter Earnings Conference Call. [Operator Instructions] And also as a reminder, today's teleconference is being recorded. At this time, we will turn the conference over to your host, Ms. Barbara Brungess. Please go ahead."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Tony. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fourth quarter and fiscal year 2012 results. I am Barbara Brungess, Vice President, Corporate and Investor Relations, and joining me today ar",166,"Thank you, Tony. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fourth quarter and fiscal year 2012 results. I am Barbara Brungess, Vice President, Corporate and Investor Relations, and joining me today are Steve Collis, AmerisourceBergen President and CEO; and Tim Guttman, Senior Vice President and CFO.
During the conference call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011.
Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the expressed permission of the company. As always, those connected by telephone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Barbara, and good morning, everyone. Before we begin, I just want to say a few words about the storm we have all experienced over the last few days. Our thoughts are with all of those who have lost loved ones, lost their homes and have otherwis",2519,"Thank you, Barbara, and good morning, everyone. Before we begin, I just want to say a few words about the storm we have all experienced over the last few days. Our thoughts are with all of those who have lost loved ones, lost their homes and have otherwise been severely impacted by the storm. I want to thank our ABC associates who have worked tirelessly to ensure that we would continue to be able to meet the needs of our customers and the patients we all ultimately serve throughout this difficult week.
Turning now to our results. I'm delighted to report solid results for our fourth quarter and our fiscal year 2012. In my first full fiscal year as CEO, we overcame a challenging year-over-year comparison while executing very well on generic conversions. We renewed and expanded our contract with our largest customer, we integrated 4 acquisitions and we returned funds in excess of our free cash flow to shareholders.
In the September quarter, our revenues were down 4% to $19.5 billion, but our GAAP earnings per share from continuing operations were up 23% to $0.65. For the fiscal year, our revenues were down about 0.5% to $79.5 billion, and our earnings per share were up 10% to $2.76, which excludes $0.04 earned by AndersonBrecon. I'm very pleased with the performance that AmerisourceBergen associates delivered in fiscal 2012. We executed extremely well against our key strategies of generics and specialty, and we are well positioned heading into fiscal 2013.
In addition, we made important investments in our more forward-looking strategies of expanding our manufacture services businesses and beginning to build out our international platform for growth.
This morning, we also announced that our Board of Directors approved a 62% increase in our annual dividend and authorized a new $750 million share repurchase program. We completed a $650 million accelerated share repurchase program during this quarter, bringing our repurchases for the fiscal year to nearly $1.2 billion. We are confident undertaking this capital deployment initiatives due to the tremendous underlying strength and resilience of our business. Since the merger that created AmerisourceBergen, we have generated free cash flow of $8.8 billion. Of this amount, we have returned $6.6 billion to investors by share repurchases and $600 million through dividends. In total, we returned 82% of our 11-year free cash flow to our shareholders. Truly outstanding performance for our business.
I am very proud that in fiscal 2012, we generated $1.1 billion in free cash flow, repaid $450 million in debt, completed nearly $800 million in acquisitions and repurchased over $1 billion of our stock. And heading into next year, we continue to have excellent financial flexibility. Our high-quality balance sheet, combined with our ability to generate cash, affords us the opportunity to continue to invest in our business, find our strategic initiatives and return value to shareholders. Our legacy of outstanding financial stewardship is one of the bedrocks in the foundation of AmerisourceBergen and one which gives us a firm footing upon which to grow our business in the years ahead.
Another important aspect of our financial stewardship has been our careful management of our existing assets, investing in care for these selected acquisitions and divesting of assets that do not serve our long-term objectives. This morning, we announced that we are pursuing the sale of AndersonBrecon, our contract pharmaceutical packaging business. While AndersonBrecon is a market leader, has excellent customer relationships, talented and dedicated associates, has performed well and is on a growth trajectory, we have not realized significant synergies between AndersonBrecon and our other lines of business. We remain committed to expanding our remaining manufacture services businesses with a particular focus on expanding our Consulting Services and specialty third-party logistics business in the U.S. and in select global markets.
The acquisitions we've made this year support those efforts and we've made excellent progress on the integrations, and all 4 are performing as expected.
The 2 largest acquisitions, TheraCom and World Courier, made modest contributions to our earnings in fiscal 2012 and are expected to contribute more meaningfully in fiscal 2013. TheraCom is part of one of our fastest growing business units, the Consulting Group. And we expect the demand for the services that this group provides will increase as manufacturers seek to bring products to market as efficiently as possible and to demonstrate the value of the products in the marketplace.
The integration of World Courier is also progressing very well, and we are pleased with the performance of its core business as it is transitioned to becoming part of AmerisourceBergen. As these 2 businesses have come together, our cultures and our vision for the future have aligned seamlessly. And I'm more excited than ever about the potential we now have to begin to expand our marketing specialty, 3PL consulting and other manufacture services outside the U.S.
After a year of substantial change, I believe we are very well positioned to continue to add to our legacy of success and innovation in the years ahead. Our diverse revenue base continues to position us well to benefit from organic growth across the entire spectrum of pharmaceutical care. While overall, pharmaceutical market growth will likely continue to be slow in calendar 2013, IMS Health sees compounded annual sales growth in the U.S. in the range of 1% to 4% and 4% to 6% worldwide through 2016. We are part of a strong and stable industry, and we have demonstrated both resilience and solid performance in a variety of economic and market situations.
As changes continue to roll across the U.S. health care markets for both our manufacture and health care provider customers, the opportunity for us to provide value should continue to increase. One of the hallmarks of the U.S. market is the quality of our relationships wholesalers have with pharmaceutical manufacturers. And we continue to put an emphasis on looking for meaningful ways to provide additional services across the supply channel in order to help them meet the challenges in today's changing health care landscape.
Just last week, I served on an international wholesale panel at the IFPW, the International Federation of Pharmaceutical Wholesalers biannual meeting. I was again reminded by listening to the comments of others on the panel about the robust and transparent relationship we are privileged to enjoy with both our provider and manufacturer customers here in the U.S.
Turning now to our 2 operating segments. Tim will provide the detailed financial results, but I would like to highlight a few key trends. In the pharmaceutical distribution segment, AmerisourceBergen Drug Corporation had a truly stellar year, delivering strong performance on generics in a historic year for new launches. The Drug Company's performance helped overcome a $0.33 headwind in EPS due to a difficult comparison with specialty generic performance in the prior year. In addition, strong results in our U.S.-based business offset disappointing results in our much more like Canadian distribution business where reimbursement changes have challenged the market and further unforeseen reimbursement cuts are on the horizon.
In addition, we continue to work out some issues with the implementation of our large retail contract. While the distribution marketing in Canada is challenged, the small but growing specialty business in Canada continues to gain traction.
Drug Company revenues in the September quarter declined 8% due in large part to a larger than expected decline in sales of our largest customer, as well as the previously reported loss of a large retail customer beginning last September.
For fiscal year 2012, the Drug Company's revenues are down 2%, somewhat lower than anticipated. However, when adjusting for nonrecurring items, the Drug Company demonstrated disciplined expense management, gross margin expansion and significant operating margin expansion. In addition, we renewed and expanded the contract with our largest customer and began to serve a significantly higher volume with their customer beginning on October 1. As you would expect with ABC, the conversion has proceeded very well, and we are excited about the relationship we are developing with our largest customer.
Given the difficult generic comparison we will have in the Drug Company in fiscal year 2013, we are optimizing our resources to ensure that they are deployed and utilized in a most efficient manner possible. Some of those efforts resulted in the severance charges we recorded in our fourth quarter. One example is that we are leveraging some of the efficiencies gained through the SAP implementation, particularly in back-office administrative areas, which has allowed us to reduce the numbers of our Drug Company operating regions from 4 to 3 regions. As you would expect, we continue to look at ways to streamline our operations, but we never sacrifice our ability to provide world-class service to our customers.
Another example of where we continue to invade is in our Good Neighbor Pharmacy program, which is the largest independent network of community pharmacies in the U.S. We believe our pharmacy customers play a critical role in the health care throughout the country by offering a compelling value proposition to patients and payers alike. We negotiate on behalf of GNP members to ensure that they continue to have access to third-party networks. Looking ahead, we are working with GNP members towards in order to help them ensure they are able to take full advantage of the expansion of health care under the health reform legislation. The Drug Company has performed admirably over the last few years while the overall market is inflected down.
The implementation of our SAP platform continues on schedule with 20 distribution center conversions complete and 6 remaining. We have made excellent progress, and we expect the remaining conversions to be completed by the end of the March quarter in 2013. We are confident that these and other investments will continue to meaningfully increase the value we bring to all of our customers.
The Drug Company is and always will be the foundation of AmerisourceBergen Corporation. The excellent and consistent financial and operating performance it has achieved over the years and the resilience it has demonstrated are hallmarks of the value we provide. Furthermore, the Drug Company is a key driver in our ability to generate tremendous cash flow and as such, enables us to fund our growth initiatives. We take deep pride in this business, and while it's performance in fiscal 2013  won't be quite as strong as it has been historically, we expect it to return to its normal growth rate in fiscal 2014 and beyond.
AmerisourceBergen's Specialty Group had another strong quarter with revenues up 6% in the quarter, which led to record revenue for the full fiscal year 2012. Revenue growth was driven by another particularly strong performance in third-party logistics and in our vaccine and physician distribution business. Our oncology business performed well at a difficult comparison. We were, however, somewhat disappointed in the processing of our Oxaliplatin during its release in mid-August.
ABSG thus continue to benefit, however, from the launch of a branded ophthalmology product earlier this year, continuing to help establish significant market share for the manufacturer. Our success in the ophthalmology market demonstrates the unique value proposition of our specialty franchise while our undisputed strength in specialty is our  oncology business. We've expanded those capabilities to become the instrumental part of the commercialization strategy for any complex product launched into the physician marketplace and beyond.
Our Consulting Services group achieved strong results for the fiscal year as demand for commercialization, reimbursement and patient support services continues to be robust. We believe this compound service offerings distinguish AmerisourceBergen in the marketplace and will be an important driver of our growth going forward. As manufacturers seek to bring new products to market, we'll expand sales of existing products in a challenging health care environment. We believe the demand for these services will only increase.
In terms of financial performance, the Consulting group delivered a solid quarter while making excellent progress in the integration of TheraCom, which is performing well. Even setting aside the contribution from TheraCom, the Lash group alone had outstanding results.
As Tim will detail, the solid performance across our business once again contributed to excellent cash flow in the quarter. Given the strength of our balance sheet, we continue to explore opportunities to deploy our capital in order to increase shareholder value, including searching for acquisitions that meet the criteria we've had in place for quite some time. That should increase our value offering to existing customers both up and down the channel. That should be within our established core competency and that should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions, and we continue to be interested in opportunities in the pharmaceutical and Specialty Distribution and Services, as well as Consulting Services.
We also remain committed to returning a minimum of 30% of our free cash flow to shareholders in the form of dividends and share repurchases, a hurdle that we have handily exceeded over the last several years.
Looking ahead, our performance in fiscal 2012 sets us up very well for continued success in fiscal 2013. As we stated in our press release, our guidance for GAAP EPS growth from continued operations in fiscal 2013 is to be in the range of $3.06 to $3.16, an 11% to 14% increase over the $2.76 that we earned in fiscal 2012, excluding, of course, the contribution from AndersonBrecon.
Tim will provide the details and our assumptions for next year, but I want to highlight that we continue to have tremendous financial flexibility, we are undertaking initiatives across our entire business to help ensure that we are as efficient and effective as we can possibly be.
The enormous strength and resilience of our business in a year of significant change for AmerisourceBergen and for the health care industry more broadly, reinforces my confidence in the long-term prospects for our business.
Demand is strong and growing for the core products we distribute, and we play an essential role in the pharmaceutical supply chain, ensuring the integrity and security of the distribution of life-improving and life-saving therapies.
Over the last year, we've made important investments in our future while we continue to focus on helping our customers and ourselves take advantage of the unprecedented growth in generics and the many opportunities in specialty.
Our distribution business is not only a cornerstone of AmerisourceBergen, but it's a cornerstone in a stable and growing industry. Our manufacture services businesses help ensure products get to market as efficiently as possible and that patients have access to both traditional medications in the most innovative and complex products.
Lastly, I believe that we have both an exceptional management team with a diverse background and deep experience that is excited about the opportunities we have in front of us. The knowledge, passion and creativity our associates bring to the market each day set us apart from our peers. I thank them all for the work they do to continue to drive innovative solutions in a dynamic environment. I am proud to be their leader. Here is Tim."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and thanks, everyone, for joining us today. We had a solid finish to what has been a good year. We're pleased with our financial results, and we have momentum entering our new fiscal year. So let's start with our review of fiscal 2012. We w",2394,"Thanks, Steve, and thanks, everyone, for joining us today. We had a solid finish to what has been a good year. We're pleased with our financial results, and we have momentum entering our new fiscal year. So let's start with our review of fiscal 2012. We will compare our performance against the guidance we gave back in July when we discussed Q3 results.
Our revenue expectation for fiscal 2012 was flat to modest growth. We were off a little bit. We finished down about 0.5%. This was due primarily to sales to our largest customer being lower than what we estimated. This decrease was offset by revenues from our 2 large acquisitions, TheraCom and World Courier.
In fiscal 2012, our operating margin expanded by 10 basis points, which was slightly above our expectation. This is the seventh consecutive year we expanded our operating margins.
Free cash flow. We have $1.1 billion in free cash flow for the year, and this exceeded our expectation of $800 million to $900 million. Finally, our GAAP diluted EPS entered a $2.80, a 10% increase over our GAAP EPS from fiscal 2011. This EPS amount includes $0.04 from AndersonBrecon, which we classified as the discontinued operation. As Steve mentioned, we plan to divest the business within the next 6 months.
You may recall that our guidance assume $20 million of nonrecurring charges for the fiscal year. Our $2.80 GAAP EPS includes $31 million of nonrecurring charges. That's $11 million higher than we expected and the equivalent of $0.03. Excluding this $0.03 negative impact, our EPS results for the fiscal year would have been $2.83.
One more important item, cash deployment. As Steve mentioned, our board approved a 62% increase in our annual dividend per share, $0.84. Why do we increase our dividend now? Three reasons: One, the long-term financial outlook for our core distribution business continues to be very positive; two, we expect growing contributions from our recent acquisitions; and three, we continue to generate consistent, significant, free cash flow.
We were pleased that we can provide added value to shareholders. Looking ahead, we expect to grow our annual dividend approximately in line with our earnings growth. We believe that our business will generate enough excess capital to continue with meaningful share repurchases and at the same time, to have flexibility to complete acquisitions in the strategic areas that we've discussed in the past.
We also announced that we completed an accelerated share repurchase for nearly $650 million, about 17 million shares. Additionally, our board approved a new share repurchase authorization of $750 million. We still have about $97 million remaining on our May 2012 authorization. In total, we have approximately $850 million remaining on share repurchase authorizations.
Now let's move to our fourth quarter results, starting with the top line. Revenues were $19.5 billion, down 4.4% compared to last year's quarter. Drug Company revenues were down about 8% and were partially offset by specialty revenues that were up nearly 6%. Our acquisitions contributed a combined $335 million of new revenues.
Gross profit was approximately $720 million in the quarter, up 19% from last September with a gross margin of 3.70%. Our acquisitions, primarily World Courier, contributed $76 million in the current quarter. We also benefited from a $15 million of antitrust settlements. We consider this income nonrecurring.
Finally, in the quarter, we had a LIFO credit of $11 million. This credit reduced our fiscal year LIFO charge to about $1 million less than we expected. Two factors contributed to our fourth quarter LIFO credit: One, our sales of brand inventory were especially high at the end of the quarter due to the purchasing patterns of a few large customers; and two, our mix of inventory was weighted heavier towards generic inventory at our LIFO calculation date.
Let's move to operating expenses. This quarter, operating expenses were $423 million, up 15%. This amount includes $65 million related to the operating expenses of our acquired companies. Also included is $29 million of nonrecurring charges related to optimizing our field operations and corporate organization. As you've come to expect from ABC, we continue to manage our expenses tightly. Excluding acquisitions and nonrecurring costs, our comparable operating expenses would have decreased about $10 million or 3% compared to the same quarter last year.
Operating income of $296 million in the quarter increased about 25%. Our operating margin was 1.52%, up by 35 basis points compared to last September quarter. When excluding the nonrecurring items from both the fourth quarter 2012 and 2011, our operating income is up $44 million or 16%. This growth demonstrates our strong performance in our core drug business, as well as contributions from our acquisitions.
Moving below the operating income line. Interest expense of approximately $24 million in the September quarter increased 22% compared to last year. This is a result of issuing new Senior Notes back in mid-November. As a reminder, we repaid $400 million of debt in September 2012.
Moving to income taxes. We had an increase in our effective income tax rate in the current quarter to 41.6%. This rate is higher than our normal tax rate of 38.6%. The primary reason for the increase is that we recorded a tax valuation allowance against our Canadian drug distribution business due to their operating loss. Going forward, we expect our ABC annualized tax rate to be about 39%.
Our GAAP diluted earnings per share in the quarter is $0.66, increased by $0.12 or 22% over the same quarter last year. In the current quarter, again, the negative impact of nonrecurring items was $0.03. Our EPS benefited from a 9% reduction in average diluted shares outstanding. At September 30, 2012, we had 235 million outstanding shares.
Let's spend a few minutes discussing our segment results for the September quarter. Starting with pharmaceutical distribution. Total revenues were $19.1 billion, down just under 6% versus the same quarter last year. Drug Company revenues were down about 8%. The decrease was due to 3 primary drivers: One, branded generic conversions offset by very strong brand price appreciation; two, lower sales to our largest customer; and three, the negative impact from the loss of former Longs Drugs last year about $400 million.
Specialty Group's revenues increased 6%, led by strong performance in 3 of its businesses with growth significantly above market rates, especially medical, ASD and ICS. Pharmaceutical distribution gross profit increased about $33 million when comparing the fourth quarter 2012 to the same quarter last year. And our gross profit margin increased 35 basis points to 3.23%. Most of the increase is due to our Drug Company business where we had strong generic revenue percentage growth in the low teens, due in part to 3 meaningful launches in the quarter. This segment also benefited from the LIFO credit.
As expected, we did see gross profit dollars associated with specialty oncology generic drugs decrease substantially, specifically gemcitabine and docetaxel, a negative impact of $0.06. We did have a minimal positive impact from the relaunch of Oxaliplatin, below expectations due to market pricing. This segment managed operating expenses very effectively. Overall, expense has decreased approximately $11 million or 3%. We continue to review spending in our distribution businesses to ensure we're at appropriate levels.
Pharmaceutical distribution operating income grew 16% or nearly $44 million to $308 million in the fourth quarter 2012. The increase was primarily the result of strong performance in our Drug Company business, which offset disappointing results in our Canadian distribution business. Overall, we're very pleased with the operating results for this segment.
Moving to the other reporting segment. As a reminder, this segment is comprised of Consulting Services and World Courier. TheraCom, our November 2011 acquisition, is included in Consulting Services. As discussed previously, our AndersonBrecon Packaging business has been excluded since this business is reported now as a discontinued operation. Segment revenues increased nearly $350 million to $422 million in the fourth quarter 2012. As mentioned previously, World Courier and TheraCom accounted for nearly $335 million of this increase. The revenues are tracking well against our expectations.
Operating income increased $21 million for the same quarter. About $6.5 million of the increase is related to an intangible impairment expense we incurred in the fourth quarter 2011 in one of our consulting businesses. Our acquisitions contributed about $0.02 to our Q4 2012 EPS. 
Let's switch to our fiscal year performance. I'll highlight a few key points. Back at Investor Day, we discussed the large negative headwind from Oxaliplatin that we've had this fiscal year, about $100 million of loss gross profit. Our Drug Company business more than offset this headwind. This year, they launched over 30 generic drugs, negotiated a number of sizable contracts, managed expenses tightly and implemented SAP in 16 DCs. On a fiscal year basis, Drug Company, excluding Canada, grew their operating income margin a very strong 18 basis points. And finally, it was a record revenue year for our Specialty business, $16.4 billion of total revenues, a lot to be pleased about.
Now let's turn to our balance sheet and cash flows. Capital expenditures were $164 million for the year, lower than expectations as a large DC automation project is shifting to fiscal 2013. Free cash flow was $1.1 billion, better than expected. This is our ninth straight year where free cash flow exceeded our net income from continuing operations. The increase was primarily due to improved committed capital at our specialty business where certain manufacturers provide extended payment terms.
Our gross debt to total debt in capital ratio at the end of September was 37%, which is slightly higher than our target range of 30% to 35%. This is due to accelerating our share repurchases. This percentage will gradually decrease during the year. During the fiscal year, we bought back just under $1.2 billion of our shares. This amount far exceeds our original guidance of $400 million for the year. Our philosophy has consistently been to upsize return to shareholders if we haven't otherwise deployed our capital and when market conditions permit. We're pleased that we continued with this practice in fiscal 2012. Our cash balance of about $1.1 billion at September 30 leaves us with financial flexibility as we move forward.
Now let's turn to expectations for 2013, EPS. We expect GAAP diluted EPS from continuing operations to be in the range of $3.06 to $3.16. This translates to EPS growth of 11% to 14%. We're using $2.76 as our base EPS. This number excludes the $0.04 from the AndersonBrecon discontinued operations.
Revenues. We expect revenue growth to be in the 6% to 9% range, driven primarily by our new Express Scripts contract. This customer will represent just over 20% of our revenues. As a comparison, the former Medco represented nearly 17% of our revenues in fiscal 2012.
Operating income. As discussed in the past, our Express Scripts business is for brand drugs and is bulk like in nature, meaning that the business has very low operating income margin. Our operating income margin assumption also includes the loss of a large food drug combo retail buying group during the year and most importantly, fewer oral solid generic launches.
In terms of operating expenses, excluding nonrecurring expenses, we expect operating expenses to increase 12% to 14% in fiscal 2013. However, most of these increases related to the full year impact of World Courier. Excluding this impact, our growth in OpEx is primarily due to cost to service our large customer and general wage and benefit inflation, offset by cost savings from our network and corporate optimization efforts. Again, our current assumptions do not include any meaningful nonrecurring expenses for fiscal 2013.
The items that I just covered all impact our operating impact and margin. For fiscal 2013, we expect our operating impact dollars to grow 3% to 5%, while our operating income margin will decrease in the low double-digit basis point range, probably in the low teens.
Free cash flow. We expect that our free cash flow will be in the $750 million to $850 million range. Capital expenditures should be in the $180 million range with less ERP spending but new spending on a number of business initiatives.
Share repurchases. We are assuming at least $200 million in share repurchases. The lower amount is due to ABC completing an ASR in Q4 2012.
Let's transition and cover high-level expectations on our segment. We can start with pharmaceutical distribution. For the Drug Company, we expect revenues to grow in the 6% to 9% range, again, due primarily to the new Express Scripts contract. On the Specialty side, we expect to grow in the 7% to 9% range, which is considerably above market growth. This includes solid growth in our oncology drug business.
Our segment operating income margin will decline in a mid-double-digit basis point range. Again, this decrease is due to our new Express Scripts contract that significantly increases our mix of lower margin brand business, the impact of previously discussed customer contract renewals and fewer generics lunching year-over-year. It is important to note that after we anniversary the impact of the Express Scripts contract, we expect to return to our normal pace of annual operating income margin expansion.
Moving to the Other segment. Revenues will increase significantly as we have World Courier for the full year versus the 5 months in fiscal year 2012. This should benefit the Other segment by about $300 million. Combined, the Consulting group and World Courier are expected to contribute 8% to 10% of our total operating income in fiscal 2013.
As a reminder, we do not give quarterly guidance, but I will say that directionally, our EPS growth will be higher in quarters 3 and 4. As you know, Q2 is traditionally our strongest EPS quarter, but we will have a tough comparative against Q2 2012 due to the contributions from generic Lipitor and Zyprexa.
I know that our comments today were longer than usual due to all the moving parts, so thanks for your attention. And let me finish by reiterating, we're pleased with our results for the quarter and the year. We expect solid performance in fiscal 2013 in a challenging year for generic launches. And we're working on a number of internal initiatives to streamline and strengthen our business. The future continues to look very bright for AmerisourceBergen.
Now here's Barbara for Q&A."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Tim. We'll now open the call to questions. [Operator Instructions] Go ahead, please, Tony.",16,"Thank you, Tim. We'll now open the call to questions. [Operator Instructions] Go ahead, please, Tony."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] We'll take our first question in queue from Bob Willoughby with Bank of America Merrill Lynch.",18,"[Operator Instructions] We'll take our first question in queue from Bob Willoughby with Bank of America Merrill Lynch."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","I heard somewhere you cited the larger purchase of branded drugs by a particularly large customer as the reason for the LIFO charges, I guess. And I'm just kind of curious, if it's bulk customer predominantly, does that purchases buyback customer impact y",49,"I heard somewhere you cited the larger purchase of branded drugs by a particularly large customer as the reason for the LIFO charges, I guess. And I'm just kind of curious, if it's bulk customer predominantly, does that purchases buyback customer impact your LIFO assumptions on any particular year?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Bob, this is Tim. No, I cited 2 reasons, the larger brand purchases by certain customers, a few of our government customers in particular, and then also just a mix of inventory between brand and generic, generic being a little bit heavier. That impacted.",61,"Bob, this is Tim. No, I cited 2 reasons, the larger brand purchases by certain customers, a few of our government customers in particular, and then also just a mix of inventory between brand and generic, generic being a little bit heavier. That impacted. And then in terms of next year, we expect to get back to a modest LIFO charge."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So it didn't sound like that in itself was a particular.",12,"Okay. So it didn't sound like that in itself was a particular."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","No, it wasn't.",3,"No, it wasn't."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And just broadly speaking, maybe for Steve, what kind of competition are you seeing from a business model perspective, given your share on the oncology market, what kind of new entrants or challenges are you seeing in that business?",40,"Okay. And just broadly speaking, maybe for Steve, what kind of competition are you seeing from a business model perspective, given your share on the oncology market, what kind of new entrants or challenges are you seeing in that business?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, we've been the leader in oncology for several years, and we still retain that position. I think we have really bolt up some unique drivers for value with our physician services organization. I think we've also built up the non-oncology businesses. I",157,"Well, we've been the leader in oncology for several years, and we still retain that position. I think we have really bolt up some unique drivers for value with our physician services organization. I think we've also built up the non-oncology businesses. I'm very proud of what we've built out in the non-oncology business and the way that we've integrated a lot of the services, say, from a Lash and Xcenda, and increasingly, World Courier. And the format of businesses we do with new manufacturers in our RCS, and a lot of the work we do with compliance in Lash. So we've got a great franchise, and we intend to support it. Just quickly on oncology, I'll tell you one of the things we're focusing on is what we call in hybrid models, which is more oncology taking place within a larger health system, and we believe we've got a dynamic role to play there as well."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Are other's making any type of inroads or different models there?",12,"Are other's making any type of inroads or different models there?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","I think obviously we've got one company that's trying to gain a foothold in specialty. I don't want to comment about this, their strategies, but we like where we are. We believe we've got the largest community-based oncology. Customers that have been loya",66,"I think obviously we've got one company that's trying to gain a foothold in specialty. I don't want to comment about this, their strategies, but we like where we are. We believe we've got the largest community-based oncology. Customers that have been loyal customers for a long time and those discussions tend to be very promising and a lot of commitment to remaining within AmerisourceBergen."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Tom Gallucci with Lazard Capital Markets.",10,"That will come from Tom Gallucci with Lazard Capital Markets."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","This is Colleen Lang on for Tom. Generics are clearly strong in the quarter. Can you talk about the performance of generics in Q4 relative to your expectations and what went better?",32,"This is Colleen Lang on for Tom. Generics are clearly strong in the quarter. Can you talk about the performance of generics in Q4 relative to your expectations and what went better?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, we really do -- well, we do focus on our generic offering, I mean, we have really 2 generic offerings, the ProGen, which is our preferred formulary. And we have many customers that take advantage of that. And then we also have our non-ProGen generic",70,"Well, we really do -- well, we do focus on our generic offering, I mean, we have really 2 generic offerings, the ProGen, which is our preferred formulary. And we have many customers that take advantage of that. And then we also have our non-ProGen generic customers, and both segments were very robust. We executed as expected. I don't know, Tim, if you have any color you'd like to add."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","I would say we had a couple of generics that launched in the third quarter that rolled in the fourth quarter, plus we had some launches in Q4 that really helped us. And then -- and let's not forget, we have a good base of our generics where we saw expansi",101,"I would say we had a couple of generics that launched in the third quarter that rolled in the fourth quarter, plus we had some launches in Q4 that really helped us. And then -- and let's not forget, we have a good base of our generics where we saw expansion that provides benefits. And utilization is also up. So I think it's really all those things together really help grow our generic top line. In my comments I said, in the low teens, we saw revenue increase. So it was a really good quarter for generics for the Drug Company."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And then on the branded side, it seems like branded inflation was particularly strong throughout your fiscal 2012. What's your expectation for '13?",25,"Okay, great. And then on the branded side, it seems like branded inflation was particularly strong throughout your fiscal 2012. What's your expectation for '13?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Colleen. It was a strong year. In fact, with our mix inventory, it was a record year for brand inflation, and we expect that to continue. Our assumption next year is in brand inflation in the 8% to 9% range.",41,"Thanks, Colleen. It was a strong year. In fact, with our mix inventory, it was a record year for brand inflation, and we expect that to continue. Our assumption next year is in brand inflation in the 8% to 9% range."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","The next question in queue will come from Robert Jones with Goldman Sachs.",13,"The next question in queue will come from Robert Jones with Goldman Sachs."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Steve, on the decision to divest the Packaging business, I was hoping you could share your thoughts in a little bit more detail there. I've always understood this to be a pretty steady high-margin business. I know it's not quite a Specialty or Distributio",58,"Steve, on the decision to divest the Packaging business, I was hoping you could share your thoughts in a little bit more detail there. I've always understood this to be a pretty steady high-margin business. I know it's not quite a Specialty or Distribution but just wondering, maybe you could share your thoughts on divesting this business now."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Bob, you're actually right. The contract packaging business has been successful and has grown significantly since we established it really by acquiring Anderson several years ago. The business has always operated as a separate entity while under the ABC u",160,"Bob, you're actually right. The contract packaging business has been successful and has grown significantly since we established it really by acquiring Anderson several years ago. The business has always operated as a separate entity while under the ABC umbrella. And while we've been pleased with this performance, we've not really realized the many synergy opportunities between contract packaging and our other lines of business. The way that we've been running the company since I've been CEO, I think we really do look at the company holistically even more so as we react to the marketplace. So I think as we've done some deep analysis, they aren't really enough touch points on the overall business development with manufacturers to warrant maintaining this is a separate entity going forward. And also the business is growing and I think the capital needs there are going to increase and we just see that we've got better opportunities to invest our capital going forward."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","On the capital deployment going forward actually, is there any change in strategy as we think about the lower buybacks that's baked in for next year? It looks like the free cash flow, $750 million to $800 million, you have $400 million from the buyback an",61,"On the capital deployment going forward actually, is there any change in strategy as we think about the lower buybacks that's baked in for next year? It looks like the free cash flow, $750 million to $800 million, you have $400 million from the buyback and the dividend, any comments on the use of the rest of that cash going forward?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, I'll just tell you. Look at what we've done this year, and I could not be more proud. I mean, $800 million in acquisitions, I think we're performing well on those acquisitions. If we did well over $1 billion in share buybacks, we're increasing our d",93,"Well, I'll just tell you. Look at what we've done this year, and I could not be more proud. I mean, $800 million in acquisitions, I think we're performing well on those acquisitions. If we did well over $1 billion in share buybacks, we're increasing our dividends. So there's not just much to like about how ABC uses our capital. I think we are -- among the best use of capital that you'll find anywhere out there. We will continue to contain to maintain our flexibility and use our balance sheet appropriately. Tim?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Yes, and I would just echo what Steve said. I think -- I don't think you can read anything into that. I mean, we -- as I mentioned in my comments, Bob, and we were very consistent. When we have excess cash, we return it in some form or fashion. So that's",85,"Yes, and I would just echo what Steve said. I think -- I don't think you can read anything into that. I mean, we -- as I mentioned in my comments, Bob, and we were very consistent. When we have excess cash, we return it in some form or fashion. So that's our guidance for now. And we think it's pretty reasonable compared with -- in relation to the ASR. And as we go through the year, we'll just -- we'll see how we're tracking."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Glen Santangelo with Crdit Suisse.",9,"That will come from Glen Santangelo with Crdit Suisse."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I just want to talk to you a little bit about the pricing environment. Sort of last quarter, you gave us somewhat of a candid assessment of how you view the sell side pricing environment. And I'm just kind of curious, now that you've had another qu",72,"Steve, I just want to talk to you a little bit about the pricing environment. Sort of last quarter, you gave us somewhat of a candid assessment of how you view the sell side pricing environment. And I'm just kind of curious, now that you've had another quarter under your belt, we've seen some contracts come and go, I'm just kind of curious if you could give us maybe an updated assessment?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, a couple of things. I mean, we typically -- about 25% to 30% of our business is up for renewal each year. And our last quarter was really unique because eventually the next week, we were able to announce exciting new contract with Express Scripts. A",134,"Well, a couple of things. I mean, we typically -- about 25% to 30% of our business is up for renewal each year. And our last quarter was really unique because eventually the next week, we were able to announce exciting new contract with Express Scripts. And so that was truly unique if you look at the timing of what we were facing then. So in that 3 months since we've last been on the call with you, we've been through several contract negotiations and honestly, they've all gone very much as expected. There's been one exception, which was a shared customer, but I would say that things have really stabilized and that the industry really remains fairly competitive. We're stable with more most large customers, not really showing an inclination to change wholesalers."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. if I could just ask one follow-up on the specialty pharmacy side, as well as sort of the Other segment. Steve, could you maybe give us your view on kind of how we should think about that portion of your business from a growth rate perspective? And a",83,"Okay. if I could just ask one follow-up on the specialty pharmacy side, as well as sort of the Other segment. Steve, could you maybe give us your view on kind of how we should think about that portion of your business from a growth rate perspective? And as a look out through 2013 and 2014, sort of any potential generic launches on the specialty side that can even come close to sort of rivaling what we saw on Hoxie Gemzar and Taxotere?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, you said specialty pharmacy. So we more are characterized by Specialty Distribution. There is a distinction, and specialty pharmacy, of course, is largely carried out by some of the retail chains but most notably, the PBMs. And those are often custo",195,"Well, you said specialty pharmacy. So we more are characterized by Specialty Distribution. There is a distinction, and specialty pharmacy, of course, is largely carried out by some of the retail chains but most notably, the PBMs. And those are often customers for us within AmerisourceBergen Drug Company. But there is more and more of this specialty product management taking place within large health systems, within mail order infusion centers. So our specialty pharmacy franchise, specialty distribution franchise is a very important characteristic for AmerisourceBergen. I think the way we understand this business, both in the community and health system setting and what we call our ultimate care setting, is really a unique characteristics and differentiates us for AmerisourceBergen. And I think that it leads to like some outsized performance in areas that you don't traditionally expect us to benefit from specialty, like in our health systems area where we've done very well. And I think you'll see more and more specialty therapies being administered in a health system setting. So, again, we keep on adding to this franchise. We've got excellent leadership, and you'll continue to see us investing and maintaining market leadership there."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Lisa Gill with JPMorgan.",8,"That will come from Lisa Gill with JPMorgan."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Tim, I had a question around your free cash flow guidance. If I look back to last year, the initial guidance was $800 million to $900 million, and you clearly did $1.1 billion. Can you maybe just talk about the $750 million to $850 million this year? Is t",73,"Tim, I had a question around your free cash flow guidance. If I look back to last year, the initial guidance was $800 million to $900 million, and you clearly did $1.1 billion. Can you maybe just talk about the $750 million to $850 million this year? Is there any impact because of the relationship with Express Scripts and inventory? Or is there anything else that's a onetime item for free cash flow?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Lisa. Yes, we do have a slight impact. I mean, on the new contract, our terms, our AR terms are slightly lower than what we had with the former Medco. So that's probably a 1- to 2-day impact. So that's part of the reason why you see that cash a li",71,"Thanks, Lisa. Yes, we do have a slight impact. I mean, on the new contract, our terms, our AR terms are slightly lower than what we had with the former Medco. So that's probably a 1- to 2-day impact. So that's part of the reason why you see that cash a little bit lower. But as always, we're going to work hard to get that up so, but that's the reason."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","And then just as a follow-on to that, just trying to understand 2 things. One, is there anything else of note in the new relationship with Express Scripts? And then secondly, Steve, I just had a question for you on this new hybrid model with the hospitals",76,"And then just as a follow-on to that, just trying to understand 2 things. One, is there anything else of note in the new relationship with Express Scripts? And then secondly, Steve, I just had a question for you on this new hybrid model with the hospitals. Is there any change in the way that you're being reimbursed or any different level of risk or anything else you're taking on in your specialty distribution business?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Tim, you go first and then I'll...",7,"Tim, you go first and then I'll..."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Yes. No, in terms of -- No, I don't think there's anything else. In terms of the Express Scripts, your first question about anything else on that Express Scripts contract, no, I don't think there's anything else really to call out. I mean, I think we've h",68,"Yes. No, in terms of -- No, I don't think there's anything else. In terms of the Express Scripts, your first question about anything else on that Express Scripts contract, no, I don't think there's anything else really to call out. I mean, I think we've hit the highlights. Again, it's pretty much all brand virtually brand, and it's a little bit over 20% of our expected revenues."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Look, we had a great relationship with Medco, and I think we've made a very profound transition to now servicing the overall Express Scripts contract, which we're pleased to be the wholesaler, and we will continue to work on the strategic relationship. Of",223,"Look, we had a great relationship with Medco, and I think we've made a very profound transition to now servicing the overall Express Scripts contract, which we're pleased to be the wholesaler, and we will continue to work on the strategic relationship. Of course, I think the priority for both organizations has been really working on implementing the contract. And now we can look forward to broadening and strengthening the relationship over the next couple of quarters. The hybrid model was the second part of your question. And now I think it's just really taking advantage of a lot of the services that we offer to community of oncologists and allowing those services to transition into more of a hospital settings. And I think it's also getting the manufacturer some of the information that they lack on the patient side and the protocol and formerly management side that we've been able to give them in the community settings. So you're seeing us make investments there, but we think that, that will preserve some of the unique in our financial, as well as therapeutic characteristics of our oncology business. So very important for us to continue to move with the markets. And again, a great example of how we're looking at the company very holistically and less hard lines between, say, specialty and drug."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Eric Coldwell with Robert W. Baird.",10,"That will come from Eric Coldwell with Robert W. Baird."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","On the lost account that you acknowledged on the call today, the regional food pharmacy combo, GPO business, I guess. I'm curious if you could help us understand the ultimate revenue impact compared to your -- what your expectations would have been had yo",122,"On the lost account that you acknowledged on the call today, the regional food pharmacy combo, GPO business, I guess. I'm curious if you could help us understand the ultimate revenue impact compared to your -- what your expectations would have been had you retained that. And you did mention that as one of the contributors to the operating margin compression, so should we assume that it's a higher operating margin contract and perhaps your overall book. And then finally, still sticking with that contract. In terms of the phasing of that lost centers, sometimes with GPO contracts, you don't lose all of the business on day 1. Can you give us some sense on the phasing of the revenue rolling off?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Sure, Eric. I think that is -- if I kind of write this 3-part question, I mean really that first one, I mean, we're not prepared to size that contract. I mean, it was a -- it's a large contract. It's got a nice mix of branded generics business. So again,",104,"Sure, Eric. I think that is -- if I kind of write this 3-part question, I mean really that first one, I mean, we're not prepared to size that contract. I mean, it was a -- it's a large contract. It's got a nice mix of branded generics business. So again, you could definitely say it's more profitable with that brand mix. Part of it we'll have for about half a year in total. So it doesn't entirely roll off in Q1. We have it through about March quarters so -- but, yes, it definitely impacts -- it's definitely an impact to our margin."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","So, Tim, I'm sorry, I guess I'll go to part 4 here, when you say that you'll have the contract through March, the total contract or a piece of it?",30,"So, Tim, I'm sorry, I guess I'll go to part 4 here, when you say that you'll have the contract through March, the total contract or a piece of it?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","We'll have a piece of it. We'll have a piece of it. So there's a piece that comes off in November and the remaining piece will come off in March, I think it's about 60-40.",36,"We'll have a piece of it. We'll have a piece of it. So there's a piece that comes off in November and the remaining piece will come off in March, I think it's about 60-40."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Ricky Goldwasser with Morgan Stanley.",9,"That will come from Ricky Goldwasser with Morgan Stanley."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Can you just provide us some more color around fiscal year '13 guidance? And what I'm basically trying to understand is what's the contribution of acquisitions? I think you mentioned that operating income in fiscal year '13 is going to grow 3% to 5%, but",70,"Can you just provide us some more color around fiscal year '13 guidance? And what I'm basically trying to understand is what's the contribution of acquisitions? I think you mentioned that operating income in fiscal year '13 is going to grow 3% to 5%, but the 8% to 10% is going to come from acquisition, so I just wanted to clarify that comment. And then I have one follow-up question."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Yes, Ricky, let me answer your question this way. Between World Courier and TheraCom, I mean, we'll have World Courier for the full year, so that...[Technical Difficulty]",28,"Yes, Ricky, let me answer your question this way. Between World Courier and TheraCom, I mean, we'll have World Courier for the full year, so that...
[Technical Difficulty]"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","Okay. Ladies and gentlemen, please standby as we reestablish the host line.",12,"Okay. Ladies and gentlemen, please standby as we reestablish the host line."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, your line -- the host line is now reestablished. [Operator Instructions]",14,"Ladies and gentlemen, your line -- the host line is now reestablished. [Operator Instructions]"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Ricky, sorry, yes, we lost power. Our building went dark, so our apologies, everyone. Getting back to your first question, Ricky, I think you're asking about impact of acquisitions. I'll answer it this way, World Courier and TheraCom should be about 4% to",52,"Ricky, sorry, yes, we lost power. Our building went dark, so our apologies, everyone. Getting back to your first question, Ricky, I think you're asking about impact of acquisitions. I'll answer it this way, World Courier and TheraCom should be about 4% to 5% of our EPS in terms of fiscal '13."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So 4% to 5% of EPS is from the acquisition. And I think that you provided a comment on the EPS, it was around 3% to 5% from EBIT?",30,"Okay. So 4% to 5% of EPS is from the acquisition. And I think that you provided a comment on the EPS, it was around 3% to 5% from EBIT?"
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","That's correct.",3,"That's correct."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. That is helpful. And then on the -- on your margin expansion guidance, and just kind of like help me better understand the numbers because when I think about your revenue guidance and your EBIT guidance, I get to EBIT margin contraction in the mid-s",70,"Okay. That is helpful. And then on the -- on your margin expansion guidance, and just kind of like help me better understand the numbers because when I think about your revenue guidance and your EBIT guidance, I get to EBIT margin contraction in the mid-single-digits versus your comments around low double digits. So if you could just help me reconcile the difference, maybe you suggest corporate versus drug distribution."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Yes, Ricky, I guess the best thing I can say on that one is as we get closer to Investor Day, we'll give more specific information by business in terms of margins. But again, let me just say that there is a big impact from the new contract with Express Sc",114,"Yes, Ricky, I guess the best thing I can say on that one is as we get closer to Investor Day, we'll give more specific information by business in terms of margins. But again, let me just say that there is a big impact from the new contract with Express Scripts. We talked just before with Eric about we gave some comments on the Topco contract, which again, with generics, I mean, that's a big impact to our margin. And then, clearly, the generic launch is being down. So those 3 items clearly impact our operating income margin and in fact, cause it to be down like we said in the low double-digit range."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Okay. Thanks, Ricky. I think in light of everyone's time, we'll wrap up the call here. Steve has some final closing remarks.",22,"Okay. Thanks, Ricky. I think in light of everyone's time, we'll wrap up the call here. Steve has some final closing remarks."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Yes, again, sorry for this. And we want to really thank you for your attention today. I hope you found the call helpful and informative. There was a lot of detail provided, and we really appreciate your attention, especially with the strong close we had t",89,"Yes, again, sorry for this. And we want to really thank you for your attention today. I hope you found the call helpful and informative. There was a lot of detail provided, and we really appreciate your attention, especially with the strong close we had there. Thanks to Sandy. I hope Tim and I conveyed to you our excitement and confidence in our company, and I hope you share our firm belief that AmerisourceBergen is a great company to invest in. Thank you, all, and have a great day."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thank you very much.",4,"Thank you very much."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","I just have a couple of closing comments. We'll be holding our Investor Day on December 12 in New York City. There'll be more information about that on our website next week. And the next conference we'll be attending will be the JPMorgan Healthcare Confe",72,"I just have a couple of closing comments. We'll be holding our Investor Day on December 12 in New York City. There'll be more information about that on our website next week. And the next conference we'll be attending will be the JPMorgan Healthcare Conference on January 9 at San Francisco. So thanks very much. And thank you for your attention today. I'll turn it back to the operator for replay information."
24809,222419523,375474,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","Thank you very much. And ladies and gentlemen, this conference will be available for replay after 1 p.m. today, running through November 8 at midnight. You may access the AT&T executive playback service at any time by dialing (320) 365-3844 using the acce",65,"Thank you very much. And ladies and gentlemen, this conference will be available for replay after 1 p.m. today, running through November 8 at midnight. You may access the AT&T executive playback service at any time by dialing (320) 365-3844 using the access code of 266794. That does conclude your conference call for today. We do thank you for your participation. You may now disconnect."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the ABC Fourth Quarter Earnings Conference Call. [Operator Instructions] And also as a reminder, today's teleconference is being recorded. And at this time, we will turn the conference call o",50,"Ladies and gentlemen, thank you for standing by, and welcome to the ABC Fourth Quarter Earnings Conference Call. [Operator Instructions] And also as a reminder, today's teleconference is being recorded. And at this time, we will turn the conference call over to your host, Ms. Barbara Brungess. Please go ahead."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Tony. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fourth quarter and fiscal year 2012 results. I am Barbara Brungess, Vice President, Corporate and Investor Relations and joining me today are",166,"Thank you, Tony. Good morning, everyone, and welcome to AmerisourceBergen's earnings conference call covering our fourth quarter and fiscal year 2012 results. I am Barbara Brungess, Vice President, Corporate and Investor Relations and joining me today are Steve Collis, AmerisourceBergen President and CEO; and Tim Guttman, Senior Vice President and CFO.
During the conference call today, we will make some forward-looking statements about our business prospects and financial expectations. We remind you that there are many risk factors that could cause our actual results to differ materially from our current expectations. For a discussion of some key risk factors, we refer you to our SEC filings, including our 10-K report for fiscal 2011.
Also, AmerisourceBergen assumes no obligation to update the matters discussed in this conference call, and this call cannot be rebroadcast without the express permission of the company. As always, those connected by telephone will have an opportunity to ask questions after our opening remarks.
Now here is Steve Collis to begin our comments."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Barbara, and good morning, everyone. Before we begin, I just want to say a few words about the storm we have all experienced over the last few days. Our thoughts are with all of those who have lost loved ones, lost their homes and have otherwis",2511,"Thank you, Barbara, and good morning, everyone. Before we begin, I just want to say a few words about the storm we have all experienced over the last few days. Our thoughts are with all of those who have lost loved ones, lost their homes and have otherwise been severely impacted by the storm. I want to thank our ABC associates who have worked tirelessly to ensure that we would continue to be able to meet the needs of our customers and the patients we all ultimately serve throughout this difficult week.
Turning now to our results. I'm delighted to report solid results for our fourth quarter and our fiscal year 2012. In my first full fiscal year as CEO, we overcame a challenging year-over-year comparison while executing very well on generic conversions. We renewed and expanded our contract with our largest customer, we integrated 4 acquisitions and we returned funds in excess of our free cash flow to shareholders.
In the September quarter, our revenues were down 4% to $19.5 billion, but our GAAP earnings per share from continuing operations were up 23% to $0.65. For the fiscal year, our revenues were down about 0.5% to $79.5 billion, and our earnings per share were up 10% to $2.76, which excludes $0.04 earned by AndersonBrecon. I'm very pleased with the performance that AmerisourceBergen associates delivered in fiscal 2012. We executed extremely well against our key strategies of generics and specialty, and we are well positioned heading into fiscal 2013.
In addition, we made important investments in our more forward-looking strategies of expanding our manufacture services businesses and beginning to build out our international platform for growth.
This morning, we also announced that our Board of Directors approved a 62% increase in our annual dividend and authorized a new $750 million share repurchase program. We completed a $650 million accelerated share repurchase program during this quarter, bringing our repurchases for the fiscal year to nearly $1.2 billion. We are confident undertaking these capital deployment initiatives due to the tremendous underlying strength and resilience of our business. Since the merger that created AmerisourceBergen, we have generated free cash flow of $8.8 billion. Of this amount, we have returned $6.6 billion to investors by share repurchases and $600 million through dividends. In total, we returned 82% of our 11-year free cash flow to our shareholders. Truly outstanding performance for our business.
I am very proud that in fiscal 2012, we generated $1.1 billion in free cash flow, repaid $450 million in debt, completed nearly $800 million in acquisitions and repurchased over $1 billion of our stock. And heading into next year, we continue to have excellent financial flexibility. Our high-quality balance sheet, combined with our ability to generate cash, affords us the opportunity to continue to invest in our business, find our strategic initiatives and return value to shareholders. Our legacy of outstanding financial stewardship is one of the bedrocks in the foundation of AmerisourceBergen and one which gives us a firm footing upon which to grow our business in the years ahead.
Another important aspect of our financial stewardship has been our careful management of our existing assets, investing in carefully selected acquisitions and divesting of assets that do not serve our long-term objectives. This morning, we announced that we are pursuing the sale of AndersonBrecon, our contract pharmaceutical packaging business. While AndersonBrecon is a market leader, has excellent customer relationships, talented and dedicated associates, has performed well and is on a growth trajectory, we have not realized significant synergies between AndersonBrecon and our other lines of business. We remain committed to expanding our remaining manufacture services businesses with a particular focus on expanding our Consulting Services and specialty third-party logistics business in the U.S. and in select global markets.
The acquisitions we've made this year support those efforts and we've made excellent progress on the integrations, and all 4 are performing as expected.
The 2 largest acquisitions, TheraCom and World Courier, made modest contributions to our earnings in fiscal 2012 and are expected to contribute more meaningfully in fiscal 2013. TheraCom is part of one of our fastest growing business units, the Consulting Group. And we expect the demand for the services that this group provides will increase as manufacturers seek to bring products to market as efficiently as possible and to demonstrate the value of the products in the marketplace.
The integration of World Courier is also progressing very well, and we are pleased with the performance of its core business as it is transitioned to becoming part of AmerisourceBergen. As these 2 businesses have come together, our cultures and our vision for the future have aligned seamlessly. And I'm more excited than ever about the potential we now have to begin to expand our marketing specialty, 3PL consulting and other manufacture services outside the U.S.
After a year of substantial change, I believe we are very well positioned to continue to add to our legacy of success and innovation in the years ahead. Our diverse revenue base continues to position us well to benefit from organic growth across the entire spectrum of pharmaceutical care. While overall pharmaceutical market growth will likely continue to be slow in calendar 2013, IMS Health sees compounded annual sales growth in the U.S. in the range of 1% to 4% and 4% to 6% worldwide through 2016. We are part of a strong and stable industry, and we have demonstrated both resilience and solid performance in a variety of economic and market situations.
As changes continue to roll across the U.S. healthcare markets for both our manufacture and healthcare provider customers, the opportunity for us to provide value should continue to increase. One of the hallmarks of the U.S. market is the quality of our relationships wholesalers have with pharmaceutical manufacturers. And we continue to put an emphasis on looking for meaningful ways to provide additional services across the supply channel in order to help them meet the challenges of today's changing healthcare landscape.
Just last week, I served on an international wholesale panel at the IFPW, the International Federation of Pharmaceutical Wholesalers biannual meeting. I was again reminded by listening to the comments of others on the panel about the robust and transparent relationship we are privileged to enjoy with both our provider and manufacturer customers here in the U.S.
Turning now to our 2 operating segments. Tim will provide the detailed financial results, but I would like to highlight a few key trends. In the pharmaceutical distribution segment, AmerisourceBergen Drug Corporation had a truly stellar year, delivering strong performance on generics in a historic year for new launches. The Drug Company's performance helped overcome a $0.33 headwind in EPS due to a difficult comparison with specialty generic performance in the prior year. In addition, strong results in our U.S.-based business offset disappointing results in our much smaller Canadian distribution business where reimbursement changes have challenged the market and further unforeseen reimbursement cuts are on the horizon.
In addition, we continue to work out some issues with the implementation of our large retail contract. While the distribution market in Canada is challenged, the small but growing specialty business in Canada continues to gain traction.
Drug Company revenues in the September quarter declined 8% due in large part to a larger than expected decline in sales of our largest customer, as well as the previously reported loss of a large retail customer beginning last September.
For fiscal year 2012, the Drug Company's revenues are down 2%, somewhat lower than anticipated. However, when adjusting for nonrecurring items, the Drug Company demonstrated disciplined expense management, gross margin expansion and significant operating margin expansion. In addition, we renewed and expanded the contract with our largest customer and began to serve a significantly higher volume with that customer beginning on October 1. As you would expect with ABC, the conversion has proceeded very well, and we are excited about the relationship we are developing with our largest customer.
Given the difficult generic comparison we will have in the Drug Company in fiscal year 2013, we are optimizing our resources to ensure that they are deployed and utilized in the most efficient manner possible. Some of those efforts resulted in the severance charges we recorded in our fourth quarter. One example is that we are leveraging some of the efficiencies gained through the SAP implementation, particularly in back-office administrative areas, which has allowed us to reduce the numbers of our Drug Company operating regions from 4 to 3 regions. As you would expect, we continue to look at ways to streamline our operations, but we never sacrifice our ability to provide world-class service to our customers.
Another example of where we continue to invest in our Good Neighbor Pharmacy program, which is the largest independent network of community pharmacists in the U.S. We believe our pharmacy customers play a critical role in the healthcare throughout the country by offering a compelling value proposition to patients and payers alike. We negotiate on behalf of GNP members to ensure that they continue to have access to third-party networks. Looking ahead, we are working with GNP member stores in order to help them ensure they are able to take full advantage of the expansion of healthcare under the health reform legislation. The Drug Company has performed admirably over the last few years while the overall market has been flat to down.
The implementation of our SAP platform continues on schedule with 20 distribution center conversions complete and 6 remaining. We have made excellent progress and we expect the remaining conversions to be completed by the end of the March quarter in 2013. We are confident that these and other investments will continue to meaningfully increase the value we bring to all of our customers.
The Drug Company is and always will be the foundation of AmerisourceBergen Corporation. The excellent consistent financial and operating performance it has achieved over the years and the resilience it has demonstrated are hallmarks of the value we provide. Furthermore, the Drug Company is a key driver in our ability to generate tremendous cash flow and as such, enables us to fund our growth initiatives. We take deep pride in this business, and while its performance in fiscal 2013 won't be quite as strong as it has been historically, we expect it to return to its normal growth rate in fiscal 2014 and beyond.
AmerisourceBergen's Specialty Group had another strong quarter with revenues up 6% in the quarter, which led to record revenue for the full fiscal year 2012. Revenue growth was driven by another particularly strong performance in third-party logistics and in our vaccine and physician distribution business. Our oncology business performed well as a difficult comparison East [ph]. We were, however, somewhat disappointed in the pricing of our Oxaliplatin during its release in mid August.
ABSG discontinued a benefit, however, from the launch of a branded ophthalmology product earlier this year, continuing to help establish significant market share for the manufacturer. Our success in the ophthalmology market demonstrates the unique value proposition of our specialty franchise while our undisputed strength in specialty is our oncology business, we've expanded those capabilities to become the instrumental part of the commercialization strategy for any complex product launched into the physician marketplace and beyond.
Our Consulting Services group achieved strong results for the fiscal year as demand for commercialization, reimbursement and patient support services continues to be robust. We believe these combined service offerings distinguish AmerisourceBergen in the marketplace and will be an important driver of our growth going forward. As manufacturers seek to bring new products to market, or expand sales of existing products in a challenging healthcare environment, we believe the demand for these services will only increase.
In terms of financial performance, the Consulting group delivered a solid quarter while making excellent progress in the integration of TheraCom, which is performing well. Even setting aside the contribution from TheraCom, the Lash group alone had outstanding results.
As Tim will detail, the solid performance across our business once again contributed to excellent cash flow in the quarter. Given the strength of our balance sheet, we continue to explore opportunities to deploy our capital in order to increase shareholder value, including searching for acquisitions that meet the criteria we've had in place for quite some time. That should increase our value offering to existing customers both up and down the channel. That should be within our established core competency and that should increase shareholder value. While we have not contemplated any further contribution from acquisitions in our guidance, we continue to be receptive to acquisitions, and we continue to be interested in opportunities in the pharmaceutical and Specialty Distribution Services, as well as Consulting Services.
We also remain committed to returning a minimum of 30% of our free cash flow to shareholders in the form of dividends and share repurchases, a hurdle that we have handily exceeded over the last several years.
Looking ahead, our performance in fiscal 2012 sets us up very well for continued success in fiscal 2013. As we stated in our press release, our guidance for GAAP EPS growth from continued operations in fiscal 2013 is to be in the range of $3.06 to $3.16, an 11% to 14% increase over the $2.76 that we earned in fiscal 2012, excluding, of course, the contribution from AndersonBrecon.
Tim will provide the details and our assumptions for next year, but I want to highlight that we continue to have tremendous financial flexibility; we are undertaking initiatives across our entire business to help ensure that we are as efficient and effective as we can possibly be.
The enormous strength and resilience of our business in a year of significant change for AmerisourceBergen and for the healthcare industry more broadly, reinforces my confidence in the long-term prospects for our business.
Demand is strong and growing for the core products we distribute, and we play an essential role in the pharmaceutical supply chain, ensuring the integrity and security of the distribution of life-improving and lifesaving therapies.
Over the last year, we've made important investments in our future while we continue to focus on helping our customers and ourselves take advantage of the unprecedented growth in generics and the many opportunities in specialty.
Our distribution business is not only a cornerstone of AmerisourceBergen, but it's a cornerstone in a stable and growing industry. Our manufacture services businesses help ensure products get to market as efficiently as possible and that patients have access to both traditional medications and the most innovative and complex products.
Lastly, I believe that we have built up an exceptional management team with a diverse background and deep experience that is excited about the opportunities we have in front of us. The knowledge, passion and creativity our associates bring to the market each day set us apart from our peers. I thank them all for the work they do to continue to drive innovative solutions in a dynamic environment. I am proud to be their leader. Here is Tim."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Steve, and thanks, everyone, for joining us today. We had a solid finish to what has been a good year. We're pleased with our financial results, and we have momentum entering our new fiscal year. So let's start with our review of fiscal 2012. We w",2395,"Thanks, Steve, and thanks, everyone, for joining us today. We had a solid finish to what has been a good year. We're pleased with our financial results, and we have momentum entering our new fiscal year. So let's start with our review of fiscal 2012. We will compare our performance against the guidance we gave back in July when we discussed Q3 results.
Our revenue expectation for fiscal 2012 was flat to modest growth. We were off a little bit. We finished down about 0.5%. This was due primarily to sales to our largest customer being lower than what we estimated. This decrease was offset by revenues from our 2 large acquisitions, TheraCom and World Courier.
In fiscal 2012, our operating margin expanded by 10 basis points, which was slightly above our expectation. This is the seventh consecutive year we expanded our operating margins.
Free cash flow. We have $1.1 billion in free cash flow for the year, and this exceeded our expectation of $800 million to $900 million. Finally, our GAAP diluted EPS ended at $2.80, a 10% increase over our GAAP EPS from fiscal 2011. This EPS amount includes $0.04 from AndersonBrecon, which we classified as a discontinued operation. As Steve mentioned, we plan to divest the business within the next 6 months.
You may recall that our guidance assumed $20 million of nonrecurring charges for the fiscal year. Our $2.80 GAAP EPS includes $31 million of nonrecurring charges. That's $11 million higher than we expected and the equivalent of $0.03. Excluding this $0.03 negative impact, our EPS results for the fiscal year would have been $2.83.
One more important item, cash deployment. As Steve mentioned, our board approved a 62% increase in our annual dividend per share to $0.84. Why do we increase our dividend now? Three reasons: 1, the long-term financial outlook for our core distribution business continued to be very positive; 2, we expect growing contributions from our recent acquisitions; and 3, we continue to generate consistent, significant free cash flow.
We were pleased that we can provide added value to shareholders. Looking ahead, we expect to grow our annual dividend approximately in line with our earnings growth. We believe that our business will generate enough excess capital to continue with meaningful share repurchases and at the same time, to have flexibility to complete acquisitions in the strategic areas that we've discussed in the past.
We also announced that we completed an accelerated share repurchase for nearly $650 million, about 17 million shares. Additionally, our board approved a new share repurchase authorization of $750 million. We still have about $97 million remaining on our May 2012 authorization. In total, we have approximately $850 million remaining on share repurchase authorizations.
Now let's move to our fourth quarter results, starting with the top line. Revenues were $19.5 billion, down 4.4% compared to last year's quarter. Drug Company revenues were down about 8% and were partially offset by specialty revenues that were up nearly 6%. Our acquisitions contributed a combined $335 million of new revenues.
Gross profit was approximately $720 million in the quarter, up 19% from last September with a gross margin of 3.70%. Our acquisitions, primarily World Courier, contributed $76 million in the current quarter. We also benefited from a $15 million of antitrust settlements. We consider this income nonrecurring.
Finally, in the quarter, we had a LIFO credit of $11 million. This credit reduced our fiscal year LIFO charge to about $1 million less than we expected. 2 factors contributed to our fourth quarter LIFO credit: 1, our sales of brand inventory were especially high at the end of the quarter due to the purchasing patterns of a few large customers; and 2, our mix of inventory was weighted heavier towards generic inventory at our LIFO calculation date.
Let's move to operating expenses. This quarter, operating expenses were $423 million, up 15%. This amount includes $65 million related to the operating expenses of our acquired companies. Also included is $29 million of nonrecurring charges related to optimizing our field operations and corporate organization. As you've come to expect from ABC, we continue to manage our expenses tightly. Excluding acquisitions and nonrecurring costs, our comparable operating expenses would have decreased about $10 million or 3% compared to the same quarter last year.
Operating income of $296 million in the quarter increased about 25%. Our operating margin was 1.52%, up by 35 basis points compared to last September quarter. When excluding the nonrecurring items from both the fourth quarter 2012 and 2011, our operating income is up $44 million or 16%. This growth demonstrates our strong performance in our core drug business, as well as contributions from our acquisitions.
Moving below the operating income line. Interest expense of approximately $24 million in the September quarter increased 22% compared to last year. This is a result of issuing new Senior Notes back in mid November. As a reminder, we repaid $400 million of debt in September 2012.
Moving to income taxes. We had an increase in our effective income tax rate in the current quarter to 41.6%. This rate is higher than our normal tax rate of 38.6%. The primary reason for the increase is that we recorded a tax valuation allowance against our Canadian drug distribution business due to their operating loss. Going forward, we expect our ABC annualized tax rate to be about 39%.
Our GAAP diluted earnings per share in the quarter is $0.66, increased by $0.12 or 22% over the same quarter last year. In the current quarter, again, the negative impact of nonrecurring items was $0.03. Our EPS benefited from a 9% reduction in average diluted shares outstanding. At September 30, 2012, we had 235 million outstanding shares.
Let's spend a few minutes discussing our segment results for the September quarter. Starting with pharmaceutical distribution. Total revenues were $19.1 billion, down just under 6% versus the same quarter last year. Drug Company revenues were down about 8%. The decrease was due to 3 primary drivers: 1, branded generic conversions offset by very strong brand price appreciation; 2, lower sales to our largest customer; and 3, the negative impact from the loss of the former Longs Drugs last year, about $400 million.
Specialty Group's revenues increased 6%, led by strong performance in 3 of its businesses with growth significantly above market rates, especially medical, ASD and ICS. Pharmaceutical distribution gross profit increased about $33 million when comparing the fourth quarter 2012 to the same quarter last year. And our gross profit margin increased 35 basis points to 3.23%. Most of the increase is due to our Drug Company business where we had strong generic revenue percentage growth in the low teens, due in part to 3 meaningful launches in the quarter. This segment also benefited from the LIFO credit.
As expected, we did see gross profit dollars associated with specialty oncology generic drugs decrease substantially, specifically gemcitabine and docetaxel, a negative impact of $0.06. We did have a minimal positive impact from the relaunch of Oxaliplatin, below expectations due to market pricing. This segment managed operating expenses very effectively. Overall, expenses decreased approximately $11 million or 3%. We continue to review spending in our distribution businesses to ensure we're at appropriate levels.
Pharmaceutical distribution operating income grew 16% or nearly $44 million to $308 million in the fourth quarter 2012. The increase was primarily the result of strong performance in our Drug Company business, which offset disappointing results in our Canadian distribution business. Overall, we're very pleased with the operating results for this segment.
Moving to the Other reporting segment. As a reminder, this segment is comprised of Consulting Services and World Courier. TheraCom, our November 2011 acquisition, is included in Consulting Services. As discussed previously, our AndersonBrecon Packaging business has been excluded since this business is reported now as a discontinued operation. Segment revenues increased nearly $350 million to $422 million in the fourth quarter 2012. As mentioned previously, World Courier and TheraCom accounted for nearly $335 million of this increase. The revenues are tracking well against our expectations.
Operating income increased $21 million for the same quarter. About $6.5 million of the increase is related to an intangible impairment expense we incurred in the fourth quarter 2011 in one of our consulting businesses. Our acquisitions contributed about $0.02 to our Q4 2012 EPS. 
Let's switch to our fiscal year performance. I'll highlight a few key points. Back on Investor Day, we discussed the large negative headwind from Oxaliplatin that we'd have this fiscal year, about $100 million of lost gross profit. Our Drug Company business more than offset this headwind. This year, they launched over 30 generic drugs, negotiated a number of sizable contracts, managed expenses tightly and implemented SAP in 16 DCs. On a fiscal year basis, Drug Company, excluding Canada, grew their operating income margin a very strong 18 basis points. And finally, it was a record revenue year for our Specialty business, $16.4 billion of total revenues, a lot to be pleased about.
Now let's turn to our balance sheet and cash flows. Capital expenditures were $164 million for the year, lower than expectations as a large DC automation project is shifting to fiscal 2013. Free cash flow was $1.1 billion, better than expected. This is our ninth straight year where free cash flow exceeded our net income from continuing operations. The increase was primarily due to improved committed capital at our specialty business where certain manufacturers provide extended payment terms.
Our gross debt to total debt in capital ratio at the end of September was 37%, which is slightly higher than our target range of 30% to 35%. This is due to accelerating our share repurchases. This percentage will gradually decrease during the year. During the fiscal year, we bought back just under $1.2 billion of our shares. This amount far exceeds our original guidance of $400 million for the year. Our philosophy has consistently been to upsize return to shareholders if we haven't otherwise deployed our capital and when market conditions permit. We're pleased that we continued with this practice in fiscal 2012. Our cash balance of about $1.1 billion at September 30 leaves us with financial flexibility as we move forward.
Now let's turn to expectations for 2013. EPS. We expect GAAP diluted EPS from continuing operations to be in the range of $3.06 to $3.16. This translates to EPS growth of 11% to 14%. We're using $2.76 as our base EPS. This number excludes the $0.04 from the AndersonBrecon discontinued operations.
Revenues. We expect revenue growth to be in the 6% to 9% range, driven primarily by our new Express Scripts contract. This customer will represent just over 20% of our revenues. As a comparison, the former Medco represented nearly 17% of our revenues in fiscal 2012.
Operating income. As discussed in the past, our Express Scripts business is for brand drugs and is bulk-like in nature, meaning that the business has very low operating income margins. Our operating income margin assumption also includes the loss of a large food/drug combo retail buying group during the year and most importantly, fewer oral solid generic launches.
In terms of operating expenses, excluding nonrecurring expenses, we expect operating expenses to increase 12% to 14% in fiscal 2013. However, most of this increase is related to the full year impact of World Courier. Excluding this impact, growth in OpEx is primarily due to cost to service our large customer and general wage and benefit inflation, offset by cost savings from our network and corporate optimization efforts. Again, our current assumptions do not include any meaningful nonrecurring expenses for fiscal 2013.
The items that I just covered all impact our operating income and margin. For fiscal 2013, we expect our operating income dollars to grow 3% to 5%, while our operating income margin will decrease in the low double-digit basis point range, probably in the low teens.
Free cash flow. We expect that our free cash flow will be in the $750 million to $850 million range. Capital expenditures should be in the $180 million range with less ERP spending but new spending on a number of business initiatives.
Share repurchases. We are assuming at least $200 million in share repurchases. The lower amount is due to ABC completing an ASR in Q4 2012.
Let's transition and cover high-level expectations on our segment. We can start with pharmaceutical distribution. For the Drug Company, we expect revenues to grow in the 6% to 9% range, again, due primarily to the new Express Scripts contract. On the Specialty side, we expect to grow in the 7% to 9% range, which is considerably above market growth. This includes solid growth in our oncology drug business.
Our segment operating income margin will decline in a mid double-digit basis point range. Again, this decrease is due to our new Express Scripts contract that significantly increases our mix of lower margin brand business, the impact of previously discussed customer contract renewals and fewer generics launching year-over-year. It is important to note that after we anniversary the impact of the Express Scripts contract, we expect to return to our normal pace of annual operating income margin expansion.
Moving to the Other segment. Revenues will increase significantly as we have World Courier for the full year versus the 5 months in fiscal year 2012. This should benefit the Other segment by about $300 million. Combined, the Consulting group and World Courier are expected to contribute 8% to 10% of our total operating income in fiscal 2013.
As a reminder, we do not give quarterly guidance, but I will say that directionally, our EPS growth will be higher in quarters 3 and 4. As you know, Q2 is traditionally our strongest EPS quarter, but we will have a tough comparative against Q2 2012 due to the contributions from generic Lipitor and Zyprexa.
I know that our comments today were longer than usual due to all the moving parts, so thanks for your attention. And let me finish by reiterating. We're pleased with our results for the quarter and the year. We expect solid performance in fiscal 2013 in a challenging year for generic launches. And we're working on a number of internal initiatives to streamline and strengthen our business. The future continues to look very bright for AmerisourceBergen.
Now here's Barbara for Q&A."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thank you, Tim. We'll now open the call to questions. [Operator Instructions] Go ahead, please, Tony.",16,"Thank you, Tim. We'll now open the call to questions. [Operator Instructions] Go ahead, please, Tony."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","[Operator Instructions] We'll take our first question in queue from Bob Willoughby with Bank of America Merrill Lynch.",18,"[Operator Instructions] We'll take our first question in queue from Bob Willoughby with Bank of America Merrill Lynch."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","I heard somewhere you cited the larger purchase of branded drugs by a particularly large customer as the reason for the LIFO charge issue, I guess. And I'm just kind of curious, if it's a bulk customer predominantly, does that -- purchases by that custome",53,"I heard somewhere you cited the larger purchase of branded drugs by a particularly large customer as the reason for the LIFO charge issue, I guess. And I'm just kind of curious, if it's a bulk customer predominantly, does that -- purchases by that customer impact your LIFO assumptions on any particular year?"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Bob, this is Tim. No, I cited 2 reasons: larger brand purchases by certain customers, a few of our government customers in particular; and then also just a mix of inventory between brand and generic, generic being a little bit heavier. That impacted. And",60,"Bob, this is Tim. No, I cited 2 reasons: larger brand purchases by certain customers, a few of our government customers in particular; and then also just a mix of inventory between brand and generic, generic being a little bit heavier. That impacted. And then in terms of next year, we expect to get back to a modest LIFO charge."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So it didn't sound like that in itself was a particular",12,"Okay. So it didn't sound like that in itself was a particular"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","No, it wasn't.",3,"No, it wasn't."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And just broadly speaking, maybe for Steve, what kind of competition are you seeing from a business model perspective, given your share on the oncology market, what kind of new entrants or challenges are you seeing in that business?",40,"Okay. And just broadly speaking, maybe for Steve, what kind of competition are you seeing from a business model perspective, given your share on the oncology market, what kind of new entrants or challenges are you seeing in that business?"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, we've been the leader in oncology for several years, and we still retain that position. I think we have really built up some unique drivers for value with our physician services organizations. I think we've also built out the non-oncology businesses",157,"Well, we've been the leader in oncology for several years, and we still retain that position. I think we have really built up some unique drivers for value with our physician services organizations. I think we've also built out the non-oncology businesses. I'm very proud of what we've built out in the non-oncology business and the way that we've integrated a lot of the services, say, from a Lash and Xcenda, and increasingly, a World Courier. And the format of businesses we do with new manufacturers in our ICS, and a lot of the work we do with compliance in Lash. So we've got a great franchise, and we intend to support it. Just quickly on oncology, I'll tell you one of the things we're focusing on is what were calling hybrid models, which is more oncology taking place within a larger health system, and we believe we've got a dynamic role to play there as well."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Are others making any type of inroads with different models, though?",11,"Are others making any type of inroads with different models, though?"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","I think obviously we've got one company that's trying to gain a foothold in specialty. I don't want to comment about their strategies, but we like where we are. We believe we've got the largest community-based oncology customers that have been loyal custo",65,"I think obviously we've got one company that's trying to gain a foothold in specialty. I don't want to comment about their strategies, but we like where we are. We believe we've got the largest community-based oncology customers that have been loyal customers for a long time. And those discussions tend to be very promising and a lot of commitment to remaining within AmerisourceBergen."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Tom Gallucci with Lazard Capital Markets.",10,"That will come from Tom Gallucci with Lazard Capital Markets."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","This is Colleen Lang on for Tom. Generics are clearly strong in the quarter. Can you talk about the performance of generics in Q4 relative to your expectations and what went better?",32,"This is Colleen Lang on for Tom. Generics are clearly strong in the quarter. Can you talk about the performance of generics in Q4 relative to your expectations and what went better?"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, we really do -- we do focus on our generic offering, I mean, we have really 2 generic offerings, the ProGen, which is our preferred formulary. And we have many customers that take advantage of that. And then we also have our non-ProGen generic custo",69,"Well, we really do -- we do focus on our generic offering, I mean, we have really 2 generic offerings, the ProGen, which is our preferred formulary. And we have many customers that take advantage of that. And then we also have our non-ProGen generic customers, and both segments were very robust. We executed as expected. I don't know, Tim, if you have any color you'd like to add."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","I would say we had a couple of generics that launched in the third quarter that rolled in the fourth quarter, plus we had some launches in Q4 that really helped us. And then -- and let's not forget, we have a good base of our generics where we saw expansi",101,"I would say we had a couple of generics that launched in the third quarter that rolled in the fourth quarter, plus we had some launches in Q4 that really helped us. And then -- and let's not forget, we have a good base of our generics where we saw expansion. That provides benefit. And utilization is also up. So I think it's really all those things together really help grow our generic top line. In my comments I said in the low teens, we saw revenue increase. So it was a really good quarter for generics for the Drug Company."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay, great. And then on the branded side, it seemed like branded inflation was particularly strong throughout your fiscal 2012. What's your expectation for '13?",25,"Okay, great. And then on the branded side, it seemed like branded inflation was particularly strong throughout your fiscal 2012. What's your expectation for '13?"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Colleen. It was. It was a strong year. In fact, with our mix of inventory, it was a record year for brand inflation, and we expect that to continue. Our assumption next year is in the brand inflation in the 8% to 9% range.",45,"Thanks, Colleen. It was. It was a strong year. In fact, with our mix of inventory, it was a record year for brand inflation, and we expect that to continue. Our assumption next year is in the brand inflation in the 8% to 9% range."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","The next question in queue will come from Robert Jones with Goldman Sachs.",13,"The next question in queue will come from Robert Jones with Goldman Sachs."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Steve, on the decision to divest the Packaging business, I was hoping you could share your thoughts in a little bit more detail there. I've always understood this to be a pretty steady high-margin business. I know it's not, a Specialty or Distribution,",57,"Steve, on the decision to divest the Packaging business, I was hoping you could share your thoughts in a little bit more detail there. I've always understood this to be a pretty steady high-margin business. I know it's not, a Specialty or Distribution, but just wondering if you could share your thoughts on divesting this business now."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Bob, you're absolutely right. The contract packaging business has been successful and has grown significantly since we established it really by acquiring Anderson several years ago. The business has always operated as a separate entity while under the ABC",160,"Bob, you're absolutely right. The contract packaging business has been successful and has grown significantly since we established it really by acquiring Anderson several years ago. The business has always operated as a separate entity while under the ABC umbrella. And while we've been pleased with its performance, we've not really realized the many synergy opportunities between contract packaging and our other lines of business. The way that we've been running the company since I've been CEO, I think we really do look at the company holistically even more so as we react to the marketplace. So I think as we've done some deep analysis, they aren't really enough touch points on the overall business development with manufacturers to warrant maintaining this as a separate entity going forward. And also the business is growing and I think the capital needs there are going to increase and we just see that we've got better opportunities to invest our capital going forward."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","On the capital deployment going forward actually, is there any change in strategy? If we think about the lower buyback that's baked in for next year, it looks like the free cash flow, $750 million to $800 million, you have $400 million from the buyback an",61,"On the capital deployment going forward actually, is there any change in strategy? If we think about the lower buyback that's baked in for next year, it looks like the free cash flow, $750 million to $800 million, you have $400 million from the buyback and the dividend. Any comments on the use of the rest of that cash going forward?"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, I'll just tell you. Look at what we've done this year, and I could not be more proud. I mean, $800 million in acquisitions. I think we're performing well on those acquisitions. Yet, we did well over $1 billion in share buybacks, we're increasing our",94,"Well, I'll just tell you. Look at what we've done this year, and I could not be more proud. I mean, $800 million in acquisitions. I think we're performing well on those acquisitions. Yet, we did well over $1 billion in share buybacks, we're increasing our dividends. So there's just not much not to like about how ABC uses our capital. I think we are -- among the best users of capital that you'll find anywhere out there. We will continue to contain to maintain our flexibility and use our balance sheet appropriately. Tim."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Yes, and I would just echo what Steve said. I think -- I don't think you can read anything into that. I mean, we -- as I mentioned in my comments, Bob, and were very consistent. When we have excess cash, we return it in some form or fashion. So that's",84,"Yes, and I would just echo what Steve said. I think -- I don't think you can read anything into that. I mean, we -- as I mentioned in my comments, Bob, and were very consistent. When we have excess cash, we return it in some form or fashion. So that's our guidance for now. And we think it's pretty reasonable compared with -- in relation to the ASR. And as we go through the year, we'll just -- we'll see how we're tracking."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Glen Santangelo with Crdit Suisse.",9,"That will come from Glen Santangelo with Crdit Suisse."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Steve, I just want to talk to you a little bit about the pricing environment. Sort of last quarter, you gave us somewhat of a candid assessment of how you view the sell side pricing environment. And I'm just kind of curious, now that you've had another qu",72,"Steve, I just want to talk to you a little bit about the pricing environment. Sort of last quarter, you gave us somewhat of a candid assessment of how you view the sell side pricing environment. And I'm just kind of curious, now that you've had another quarter under your belt, we've seen some contracts come and go, I'm just kind of curious if you could give us maybe an updated assessment."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, a couple of things. I mean, we typically -- about 25% to 30% of our business is up for renewal each year. And last quarter was really unique because literally the next week, we were able to announce a exciting new contract with Express Scripts. And",133,"Well, a couple of things. I mean, we typically -- about 25% to 30% of our business is up for renewal each year. And last quarter was really unique because literally the next week, we were able to announce a exciting new contract with Express Scripts. And that was truly unique if you look at the timing of what we were facing then. So in the 3 months since we've last been on a call with you, we've been through several contract negotiations and honestly, they've all gone very much as expected. There's been one exception, which is with a shared customer, but I would say that things have really stabilized and that the industry really remains fairly competitive. We're stable with most large customers not really showing an inclination to change wholesalers."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. If I could just ask one follow-up on the specialty pharmacy side, as well as sort of the Other segment. Steve, could you maybe give us your view on kind of how we should think about that portion of your business from a growth rate perspective? And a",83,"Okay. If I could just ask one follow-up on the specialty pharmacy side, as well as sort of the Other segment. Steve, could you maybe give us your view on kind of how we should think about that portion of your business from a growth rate perspective? And as a look out through 2013 and 2014, sort of any potential generic launches on the specialty side that can even come close to sort of rivaling what we saw on OxiGemzar [ph] and Taxotere?"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Well, you said specialty pharmacy. So we more are characterized by Specialty Distribution. There is a distinction, and specialty pharmacy, of course, is largely carried out by some of the retail chains but most notably, the PBMs. And those are often custo",194,"Well, you said specialty pharmacy. So we more are characterized by Specialty Distribution. There is a distinction, and specialty pharmacy, of course, is largely carried out by some of the retail chains but most notably, the PBMs. And those are often customers for us within AmerisourceBergen Drug Company. But there is more and more of this specialty product management taking place within large health systems, within mail order infusion centers. So our specialty pharmacy franchise, specialty distribution franchise is a very important characteristic for AmerisourceBergen. I think the way we understand this business, both in the community and health system setting and what we call our ultimate care setting, is really unique characteristics and differentiators for AmerisourceBergen. And I think that it leads to like some outsized performance in areas that you don't traditionally expect us to benefit from, especially, like in our health systems area where we've done very well. And I think you see more and more specialty therapies being administered in a health system setting. So again, we keep on adding to this franchise. We've got excellent leadership here, and you'll continue to see us investing and maintaining market leadership there."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Lisa Gill with JPMorgan.",8,"That will come from Lisa Gill with JPMorgan."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Tim, I had a question around your free cash flow guidance. If I look back to last year, the initial guidance was $800 million to $900 million, and you clearly did $1.1 billion. Can you maybe just talk about the $750 million to $850 million this year? Is t",73,"Tim, I had a question around your free cash flow guidance. If I look back to last year, the initial guidance was $800 million to $900 million, and you clearly did $1.1 billion. Can you maybe just talk about the $750 million to $850 million this year? Is there any impact because of the relationship with Express Scripts and inventory? Or is there anything else that's a onetime item for free cash flow?"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thanks, Lisa. Yes, we do have a slight impact. I mean, on the new contract, our terms, our AR terms are slightly lower than what we had with the former Medco. So that's probably a 1- to 2-day impact. So that's part of the reason why you see that cash a li",72,"Thanks, Lisa. Yes, we do have a slight impact. I mean, on the new contract, our terms, our AR terms are slightly lower than what we had with the former Medco. So that's probably a 1- to 2-day impact. So that's part of the reason why you see that cash a little bit lower. But as always, we're going to work hard to get that up so -- but that's the reason."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","And then just as a follow-on to that, just trying to understand 2 things. One, is there anything else of note in the new relationship with Express Scripts? And then secondly, Steve, I just had a question for you on this new hybrid model with the hospitals",76,"And then just as a follow-on to that, just trying to understand 2 things. One, is there anything else of note in the new relationship with Express Scripts? And then secondly, Steve, I just had a question for you on this new hybrid model with the hospitals. Is there any change in the way that you're being reimbursed or any different level of risk or anything else you're taking on in your specialty distribution business?"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Tim, you go first and then I'll...",7,"Tim, you go first and then I'll..."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Yes. No, in terms of -- no, I don't think there's anything else. In terms of the Express Scripts, your first question about anything else in that Express Scripts contract, no, I don't think there's anything else really to call out. I mean, I think we've h",68,"Yes. No, in terms of -- no, I don't think there's anything else. In terms of the Express Scripts, your first question about anything else in that Express Scripts contract, no, I don't think there's anything else really to call out. I mean, I think we've hit the highlights. Again, it's pretty much all brand, virtually brand, and it's a little bit over 20% of our expected revenues."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Look, we had a great relationship with Medco, and I think we've made a very profound transition to now servicing the overall Express Scripts contract, which we're pleased to be the wholesaler, and we will continue to work on the strategic relationship. Of",220,"Look, we had a great relationship with Medco, and I think we've made a very profound transition to now servicing the overall Express Scripts contract, which we're pleased to be the wholesaler, and we will continue to work on the strategic relationship. Of course, I think the priority for both organizations has been really working on implementing the contract. And now we can look forward to broadening and strengthening the relationship over the next couple of quarters. The hybrid model was the second part of your question. And no, I think it's just really taking advantage of a lot of the services that we offer to community oncologists and allowing those services to transition into more of a hospital setting. And I think it's also getting the manufacturers some of the information that they lack on the patient side and the protocol and formerly management side that we've been able to give them in the community settings. So you're seeing us make investments there, but we think that, that will preserve some of the unique financial as well as therapeutic characteristics of our oncology business. So very important for us to continue to move with the markets. And again, a great example of how we're looking at the company very holistically and less hard lines between, say, specialty and drug."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Eric Coldwell with Robert W. Baird.",10,"That will come from Eric Coldwell with Robert W. Baird."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","On the lost account that you acknowledged on the call today, the regional food/pharmacy combo, GPO business, I guess. I'm curious if you could help us understand the ultimate revenue impact compared to your -- what your expectations would have been had yo",122,"On the lost account that you acknowledged on the call today, the regional food/pharmacy combo, GPO business, I guess. I'm curious if you could help us understand the ultimate revenue impact compared to your -- what your expectations would have been had you retained that. And you did mention that as one of the contributors to the operating margin compression, so should we assume that it's a higher operating margin contract than perhaps your overall book. And then finally, still sticking with that contract. In terms of the phasing of that loss, I know sometimes with GPO contracts, you don't lose all of the business on Day 1. Can you give us some sense on the phasing of the revenue rolling off?"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Sure, Eric. I think that is -- if I kind of write that as a 3-part question, I mean really that first one, I mean, we're not prepared to size that contract. I mean, it was a -- it's a large contract. It's got a nice mix of brand and generic business. So a",107,"Sure, Eric. I think that is -- if I kind of write that as a 3-part question, I mean really that first one, I mean, we're not prepared to size that contract. I mean, it was a -- it's a large contract. It's got a nice mix of brand and generic business. So again, you could definitely say it's more profitable with that brand mix. Part of it we'll have for about 1/2 the year in total. So it doesn't entirely roll off in Q1. We have it through about March quarter so -- but, yes, it definitely impacts -- it's definitely an impact to our margin."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","So Tim, I'm sorry, I guess I'll go to Part 4 here, when you say that you'll have the contract through March, the total contract or a piece of it?",30,"So Tim, I'm sorry, I guess I'll go to Part 4 here, when you say that you'll have the contract through March, the total contract or a piece of it?"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","We'll have a piece of it. We'll have a piece of it. There's a piece that comes off in November and the remaining piece will come off in March, I think it's about 60-40.",35,"We'll have a piece of it. We'll have a piece of it. There's a piece that comes off in November and the remaining piece will come off in March, I think it's about 60-40."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","That will come from Ricky Goldwasser with Morgan Stanley.",9,"That will come from Ricky Goldwasser with Morgan Stanley."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Can you just provide us some more color around fiscal year '13 guidance? And what I'm basically trying to understand is what's the contribution of acquisitions? I think you mentioned that operating income in fiscal year '13 is going to grow 3% to 5%, but",70,"Can you just provide us some more color around fiscal year '13 guidance? And what I'm basically trying to understand is what's the contribution of acquisitions? I think you mentioned that operating income in fiscal year '13 is going to grow 3% to 5%, but that 8% to 10% is going to come from acquisition, so I just wanted to clarify that comment. And then I have one follow-up question."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Yes, Ricky, let me answer your question this way. Between World Courier and TheraCom, I mean, we'll have World Courier for the full year, so that...[Technical Difficulty]",28,"Yes, Ricky, let me answer your question this way. Between World Courier and TheraCom, I mean, we'll have World Courier for the full year, so that...
[Technical Difficulty]"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","Okay. Ladies and gentlemen, please standby as we reestablish the host line.",12,"Okay. Ladies and gentlemen, please standby as we reestablish the host line."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","Ladies and gentlemen, your line -- the host line is now reestablished. [Operator Instructions]",14,"Ladies and gentlemen, your line -- the host line is now reestablished. [Operator Instructions]"
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Ricky, sorry, yes, we lost power. Our building went dark, so apologies, everyone. Getting back to your first question, Ricky, I think you're asking about impact of acquisitions. I'll answer it this way, World Courier and TheraCom should be about 4% to 5%",51,"Ricky, sorry, yes, we lost power. Our building went dark, so apologies, everyone. Getting back to your first question, Ricky, I think you're asking about impact of acquisitions. I'll answer it this way, World Courier and TheraCom should be about 4% to 5% of our EPS in terms of fiscal '13."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. So 4% to 5% of EPS is from the acquisition. And I think that you provided a comment on the EPS; it was around 3% to 5% from EBIT.",30,"Okay. So 4% to 5% of EPS is from the acquisition. And I think that you provided a comment on the EPS; it was around 3% to 5% from EBIT."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","That's correct.",3,"That's correct."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Analysts","Okay. And then on the -- on your margin expansion guidance, and just kind of like help me better understand the numbers because when I think about your revenue guidance and your EBIT guidance, I get to EBIT margin contraction in the mid single digits vers",71,"Okay. And then on the -- on your margin expansion guidance, and just kind of like help me better understand the numbers because when I think about your revenue guidance and your EBIT guidance, I get to EBIT margin contraction in the mid single digits versus your comments around low double digits. So if you could just help me reconcile the difference, maybe you should just -- corporate versus drug distribution."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Yes, Ricky, I guess the best thing I can say on that one is as we get closer to Investor Day, we'll give more specific information by business in terms of margins. But again, let me just say that there is a big impact from the new contract with Express Sc",113,"Yes, Ricky, I guess the best thing I can say on that one is as we get closer to Investor Day, we'll give more specific information by business in terms of margins. But again, let me just say that there is a big impact from the new contract with Express Scripts. We talked just before with Eric about we gave some comments on that Topco contract, which again, with generics, I mean, that's a big impact to our margin. And then, clearly, the generic launches being down. So those 3 items clearly impact our operating income margin and in fact, cause it to be down like we said in the low double-digit range."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Okay. Thanks, Ricky. I think in light of everyone's time, we'll wrap up the call here. But Steve has some final closing remarks.",23,"Okay. Thanks, Ricky. I think in light of everyone's time, we'll wrap up the call here. But Steve has some final closing remarks."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Yes, again, sorry for this. And we want to really thank you for your attention today. I hope you found the call helpful and informative. There was a lot of detail provided, and we really appreciate your attention, especially with the strong close we had t",89,"Yes, again, sorry for this. And we want to really thank you for your attention today. I hope you found the call helpful and informative. There was a lot of detail provided, and we really appreciate your attention, especially with the strong close we had there thanks to Sandy. I hope Tim and I conveyed to you our excitement and confidence in our company, and I hope you share our firm belief that AmerisourceBergen is a great company to invest in. Thank you, all, and have a great day."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","Thank you very much.",4,"Thank you very much."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Executives","I just have a couple of closing comments. We'll be holding our Investor Day on December 12 in New York City. There'll be more information about that on our website next week. And the next conference we'll be attending will be the JPMorgan Healthcare Confe",72,"I just have a couple of closing comments. We'll be holding our Investor Day on December 12 in New York City. There'll be more information about that on our website next week. And the next conference we'll be attending will be the JPMorgan Healthcare Conference on January 9 in San Francisco. So thanks very much. And thank you for your attention today. I'll turn it back to the operator for replay information."
24809,222419523,375853,"AmerisourceBergen Corporation, Q4 2012 Earnings Call, Nov 01, 2012",2012-11-01,"Earnings Calls","Cencora, Inc.","Operator","Thank you very much. And ladies and gentlemen, this conference will be available for replay after 1 p.m. today, running through November 8 at midnight. You may access the AT&T executive playback service at any time by dialing (320) 365-3844, using the acc",65,"Thank you very much. And ladies and gentlemen, this conference will be available for replay after 1 p.m. today, running through November 8 at midnight. You may access the AT&T executive playback service at any time by dialing (320) 365-3844, using the access code of 266794. That does conclude your conference call for today. We do thank you for your participation. You may now disconnect."
